=== МЕТАДАННЫЕ ===
{
  "original_filename": "ehz467.pdf",
  "converted_date": "2026-01-31T14:49:18.854071",
  "file_size_bytes": 4626921,
  "original_format": "pdf",
  "document_type": "Guidelines",
  "source_folder": "Guidelines",
  "full_path": "00_RAW_CARDIOLOGY/Guidelines/ehz467.pdf"
}

=== СОДЕРЖАНИЕ ===

--- Страница 1 ---
ESC GUIDELINES
EuropeanHeartJournal(2020)41,655(cid:2)720
doi:10.1093/eurheartj/ehz467
2019 ESC Guidelines for the management of
patients with supraventricular tachycardia
The Task Force for the management of patients with supraventricu-
lar tachycardia of the European Society of Cardiology (ESC)
Developed in collaboration with the Association for European
Paediatric and Congenital Cardiology (AEPC)
Authors/Task Force Members: Josep Brugada* (Chairperson) (Spain),
Demosthenes G. Katritsis* (Chairperson) (Greece), Elena Arbelo (Spain),
Fernando Arribas (Spain), Jeroen J. Bax (Netherlands),
Carina Blomstro¨m-Lundqvist (Sweden), Hugh Calkins (United States of America),
Domenico Corrado (Italy), Spyridon G. Deftereos (Greece), Gerhard-Paul Diller
(Germany), Juan J. Gomez-Doblas (Spain), Bulent Gorenek (Turkey), Andrew Grace
(United Kingdom), Siew Yen Ho (United Kingdom), Juan-Carlos Kaski (United
Kingdom), Karl-Heinz Kuck (Germany), Pier David Lambiase (United Kingdom),
Frederic Sacher (France), Georgia Sarquella-Brugada1 (Spain),
Piotr Suwalski (Poland), and Antonio Zaza (Italy)
*Correspondingauthors:JosepBrugada,CardiologyDepartment,HospitalClinic,andPediatricArrhythmiaUnit,HospitalSantJoandeDe´u,UniversityofBarcelona,Spain.
Tel:þ3434609022351,Fax:þ3434932271777,Email:jbrugada@clinic.cat.
DemosthenesG.Katritsis,DepartmentofCardiology,HygeiaHospital,E.Stavrou4,15123Athens,Greece,Tel:þ306944845505,Fax:þ302106722535,
Email:dkatrits@dgkatritsis.gr.
Author/TaskForceMemberAffiliations:listedintheAppendix.
ESCCPGandNationalCardiacSocietiesdocumentreviewers:listedintheAppendix.
1RepresentingtheAEPC.
ESCentitieshavingparticipatedinthedevelopmentofthisdocument:
Associations:AcuteCardiovascularCareAssociation(ACCA),EuropeanAssociationofCardiovascularImaging(EACVI),EuropeanAssociationofPreventiveCardiology
(EAPC),EuropeanHeartRhythmAssociation(EHRA),HeartFailureAssociation(HFA).
Councils:CouncilforCardiologyPractice.
WorkingGroups:CardiacCellularElectrophysiology,CardiovascularPharmacotherapy,CardiovascularSurgery,DevelopmentAnatomyandPathology,Grown-upCongenital
HeartDisease.
ThecontentoftheseESCGuidelineshasbeenpublishedforpersonalandeducationaluseonly.Nocommercialuseisauthorized.NopartoftheESCGuidelinesmaybetrans-
latedorreproducedinanyformwithoutwrittenpermissionfromtheESC.PermissioncanbeobtaineduponsubmissionofawrittenrequesttoOxfordUniversityPress,the
publisheroftheEuropeanHeartJournalandthepartyauthorizedtohandlesuchpermissionsonbehalfoftheESC(journals.permissions@oxfordjournals.org).
Disclaimer:TheESCGuidelinesrepresenttheviewsoftheESCandwereproducedaftercarefulconsiderationofthescientificandmedicalknowledge,andtheevidenceavail-
ableatthetimeoftheirpublication.TheESCisnotresponsibleintheeventofanycontradiction,discrepancy,and/orambiguitybetweentheESCGuidelinesandanyotheroffi-
cialrecommendationsorguidelinesissuedbytherelevantpublichealthauthorities,inparticularinrelationtogooduseofhealthcareortherapeuticstrategies.Health
professionalsareencouragedtotaketheESCGuidelinesfullyintoaccountwhenexercisingtheirclinicaljudgment,aswellasinthedeterminationandtheimplementationofpre-
ventive,diagnostic,ortherapeuticmedicalstrategies;however,theESCGuidelinesdonotoverride,inanywaywhatsoever,theindividualresponsibilityofhealthprofessionalsto
makeappropriateandaccuratedecisionsinconsiderationofeachpatient’shealthconditionandinconsultationwiththatpatientand,whereappropriateand/ornecessary,the
patient’scaregiver.NordotheESCGuidelinesexempthealthprofessionalsfromtakingintofullandcarefulconsiderationtherelevantofficialupdatedrecommendationsor
guidelinesissuedbythecompetentpublichealthauthorities,inordertomanageeachpatient’scaseinlightofthescientificallyaccepteddatapursuanttotheirrespectiveethical
andprofessionalobligations.Itisalsothehealthprofessional’sresponsibilitytoverifytheapplicablerulesandregulationsrelatingtodrugsandmedicaldevicesatthetimeof
prescription.
VC TheEuropeanSocietyofCardiology2019.Allrightsreserved.
Forpermissionspleaseemail:journals.permissions@oup.com.
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 2 ---
656 ESCGuidelines
DocumentReviewers:TomDePotter[CommitteeforPracticeGuidelines(CPG)ReviewCoordinator]
(Belgium),ChristianSticherling(CPGReviewCoordinator)(Switzerland),VictorAboyans(France),
CristinaBasso(Italy),MarioBocchiardo(Italy),WernerBudts(Belgium),VictoriaDelgado
(Netherlands),DobromirDobrev(Germany),DonnaFitzsimons(UnitedKingdom),SofieGevaert
(Belgium),HeinHeidbuchel(Belgium),GerhardHindricks(Germany),PeterHlivak(Slovakia),
PrapaKanagaratnam(UnitedKingdom),HugoKatus(Germany),JosefKautzner(CzechRepublic),
ThomasKriebel1(Germany),PatrizioLancellotti(Belgium),UlfLandmesser(Germany),
ChristopheLeclercq(France),BasilLewis(Israel),YuryLopatin(RussianFederation),Be´laMerkely
(Hungary),ThomasPaul(Germany),NikolaPavlovic(cid:2)(Croatia),SteffenPetersen(UnitedKingdom),
AnnaSoniaPetronio(Italy),TatjanaPotpara(Serbia),MarcoRoffi(Switzerland),DanielScherr(Austria),
EvgenyShlyakhto(RussianFederation),IainA.Simpson(UnitedKingdom),KatjaZeppenfeld
(Netherlands)
ThedisclosureformsofallexpertsinvolvedinthedevelopmentoftheseGuidelinesareavailableonthe
ESCwebsitewww.escardio.org/guidelines
FortheSupplementaryDatawhichincludebackgroundinformationanddetaileddiscussionofthedata
thathaveprovidedthebasisfortheGuidelinesseehttps://academic.oup.com/eurheartj/article-lookup/doi/
10.1093/eurheartj/ehz467#supplementary-data
Clickheretoaccessthecorresponding chapterinESCCardioMed-Section40Supraventricular
tachycardias
Onlinepublish-ahead-of-print31August2019
...................................................................................................................................................................................................
Keywords Guidelines (cid:129) arrhythmia (cid:129) tachycardia (cid:129) supraventricular (cid:129) flutter (cid:129) atrioventricular (cid:129) re-entrant (cid:129) focal
(cid:129) macro(cid:2)re-entrant (cid:129) junctional (cid:129) nodal (cid:129) pre-excitation (cid:129) ablation
.
.
Table of contents . 9.2.1.3QRSaxis ...........................................668
.
.
.. 9.2.1.4Chestleadconcordance .............................668
.
1Preamble ....................................................... 659 .. 9.2.1.5Rightbundlebranchblockmorphology................669
.
2Introduction .................................................... 661 .. 9.2.1.6Leftbundlebranchblockmorphology .................669
.
2.1Evidencereview ............................................ 661 .. 9.2.2Electrophysiologystudy ................................ 670
.
2.2Relationshipswithindustryandotherconflictsofinterest .... 661 .. 9.3Irregulartachycardias ....................................... 670
.
2.3Whatisnewinthe2019Guidelines? ........................ 661 .. 10Acutemanagementintheabsenceofanestablisheddiagnosis ... 670
.
2.3.1Changeinrecommendationsfrom2003to2019 ........ 661 .. 10.1Regulartachycardias....................................... 670
. 2.3.2Newrecommendationsin2019......................... 662 .. 10.1.1NarrowQRS(<_120ms)tachycardias .................. 670
. 2.3.3Newrevisedconcepts .................................. 662 .. 10.1.1.1Haemodynamicallyunstablepatients ...............670
.
3Definitionsandclassification..................................... 662 .. 10.1.1.2Haemodynamicallystablepatients..................670
.
4Electrophysiologicalmechanismsofsupraventricular .. 10.1.2WideQRS(120ms)tachycardias ...................... 672
.
.
tachycardia ....................................................... 663 . 10.1.2.1Haemodynamicallyunstablepatients ...............672 .
.
5Cardiacanatomyfortheelectrophysiologist ..................... 664 . 10.1.2.2Haemodynamicallystablepatients..................672
.
.
6Epidemiologyofsupraventriculartachycardia .................... 664 . 10.2Irregulartachycardias ...................................... 673
.
. 7Clinicalpresentation ............................................ 664 . 11Specifictypesofsupraventriculartachycardia ................... 673
.
.
8Initialevaluationofpatientswithsupraventriculartachycardia ..... 665 . 11.1Atrialarrhythmias ......................................... 673
.
.
9Differentialdiagnosisoftachycardias ............................. 665 . 11.1.1Sinustachycardia ...................................... 673
.
.
9.1NarrowQRS(<_120ms)tachycardias ....................... 665 . 11.1.1.1Physiologicalsinustachycardia ......................673
.
.
9.1.1Electrocardiographicdifferentialdiagnosis ............... 665 . 11.1.1.2Inappropriatesinustachycardia .....................673
.
.
9.1.1.1Initiationandterminationofthetachycardia ...........665 . 11.1.1.2.1Diagnosis ................................673
.
.
9.1.1.2Regularityoftachycardiacyclelength .................665 . 11.1.1.2.2Therapy .................................673
.
.
9.1.1.3P/QRSrelationship ..................................665 . 11.1.1.3Sinusnodere-entranttachycardia ...................674
.
.
9.1.2Vagalmanoeuvresandadenosine ....................... 667 .. 11.1.1.3.1Diagnosis ................................674
.
9.1.3Electrophysiologystudy ................................ 668 .. 11.1.1.3.2Therapy .................................674
.
9.2WideQRS(>120ms)tachycardias .......................... 668 .. 11.1.1.4Posturalorthostatictachycardiasyndrome ...........674
.
9.2.1Electrocardiographicdifferentialdiagnosis ............... 668 .. 11.1.1.4.1Diagnosis ................................674
.
9.2.1.1Atrioventriculardissociation ..........................668 .. 11.1.1.4.2Therapy .................................675
.
9.2.1.2QRSduration .......................................668 . 11.1.2Focalatrialtachycardia ................................ 675
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 3 ---
ESCGuidelines 657
.
.
11.1.2.1Diagnosis .........................................675 . 12.2Catheterandsurgicalablation.............................. 696
.
.
11.1.2.2Acutetherapy .....................................675 . 12.3Specificdiseasestates ..................................... 696
.
.
11.1.2.3Catheterablation ..................................675 . 12.3.1Atrialseptaldefect .................................... 696
.
.
11.1.2.4Chronictherapy ...................................677 . 12.3.2Ebstein’sanomaly ..................................... 696
.
.
11.1.3Multifocalatrialtachycardia ............................ 678 . 12.3.3Transpositionofthegreatarteries(dextro-transposition
.
.
11.1.3.1Therapy ...........................................678 . ofthegreatarteries)afteratrialswitchoperation
.
.
11.1.4Macro-re-entrantatrialtachycardias ................... 678 . (MustardorSenning) ........................................ 696
.
.
11.1.4.1Cavotricuspidisthmus-dependent . 12.3.4TetralogyofFallot..................................... 697
.
.
macro-re-entrantatrialtachycardia ..........................678 .. 12.3.5Fontanrepairs ........................................ 697
.
11.1.4.1.1Typicalatrialflutter:common .. 13Supraventriculartachycardiainthepaediatricpopulation ........ 697
.
(counter-clockwise)andreverse(clockwise) ...........678 .. 13.1Foetalarrhythmias ........................................ 697
.
11.1.4.1.2Diagnosis ................................678 .. 14Supraventriculartachycardiainpregnancy ...................... 697
.
11.1.4.1.3Acutetherapy............................679 .. 14.1Maternal,obstetric,andoffspringrisk....................... 698
.
11.1.4.1.4Catheterablation ........................681 .. 14.2Therapy .................................................. 698
.
11.1.4.1.5Chronictherapy ..........................681 .. 14.2.1Antiarrhythmicdrugs.................................. 698
.
11.1.4.1.6Anticoagulation ..........................681 .. 14.2.2Electricalcardioversion................................ 699
.
11.1.4.1.7Othercavotricuspidisthmus-dependent .. 14.2.3Catheterablation ..................................... 699
.
macro-re-entrantatrialtachycardia ..................681 .. 15Tachycardia-inducedcardiomyopathy .......................... 699
.
11.1.4.2Non-cavotricuspidisthmus-dependent .. 15.1Definition ................................................. 699
.
macro-re-entrantatrialtachycardia ..........................681 .. 15.2Mechanism ............................................... 699
.
.
11.1.4.2.1Rightatriummacro-re-entrantatrial . 15.3Diagnosis ................................................. 699
.
.
tachycardia ........................................681 . 15.4Therapy .................................................. 699
.
.
11.1.4.2.2Leftatriummacro-re-entrantatrial . 16Supraventriculartachycardiainsports .......................... 700
.
.
tachycardia ........................................682 . 17Supraventriculartachycardiaanddrivingrestrictions ............ 700
.
.
11.2Atrioventricularjunctionalarrhythmias ..................... 683 . 18Keymessages ................................................. 701
.
.
11.2.1Atrioventricularnodalre-entranttachycardia .......... 683 . 19Gapsintheevidence .......................................... 701
.
.
11.2.1.1Diagnosis .........................................683 . 20Evidence-based‘whattodo’and‘whatnottodo’messages
.
.
11.2.1.1.112leadelectrocardiogramduring . fromtheGuidelines .............................................. 702
.
.
tachycardia ........................................683 . 21Areasforfurtherresearch ..................................... 705
.
.
11.2.1.1.2Electrophysiologystudy ...................684 . 22Supplementarydata ........................................... 705
.
.
11.2.1.1.3Typicalatrioventricularnodal .. 23Appendix ..................................................... 705
.
re-entranttachycardia ..............................684 .. 24References .................................................... 706
.
11.2.1.1.4Atypicalatrioventricularnodal ..
.
re-entranttachycardia ..............................684 ..
.
11.2.1.2Therapy ...........................................684 ..
.
11.2.1.2.1Acutetherapy............................685 .. Recommendations
. 11.2.1.2.2Catheterablation ........................685 .. RecommendationsfortheacutemanagementofnarrowQRS
.
11.2.1.2.3Chronictherapy ..........................685 .. tachycardiaintheabsenceofanestablisheddiagnosis .............. 670
.
11.2.2Non-re-entrantjunctionaltachycardias ................ 686 .. RecommendationsfortheacutemanagementofwideQRS .
11.3Atrioventriculararrhythmias ............................... 686 .. tachycardiaintheabsenceofanestablisheddiagnosis .............. 672 .
11.3.1Accessorypathways .................................. 686 .. Recommendationsforthetherapyofsinustachycardias ............ 674
.
11.3.2Wolff(cid:2)Parkinson(cid:2)Whitesyndrome .................. 687 .. Recommendationsforthetherapyoffocalatrialtachycardia........ 676
.
.
11.3.3Orthodromicatrioventricularre-entranttachycardia ... 687 . Recommendationsforthetherapyofmultifocalatrialtachycardia... 678
.
.
11.3.4Antidromicatrioventricularre-entranttachycardia ..... 688 . Recommendationsforthetherapyofmacro-re-entrantatrial
.
.
11.3.5Accessorypathwayasabystander ..................... 688 . arrhythmias ...................................................... 679
.
.
11.3.6Pre-excitedatrialfibrillation ........................... 688 . Recommendationsforthemanagementofatrioventricular
.
.
11.3.7Concealedaccessorypathways ........................ 688 . nodalre-entranttachycardia ...................................... 684
.
.
11.3.8Permanentjunctionalreciprocatingtachycardia......... 689 .. Recommendationsforthetherapyofatrioventricularre-entrant
.
11.3.9Atypicalformsofpre-excitation ....................... 689 .. tachycardiaduetomanifestorconcealedaccessorypathways ...... 690
.
11.3.10Therapy ............................................. 690 .. Recommendationsfortheacutetherapyofpre-excitedatrial
.
11.3.10.1Acutetherapy ....................................690 .. fibrillation ........................................................ 691
.
11.3.10.2Catheterablation.................................692 .. Recommendationsforthemanagementofpatientswith
.
11.3.10.3Chronictherapy ..................................692 .. asymptomaticpre-excitation ...................................... 693
.
11.3.11Theasymptomaticpatientwithpre-excitation ........ 692 .. Recommendationsforthetherapyofsupraventriculartachycardias
.
12Supraventriculartachycardiainadultswithcongenitalheart .. incongenitalheartdiseaseinadults ................................ 696
.
disease ........................................................... 695 .. Recommendationsforthetherapyofsupraventriculartachycardia
.
12.1Pharmacologicalantiarrhythmictherapy .................... 695 . inpregnancy ..................................................... 698
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 4 ---
658 ESCGuidelines
.
.
Recommendationsforthetherapyofsupraventriculartachycardia . Figure15Chronictherapyofatrioventricularnodal
.
.
inpatientswithsuspectedorestablishedheartfailuredueto . re-entranttachycardia............................................. 686
.
.
tachycardiomyopathy............................................. 699 . Figure16TheStGeorge’salgorithmforlocalizationof
.
.
RecommendationsfortheacutemanagementofnarrowQRS . accessorypathways .............................................. 687
.
.
tachycardiaintheabsenceofanestablisheddiagnosis .............. 702 . Figure17Localizationofaccessorypathwaysinthepresence
.
.
. ofmaximum(spontaneousorevoked)pre-excitation .............. 688
.
.
List of tables .. Figure18Atrioventricularre-entranttachycardia .................. 689
.
. Figure19Acutetherapyofatrioventricularre-entrant
.
Table1Classesofrecommendations .............................. 660 .
.. tachycardia. ...................................................... 691
Table2Levelsofevidence ........................................ 660 .
.. Figure20Acutetherapyofpre-excitedatrialfibrillation. ............ 692
Table3Changesindrugrecommendationssince2003 ............ 661 .
.. Figure21Chronictherapyofatrioventricularre-entrant
Table4Newrecommendationsin2019 ........................... 662 .
.. tachycardia. ...................................................... 692
Table5Conventionalclassificationofsupraventricular .
.. Figure22Riskstratificationandtherapyofpatientswith
tachycardia ....................................................... 663 .
.. asymptomaticpre-excitation. ..................................... 694
Table6DifferentialdiagnosisofnarrowandwideQRS .
.
.
tachycardias ...................................................... 663 .
.
.
Table7Initialevaluationofthepatientwithsupraventricular .. Abbreviations and acronyms .
tachycardia ....................................................... 664 ..
.
Table8PossibleresponsesofnarrowQRStachycardiatovagal ..
þ/- QRScomplexequiphasic
.
manoeuvresandadenosine ....................................... 667 ..
þve QRScomplex-positive
.
Table9Summaryofkeyelectrocardiographiccriteriathatsuggest ...
(cid:2)ve QRScomplex-negative
ventriculartachycardiaratherthansupraventriculartachycardia ...
ACHD Adultcongenitalheartdisease
inwidecomplextachycardia ...................................... 668 ...
AEPC AssociationforEuropeanPaediatricandCongenital
Table10Causesofphysiologicalsinustachycardia ................. 673 ...
Cardiology
Table11Averagesuccessandcomplicationsratesofcatheter ...
AF Atrialfibrillation
ablationforsupraventriculartachycardia........................... 677 ...
AH Atrial(cid:2)His
Table12Classificationofatrioventricularnodalre-entrant ...
AMP Adenosinemonophosphate
tachycardiatypes ................................................. 684 ...
AP Accessorypathway
.
Table13Recommendationsforsportsparticipationinathletes .. AT Atrialtachycardia
.
withventricularpre-excitationandsupraventriculararrhythmias ... 700 .. AV Atrioventricular
.
Table14EuropeanWorkingGroup2013reportondriving .. AVN Atrioventricularnode
.
andcardiovasculardisease:drivinginarrhythmiasandconduction .. AVNRT Atrioventricularnodalre-entranttachycardia
.
disorders:supraventriculartachycardia ............................ 701 .. AVRT Atrioventricularre-entranttachycardia
.
.
. BBB Bundlebranchblock
.
List of figures .. b.p.m. Beatsperminute
.
.
Figure1DifferentialdiagnosisofnarrowQRStachycardia. .......... 666 .. CHA2DS2- Cardiacfailure,Hypertension,Age>_75(Doubled),
. . VASc Diabetes,Stroke(Doubled)(cid:2)Vasculardisease,
Figure2Responsesofnarrowcomplextachycardiasto .
.
. Age65(cid:2)74andSexcategory(Female)
adenosine. ....................................................... 667 .
.
. CL Cyclelength
Figure3Examplesofpositiveandnegativechestlead . .
. CMR Cardiacmagneticresonance
concordance. .................................................... 669 . .
. CT Computedtomography
Figure4AcutetherapyofnarrowQRStachycardiaintheabsence .
.
. CTI Cavotricuspidisthmus
ofanestablisheddiagnosis. ........................................ 671 .
.
. CV Conductionvelocity
Figure5Acutetherapyofwidecomplextachycardiainthe .
.
absenceofanestablisheddiagnosis ................................ 672
.. CYP CytochromeP450
.
Figure6Therapyofsinustachycardias ............................. 674
.. DAD Delayedafter-depolarization
.
Figure7Focalatrialtachycardia ................................... 676
.. DC Directcurrent
.
Figure8Acutetherapyoffocalatrialtachycardia ................... 677
.. DCS Distalcoronarysinus
.
Figure9Chronictherapyoffocalatrialtachycardia ................. 677
... EA Enhancedautomaticity
Figure10Counter-clockwiseandclockwiseatrialflutter
... EAD Earlyafter-depolarization
with2:1atrioventricularconduction ............................... 678
... ECG Electrocardiogram/electrocardiographic
Figure11Acutetherapyofstableatrialflutterormacro-re-entrant
... EPS Electrophysiologystudy
atrialtachycardia. ................................................. 680
... ERP Effectiverefractoryperiod
Figure12Chronictherapyofatrialflutter/macro-re-entrant
... ESC EuropeanSocietyofCardiology
atrialtachycardia ................................................. 682
... HA His(cid:2)atrialinterval
Figure13Atrioventricularnodalre-entranttachycardia ............ 683
... HCN Hyperpolarization-activatedcyclicnucleotide-gated
.
Figure14Acutetherapyofatrioventricularnodalre-entrant .. potassiumchannel
.
tachycardia. ...................................................... 685 . HF Heartfailure
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 5 ---
ESCGuidelines 659
.
.
HFrEF Heartfailurewithreducedejectionfraction .. responsible health professional(s) in consultation with the patient
.
HPS His(cid:2)Purkinjesystem .. andcaregiverasappropriate.
.
HV His(cid:2)ventrcularinterval .. Agreatnumberofguidelineshavebeenissuedinrecentyearsby
.
ICaL L-typeCa2þcurrent .. theEuropeanSocietyofCardiology(ESC),aswellasbyothersoci-
.
ICD Implantablecardioverterdefibrillator .. etiesandorganisations.Becauseoftheirimpactonclinicalpractice,
.
IST Inappropriatesinustachycardia .. quality criteria for the development ofguidelines have been estab-
.
i.v. Intravenous .. lishedinordertomakealldecisionstransparenttotheuser.Therec-
.
JET Junctionalectopictachycardia .. ommendations for formulating and issuing ESC Guidelines can be
.
LA Leftatrial/atrium .. found on the ESC website (http://www.escardio.org/Guidelines-&-
.
LAL Leftanterolateral .. Education/Clinical-Practice-Guidelines/Guidelines-development/Writ
.
LBBB Leftbundlebranchblock .. ing-ESC-Guidelines).TheESCGuidelinesrepresenttheofficialposi-
.
LL Leftlateral .. tionoftheESConagiventopicandareregularlyupdated.
.
LP Leftposterior .. TheESCcarriesoutanumberofregistrieswhichareessentialto
.
LPL Leftposterolateral .. assess,diagnostic/therapeuticprocesses,useofresourcesandadher-
.
LPS Leftposteroseptal .. encetoGuidelines.Theseregistriesaimatprovidingabetterunder-
.
LV Leftventricle/ventricular .. standingofmedicalpracticeinEuropeandaroundtheworld,based
.
MI Myocardialinfarction ... ondatacollectedduringroutineclinicalpractice.
MRAT Macro-re-entrantatrialtachycardia ... Theguidelinesaredevelopedtogetherwithderivativeeducational
MS Mid-septal ... materialaddressingtheculturalandprofessionalneedsforcardiolo-
NT-proBNP N-terminalpro-B-typenatriureticpeptide ... gists and allied professionals. Collecting high-quality observational
.
PJRT Permanentjunctionalreciprocatingtachycardia .. data, at appropriate time interval following the release of ESC
.
p.o. Peros(bymouth) .. Guidelines, will help evaluate the level of implementation of the
.
POTS Posturalorthostatictachycardiasyndrome .. Guidelines,checkinginprioritythekeyendpointsdefinedwiththe
.
PPM Permanentpacemaker .. ESCGuidelinesandEducationCommitteesandTaskForcemembers
.
PRKAG2 ProteinkinaseAMP-activatednon-catalyticsubunit .. incharge.
.
gamma2 .. TheMembersofthisTaskForcewereselectedbytheESC,includ-
.
PV Pulmonaryvein .. ing representation from its relevant ESC sub-specialty groups, in
.
RA Rightatrial/anterior .. order to representprofessionalsinvolved withthe medicalcare of
.
RAS Rightanteroseptal .. patientswiththispathology.Selectedexpertsinthefieldundertooka
.
RBBB Rightbundlebranchblock .. comprehensivereviewofthepublishedevidenceformanagementof
.
RCT Randomizedclinicaltrial .. a given condition according to ESC Committee for Practice
.
RL Rightlateral .. Guidelines(CPG)policy.Acriticalevaluationofdiagnosticandthera-
.
RP Rightposterior .. peutic procedures was performed, including assessment of the
.
RPS Rightposteroseptal .. risk(cid:2)benefitratio.Thelevelofevidenceandthestrengthoftherec-
.
RyR SarcoplasmicreticulumCa2þchannel .. ommendationofparticularmanagementoptionswereweighedand
.
SPERRI Shortestpre-excitedRRintervalduringatrial .. gradedaccordingtopredefinedESCscales,asoutlinedintables1and
. fibrillation .. 2below.
.
SR Sarcoplasmicreticulum .. Theexpertsofthewritingandreviewingpanelsprovideddeclara-
.
SVT Supraventriculartachycardia ... tionofinterestformsforallrelationshipsthatmightbeperceivedas
TA Triggeredactivity ... realorpotentialsourcesofconflictsofinterest.Theseformswere
TCM Tachycardiomyopathy ... compiledintoonefileandcanbefoundontheESCwebsite(http://
TDI TissueDopplerimaging ... www.escardio.org/guidelines).Anychangesindeclarationsofinterest
.
VA Ventriculoatrial .. that arise during the writing period were notified to the ESC and
.
VT Ventriculartachycardia .. updated. The Task Force received its entire financial support from
.
WL Wavelength .. theESCwithoutanyinvolvementfromthehealthcareindustry.
.
WPW Wolff-Parkinson-White .. TheESCCPGsupervisesandcoordinatesthepreparationofnew
.
. Guidelines.TheCommitteeisalsoresponsiblefortheendorsement
.
.
. processoftheseGuidelines.TheESCGuidelinesundergoextensive
.
.
. reviewbytheCPGandexternalexperts.Afterappropriaterevisions
.
.
1 Preamble . theGuidelinesareapprovedbyalltheexpertsinvolvedintheTask
.
.
. Force.ThefinalizeddocumentisapprovedbytheCPGforpublica-
.
.
Guidelinessummarizeandevaluateavailableevidencewiththeaimof .. tionintheEuropeanHeartJournal.TheGuidelinesweredeveloped
.
assisting health professionals in proposing the best management .. after careful consideration of the scientific and medical knowledge
.
strategiesforanindividualpatientwithagivencondition.Guidelines .. andtheevidenceavailableatthetimeoftheirdating.
.
and their recommendations should facilitate decision making of .. ThetaskofdevelopingESCGuidelinesalsoincludesthecreation
.
health professionals in their dailypractice.However,the final deci- .. ofeducationaltoolsandimplementationprogrammesfortherecom-
.
sions concerning an individual patient must be made by the . mendationsincludingcondensedpocketguidelineversions,summary
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 6 ---
660 ESCGuidelines
Table1 Classesofrecommendations
Wording to use
Class I Evidence and/or general agreement Is recommended or is indicated
that a given treatment or procedure is
Class II
Class IIa Weight of evidence/opinion is in Should be considered
Class IIb May be considered
established by evidence/opinion.
Class III Evidence or general agreement that the Is not recommended
given treatment or procedure is not
useful/effective, and in some cases
may be harmful.
Table2 Classesofrecommendations
Level of Data derived from multiple randomized clinical trials
evidence A or meta-analyses.
Level of Data derived from a single randomized clinical trial
evidence B or large non-randomized studies.
Level of Consensus of opinion of the experts and/or small studies,
evidence C retrospective studies, registries.
.
slides, booklets with essential messages, summary cards for non- .. favourably influenced by the thorough application of clinical
.
specialists and an electronic version for digital applications .. recommendations.
.
(smartphones,etc.).Theseversionsareabridgedandthus,formore .. HealthprofessionalsareencouragedtotaketheESCGuidelines
.
detailed information, the user should always access to the full .. fullyintoaccountwhenexercisingtheirclinicaljudgment,aswellasin
.
text version of the Guidelines, which is freely available via the .. thedeterminationandtheimplementationofpreventive,diagnostic
.
ESCwebsiteandhostedontheEHJwebsite.TheNationalSocieties .. ortherapeuticmedicalstrategies.However,theESCGuidelinesdo
.
of the ESC are encouraged to endorse, translate and implement .. notoverride in any waywhatsoeverthe individual responsibilityof
.
all ESC Guidelines. Implementation programmes are needed .. healthprofessionals to makeappropriateand accurate decisions in
.
.
because it has been shown that the outcome of disease may be . considerationofeachpatient’shealthconditionandinconsultation
snoitadnemmocer
fo
sessalC
9102
CSE
©
9102
CSE
©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 7 ---
ESCGuidelines 661
.
withthatpatientorthepatient’scaregiverwhereappropriateand/or .. 2.3 What is new in the 2019 Guidelines?
.
necessary. Itis alsothehealth professional’s responsibility to verify ...
2.3.1Changeinrecommendationsfrom2003to2019
therulesandregulationsapplicableineachcountrytodrugsanddevi- ...
Owing to the factthatthe previous Guidelines on SVT werepub-
cesatthetimeofprescription. ...
lished16yearsago,manydrugsthatwererecommendedatthattime
.
.. are not considered in the 2019 Guidelines. In addition, techniques
.
.. andindicationsofablationtechniqueshavechanged.Theserecom-
.
2 Introduction .. mendationchangesareindicatedforeachsectioninTable3below.
.
.
Supraventricular arrhythmias are common and patients are often Table3 ChangesinSVTGuidelinesrecommendations
symptomatic, requiring management with drugs and electrophysio- since2003
logical procedures. The ESC published management Guidelines for
2003 2019
supraventricular tachycardias (SVTs) in 20031; corresponding US
AcutemanagementofnarrowQRS
guidelineshavealsobeenpublished,themostrecentbeingin2015.2
tachycardias
Thereisaneedtoprovideexpertrecommendationsforprofessio-
Verapamilanddiltiazem I IIa
nalsparticipatinginthecareofpatientspresentingwithSVT.Inaddi-
Beta-blockers IIb IIa
tion,severalassociatedconditionswhereSVTsmaycoexistneedto
Amiodaroneanddigoxinarenotmentionedinthe beexplainedinmoredetail.Toaddressthistopic,aTaskForcewas
2019Guidelines
convenedbytheESC,withtheremittocomprehensivelyreviewthe
publishedevidenceandtopublishGuidelinesonthemanagementof AcutemanagementofwideQRS
patientswithSVT,withup-to-dateconsensusrecommendationsfor tachycardias
clinicalpractice.Thisdocumentsummarizescurrentdevelopmentsin Procainamide I IIa
thefield,withafocusonadvancessincethelastESCGuidelineswere Adenosine IIb IIa
published, andprovides general recommendations forthe manage- Amiodarone I IIb
mentofadultswithSVTbasedontheprinciplesofevidence-based Sotalolandlidocainearenotmentionedinthe
medicine. 2019Guidelines
Therapyofinappropriatesinus
2.1 Evidence review tachycardia
MembersoftheTaskForcewereaskedtoperformadetailedlitera- Beta-blockers I IIa
turereview,weighthestrengthofevidencefororagainstaparticular Verapamil/diltiazemandcatheterablationarenot
treatment or procedure, and include estimates of expected health mentionedinthe2019Guidelines
outcomeswheredataexist.Patient-specificmodifiers,comorbidities, Therapyofposturalorthostatictachy-
and issues ofpatientpreference that might influence thechoice of cardiasyndrome
particulartestsortherapieswereconsidered,aswerefrequencyof Saltandfluidintake IIa IIb
follow-up and cost-effectiveness. In controversial areas, or with Head-uptiltsleep,compressionstockings,selective
regardtoissueswithoutevidenceotherthanusualclinicalpractice, beta-blockers,fludrocortisone,clonidine,methyl-
consensuswasachievedbyagreementoftheexpertpanelafterthor- phenidate,fluoxetine,erythropoietin,ergotamine/
ough deliberation. The document was peer-reviewed by official octreotide,andphenobarbitonearenotmentioned
externalreviewers. inthe2019guidelines.
Thestrengthsoftherecommendationsandlevelsofevidenceof
TherapyoffocalAT
particularmanagementoptionswereweighedandgradedaccording
Acute
topredefinedscales,asoutlinedaboveinTables1and2,respectively.
Flecainide/propafenone IIa IIb
Overall, these Guidelines include evidence and expert opinions
Amiodarone IIa IIb
from several countries. The pharmacological and non-
Procainamide,sotalol,anddigoxinarenotmen-
pharmacologicalantiarrhythmicapproachesdiscussedmaytherefore
tionedinthe2019Guidelines
includedrugsthatdonothavetheapprovalofgovernmentalregula-
toryagenciesinallcountries. Chronic
Beta-blockers I IIa
Verapamilanddiltiazem I IIa
2.2 Relationships with industry and other
Sotalolanddisopyramidearenotmentionedin
conflicts of interest
the2019Guidelines
ItisESCpolicytosponsorpositionpapersandGuidelineswithout
Therapyofatrialflutter
commercialsupport,andallmembersvolunteeredtheirtime.Thus,
Acute
allmembersofthewritinggroup,aswellasthereviewers,havedis-
Atrialortransoesophagealpacing I IIb
closedanypotentialconflictsofinterestindetail.Thedetailsofthese
Ibutilide IIa I
declarationswillbepostedontheESCwebsiteuponpublicationof
theseGuidelines. Flecainide/propafenone IIb III
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 8 ---
662 ESCGuidelines
Table3 Continued i.v.amiodaroneisnotrecommendedforpre-excitedAF. III
PerformanceofanEPStorisk-stratifyindividualswith
IIa
2003 2019
asymptomaticpre-excitationshouldbeconsidered.
Verapamilanddiltiazem I IIa
Catheterablationisrecommendedinasymptomatic
Beta-blockers I IIa patientsinwhomelectrophysiologytestingwiththe
Digitalisisnotmentionedinthe2019Guidelines useofisoprenalineidentifieshigh-riskproperties,such I
Chronic asSPERRI<_250ms,APERP<_250ms,multipleAPs,
Dofetilide,sotalol,flecainide,propafenone,procai- andaninducibleAP-mediatedtachycardia.
namide,quinidine,anddisopyramidearenotmen- Non-invasiveevaluationoftheconductingproperties
tionedinthe2019Guidelines oftheAPinindividualswithasymptomaticpre-excita- IIb
TherapyofAVNRT tionmaybeconsidered.
Acute Catheterablationmaybeconsideredinapatientwith
Amiodarone,sotalol,flecainide,andpropafenone asymptomaticpre-excitationandlow-riskAPatinva- IIb
arenotmentionedinthe2019Guidelines siveornon-invasiveriskstratification.
Chronic Catheterablationsshouldbeconsideredinpatients
Verapamilanddiltiazem I IIa withasymptomaticpre-excitationandLVdysfunction IIa
duetoelectricaldyssynchrony.
Beta-blockers I IIa
AVnodalablationwithsubsequentpacing(‘ablateand
Amiodarone,sotalol,flecainide,propafenone,and
pace’),eitherbiventricularorHis-bundlepacing,is
the‘pill-in-thepocket’approacharenotmen- I
recommendedifatachycardiaresponsibleforTCM
tionedinthe2019Guidelines
cannotbeablatedorcontrolledbydrugs.
TherapyofAVRT
Duringthefirsttrimesterofpregnancy,itisrecommended
Flecainide/propafenone IIa IIb I
thatallantiarrhythmicdrugsareavoided,ifpossible.
Beta-blockers IIb IIa
Inpregnantwomen,beta-1selectiveblockers(except
Amiodarone,sotalol,andthe‘pill-in-thepocket’
atenolol)orverapamil,inorderofpreference,should
approacharenotmentionedinthe2019 IIa
beconsideredforpreventionofSVTinpatientswith-
Guidelines
outWPWsyndrome.
SVTinpregnancy
Inpregnantwomen,flecainideorpropafenoneshould
Verapamil IIb IIa
beconsideredforpreventionofSVTinpatientswith
IIa
Catheterablation IIb IIa* WPWsyndromeandwithoutischaemicorstructural
Sotalol,propranolol,quinidine,andprocainamide heartdisease.
arenotmentionedinthe2019Guidelines.
AF=atrialfibrillation;AP=accessorypathway;AT=atrialtachycardia;AV=
*:whenfluorolessablationisavailable.AT=atrialtachycardia;AVNRT=atrio- atrioventricular;EPS=electrophysiologystudy;ERP=effectiverefractoryperiod;
ventricular nodal re-entrant tachycardia; AVRT = atrioventricular re-entrant i.v.=intravenous;LV=leftventricular;POTS:posturalorthostatictachycardia
tachycardia. syndrome; SPERRI = shortest pre-excited RR interval during atrial fibrillation;
SVT = supraventricular tachycardia; TCM = tachycardiomyopathy; WPW =
Wolff-Parkinson-White.
2.3.2Newrecommendationsin2019 .
.
. 2.3.3Newrevisedconcepts
. .
. • Drug therapy for inappropriate sinus tachycardia and focal atrial
. Table4 Newrecommendationsin2019 .. tachycardia.
.
.. • Therapeutic optionsforacuteconversionand anticoagulationof
Ivabradinealoneorincombinationwithabeta- ...
atrialflutter.
blockershouldbeconsideredinsymptomaticpatients IIa .. • Therapyofatrioventricularnodalre-entranttachycardia.
.
withinappropriatesinustachycardia. .. • Therapyofantidromicatrioventricularre-entranttachycardiaand
.
Ibutilide(i.v.)ibutilidemaybeconsideredforacute .. pre-excitedatrialfibrillation.
therapyoffocalatrialtachycardia.
IIb ...
• Managementofpatientswithasymptomaticpre-excitation.
.
. • Diagnosisandtherapyoftachycardiomyopathy.
Ivabradineforposturalorthostatictachycardiasyn- ..
.
drome,andivabradinewithabeta-blockerforchronic IIb ..
.
therapyoffocalatrialtachycardia,maybeconsidered. ..
. 3 Definitions and classification
PatientswithatrialflutterwithoutAFshouldbecon- ..
.
sideredforanticoagulation,butthethresholdforini- IIa ..
.. Theterm‘SVT’literallyindicatestachycardia[atrialrates>100beats
tiationisnotestablished. .
.. perminute(b.p.m.)atrest],themechanismofwhichinvolvestissue
Ibutilide(i.v.),ori.v.ororal(in-hospital)dofetilideare .
I .. fromtheHisbundleorabove.2,3Traditionally,SVThasbeenusedto
recommendedforconversionofatrialflutter. .
.. describeallkindsoftachycardiasapartfromventriculartachycardias
High-rateatrialpacingisrecommendedfortermina- ...
(VTs)andAF.Ithasthereforeincludedtachycardiassuchasatrioven-
tionofatrialflutterinthepresenceofanimplanted I ..
tricular(AV)re-entryduetoaccessoryconnections,whichisnot,in
pacemakerordefibrillator.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 9 ---
ESCGuidelines 663
Table5 Conventionalclassificationofsupraventricular Table6 DifferentialdiagnosisofnarrowandwideQRS
tachycardias tachycardias
Atrialtachycardias NarrowQRS((cid:3)120ms)tachycardias
Sinustachycardia Regular
• Physiologicalsinustachycardia • Physiologicalsinustachycardia
• Inappropriatesinustachycardia • Inappropriatesinustachycardia
• Sinusnodalre-entranttachycardia • Sinusnodalre-entranttachycardia
FocalAT • FocalAT
MultifocalAT • AtrialflutterwithfixedAVconduction
• AVNRT
MRAT
• JET(orothernon-re-entrantvariants)
• Cavotricuspidisthmus-dependentMRAT
• OrthodromicAVRT
(cid:2)Typicalatrialflutter,counter-clockwise(common)orclockwise
• IdiopathicVT(especiallyhighseptalVT)
(reverse)
Irregular
(cid:2)Othercavotricuspidisthmus-dependentMRAT
• Non-cavotricuspidisthmus-dependentMRAT • AF
(cid:2)RAMRAT • FocalAToratrialflutterwithvaryingAVblock
(cid:2)LAMRAT • MultifocalAT
AF WideQRS(>120ms)tachycardias
AVjunctionaltachycardias Regular
Atrioventricularnodalre-entranttachycardia(AVNRT) • VT/flutter
• Typical • Ventricularpacedrhythm
• Atypical • AntidromicAVRT
• SVTswithaberration/BBB(pre-existingorrate-dependentduring
Non-re-entrantjunctionaltachycardia
tachycardia)
• JET(junctionalectopicorfocaljunctionaltachycardia)
• Atrialorjunctionaltachycardiawithpre-excitation/bystanderAP
• Othernon-re-entrantvariants
• SVTwithQRSwideningduetoelectrolytedisturbanceorantiarrhyth-
Atrioventricularre-entranttachycardia(AVRT)
micdrugs
• Orthodromic(includingPJRT)
Irregular
• Antidromic(withretrogradeconductionthroughtheAVNor,rarely,
• AForatrialflutterorfocalATwithvaryingblockconductedwith
overanotherpathway)
aberration
• AntidromicAVre-entranttachycardiaduetoanodo-ventricular/fascic-
AF=atrialfibrillation; AT =atrialtachycardia;AV=atrioventricular; AVN=
ularAPwithvariableVAconduction
atrioventricularnode;JET=junctionalectopictachycardia;RA=rightatrial;LA
=leftatrial;MRAT=macro-re-entrantatrialtachycardia;PJRT=permanentjunc- • Pre-excitedAF
tionalreciprocatingtachycardia;RA=rightatrial. • PolymorphicVT
• Torsadedepointes
essence,asupraventricularrhythm(Table5).Theterm‘narrowQRS • Ventricularfibrillation
tachycardia’ indicates those with a QRS duration <_120 ms. A wide Occasionally,AFwithveryfastventricularresponsemayapparently
QRS tachycardia refers to one with a QRS duration >120 ms resemblearegularnarrowQRStachycardia.
(Table6).Inclinicalpractice,SVTmaypresentasnarroworwideQRS AF=atrialfibrillation;AP=accessorypathway;AT=atrialtachycardia;AV=
tachycardias,mostofwhich,althoughnotinvariably,manifestasregu- atrioventricular;AVNRT=atrioventricularnodalre-entranttachycardia;AVRT=
atrioventricularre-entranttachycardia;BBB=bundlebranchblock;JET=junc-
larrhythms.TheseGuidelinesdonotcoverAF,whichisthesubjectof
tionalectopictachycardia;SVT=supraventriculartachycardia;VA=ventriculoa-
separateclinicalGuidelines4andvariousconsensusdocuments.5(cid:2)7 trial;VT=ventriculartachycardia.
.
4 Electrophysiological
... membranepotential,namedearlyordelayed‘after-depolarizations’.In
.. suchcases,theresultingarrhythmiastakethenameof‘triggeredactiv-
mechanisms of supraventricular ... ity’.8Arrhythmiasresultingfromenhancedautomaticityandtriggered
.
tachycardia .. activity are defined as ‘non-re-entrant’. Arrhythmias can also arise
.
.
. when myocardial regions activated later in propagation re-excite
.
.
Arrhythmiacanoriginatefromabnormalimpulseinitiationinanindivid- .. regions that have already recovered excitability. This results from
.
ualmyocyteor,morerealistically,inacloseclusterofmyocytes.This .. abnormal propagation of the excitation wavefront and/or of tissue
.
canoccurinnon-pacemakercellsthroughamechanismsimilartothe .. refractoriness.Thismechanism,named‘re-entry’,isbasedonthesyn-
.
physiologicalautomaticityofpacemakercells[sinusnodeandAVnode .. cytial nature of myocardial tissue and is thus radically different from
(AVN)],andisthusnamed‘abnormal’or‘enhancedautomaticity’.An
... focalimpulseinitiation.8Adetaileddiscussionandschematicrepresen-
.
alternativeformofabnormalimpulseinitiationinvolvesoscillationsof . tationofcommonSVTcircuitsisprovidedintheSupplementaryData.
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 10 ---
664 ESCGuidelines
.
5 Cardiac anatomy for the .. variousquestionnairesareusefulintheauditofablationtechniques.
.
.
. Womenaremoreoftenprescribedantiarrhythmicdrugsbeforeabla-
electrophysiologist .
.. tion for SVT than men,28 and recurrence rates following AVNRT
.
.
. ablationarehigherinyoungwomen.29However,overall,nosignifi-
Knowledge of anatomical structures inside and outside the atrial .
.
chambers is of clinical importance, especially when interventional
... cantdifferencesinhealth-relatedqualityoflifeoraccesstohealthcare
proceduresarebeingconsidered.Adetaileddiscussionisprovidedin
... resourcesbetweenmenandwomenhavebeenreported.28
.
theSupplementaryData. ..
.
.
. 7 Clinical presentation
.
.
.
.
.
6 Epidemiology of .. TheimpactofSVTonanindividualisbasedonarangeoffactorsand
.
supraventricular tachycardia
... mayresultinpalpitations,fatigue,light-headedness,chestdiscomfort,
.. dyspnoea, and altered consciousness.30 Rapid rhythms are more
.
.. likely to present with a clear history and acutely than less-rapid
EpidemiologicalstudiesontheSVTpopulationarelimited.Inthegen- .
.. rhythms, but SVT usually produces symptoms.31 The duration of
eral population, the SVT prevalence is 2.25/1000 persons and the .
.. symptomsandthepatient’sageatonsetareimportant.Anindividual
incidenceis35/100000person-years.Womenhaveariskofdevelop- .
.. withanonsetintheteenageyearsoryoungerislesslikelytohaveAT
ingSVTthatistwotimesgreaterthanthatofmen,andpersonsaged .
.
. or AF continuing into adulthood. Such a long history will point
>_65yearsorhavemorethanfivetimestheriskofdevelopingSVT .
.. towardsare-entrantmechanism.32Dyspnoea,orotherclinicalsigns
thanyoungerindividuals.PatientswithloneparoxysmalSVTvs.those .
.
. and symptoms of HF, can occur when the patient has developed
withcardiovasculardiseaseareyounger,haveafasterSVTrate,have .
.. TCM.Light-headednessinassociationwithSVTisnotinfrequent.30
anearlieronsetofsymptoms,andaremorelikelytohavetheircondi- .
.. Presyncopeandsyncopearelesscommon,33,34andtendtobeasso-
tionfirstdocumentedintheemergencydepartment.9Inapaediatric .
.. ciated with presentation in older individuals.32 In older patients,
cohort study of 1967911 live births between 2000(cid:2)08, 2021 ..
. symptomsmaybemoreextreme—withdizziness,presyncope,and
patients (51.6% male, overall incidence 1.03/1000) had SVT ..
. syncope—in view ofthe less-accommodatingcharacteristicsofthe
[Wolff-Parkinson-White (WPW) syndrome accounted for 16.2%]. ..
. circulation;dropsinbloodpressureareusuallyimmediateandtend
Bytheageof15years,theannualriskofsuddendeathwas0.01%per ...
torecover.35Insomepatients,adescriptionofpolyuria(possiblydue
patient-year.10 ..
. toatrialstretch-inducedatrialnatriureticpeptideactivity)canbeelu-
Inspecializedcentres,AVNRTisthemostfrequentlytreatedsub- ..
strate after AF, followed by atrial flutter and AVRT, in patients
... cidated, although this is infrequent.36 Direct risks due to SVT are
referred for catheter ablation.11(cid:2)13 Women are more likely to be
... unusual, but in specific situations (e.g. in patients with WPW syn-
affected by AVNRT than men (ratio (cid:4)70:30),14(cid:2)16 while the con-
... dromeandAF,22orafteratrialswitchoperation37)mayleadtosud-
verse is true for AVRT (ratio 45:55).14 A relationship with the
... dencardiacdeath.
monthlycyclehasbeensuggested,17andepisodesaremorefrequent
... AsuddenonsetmorelikelypointstoAVNRTorAVRT,although
duringpregnancyinwomenwithpre-existingSVT.18
... anATmayalsopresentinthisway.32Characteristicsintermsofthe
.. regularity orirregularityare helpful. Theduration ofindividualepi-
Inthegeneralpopulation,theprevalenceofaWPWpatternon .
. sodes may help in terms of differentiation. Re-entrant tachycardias
surface electrocardiogram (ECG) ranges from 0.15(cid:2)0.25%,19
increasing to 0.55% among first-degree relatives of affected
patients.20 However, not all patients develop SVT and Table7 Initialevaluationofthepatientwithsupraven-
triculartachycardia
intermittentpre-excitationisnotrare.Comparedwiththeremaining
population,thepre-excitationpopulationisgenerallyyounger,pre- Standard
dominantly male, and has less comorbidity.21,22 The proportion of • History,physicalexamination,and12leadECG
patientswithAVRTdecreaseswithage,whereastheproportionof • Fullbloodcounts,biochemistryprofile,andthyroidfunction
thosewithAVNRTandATincreaseswithage.14 • AnECGduringtachycardiashouldbesought
Theepidemiologyofatrialflutterisnotknownwithcertainty,as • Transthoracicechocardiography
atrialflutterandAFcancoexist.TheprevalenceofAFbeforeflutter
Optional
ablationrangesfrom24(cid:2)62%,andafterablationcouldbe30(cid:2)70%.
• Exercisetolerancetesting
Theoverallincidenceofatrialflutteris88/100000person-yearsin
• 24hECGmonitoring,transtelephonicmonitoring,oranimplantable
theUSpopulationannually.Adjustedforage,theincidenceofatrial
looprecorder
flutter in men (125/100000) is >2.5 times that of women (59/
• Myocardialischaemiatestinginpatientswithriskfactorsforcoronary
100000) and increases exponentially with age. Patients with atrial
arterydisease(includingmenaged>40yearsandpost-menopausal
flutteraremorelikelytohavebeensmokers,havealongerPRinter-
women)
val,historyofmyocardialinfarction(MI),andhistoryofheartfailure
• AnEPSshouldbeconsideredforadefinitivediagnosisandwhencathe-
(HF).23
terablationisanticipated
Catheter ablation is now used extensively for most varieties of
SVT, and patient-reported outcome measures have shown that
ECG=electrocardiogram;EPS=electrophysiologystudy.
patients experience significant improvements in their quality of life
following ablation.24(cid:2)27 Patient-reported outcome measures using
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 11 ---
ESCGuidelines 665
.
.
tendtolastlongerthanATepisodes,whichmayoccurinaseriesof . activationoftheHisbundlecanalsooccurinhighseptalVTs,thus
.
repetitiveruns.32Cleardescriptionsofpoundingintheneck(theso- .. resultinginrelativelynarrowQRScomplexes(110(cid:2)140ms).44
.
.
called‘frogsign’)or‘shirtflapping’wouldpointtothepossiblecom- .
.
.
petinginfluencesofatrialandventricularcontractiononthetricuspid .
.
valve,andtoAVNRTasalikelycause.15,38,39 ... 9.1.1Electrocardiographicdifferentialdiagnosis
.
SVTmaybeunrecognizedatinitialmedicalevaluationandtheclini- .. IntheabsenceofanECGrecordedduringthetachycardia,a12lead
calcharacteristicscanmimicpanicdisorder.40Inpatientswithpossi- ... ECGinsinusrhythmmayprovidecluesforthediagnosisofSVTand
.
ble sinus tachycardia in association with anxiety and postural .. should be scrutinized for any abnormality. The presence of pre-
.
orthostatictachycardiasyndrome(POTS),itisimportanttoruleout .. excitationinapatientwithahistoryofregularparoxysmalpalpitationsis
.
thepossibilityofare-entranttachycardia. .. generallysuggestiveofAVRT.Theabsenceofapparentpre-excitation
.
.. doesnotruleoutthediagnosisofAVRT,asitmaybeduetoacon-
.
.. cealedaccessorypathway(AP)thatconductsonlyretrogradelyorto
.
8 Initial evaluation of patients with .. anatypical(Mahaim)pathway,whichislatentatsinusrhythm.
.
supraventricular tachycardia
... AnECGtakenduringtachycardiaisveryusefulintheefficientdiag-
.. nosisofSVT,althoughitmayfailtoleadtoaspecificdiagnosis.45It
.
.. maynotbeavailableinpatientswithveryshortorinfrequentperiods
Completehistorytaking,includingfamilyhistory,andphysicalexami- .
. . ofpalpitations.
nationareessential.Asdiscussed,clinicalhistoryisespeciallyrelevant .
.
.
incasesofpalpitationswithoutECGdocumentationofthetachycar- .
.
. 9.1.1.1Initiationandterminationofthetachycardia
dia. Initial evaluation points to a re-entrant arrhythmia when the .
.
. SuddenprolongationofthePRintervaloccursintypicalAVNRTafter
mode of onset/termination is sudden, is often associated with a .
.
. anatrialectopicbeat.AnATmayalsobeinitiatedbyanatrialectopic
change of position, and the tachycardia is perceived as regular. .
.
. beat,butisnotdependentonmarkedPRprolongation.Automatic,
Initiation of the episode(s), frequency, and conditions of triggering .
.
the arrhythmia are important clues for a specific diagnosis.3 There .. focalATsarecharacterizedbygradualacceleration(warm-upphe-
.. nomenon) followed by deceleration (cool-down phenomenon),46
maybeevidencethatspecificactionsleadtoarrhythmiatermination. .
.
Thesecouldincludestandardvagalmanoeuvres,41butalsoabortive .. and may also be incessant with short interruption by sinus beats.
.
. PrematureatrialorventricularbeatsmaytriggerAVRT.Premature
measuressuchasdrinkingaglassoficedwater.Also,responsesto ..
theadministrationofdrugs(e.g.adenosineorverapamil),whereter-
... ventricularcomplexesareacommontriggerofatypicalAVNRT,but
minationhasbeenobservedbutECGsaremissing,mayprovidediag-
... rarelyinducetypicalAVNRT,andonlyexceptionallyAT.
.
nostichelp. ..
Fullbloodcountsandabiochemistryprofile—includingrenalfunc-
... 9.1.1.2Regularityoftachycardiacyclelength
tion,electrolytes,andthyroidfunctiontests—canbeusefulinspecific
... The regularity of the RR interval should be assessed (Figure 1).
cases (Table 7). An ECG recorded during tachycardia is ideal, and
... IrregulartachycardiasmayrepresentfocalormultifocalAT,focalAF,
patients should be encouraged to seek medical assistance and
... andatrialflutterwithvaryingAVconduction.Patternsofirregularity
recordingoftheirECGduringepisodes.A12leadrestingECGand
... can sometimes be found, such as in atrial flutter conducted with
baselineechocardiographicassessmentarenecessary.Itmaybeuse-
... Wenckebach periodicity. Irregular arrhythmias, such as multifocal
fultodo24hECGrecordings,buttachycardiaepisodesareusually
... AT, typically display variableP-wave morphologies,and varyingPP,
sporadicandmaynotbefrequentenoughtoberecordedonambula-
... RR,andPRintervals.AtrialfluttercanhavefixedAVconductionand
.. presentasaregulartachycardia,andevenAFmayappearalmostreg-
torymonitoring.Transtelephonicmonitoring,mobilerecordingdevi- .
.
. ular when very fast. Re-entrant tachycardias, whether micro(cid:2) or ces,or,veryrarely,animplantablelooprecordermayberequired. .
.
. macro-re-entries,areusuallyregular.Incessanttachycardiasmaybe Wrist-worn, optically based heart rate monitors are user-friendly, .
.
butappropriatevalidationofthedeviceusedisimperative.42Atoler- .. theso-calledpermanentjunctionalreciprocatingtachycardia(PJRT),
.
. focal AT, or, rarely, atypical AVNRT. Cycle length (CL) alternans
anceexercisetestmayalsobeusefulinpatientswithapparentpre- .
.
. (alsocalledRRalternans)maybeseeninAVNRT,butthesechanges
excitation and in cases of catecholamine-dependent arrhythmias. .
.. are<15%ofthetachycardiaCL.47Iftheirregularityexceeds15%of
Myocardialischaemiatestingisalsoneededinpatientswithanginaor .
significantriskfactorsforcoronaryarterydisease.43Anelectrophysi-
... theCL,afocalarrhythmiaismuchmorelikely.48QRSalternansisa
.
. rare phenomenon in slow SVTs, which may not be related to CL
ologystudy(EPS)isusuallynecessarytoestablishthediagnosis,par- .
.. alternans,andhasbeeninitiallydescribedwithAVRT.49,50However,
ticularlywhencatheterablationisanticipated. .
.. thismaybeseeninanyfastSVT.51
.
.
. A change in ventricular CL preceded by a change in atrial CLis
.
.
9 Differential diagnosis of
.. seeninAToratypicalAVNRT.AchangeinventricularCLpreceding
.
.. a change in subsequent atrial CL favours typical AVNRT or
tachycardias ... AVRT.47,52Afixedventriculoatrial(VA)intervalinthe presenceof
.
.. variableRRintervalsexcludesAT.45
9.1 Narrow QRS ((cid:3)120 ms) tachycardias ..
.
.
NarrowQRScomplexesareduetorapidactivationoftheventricles .. 9.1.1.3P/QRSrelationship
.
viatheHis(cid:2)Purkinjesystem(HPS),whichsuggeststhattheoriginof .. AccordingtotheirP/QRSrelationships,SVTsareclassifiedashaving
.
the arrhythmia is above or within the His bundle. However, early . shortorlongRPintervals.Short-RPSVTsarethosewithRPintervals
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 12 ---
666 ESCGuidelines
Narrow QRS tachycardia
(QRS≤120 ms)
Regular
tachycardia
Yes No
AF
Focal AT or flutter with variable AV conduction
No Visible Multifocal AT
P waves?
Yes
Atrial rate
greater than
ventricular rate?
Yes No
Atrial flutter Ventricular rate
Focal AT greater than
AVNRT (rare) atrial rate
Yes No
High septal VT
JET
Consider
AVNRT (rare)
RP Interval
Nodoventricular/fascicular-nodal
re-entry (rare)
Sh Ror Pt ≤ ( 9R 0P m<P sR) Sh Ror Pt > ( 9R 0P m<P sR) Long (RP≥PR)
Typical AVNRT
AVRT Focal AT
Focal AT
Atypical AVNRT AVRT
JET
Focal AT Atypical AVNRT
AVRT (rare)
Figure 1 Differential diagnosis of narrow QRS tachycardia. Recording of a retrograde P wave should be sought by obtaining a 12 lead
Electrocardiogramand,ifnecessary,usingtheLewisleadsorevenanoesophagealleadconnectedtoapre-cordiallead(V1)withuseofalligatorclamps.
The90mscut-offisaratherarbitrarynumberusedforsurfaceelectrocardiogrammeasurementsifPwavesarevisibleandisbasedonlimiteddata.Inthe
electrophysiologylaboratory,thecut-offoftheventriculoatrialintervalis70ms.Junctionalectopictachycardiamayalsopresentwithatrioventriculardis-
sociation.
AF=atrialfibrillation;AT=atrialtachycardia;AV=atrioventricular;AVNRT=atrioventricularnodalre-entranttachycardia;AVRT=atrioventricularre-
entranttachycardia;JET=junctionalectopictachycardia;RP=RPinterval;VT=ventriculartachycardia.
9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 13 ---
ESCGuidelines 667
.
shorterthanone-halfthetachycardiaRRinterval,whereaslong-RP .. verapamil- but not adenosine-sensitive. Most VTs, as opposed to
.
SVTsdisplayRP>_PR(Figure1).Rarely,recordingofUwavesduring .. SVTs,donotrespondtocarotidsinusmassage,butanarrowQRS
.
typicalAVNRTmaysimulatealong-RPtachycardia.53 .. VToriginatingattheleftbundlebranchandterminatedwithcarotid
.
OnEPS,averyshortVAinterval(<_70ms)usuallyindicatestypical .. sinusmassagehasbeenreported.62
.
.
AVNRT,orlesscommonlyfocalAT,buthasalsobeenreportedin .
AVRT.54ForsurfaceECGmeasurements,acut-offintervalof90ms
hasbeenshowntobeusefulandcanbeusedifPwavesarevisible,55
Table8 PossibleresponsesofnarrowQRStachycardia
butdataonactualRPmeasurementsduringvarioustypesofSVTare tovagalmanoeuvresandadenosine
scarce.
(1) SlowingofAVNconductionandinductionofintermittentAVblock.
Pwavessimilartothoseinnormalsinusrhythmsuggestappropri-
Atrialelectricalactivitycanthusbeunmasked,revealingdissociatedP
ateorinappropriatesinusnodaltachycardia,sinusnodalre-entrant
waves(focalAT,atrialflutter,orAFwaves).
tachycardia,orfocalATarisingclosetothesinusnode.Pwavesdif-
(2) Temporarydecreaseintheatrialrateofautomatictachycardias(focal
ferentfromthoseinsinusrhythm,andconductedwithaPRinterval
AT,sinustachycardia,andJET).
equaltoorlongerthanthePRinsinusrhythm,aretypicallyseenin
(3) Tachycardiatermination.Thiscanhappenbyinterruptingthere-entry
focalAT.InAT,theconductiontotheventriclesmaybefast(1:1)or
circuitinAVNRTandAVRTbyactingontheAVNthatispartofthe
slow(3:1or4:1).Thepossibilityofatrialflutterwith2:1conduction
circuit.Morerarely,sinusnodalre-entryandATsduetotriggered shouldalsobeconsiderediftheventricularrateduringSVTis(cid:4)150
activitycanslowdownandterminate.
b.p.m.,astheatrialactivityisusually250-330b.p.m.Inthepresence
(4) Noeffectisobservedinsomecases.
ofantiarrhythmicmedicationinthissetting,loweringtheatrialrate
may result in a higher ventricular rate in the absence of AV nodal
blockade. AF =atrialfibrillation;AT=atrialtachycardia; AV =atrioventricular; AVN=
atrioventricular node; AVNRT = atrioventricular nodal re-entrant tachycardia;
Inthecaseofrelativelydelayedretrogradeconductionthatallows
AVRT = atrioventricular re-entrant tachycardia; JET = junctional ectopic
theidentificationofretrogradePwaves,apseudordeflectioninlead tachycardia.
V1andapseudoSwaveintheinferiorleadsaremorecommonin
typicalAVNRTthaninAVRTorAT.56,57Thesecriteriaarespecific
(91(cid:2)100%) but modestly sensitive (58 and 14%, respectively).56 A
differenceinRPintervalsinleadsV1andIII>20msisalsoindicative
ofAVNRTratherthanAVRTduetoaposteroseptalpathway.57The
presenceofaQRSnotchinleadaVLhasalsobeenfoundtobeareli- Adenosine
ablecriterionsuggestingAVNRT,58whileapseudorinaVRhasbeen in regular, narrow QRS tachycardia
showntohavegreatersensitivityandspecificitythanapseudorinV1
for the diagnosis of typical AVNRT.59 However, in all referenced
studies, cases of AT or atypical AVNRT were limited or entirely Response Diagnosis
absent.
AV block or dissociation during narrow QRS tachycardia is not
Inadequate dose/
often seen, but it rules out AVRT as both atria and ventricles are No effect delivery
partsofthecircuit.Thedevelopmentofbundlebranchblock(BBB) High septal VT
duringSVTmayalsobehelpfulinthediagnosisofAVRT.BBBipsilat-
eraltotheAPcanresultinCLprolongationduetoVAprolongation,
Sinus tachycardia
as the ventricular arm of the circuit is prolonged by conduction Gradual slowing Automatic focal AT
through the interventricular septum from the conducting bundle then reacceleration Junctional ectopic
tachycardia
branch.60 However, it should be noted that lengthening of the VA
interval may not necessarily result in CL prolongation, due to a
potentialswitchofantegradeconductionfromtheslowtothefast AVNRT
AVRT
AVnodalpathway.
Sudden termination Sinus nodal re-entry
Triggered focal AT
(DADs)
9.1.2Vagalmanoeuvresandadenosine
Vagal manoeuvres (such as carotid sinus massage) and adenosine Persisting atrial Atrial flutter tachycardia with
injection may help in clinical diagnosis, particularly in situations in transient high-grade Micro-re-entrant
focal AT
whichtheECGduringtachycardiaisunclear.Possibleresponsesto AV block
vagalmanoeuvresandadenosineareshowninTable8andFigure2.
Terminationofthe arrhythmiawithaPwaveafterthe lastQRS
Figure2Responsesofnarrow-complextachycardiastoadenosine.
complexisveryunlikelyinAT,andmostcommoninAVRTandtypi-
AT=atrialtachycardia;AV=atrioventricular;AVNRT=atrioventricular
calAVNRT.TerminationwithaQRScomplexisoftenseeninAT, nodalre-entranttachycardia;AVRT=atrioventricularre-entranttachy-
andpossiblyinatypicalAVNRT.Adenosinedoesnotinterruptmac- cardia; DADs = delayed after-depolarizations; VT = ventricular
ro-re-entrant ATs (MRATs).61 Fascicular VTs, in particular, are tachycardia.
9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 14 ---
668 ESCGuidelines
9.1.3Electrophysiologystudy
Table9 Summaryofkeyelectrocardiographiccriteria
Several electrophysiological techniques and manoeuvres can be
thatsuggestventriculartachycardiaratherthansupraven-
employedintheelectrophysiologylaboratoryfordifferentialdiagno- triculartachycardiainwidecomplextachycardia
sis of regular narrow QRS tachycardia.45 A detailed discussion is
beyondthescopeoftheseGuidelines. AVdissociation Ventricularrate>atrialrate
Fusion/capturebeats DifferentQRSmorphologyfromthat
oftachycardia
9.2 Wide QRS (>120 ms) tachycardias
Chestleadnegative Allprecordialchestleads
WideQRStachycardiascanbeVT,SVTconductingwithBBBaberra- concordance negative
tion,orantegradeconductionoveranAP,withreportedproportions RSinprecordialleads -AbsenceofRSinprecordialleads
of80,15,and5%,respectively.63ThecorrectdiagnosisofaVTiscrit-
-RS>100msinanyleada
icaltomanagement,asmisdiagnosisandadministrationofdrugsusu-
QRScomplexinaVR • InitialRwave
allyutilizedforSVTcanbeharmfulforpatientsinVT.64Therefore,
• InitialRorQwave>40ms
thedefaultdiagnosisshouldbeVTuntilprovenotherwise.The
• Presenceofanotchofapredomi-
differentialdiagnosisincludes:65
nantlynegativecomplex
(1) SVTwithBBB.Thismayariseduetopre-existingBBBorthedevel- QRSaxis290to6180(cid:5) BothinthepresenceofRBBBand
opmentofaberrancyduringtachycardia(so-calledphase3block), LBBBmorphology
which is more commonly, although not invariably, a right BBB Rwavepeaktime Rwavepeaktime>_50ms
(RBBB)patternduetothelongerRPoftherightbundlebranch. inleadII
(2) SVT with antegrade conduction over an AP, ‘pre-excited SVT’, RBBBmorphology LeadV1:MonophasicR,Rsr’,biphasic
whichparticipatesinthecircuit(antidromicAVRT)orisabystander qRcomplex,broadR(>40ms),anda
duringAF,focalAT/atrialflutter,orAVNRT. double-peakedRwavewiththeleft
(3) SVTwithwideningofQRSintervalinducedbydrugsorelectrolyte peaktallerthantheright(theso-called
disturbances.ClassIAandICdrugscauseuse-dependentslowingof ‘rabbitear’sign)
conduction, and class III drugs prolong refractoriness at LeadV6:R:Sratio<1(rS,QSpatterns)
His(cid:2)Purkinjetissuemorethanintheventricularmyocardium.They LBBBmorphology LeadV1:BroadRwave,slurredor
can both result in atypical BBB morphologies during SVT that notched-downstrokeoftheSwave,
mimicsVT. anddelayednadirofSwave
(4) Pacemaker-related endless loop tachycardia and artefacts, which LeadV6:QorQSwave
canalsomimicVT.
AV=atrioventricular;LBBB=leftbundlebranchblock;RBBB=rightbundle
branchblock.
aRS:beginningofRtodeepestpartofS.
9.2.1Electrocardiographicdifferentialdiagnosis
Ifthe12leadECGisavailableinsinusrhythm,itcanprovideuseful .
diagnosticinformation.Specifically,iftheQRSmorphologyisidentical
... 9.2.1.2QRSduration
.
. A QRS duration >140 ms with RBBB or >160 ms with left BBB
duringsinusrhythmandtachycardia,thearrhythmiaismostlikelynot . .
. (LBBB)patternsuggestsVT.Thesecriteriaarenothelpfulfordiffer-
aVT.However,bundlebranchre-entrantVTsandhighseptalVTs . .
. entiatingVTfromSVTinspecificsettings,suchaspre-excitedSVT,
exitingclosetotheconductionsystemcanhavesimilarmorphologies .
.. orwhenclassICorclassIAantiarrhythmicdrugsareadministered.67
tosinusrhythm.ThepresenceofacontralateralBBBpatterninsinus .
.
. rhythmismoreindicativeofVT. .
.
. 9.2.1.3QRSaxis .
.
. AsVTcircuits(especiallypost-MIorincardiomyopathies)frequently
9.2.1.1Atrioventriculardissociation .
.
. lie outside the normal His(cid:2)Purkinje network, significant axis shifts
ThepresenceofeitherAVdissociationorcapture/fusionbeatsinthe .
. . arelikelytooccur,enablingdiagnosis.Therefore,inpatientswithSVT
12leadECGduringtachycardiaarekeydiagnosticfeaturesofVT.AV .
.
. andaberrancy,theQRSaxisisconfinedbetween-60andþ120(cid:5).In
dissociationmaybedifficulttorecognizebecausePwavesareoften .
.
hiddenbywideQRSandTwavesduringawideQRStachycardia.P
.. particular,extremeaxisdeviation(axisfrom-90to±180(cid:5))isstrongly
.
wavesareusuallymoreprominentininferiorleadsandinmodified
... indicativeofVT,bothinthepresenceofRBBBandLBBB.65
.
chestleadplacement(Lewislead).63 ..
The relationship between atrial and ventricular events is 1:1 or
... 9.2.1.4Chestleadconcordance
greater(moreatrialthanventricularbeats)inmostSVTs(Table9).
... The presence of negative chest lead concordance (all QRS com-
AVNRT can be associated with 2:1 conduction,66 but this is rare. ... plexesnegativeV1(cid:2)V6)(Figure3)isalmostdiagnosticofVT,witha
AlthoughVAconductioncanbefoundin<_50%ofpatientswithVT
... specificity>90%,butisonlypresentin20%ofVTs.Positiveconcord-
anda1:1relationshipispossible,mostVTshavearelationship<1:1
... ancecanbeindicativeofVToranantidromictachycardiautilizinga
(moreQRScomplexesthanPwaves).
.. leftposteriororleftlateralAP.68
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 15 ---
ESCGuidelines 669
Antidromic AVRT VT with negative VT with positive
concordance concordance
Figure3ExamplesofpositiveandnegativechestleadconcordanceinVT.
AVRT=atrioventricularre-entranttachycardia;VT=ventriculartachycardia.
.
.
9.2.1.5Rightbundlebranchblockmorphology . the Swave,and delayed nadirofthe Swave arestrongpredictors
.
.
Lead V1: Typical RBBB aberrancy has a small initial r’, because in . ofVT.
.
.
RBBBthehighseptumisactivatedprimarilyfromtheleftseptalbun- . LeadV6:IntrueLBBB,noQwaveispresentinthelateralprecor-
.
.
dle.Therefore,thefollowingpatternsareevident:rSR0,rSr0,orrR0in . dialleads.Therefore,thepresenceofanyQorQSwaveinleadV6
.
.
leadV1.However,inVT,theactivationwavefrontprogressesfrom . favoursVT,indicatingthattheactivationwavefrontismovingaway
.
.
theleftventricle(LV)totherightprecordialleadV1,inawaythata .. fromtheLVapicalsite.
.
prominent R wave (monophasic R, Rsr0, biphasic qR complex, or .. These morphology criteria are not fulfilled in any lead in 4% of
.
broad R >40 ms) will be more commonly seen in lead V1. .. SVTsand6%ofVTs,andinone-thirdofcaseswhenonelead(V1or
.
Additionally,adouble-peakedRwave(Mpattern)inleadV1favours .. V6)favoursonediagnosis,theotherfavourstheoppositediagnosis
.
VTiftheleftpeakistallerthantherightpeak(theso-called‘rabbit .. (VTinoneleadandSVTintheother,andviceversa).69,70
.
ear’sign).AtallerrightrabbitearcharacterizestheRBBBaberrancy .. Anumberofalgorithmshavebeendevelopedtodifferentiate
.
butdoesnotexcludeVT. .. VT from SVT.69,71,72 Detailed presentation and comments are
. Lead V6: A small amount of normal right ventricular voltage is .. beyond the scope of these Guidelines, and can be found in the
. directedawayfromleadV6.AsthisisasmallvectorinRBBBaber- .. 2018 European Heart Rhythm Association/Heart Rhythm
.
rancy,theR:Sratiois>1.InVT,alloftherightventricularvoltage,and .. Society/Asia Pacific Heart Rhythm Society/Sociedad
.
someoftheleft,isdirectedawayfromV6,leadingtoanR:Sratio<1 .. Latinoamericana de Estimulacio(cid:2)n Card(cid:2)ıaca y Electrofisiolog(cid:2)ıa
.
(rSandQSpatterns).AnRBBBmorphologywithanR:SratioinV6of .. consensusdocument.3
.
<1isseenrarelyinSVTwithaberrancy,mainlywhenthepatienthas .. All of these criteria have limitations. Conditions such as bundle
.
.
aleftaxisdeviationduringsinusrhythm. . branchre-entranttachycardia,fascicularVT,VTwithexitsiteclose
.
.
Differentiating fascicular VT from SVT with bifascicular block . to the His(cid:2)Purkinje system, and wide QRS tachycardia occurring
.
.
(RBBBandleftanteriorhemiblock)isverychallenging.Featuresthat . duringantiarrhythmicdrugtreatmentaredifficulttodiagnoseusing
.
.
indicateSVTinthiscontextincludeQRS>140ms,overallnegative . thementionedmorphologicalcriteria.DifferentiatingVTfromanti-
.
QRSinaVR,andanR/Sratio>1inV6.44 .. dromic AVRT is extremely difficult for the very fact that the QRS
.
.
. morphologyinantidromicAVRTissimilartothatofaVT,withitsori-
.
.
9.2.1.6Leftbundlebranchblockmorphology . ginattheinsertionoftheAPintheventricularmyocardium.Analgo-
.
.
Lead V1: As stated above for RBBB, for the same reasons, the . rithmhasbeenderivedfordifferentialdiagnosis,basedontheanalysis
.
.
presence of a broad R wave, slurred or notched-down stroke of . of 267 wide QRS tachycardias, consisting of VT and antidromic
9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 16 ---
670 ESCGuidelines
AVRT.Thederivedcriteriawerefoundtooffersensitivityof75%and
Recommendationsfortheacutemanagementofnar-
specificityof100%,73andthealgorithmwasalsovalidatedinanother
rowQRStachycardiaintheabsenceofanestablished
study,74butexperienceisstilllimited. diagnosis
Infact,severalindependentstudieshavefoundthatvariousECG-
based methods have specificities of 40(cid:2)80% and accuracies of Recommendation Classa Levelb
(cid:4)75%.44,68,75(cid:2)80Indeed,asimilardiagnosticaccuracyof(cid:4)75%would
Haemodynamicallyunstablepatients
beachievedeffortlesslybyconsideringeverywideQRStachycardia
SynchronizedDCcardioversionisrecom-
to be a VT, because only 25(cid:2)30% are SVTs. Therefore, emerging
mendedforhaemodynamicallyunstable I B
approachestointegratethesealgorithmsandprovidemoreaccurate
patients.86(cid:2)88
scoring systems are being evaluated.81 Furthermore, conventional
Haemodynamicallystablepatients
ECGcriteriahavereducedthesensitivitytodistinguishVTfromSVT
A12leadECGduringtachycardiais
with aberrancy in patients with idiopathic VT. This is most pro- I C
recommended.
nouncedinVTsoriginatingfromseptalsites,particularlyPurkinjesites
andtheseptaloutflowtractregions.82 Vagalmanoeuvres,preferablyinthesupine
positionwithlegelevation,are I B
recommended.41,89(cid:2)91
9.2.2Electrophysiologystudy
Adenosine(6(cid:2)18mgi.v.bolus)isrecom-
Oncertainoccasions,anEPSisnecessaryfordiagnosis. mendedifvagalmanoeuvresfail.92(cid:2)94 I B
Verapamilordiltiazem(i.v.)shouldbeconsid-
9.3 Irregular tachycardias ered,ifvagalmanoeuvresandadenosine IIa B
AnirregularventricularrhythmmostcommonlyindicatesAF,multi- fail.92,94(cid:2)98
focalAT,orfocalAT/atrialflutterwithvariableAVconduction,and Beta-blockers(i.v.esmololormetoprolol)
mayoccurinthecontextofbothnarrowandbroadQRScomplexes. shouldbeconsideredifvagalmanoeuvresand IIa C
WhenAFisassociatedwithrapidventricularrates,theirregularityof adenosinefail.97,99,100
thisventricularresponseislesseasilydetectedandcanbemisdiag- Synchronizeddirect-currentcardioversionis
nosed as a regular SVT.83 If the atrial rate exceeds the ventricular recommendedwhendrugtherapyfailstocon- I B
rate,thenatrialflutterorAT(focalormultifocal)isusuallypresent. vertorcontrolthetachycardia.87,88
PolymorphicVTand,rarely,monomorphicVTmayalsobeirregular.
i.v.beta-blockersarecontraindicatedinthepresenceofdecompensatedHF.
Occasionally,ajunctional,non-re-entranttachycardiamayhaveavar-
i.v.verapamilanddiltiazemarecontraindicatedinthepresenceofhypotensionor
iablerate. HFrEF.
Specifically, the differential diagnosis of an irregular wide QRS DC =direct current; ECG =electrocardiogram; HF =heartfailure; HFrEF=
heartfailurewithreducedejectionfraction;i.v.=intravenous.
tachycardia is either pre-excited AF or polymorphic VT, or AT
aClassofrecommendation.
with variable block in the context of aberrancy. Pre-excited AF bLevelofevidence.
manifests itself by irregularity, a varying QRS morphology, and a
rapid ventricular rate (owing to the short RP of the AP). The
changingQRSmorphologyresultsfromvaryingdegreesoffusion
. duetoactivationoverboththeAPandtheAVN,whichalsoresult .. 10.1.1.1Haemodynamicallyunstablepatients
.
invariationinthewidthofthedeltawave.Afurthercauseofvary- .. Immediate direct-current (DC) cardioversion is the first choice in
.
ingQRSmorphologyinthiscontextwillbeifmorethanoneante- .. haemodynamically compromised patients with narrow QRS
.
gradeAPispresentwithintermittentconductionovereach.The .. tachycardia.86(cid:2)88,101
.
ventricular rate tends to be higher than in those with non-pre- ..
.
excitedAF.84 .. 10.1.1.2Haemodynamicallystablepatients
.
.. Vagalmanoeuvrescanbeusedtoterminateanepisodeofnarrow
.
.. QRSSVT.41Theeffectivenessofconventionalvagalmanoeuvresin
.
10 Acute management in the .. terminating SVT, when correctly performed, has been reported as
.
.. between19and54%.41,89(cid:2)91,102,103Vagalmanoeuvresincludediffer-
absence of an established .
.
. enttechniquesusedtostimulatethereceptorsintheinternalcarotid
.
diagnosis .. arteries. This stimulation causes a reflex stimulation of the vagus
.
.
. nerve,whichresultsinthereleaseofacetylcholine,whichmayinturn
.
10.1 Regular tachycardias .. slowtheelectricalimpulsethroughtheAVNandslowtheheartrate.
.
.
10.1.1NarrowQRS((cid:3)120ms)tachycardias .. Manyofthesemanoeuvrescanbeperformedwithminimalriskatthe
.
PatientswithSVTarecommonandpotentiallyrecurrentattenders .. bedsideorinanofficesetting,andcanbebothdiagnosticandthera-
.
in emergency departments, with an estimated 50 000 visits each .. peutic. The Valsalva manoeuvre is a safe and internationally recom-
.
yearintheUSA.85Theinitialapproachtoacutemanagementtends .. mended first-line emergency treatment for SVT, although a recent
.
to be non-drug-based, with escalation to intravenous (i.v.) drugs .. Cochranereviewfoundinsufficientevidencetosupportorrefuteits
.
or electrical cardioversion in the absence of early correction .. utility.89 The Valsalva manoeuvre has generally been shown to be
.
(Figure4). . mosteffectiveinadults,andinAVRTratherthanAVNRT.Amodified
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 17 ---
ESCGuidelines 671
.
.. thansmallerdistalveins.108Dosingshouldthenbeincremental,start-
.
Narrow QRS .. ingat6mginadultsfollowedby12mg.An18mgdoseshouldthen
.
tachycardia .. beconsidered,alsotakingintoaccounttolerability/sideeffectsinthe
.
.
. individualpatient.Adenosinehasaveryshortplasmahalf-lifedueto
.
.
. enzymaticdeaminationtoinactiveinosinebeingachievedinseconds,
.
.. with end-organ clinical effects complete within 20(cid:2)30 s.107 Thus,
Hae inm so tad by in lita ymic ....
repeatadministrationissafewithin1minofthelastdose.2,3Thedose
.
No Yes
.. rangebetweenpatientsmaybeverywide,107with>90%successgen-
.
.. erally expected.94,109 Some drugs (e.g. dipyridamole and theophyl-
.
.. line)mayonoccasionaffectdoserequirements,butanyinfluenceof
Vagal manoeuvres Synchronized .
(I B) cardioversion
.. recentintakeofcaffeinatedbeveragesisdisputed.110,111
.
(I B) .. Transientdyspnoeaiscommonwithincreasedventilation,andis
.
If ineffective .. more likely to result from the stimulation of pulmonary vagal C
.
.. fibres.112Facialflushingmayoccur,associatedwithvasodilatationand
i.v. adenosine .
(I B)
... increasedskintemperature.107Chestpain,variableintermsofradia-
.. tionoverthethorax,maysuggestischaemicoroesophagealorigins,
.
If ineffective .. andhasbeenassociatedwithincreasedcoronarysinusbloodflowso
.
.. maywellbeofcardiacorigin.107
.
.. Depressionofsinoatrialnodefunctionistobeexpectedbasedon
.
i.v. v de ir lta ip aza em mil or
i.v. beta-blocker
..... e us nt ua sb uli as lh .1e 0d 5,107ph Na orm nea tc ho el lo eg sy s,, adb eu nt osinp ero alo dn mg ie nd istrab tir oa ndy sc ha ord ui la
d
bi es
(IIa C) .
(IIa B) .. approached cautiously in those with known sinus node disease.113
. .
. Perceivedrisksofbradycardiainrecipientsofdenervatedorthotropic
.
.
. hearttransplants,inwhomSVTiscommon,havepromptedarelative
If ineffective ...
contraindication.114,115However,morerecentsubstantiveevidence
.
.. supportsadenosineuseinthisgroupwithnoparticularcautions.116
Figure4 AcutetherapyofnarrowQRStachycardiaintheabsenceof ..
. AFmayoccurfollowingadenosineadministrationasaresultofeither
anestablisheddiagnosis. ...
directpulmonaryvein(PV)triggering117orincreasingheterogeneity
i.v.=intravenous. ...
of repolarization,118 and appears more commonly associated with
.
.
. AVRT than AVNRT.93 Adenosine may also occasionally cause or
.
.
approach to the Valsalva manoeuvre provides a considerable .. acceleratepre-excitedatrialarrhythmias.119,120
.
enhancement of conversion success rates (43 vs. 17% conversion .. Clinicallyimportantbronchoconstrictionhasbeenrarelyreported
.
rate).41ThisenhancedmethodrequirestheValsalvatobecompleted .. inthose receiving i.v.adenosinefor SVT,121 and this observationis
.
semi-recumbent,withsupinerepositioningandpassivelegraiseafter .. furthersupportedbythelargeexperienceobtainedwhenadenosine
.
theValsalvastrain.Blowingintoa10mLsyringewithsufficientforce .. infusions have been given for cardiac stress testing.105,122,123
.
tomovetheplungermaystandardizetheapproach.104Carotidsinus .. Furthermore,despiteinhaledadenosineproducingbronchoconstric-
. massageisperformedwiththepatient’sneckinanextendedposi- .. tioninpeoplewithasthma,124i.v.administrationhashadnoimpact
.
tion,withtheheadturnedawayfromthesidetowhichpressureis .. ontheairwaysinclinicalexperimentalstudies.125Therehavebeen
.
applied.Itshouldalwaysbeunilateralasthereisapotentialriskwith .. isolated reports of clinically well-documented bronchoconstriction
.
bilateralpressure,anditshouldbelimitedto5s.Thepatientshould .. occurring inpatientswithorwithoutrespiratorydisease,thussug- .
bemonitored.Thistechniqueshouldbeavoidedinpatientswithpre- .. gesting that care is required in patients with asthma.121,126,127
.
vioustransientischaemicattackorstroke,andinpatientswithcarotid .. However, adenosine can be used cautiously in those with asthma,
.
bruits.3 .. although verapamil may be a more appropriate choice in patients
.
.
Other manoeuvres, such as facial immersion in cold water or . withsevereasthma.
.
.
forcefulcoughing,arerarelyusednow. . Adenosinetriphosphatemayalsobeusedbutclinicalexperienceis
.
.
Adenosine,anendogenouspurinenucleoside(6(cid:2)18mgi.v.bolus) . limited.
.
is the first drug of choice.92(cid:2)94 Pharmacologically relevant electro- .. Calcium channel blockers (verapamil/diltiazem i.v.) and beta-
.
.
physiologicalinfluencesaremediatedthroughcardiacadenosineA . blockers(e.g.esmololandmetoprololi.v.)areofvalue,particularly
1 .
receptors.105,106 Clinical EPSs have documented progressive dose- .. in patients with frequent atrial or ventricular premature beats.
.
.
related prolongation of AV conduction [due to effects on the . Verapamil[0.075-0.15mg/kgi.v.(average5-10mg)over2min]or
.
.
atrial(cid:2)His(AH)interval,andnoneontheHVinterval],culminatingin .. i.v. diltiazem [0.25 mg/kg (average 20 mg) over 2 min] has been
.
transient AV block that is then responsible for tachycardia .. shown to terminate SVT in 64(cid:2)98% of patients, but is associated
.
termination.107 .. withariskofhypotension.92,94(cid:2)98,128Thesedrugsshouldbeavoided
.
Themeandoserequiredforterminationis(cid:4)6mg.Toachieveeffi- .. inpatientswithhaemodynamicinstability,HFwithreducedLVejec-
.
cient rhythm correction, injection should be as a rapid bolus with .. tion fraction (<40%), a suspicion of VT, or pre-excited AF. Beta-
.
immediatesalineflush.Large,centrallylocated(e.g.antecubital)veins .. blockers(i.v.),such asshort-actingesmolol(0.5 mg/kgi.v. bolusor
.
arelikelytodelivermoreeffectivedrugconcentrationstotheheart . 0.05-0.3mg/kg/mininfusion)ormetoprolol(2.5(cid:2)15mggiveni.v.in
9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 18 ---
672 ESCGuidelines
2.5mgboluses),aremoreeffectiveinreducingthetachycardiarate
thaninterminatingit.97,99,100,128Althoughevidencefortheeffective- Wide QRS
ness of beta-blockers in terminating SVT is limited, they have an tachycardia
excellent safety profile in haemodynamically stable patients. Beta-
blockers are contraindicated in patients with decompensated HF.
Cautionisneededwithconcomitantuseofi.v.calciumchannelblock-
Haemodynamic
ersandbeta-blockers,becauseofpossiblepotentiationofhypoten-
instability
sive and bradycardic effects. In the first clinical trial of etripamil, a
No Yes
short-acting L-type calcium channel blocker with a rapid onset of
actionafterintranasaladministration,conversionratesfromSVTto
sinusrhythmrangedfrom65(cid:2)95%.129 Vagal manoeuvres Synchronized
(I C) cardioversion
(I B)
10.1.2WideQRS(120ms)tachycardias If ineffective
The acute management of a patient with wide QRS tachycardia
depends on the haemodynamic stability of the patient i.v. adenosine
(if no evidence of
(Figure5).106,130,131
pre-excitation
on resting ECG)
Recommendationsfortheacutemanagementofwide (IIa C)
QRStachycardiaintheabsenceofanestablished
diagnosis If ineffective
Recommendation Classa Levelb
Haemodynamicallyunstablepatients i.v. procainamide i.v. amiodarone
(IIa B) (IIb B)
SynchronizedDCcardioversionisrecommended
I B
inhaemodynamicallyunstablepatients.86,130
Haemodynamicallystablepatients
If ineffective
A12leadECGduringtachycardiais
I C
recommended. Figure5 Acutetherapyofwidecomplextachycardiaintheabsenceof
Vagalmanoeuvres,preferablyinthesupine anestablisheddiagnosis.
I C
positionwithlegelevation,arerecommended. AVRT=atrioventricularre-entranttachycardia;i.v.=intravenous.
Adenosineshouldbeconsideredifvagal
manoeuvresfailandthereisnopre-excitation IIa C
onarestingECG. ...
10.1.2.2Haemodynamicallystablepatients
Procainamide(i.v.)shouldbeconsideredif
IIa B
...
InapatientwithwideQRStachycardiawhoishaemodynamicallysta-
vagalmanoeuvresandadenosinefail.132 ...
ble,theresponsetovagalmanoeuvresmayprovideinsightintothe
. Amiodarone(i.v.)maybeconsideredifvagal
IIb B
... mechanism responsible for the arrhythmia. SVT with aberrancy, if
manoeuvresandadenosinefail.132 ..
definitivelyidentified,maybetreatedinthesamemannerasnarrow
.
SynchronizedDCcardioversionisrecom- .. complexSVT,withvagalmanoeuvresordrugs(adenosineandother
.
mendedifdrugtherapyfailstoconvertor I B .. AVN-blocking agents such as beta-blockers or calcium channel
.
controlthetachycardia.86,130 .. blockers).117(cid:2)119,129
.
.
VerapamilisnotrecommendedinwideQRS- . SomedrugsusedforthediagnosisortreatmentofSVT(e.g.vera-
.
.
complextachycardiaofunknown III B . pamil)cancauseseverehaemodynamicdeteriorationinpatientswith
.
aetiology.64,133,134 .. a previously stableVT.64,133,134 Thus, theyshouldonly be used for
.
.
. thetreatmentofpatientsinwhomthediagnosisofSVTisfullyestab-
.
DC=directcurrent;ECG=electrocardiogram;i.v.=intravenous. .
aClassofrecommendation. .. lishedandsecure.Adenosinemaybehelpfulbymeansofallowinga
.
bLevelofevidence. .. diagnosis orinterrupting anadenosine-sensitive VT, but it must be
.
. avoided if pre-excitation on resting ECG suggests a pre-excited
.
.
.. tachycardia. There is a risk that in antidromic re-entry, adenosine
.
10.1.2.1Haemodynamicallyunstablepatients .. mayprecipitatecardiacarrestifthereisinductionofAFbyadenosine,
.
HaemodynamicinstabilitymayoccurwithanywideQRStachycardia, .. asmayoccasionallyoccur.135
.
regardless of the cause, but is more likely in patients with VT. .. For pharmacological termination of a haemodynamically stable
.
Synchronizedcardioversionisrecommendedforanypersistentwide .. wideQRS-complextachycardiaofunknownaetiology,i.v.procaina-
.
QRStachycardiaresultinginhypotension,acutelyalteredmentalsta- .. mide or amiodarone can be used in-hospital.132,136(cid:2)138 In the
.
tus,chestpain,acuteHFsymptoms,orsignsofshock.86,87 .. PROCAMIO trial132 in patients with well-tolerated wide QRS
.
.
9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 19 ---
ESCGuidelines 673
.
tachycardia,withorwithoutreducedLVejectionfraction,procaina- .. mechanismofISTremainspoorlyunderstoodandislikelytobemul-
.
midewasassociatedwithfewermajorcardiacadverseeventsanda .. tifactorial (e.g. dysautonomia, neurohormonal dysregulation, and
.
higher proportion of tachycardia termination within 40 min com- .. intrinsicsinusnodehyperactivity).Recently,again-of-functionmuta-
.
paredwithamiodarone. .. tionofthepacemakerhyperpolarization-activatedcyclicnucleotide-
.
Incasethemechanismofthearrhythmiaisnotfullyunderstood, .. gated 4 (HCN4) channel has been reported in a familial form of
.
thearrhythmiashouldbetreatedasVT. .. IST.141ThereisalsoevolvingevidencethatimmunoglobulinGanti-
.
.. betareceptorantibodiesarefoundinIST.142TheprognosisofISTis
.
10.2 Irregular tachycardias .. generallyconsideredbenign140andthearrhythmiahasnotbeenasso-
.
.
A wide QRS irregular tachycardia is usually a manifestation of AF. . ciatedwithtachycardia-inducedcardiomyopathy.
.
.
Rarely,polymorphicVTand,veryrarely,monomorphicVTmayalso .
.
.
presentasirregulartachycardias.Electricalcardioversionistheacute .. 11.1.1.2.1Diagnosis.PatientswithISThaveawidespectrumofclinical
.
treatmentofchoiceinirregularpre-excitedtachycardiasassociated . presentationsrangingfromusuallyasymptomaticorminimallysymp-
.
.
withhaemodynamicinstability.Specifictherapyofpre-excitedAFis .. tomaticpalpitationstodyspnoea,exerciseintolerance,dizziness,and
.
discussedinsection11. .. light-headedness.ThediagnosisofISTisoneofexclusionofPOTS,
.
IftherhythmiswelltoleratedwithanarrowQRS-complexirregu- .. sinusre-entranttachycardia,or focalATfromthe superiorpartof
.
lar tachycardia, this shouldbe considered likely to be AF, and rate .. the crista terminalis or right superior PV. Characteristically, 24 h
.
controlwithbeta-blockersorcalciumchannelblockers,andelective .. Holtermonitoringdemonstratesameanheartrate>90b.p.m.with
.
chemical orelectrical cardioversiononce thromboprophylaxis is in .. an exaggerated heart rate response >100 b.p.m. during waking
.
place,maybeappropriate.4 .. hours.140 Tolerance exercise testing might also be considered to
.
.. documenttheexaggeratedheartrateorbloodpressureresponseto
.
.. minimalexercise.AnEPSisgenerallynotrequiredinmakingthediag-
11 Specific types of ...
nosis, and should not be routinely performed unless, rarely, sinus
.
supraventricular tachycardia .. nodere-entryissuspected.
.
.
.
.
.
11.1 Atrial arrhythmias . 11.1.1.2.2 Therapy. Reassurance and lifestyle interventions such as
.
.
. exercisetraining,volumeexpansion,andavoidanceofcardiacstimu-
11.1.1Sinustachycardia .
.. lants should be tried before drug treatment (Figure 6).139,143,144 As
Sinustachycardiaisdefinedasasinusrate>100b.p.m.OntheECG, .
.
. theprognosisofISTisbenign,treatmentisaimedatsymptomreduc-
thePwaveispositiveinleadsI,II,andaVF,andbiphasic/negativein .
.
. tion and may not be necessary. Beta-blockers have been used in
leadV1. .
.
. patientswithISTforseveralyears,butmaybeneededatdoseshigh
.
.
. enoughtocauseintolerablesideeffectssuchaschronicfatigue.Non-
11.1.1.1Physiologicalsinustachycardia .
.
. dihydropyridinecalcium channel blockers mayalsobe used, but at
Thedeterminantsofphysiologicalsinustachycardiaare,bydefinition, .
.
. dosesthatmaycausehypotension,andtheevidenceregardingthese
physiological(effort,stress,orpregnancy),andmayalsoarisesecon- .
.. drugs is limited.139,145 Ivabradine, a selective blocker of the ‘pace-
dary to other medical conditions or drugs (Table 10).The 12 lead .
.
. makercurrent’(I)insinoatrialmyocytesthatdirectlyslowtheheart
ECG shows P-wave morphology typical of normal sinus rhythm. . f
.
Physiologicalsinustachycardiaistreatedbyidentifyingandeliminating
.. rate, has been found to be safe and effective in several small tri-
.
thecause.
... als.146(cid:2)150 However, blockade of the I
f
may perturb the feedback
.. loopunderlyingbaroreceptorcontrolofautonomicbalance,thereby
.
11.1.1.2Inappropriatesinustachycardia
... increasingsympatheticactivitytotheheart.151Ifthiseffectoccurred
ISTisdefinedasafastsinusrhythm(>100b.p.m.)atrestorminimal ... chronicallyattherapeuticdosages,itwouldbeamatterofconcern
activitythatisoutofproportionwiththelevelofphysical,emotional, ... forits remodellingand pro-arrhythmic potential. Ivabradineshould
pathological,orpharmacologicalstress.139Thetachycardiatendsto ... be preferably co-administered with a beta-blocker when possible;
bepersistent,andmostoftheaffectedpatientsareyoungandfemale,
... thiscombinationmayalsobemorebeneficialthaneachdrugalone
butthisdisorderisnotlimitedtothatpopulation.140Theunderlying .. for IST.152 Ivabradine should not be taken during pregnancy or
Table10 Causesofphysiologicalsinustachycardia
Physiologicalcauses Emotion,physicalexercise,sexualintercourse,pain,pregnancy
Pathologicalcauses Anxiety,panicattack,anaemia,fever,dehydration,infection,malignancies,hyperthyroidism,hypoglycaemia,
pheochromocytoma,Cushing’sdisease,diabetesmellituswithevidenceofautonomicdysfunction,pulmonaryembolus,
myocardialinfarction,pericarditis,valvedisease,congestiveheartfailure,shock
Drugs Epinephrine,norepinephrine,dopamine,dobutamine,atropine,beta-2adrenergicreceptoragonists(salbutamol),
methylxanthines,doxorubicin,daunorubicin,beta-blockerwithdrawal
Illicitdrugs Amphetamines,cocaine,lysergicaciddiethylamide,psilocybin,ecstasy,crack,cocaine
Other Caffeine,alcohol
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 20 ---
674 ESCGuidelines
breastfeeding.153 As a substrate of cytochrome p450 (CYP) 3A4,
ivabradineshouldbeavoidedorusedwithcautionwithconcomitant
Sinus tachycardia
administrationofCYP44Ainhibitors(ketoconazole,verapamil,diltia-
zem,clarithromycin,andgrapefruitjuice)orinducers(rifampinand
carbamazepine).154Thelimitedanddisappointingevidence,reported
Treatment of reversible causes
from small observational studies, suggests that catheter ablation (I C)
shouldnotbeconsideredaspartoftheroutinemanagementofmost
If ineffective
patientswithIST.155(cid:2)161
Recommendationsforthetherapyofsinustachycardias Ivabradine Beta-blocker
(IIa B) (IIa C)
Recommendation Classa Levelb
If ineffective If ineffective
Inappropriatesinustachycardia
Evaluationandtreatmentofreversiblecauses Symptomatic
I C
isrecommended.139,144,162 and recurrent sinus
node re-entry
Ivabradinealoneorincombinationwitha
Yes No
beta-blockershouldbeconsideredinsympto- IIa B
maticpatients.146(cid:2)149,151,152
Ivabradine with a
Beta-blockersshouldbeconsideredinsymp- Drug therapy beta-blocker
tomaticpatients.139,147 IIa C desirable (IIa B)
Yes No
Sinusnodalre-entranttachycardia
Non-dihydropyridinecalciumchannelblock- Verapamil or Catheter
ers(verapamilordiltiazem)intheabsenceof diltiazem ablation
HFrEF,maybeconsideredinsymptomatic IIb C (IIb C) If ineffective (IIa C)
patients.163
Catheterablationshouldbeconsideredin Figure6Therapyofsinustachycardias.
symptomaticpatientswhodonotrespondto IIa C
drugtherapy.164(cid:2)166
Posturalorthostatictachycardiasyndrome
.
Aregularandprogressiveexercisepro- .. 11.1.1.3.2Therapy.Medicaltreatmentisempirical,andnodrugshave
grammeshouldbeconsidered.167(cid:2)169
IIa B ...
been studied in controlled trials. Verapamil and amiodarone have
.
Theconsumptionof>_2(cid:2)3Lofwaterand
... demonstratedvariablesuccess,whereasbeta-blockersareofteninef-
10(cid:2)12gofsodiumchloridedailymaybe IIb C
... fective.163Sinusnodere-entranttachycardiamaybeeffectivelyand
considered.170,171 ... safelytreatedwithcatheterablationtargetingthesiteofearliestatrial
Midodrine,low-dosenon-selectivebeta- ... activationwithrespecttothePwave.Thisapproachhasbeenshown
blocker,orpyridostigminemaybe IIb B
... tobefeasiblewithagoodlong-termoutcome.164(cid:2)166
.
considered.167,170,172(cid:2)174 ..
.. 11.1.1.4Posturalorthostatictachycardiasyndrome
Ivabradinemaybeconsidered.175 IIb C .
. . POTS is defined as a clinical syndrome usually characterized by an
.
. HFrEF=heartfailurewithreducedejectionfraction. . increaseinheartrateof>_30b.p.m.whenstandingfor>30s(or>_40
.
aClassofrecommendation. ..
b.p.m.inindividualsaged12-19years)andanabsenceoforthostatic
bLevelofevidence. ...
hypotension(>20mmHgdropinsystolicbloodpressure).177,178
.
.
. TheprevalenceofPOTSis0.2%anditrepresentsthemostcom-
.
.. mon cause of orthostatic intolerance in the young,178 with most
11.1.1.3Sinusnodere-entranttachycardia .
.
. patients aged between 15 and 25 years, and >75% being female.
Sinus node re-entrant tachycardia arises from a re-entry circuit .
.
. Although the long-term prognosis of POTS has been poorly
involvingthesinusnodeand,incontrasttoIST,ischaracterizedby .
.
paroxysmalepisodesoftachycardia.176Thisuncommonarrhythmia .. explored,(cid:4)50%ofpatientsspontaneouslyrecoverwithin1-3years.
.
. A number of mechanisms have been described in patients with
may be associated with paroxysmalsymptoms of palpitation, dizzi- .
.
. POTS, including autonomic nervous system dysfunction,
ness,andlight-headedness.OntheECG,thepolarityandconfigura- .
.
tion of the P waves are similar to the configuration of sinus
.. peripheral autonomic denervation, hypovolaemia, hyperadrenergic
.
Pwaves.163 ... stimulation, diabetic neuropathy, deconditioning, anxiety, and
.. hypervigilance.178(cid:2)181
.
.
11.1.1.3.1Diagnosis.Thediagnosisofsinusnodere-entranttachycar- ..
diaissuspectedonECGandHolterECG.Itcanbeconfirmedwith
... 11.1.1.4.1Diagnosis.POTSisdiagnosedduringa10minactivestand
anEPS.
... test or head-up tilt test with non-invasive haemodynamic
9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 21 ---
ESCGuidelines 675
.
.
monitoring.TheevaluationofapatientsuspectedofhavingPOTS . sustainedorincessant.Dynamicformswithrecurrentinterruptions
.
.
shouldeliminateothercausesofsinustachycardiasuchashypovo- . andreinitiationsmaybefrequent.
.
.
laemia, anaemia, hyperthyroidism, pulmonary embolus, or pheo- . InpatientswithPV-relatedAT,thefocusislocatedattheostium
.
chromocytoma.178 The clinical history should focus on defining .. ofthevein(orwithin1cmofthedesignatedostium)184ratherthan
.
the chronicity of the condition, possible causes of orthostatic .. furtherdistally(2(cid:2)4cm).185
.
.
tachycardia, modifying factors, impact on daily activities, and .
.
.
potentialtriggers. . 11.1.2.1Diagnosis
.
.
. Pwaveidentificationfroma12leadECGrecordingduringtachycar-
.
.
11.1.1.4.2 Therapy. Non-pharmacological treatments should be .. dia is critical (Figure 7). Depending on the AV conduction and AT
.
attemptedfirstinallpatients.Theseincludewithdrawingmedications .. rate,thePwavesmaybehiddenintheQRSorTwaves.ThePwaves
.
that might worsen POTS, such as norepinephrine transport inhibi- .. aremonomorphicwithstableCL,whichhelpstoruleoutorganized
.
tors, increasing blood volume with enhanced salt and fluid intake, .. AF.Adenosineinjectioncanhelpbyslowingtheventricularrateor,
.
reducing venous pooling with compression garments, and limiting .. lessfrequently,byterminatingfocalAT.AdiscretePwavewithan
.
deconditioning. Patients should engage in a regular, graduated, and .. interveningisoelectricintervalsuggestsafocalAT.However,distin-
.
supervised exercise programme featuring aerobic reconditioning .. guishingfocalfrommacro-re-entrantarrhythmiasbysurfaceECGis
.
withsomeresistancetrainingforthethighs.Initially,exerciseshould .. notalwayspossible.Thepresenceofanisoelectriclinedoesnotrule
.
be restricted to non-upright exercise, including the use of rowing .. out a macro-re-entrant mechanism, particularly in the presence of
.
machines and swimming, to minimize orthostatic stress on the .. scaratrialtissue(fromstructuralheartdiseaseorpreviousextensive
.
heart.180(cid:2)182 .. ablation/surgeryprocedures).Inanormalheartandintheabsenceof
.
If non-pharmacological approaches prove ineffective, pharmaco- .. previousablation,theusualECGlocalizationrulesapply,186buttheir
.
.
logicaltherapiesmaybetargetedatspecificaspects.Patientsstrongly . valueinlocalizingtheoriginofthearrhythmiaisalsolimitedinthis
.
.
suspectedofhavinghypovolaemiashoulddrink>_2(cid:2)3Lofwaterper . context.FocalATmayarisefromanysiteinbothatria,butparticular
.
.
day,anddietarysaltintakeshouldbeincreasedto(cid:4)10(cid:2)12g/dayif . sitesofpredilectioninthenormalheartratearethecristaterminalis,
.
.
tolerated.Midodrinesignificantlyreducesorthostatictachycardiabut . thetricuspidandmitralvalveannulus,andwithinthethoracicveins
.
toalesserdegreethani.v.saline.170Midodrinehasarapidonsetwith .. joiningtheatria.46,186AnegativePwaveinleadIandaVLsuggestsan
.
.
onlybriefeffects and is usuallyadministered threetimesdaily.The . LAorigin.V1isnegativewhenthearrhythmiasourceorexitisinthe
.
.
drug should only be administered during daytime hours as it can . lateralrightatrium,whileseptalrightatrial(RA)andLAoriginsshow
.
.
causesupine hypertension. To reduceunpleasant sinustachycardia . biphasicorpositivePwaves(Figure7).NegativePwavesintheinfe-
.
.
and palpitations, low-dose propranolol [10(cid:2)20 mg per os (p.o.)] .. riorleadssuggestacaudalorigin,whereaspositivePwavesinthose
.
acutely lowers standing heart rate and improves symptoms in .. leadsfavourasuperiorlocation.
.
patientswithPOTS,whilehigherdosesofpropranololarelesswell ..
.
tolerated.172Long-actingpropranololdoesnotimprovethe quality .. 11.1.2.2Acutetherapy
.
of life of patients with POTS.167 Non-selective beta-blockers are .. Harddataforanevidence-basedchoiceofdrugsfortheacutether-
.
preferable because they additionally block epinephrine-mediated .. apyoffocalATarescarce.Ingeneral,acutetherapymaybeinitiated
.
beta-2-vasodilation, but other beta-blockers have not been .. withbeta-blockersorcalciumchannelblockers,whichmayterminate
.
adequatelystudied.Pyridostigmine,acholinergicagonistthatworks .. focal ATs or slow the ventricular rate (Figure 8).92,94,187,188
. byinhibitingacetylcholinesterase,canincreaseparasympatheticauto- .. Adenosine (i.v.) may terminate AT [delayed after-depolarizations
.
nomic tone and has a lower risk of hypertension compared with .. (DAD)-triggeredAT],butthetachycardiamayalsocontinuewithAV
.
othermedications.Potentialsideeffectsincludeabdominalcramping, .. block.ClassIA,IC,andIIIdrugsmayalsobeeffective,byprolonging
.
diarrhoea, and muscle cramps.173,174 Ivabradine slows sinus rates .. refractorinessorsuppressingautomaticity.189(cid:2)191Amiodaronemay .
withoutaffectingbloodpressure,andinanopen-labelstudy(cid:4)60%of .. alsobeusedforcardioversionorslowingoftheventricularrate,192
.
patients with POTS had symptomatic improvement.175 Ivabradine .. but the efficacy of rate control is unproven in critically ill patients
.
should ideally be administered with concomitant beta-blockers for .. with atrial arrhythmias.193 DC cardioversion is usually effective in
.
long-termtherapy.151 .. acutely terminating the tachycardia, irrespective of the mechanism.
.
.
. However,inincessantformsoffocalATduetoenhancedautomatic-
.
.
. ity, the arrhythmia reinitiates, and repeating DC cardioversion is
.
.
. unlikelytobeappropriate.
.
.
11.1.2Focalatrialtachycardia .
.
.
FocalATisdefinedasanorganizedatrialrhythm>_100b.p.m.initiated . 11.1.2.3Catheterablation
.
.
fromadiscreteoriginandspreadingoverbothatriainacentrifugal .. Catheter ablation is the treatment of choice for recurrent focal
.
pattern.Theventricularratevaries,dependingonAVnodalconduc- .. AT, especially for incessant AT due to which TCM ensues
.
tion. Inasymptomatic young people(<50years ofage), thepreva- .. (Figure 9).196 Distinguishing macro-re-entrant from focal ATs is
.
lenceoffocalAThasbeenreportedtobeaslowas0.34%withan .. critical for the ablation strategy. Focal ATs, as well as localized/
.
increasedprevalenceof0.46%insymptomaticarrhythmiapatients.183 .. micro-re-entry ATs, display a centrifugal activation pattern that
.
Moststudieshavereportednoinfluenceofsex. .. spreadsthroughouttheatria.MappingandablationoffocalATsis
.
Symptoms may include palpitations, shortness of breath, chest .. basedondeterminingtheearliestactivationsite.InPV-relatedAT,
.
pain, and rarely syncope or presyncope. The arrhythmia may be . focal ablation may be performed, but electrical isolation of both
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 22 ---
676 ESCGuidelines
A B C
Figure7 Focalatrialtachycardia.(A)Focalatrialtachycardiaoriginatingatthelateralrightatriumconductedinitiallywithfullandthenincompleteright
branchbundleblockaberration.(B)Focalatrialtachycardiaoriginatingattheleftatrium(leftsuperiorpulmonaryvein).(C)Focalatrialtachycardiafromthe
rightatrialappendage.Atrioventriculardissociationduringcarotidsinusmassage(Pwavesindicatedbyarrows).
Recommendationsforthetherapyoffocalatrialtachycardia
Recommendation Classa Levelb
Acutetherapy
Haemodynamicallyunstablepatients
SynchronizedDCcardioversionisrecommendedforhaemodynamicallyunstablepatients.86(cid:2)88 I B
Haemodynamicallystablepatients
Adenosine(6(cid:2)18mgi.v.bolus)shouldbeconsidered.92(cid:2)94 IIa B
Beta-blockers(i.v.esmololormetoprolol)shouldbeconsideredintheabsenceofdecompensatedHF,ifadenosinefails.187,188 IIa C
Verapamilordiltiazem(i.v.)shouldbeconsideredforhaemodynamicallystablepatientsintheabsenceofhypotensionorHFrEF,
IIa C
ifadenosinefails.92,94
Iftheabovemeasuresfail,thefollowingmaybeused:
• i.v.ibutilide191;
IIb C
• ori.v.flecainideorpropafenone189,190;
• ori.v.amiodarone.192
SynchronizedDCcardioversionisrecommendedwhendrugtherapyfailstoconvertorcontrolthetachycardia.87,88 I B
Chronictherapy
CatheterablationisrecommendedforrecurrentfocalAT,especiallyifincessantorcausingTCM.184,187,194(cid:2)197 I B
Beta-blockersornon-dihydropyridinecalciumchannelblockers(verapamilordiltiazemintheabsenceofHFrEF),orpropafenoneorfle-
IIa C
cainideintheabsenceofstructuralorischaemicheartdisease,shouldbeconsideredifablationisnotdesirableorfeasible.188(cid:2)190,198
Ivabradinewithabeta-blockermaybeconsiderediftheabovemeasuresfail.199,200 IIb C
Amiodaronemaybeconsiderediftheabovemeasuresfail.201,202 IIb C
i.v.verapamilanddiltiazemarecontraindicatedinthepresenceofhypotensionorHFrEF.
i.v.beta-blockersarecontraindicatedinthepresenceofdecompensatedheartfailure.
i.v.ibutilideiscontraindicatedinpatientswithprolongedQTcinterval.
i.v.flecainideandpropafenonearecontraindicatedinpatientswithischaemicorstructuralheartdisease.TheyalsoprolongtheQTcintervalbutmuchlessthanclassIIIagents.
i.v.amiodaroneprolongstheQTcbuttorsadesdespointesisrare.
AT=atrialtachycardia;DC=directcurrent;HF=heartfailure;HFrEF=heartfailurewithreducedejectionfraction;i.v.=intravenous;TCM=tachycardiomyopathy.
aClassofrecommendation.
bLevelofevidence.
9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 23 ---
ESCGuidelines 677
.
.
the culprit PV along with other PVs may be preferred. Catheter .. blockers may be effective, and there is a low risk of side effects
.
ablationisreportedtohavea75(cid:2)100%successrate.184,187,194(cid:2)197 .. (Figure9).188ClassICdrugsmaybeeffectiveiffirst-linetherapyhas
.
Table11presentsasynopsisofsuccessratesandcomplicationsof .. failed.189,190,198IvabradinemayalsobeeffectiveinfocalAT,199,200and
.
catheter ablation for the most common SVTs in the current .. ideally should be given with a beta-blocker. Amiodarone has been
.
era.11(cid:2)13,203(cid:2)208 .. triedintheyoungandpaediatricpopulations,201,202andtheoretically
.
.. shouldbeattractiveinpatientswithimpairedLVfunction.However,
.
11.1.2.4Chronictherapy .. itslong-termefficacyislimitedbyitssideeffects.
.
Studies addressing chronic therapy are also limited, and thus firm .
conclusions cannot be drawn. Beta-blockers and calcium channel
Focal AT
Focal AT
Recurrent or
incessant
Haemodynamic
Yes No
instability
No Yes
Catheter ablation Drug therapy
(I B) No desirable
Adenosine Synchronized
(IIa B) cardioversion
(I B) Yes
If ineffective
Beta-blocker or
verapamil or diltiazem
or propafenone
or flecainide
i.v. verapamil i.v. (IIa C)
or diltiazem beta-blocker
(IIa C) (IIa C) If ineffective
If ineffective Ivabradine with a
beta-blocker
(IIb C)
i.v. ibutilde If ineffective
or flecainide If ineffective
or propafenone Amiodarone
or amiodarone (IIb C)
If ineffective (IIb C)
or not tolerated
Figure8Acutetherapyoffocalatrialtachycardia. Figure9Chronictherapyoffocalatrialtachycardia.
AT=atrialtachycardia;i.v.=intravenous. AT=atrialtachycardia.
Table11 Averagesuccessandcomplicationratesofcatheterablationforsupraventriculartachycardia
Acutesuccess(%) Recurrence(%) Complications(%) Mortality(%)
FocalAT 85 20 1.4a 0.1
Cavotricuspid-dependentatrialflutter 95 10 2b 0.2
AVNRT 97 2 0.3c 0.01
AVRT 92 8 1.5d 0.1
Successrates,recurrence,andcomplicationsforfocalatrialtachycardiaandatrioventricularre-entranttachycardiavary,beingdependentonthelocationofthefocusorpath-
way,respectively.11(cid:2)13,203(cid:2)208
aVascularcomplications,AVblock,andpericardialeffusion.
bVascularcomplications,stroke,myocardialinfarction,andpericardialeffusion.
cVascularcomplications,AVblock,andpericardialeffusion.
dVascularcomplications,AVblock,myocardialinfarction,pulmonarythromboembolism,andpericardialeffusion.
AT=atrialtachycardia;AV=atrioventricular;AVNRT=atrioventricularnodalre-entranttachycardia;AVRT=atrioventricularre-entranttachycardia.
9102
CSE©
9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 24 ---
678 ESCGuidelines
.
.
11.1.3Multifocalatrialtachycardia .. dysfunction,orAVblock.Therehasalsobeenacasereportonthe
.
MultifocalATisdefinedasarapid,irregularrhythmwithatleastthree .. successfuluseofibutilide.215Insymptomaticandmedicallyrefractory
.
distinctmorphologiesofPwavesonthesurfaceECG.MultifocalATis .. casesinwhichLVdeteriorationisseen,AVnodalmodificationmay
.
commonlyassociatedwithunderlyingconditions,includingpulmonary .. beusedforthecontrolofventricularrate.216
.
disease,pulmonaryhypertension,coronarydisease,andvalvularheart ..
.
disease, aswell ashypomagnesaemia and theophylline therapy.209 It ..
.
mayalsobeseeninhealthyinfantsunder1yearofage,andcarriesa .. 11.1.4Macro-re-entrantatrialtachycardias
.
goodprognosisintheabsenceofunderlyingcardiacdisease.210 .. Atrial flutter and focal AT are traditionally defined according to the
.
ItmaybedifficulttodistinguishmultifocalATfromAFonasingle .. ECGappearance:continuousregularelectricalactivity,mostcommonly
.
ECGtrace,soa12leadECGisindicatedtoconfirmthediagnosis. .. a saw-tooth pattern, vs. discrete P waves with an isoelectric line in
.
OntheECG,theatrialrateis>100b.p.m.UnlikeAF,thereisadis- .. between.ECGswithflutter-likeappearancesaremostlyduetomacro-
.
tinctisoelectricperiodbetweenvisiblePwaves.ThePP,PR,andRR .. re-entrantatrialcircuitsbutmicro-re-entryisalsopossible.However,
.
intervals are variable. Although it is assumed that the variability of .. MRATs with a significant part of the activation of the circuit in pro-
.
P-wavemorphologyimpliesamultifocalorigin,therehavebeenvery
.. tectedareasmaydisplayafocalATpattern,withdiscretePwaves.220
.
.
fewmappingstudiesofmultifocalAT. .
.
.. 11.1.4.1Cavotricuspidisthmus-dependentmacro(cid:2)re-entrantAT
.
.
11.1.3.1Therapy .
.
Thefirst-linetreatmentismanagementoftheunderlyingcondition.
.. 11.1.4.1.1 Typicalatrial flutter: common(counter-clockwise) and
. . reverse (clockwise). Typical common atrial flutter is the most fre-
Magnesium(i.v.)mayalsobehelpfulinpatients,eveninthosewith .
.
. quentcavotricuspidisthmus(CTI)-dependentflutter,i.e.amacro-re-
normalmagnesiumlevels.211Antiarrhythmicmedications,ingeneral, ..
. entrycircuitaroundthetricuspidannulususingtheCTIasacritical
are not helpful in suppressing multifocal AT.209 Management often ..
. passageattheinferiorboundary.ActivationgoesdownwardintheRA
involvesslowingconductionattheAVNleveltocontrolheartrate. ..
. freewall,throughtheCTI,andascendsintherightseptum.Activation
VerapamilhassomeefficacyinpatientswithmultifocalATwhodo ..
. oftheLAispassive.Theupperpartofthecircuitmaybeanterioror
not have ventricular dysfunction, sinus node dysfunction, or AV ..
. posteriortothesuperiorvenacava.Thisactivationisalsoknownas
block.212,213 Metoprolol has been found to be superior to verapa- ..
mil,214andbeta-blockerscanbeusedwithcautiontotreatmultifocal
... counter-clockwise (or anticlockwise) when seen from the apex.
AT in the absence of respiratory decompensation, sinus node
... Whenthecircuitisactivatedintheoppositedirection,i.e.clockwise,
.. itresultsinadifferentECGpattern,thencalledtypicalreverseflutter.
.
.
Recommendationsforthetherapyofmultifocalatrial ..
tachycardia
... 11.1.4.1.2Diagnosis.Incounter-clockwiseflutter,thecircuitresultsin
.. regular atrial activation from 250(cid:2)330 b.p.m., with negative saw-
.
Recommendation Classa Levelb . toothwavesininferiorleadsandpositivewavesinV1(Figure10).In
Acutetherapy
Treatmentofanunderlyingconditionisrec- A B
I C
ommendedasafirststep,iffeasible.209
i.v.beta-blockers,ori.v.non-dihydropyridine
calciumchannelblockers(verapamilordiltia- IIa B
zem)shouldbeconsidered.213,214
Chronictherapy
Oralverapamilordiltiazemshouldbeconsid-
eredforpatientswithrecurrentsymptomatic IIa B
multifocalATintheabsenceofHFrEF.217,218
Aselectivebeta-blockershouldbeconsidered
forpatientswithrecurrentsymptomaticmulti- IIa B
focalAT.214,219
AVnodalablationfollowedbypacing(prefera-
blebiventricularorHis-bundlepacing)should
beconsideredforpatientswithLVdysfunction IIa C
duetorecurrentmultifocalATrefractoryto
drugtherapy.216
AT=atrialtachycardia;HF=heartfailure;HFrEF=heartfailurewithreduced
ejectionfraction;i.v.=intravenous;LV=leftventricular.
i.v.verapamilanddiltiazemarecontraindicatedinthepresenceofhypotensionor
HFrEF.
i.v.beta-blockersarecontraindicatedinthepresenceofdecompensatedheart
failure. Figure10 Counter-clockwise(A)andclockwise(B)atrialflutterwith
aClassofrecommendation. 2:1atrioventricularconduction.
bLevelofevidence.
9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 25 ---
ESCGuidelines 679
.
clockwise flutter, ECG flutter waves in inferior leads look positive .. Beyond symptoms associated with high-rate and loss of atrial kick,
.
andbroad,andarefrequentlybimodalnegativeinV1.220,221Typical .. reversible systolic dysfunction and subsequent TCM are not
.
atrial flutter has a strong reproducible anatomical dependence,222 .. unusual.233,234
.
.
resultinginthemorphologicalreproducibilityoftheECG.However, .
.
thiswell-recognizedECGpatternmaybesignificantlychangedwhen .. 11.1.4.1.3Acutetherapy.Althoughthefirststepshouldberatecon-
.
atrialactivationhasbeenmodified,asitisincardiacsurgeryinvolving .. trolwhentheventricularrateishigh,thismaybedifficulttoachieve.
.
atrialtissue,afterextensiveradiofrequencyablation,orinadvanced
.. AVnodalblockingdrugs,235(cid:2)238includingamiodaroneappliedmostly
.
atrialdisease.223,224Antiarrhythmicdrugsmayalsomodifythetypical .. inHForcriticallyillpatients,239,240maybeofhelp,butcardioversion
.
ECG pattern.225 Inthesesituations, anatypicalECG doesnot rule .. maybenecessary(Figure11).
.
outacircuitoftypicalflutterusingtheCTI.226 .. Insomecases,presentingwith2:1AVblock,thediagnosisofatrial
.
TypicalflutterisrelatedtoAFinclinicalpractice,withbothbeing .. fluttermaynotbeobviousontheECG.Inthesesituations,i.v.adeno-
.
associated with similar clinical settings and coexisting in the same .. sinemayincreasethedegreeofAVblockandrevealthetypicalECG
.
patients:AFmaytriggeratrialflutter,andaftertypicalflutterablation .. pattern.However,adenosinecanproduceareboundincreaseinAV .
AFisfrequent.23,227(cid:2)229Typicalfluttermayalsofrequentlyoccurin .. conductionto1:1andmayalsoprecipitateAF.271,272Thus,itshould
.
.
patients treated for AF with class IC drugs or amiodarone. In this .. only be used if deemed necessary for diagnosis and resuscitation
.
case,flutterratemaybereducedto<200b.p.m.facilitating1:1AV .. equipmentisavailable.
.
conduction.Theactionofantiarrhythmicdrugsonventricularactiva- .. Ratecontrolshouldbethefirststepinverysymptomaticpatients
.
tionmayresultinwideQRStachycardia.230(cid:2)232 .. withrapidventricularrates.Thisisaparticularlydifficultgoalinatrial
Recommendationsforthetherapyofmacro2re-entrantatrialarrhythmias
Recommendations Classa Levelb
Anticoagulation,asinAF,isrecommendedforpatientswithatrialflutterandconcomitantAF.4 I B
PatientswithatrialflutterwithoutAFshouldbeconsideredforanticoagulation,butthethresholdforinitiationhasnotbeen
IIa C
established.241(cid:2)247
Acutetherapy
Haemodynamicallyunstablepatients
SynchronizedDCcardioversionisrecommendedforhaemodynamicallyunstablepatients.248,249 I B
Haemodynamicallystablepatients
i.v.ibutilideori.v.ororal(in-hospital)dofetilidearerecommendedforconversiontosinusrhythm.250(cid:2)257 I B
Low-energy(<_100Jbiphasic)electricalcardioversionisrecommendedforconversiontosinusrhythm.248,249 I B
High-rateatrialpacingisrecommendedforterminationofatrialflutterinthepresenceofanimplantedpacemakeror
I B
defibrillator.258(cid:2)260
i.v.beta-blockersornon-dihydropyridinecalciumchannelblockers(verapamilordiltiazem)(i.v.),shouldbeconsideredforcontrolof
IIa B
rapidventricularrate.235(cid:2)238
Invasiveandnon-invasivehigh-rateatrialpacingmaybeconsideredforterminationofatrialflutter.258,261 IIb B
i.v.amiodaronemaybetriediftheabovearenotavailableordesirable.239,240 IIb C
Propafenoneandflecainidearenotrecommendedforconversiontosinusrhythm.250 III B
Chronictherapy
Catheterablationshouldbeconsideredafterthefirstepisodeofsymptomatictypicalatrialflutter.262,263 IIa B
Catheterablationisrecommendedforsymptomatic,recurrentepisodesofCTI-dependentflutter.262(cid:2)264 I A
Catheterablationinexperiencedcentresisrecommendedforsymptomatic,recurrentepisodesofnon-CTI-dependent
I B
flutter.224,265(cid:2)269
CatheterablationisrecommendedinpatientswithpersistentatrialflutterorinthepresenceofdepressedLVsystolicfunctiondue
I B
toTCM.233,234
Beta-blockersornon-dihydropyridinecalciumchannelblockers(verapamilordiltiazem,intheabsenceHFrEF)shouldbeconsidered
IIa C
ifablationisnotdesirableorfeasible.237,270
Amiodaronemaybeconsideredtomaintainsinusrhythmiftheabovemeasuresfail.263 IIb C
AVnodalablationwithsubsequentpacing(‘ablateandpace’),eitherbiventricularorHis-bundlepacing,shouldbeconsideredifallthe
IIa C
abovefailandthepatienthassymptomaticpersistentmacro-re-entrantatrialarrhythmiaswithfastventricularrates.
i.v.verapamilanddiltiazemarecontraindicatedinthepresenceofhypotensionorHFrEF.
i.v.beta-blockersarecontraindicatedinthepresenceofdecompensatedheartfailure.
i.v.ibutilide,andi.v.andoraldofertilidearecontraindicatedinpatientswithprolongedQTcinterval.
i.v.amiodaroneprolongstheQTcbuttorsadesdespointesisrare.
AF=atrialfibrillation;AV=atrioventricular;CTI=cavotricuspidisthmus;DC=directcurrent;HFrEF=heartfailurewithreducedejectionfraction;i.v.=intravenous;LV=left
ventricular;TCM=tachycardiomyopathy.
aClassofrecommendation.
bLevelofevidence.
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 26 ---
680 ESCGuidelines
Atrial flutter/MRAT
Haemodynamic
instability
No Yes
Synchronized
cardioversion
Rhythm control
(I B)
strategy
No Yes
i.v. beta-blocker
or Electrical
i.v. diltiazem or verapamil cardioversion
(IIa B) preferred
Yes No
Low-energy
synchronized cardioversion PPM/ICD
(I B) present?
No Yes
i.v. ibutilide Ηigh-rate
or dofetilide i.v. or
atrial pacing
oral (in-hospital)
(I B)
(I B)
If not available
or contra-indicated
Invasive or non-invasive
i.v. amiodarone high-rate atrial pacing
(IIb C)
(IIb B)
Figure11Acutetherapyofstableatrialflutterormacro-re-entrantatrialtachycardia.
ICD=implantablecardioverterdefibrillator;i.v.=intravenous;MRAT=macro-re-entrantatrialtachycardia;PPM:permanentpacemaker.
9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 27 ---
ESCGuidelines 681
.
.
flutterandeventhecombinationofAVN-blockingdrugs(digoxin, .. comparedwiththoseinAF.247,282Thethrombo-embolicriskof
.
beta-blockers,andcalciumchannelblockers)235(cid:2)238mayfail,mak- .. atrial flutter, although lower than that of AF,246 is still signifi-
.
ingcardioversiontosinusrhythmnecessary.Dofetilideandibuti- .. cant.241(cid:2)244That,togetherwiththeassociationwithAF,justifies
.
lide, pure class III antiarrhythmic drugs, are generally effective in .. thromboprophylaxis, and anticoagulation has been recom-
.
interrupting atrial flutter in i.v. administration (dofetilide may be .. mendedasinAF.2,3Theserecommendationsextendtotheacute
.
alsogivenorallyforthispurpose),whileclassIAandICdrugshave .. setting for cardioversion when flutter lasts for >48 h.278
.
littleornoeffect.250(cid:2)257ClassICantiarrhythmicdrugsshouldnot .. However,itshouldbenotedthatthereisalackofprospective,
.
beusedintheabsenceofAV-blockingagentsbecauseoftherisk .. dedicated,randomizedstudiesonthesubject.Furthermore,the
.
of slowing the atrial rate, which may result in 1:1 AV conduc- ... valueoftheCHA 2DS 2-VASc[Cardiacfailure,Hypertension,Age
tion.273,274 Amiodarone may not be very effective acutely to re- .. >_75(Doubled),Diabetes,Stroke(Doubled)(cid:2)Vasculardisease,
.
establishsinusrhythm,butitdoeshelptocontroltheventricular .. Age 65(cid:2)74 and Sex category (Female)] score in preventing
.
rate if it is too fast.275,276 Low-energy electrical cardioversion is .. ischaemicstrokeinpatientswithatrialflutterhasnotbeenestab-
.
commonlyusedwithhaemodynamiccompromiseorafterfailure .. lished,245andinpatientswithoutconcomitantAFthethreshold
.
.
ofpreviousactions,butitcouldbethefirstchoiceduetoitshigh . fortheinitiationofanticoagulationappearstobehigherthanthat
.
efficacy.Electricalcardioversionforatrialflutterismoreeffective .. forpatientswithAF.246
.
andlessenergyisrequired,comparedwithAF.248,249Whenatrial ..
.
.
electrodesareinplace,high-ratestimulationcanbeusedtocon- .. 11.1.4.1.7 Other cavotricuspid isthmus-dependent macro(cid:2)re-
vert flutter, sometimes through AF.258,259 If pacing induces AF, .. entrant atrial tachycardia. An atypical ECG pattern may not
. thismayallowbettercontroloftheventricularratethanflutter. .. excludeCTI-dependentMRAT.283Lower-loopre-entryreferstoa
.
.
Atrialstimulationcanalsobedonewithpercutaneousendocardial . circuitrotatingaroundtheinferiorvenacavainsteadofaroundthe
.
electrodesorfromtheoesophagus;thisismostlydoneinpaediat- .. tricuspid annulus. It may be clockwise or counter-clockwise.284,285
.
.
rics.261 Pre-treatment with procainamide may facilitate conver- . Whenrotatingcounter-clockwise,itmightbeconsideredavariantof
.
.
sionofatrialflutterbyatrialpacing.277Dataonpre-cardioversion .. typical counter-clockwise flutter with a caudal shift of the cranial
.
anticoagulationarelacking,butmostprobablypatientsshouldbe .. turningpointposteriortotheentryofthesuperiorvenacava,result-
.
treatedthesameasthosewithAF.4,278 .. ing in a similar ECG appearance. ‘Figure-of-eight double-loop re-
.
. entry’ may also occur around the inferior vena cava and tricuspid
.
.
11.1.4.1.4Catheterablation.Catheterablationisthemosteffective .. annulus, and mimic typicalclockwiseatrialflutter.285 Othercircuits
.
therapytomaintainsinusrhythm,andisclearlysuperiortoamio- .. usingpartoftheCTIorevenrestrictedinsideit,areinessenceCTI-
.
darone.262,263 Ablation of CTI with confirmed bidirectional con- .. dependent with a similar ECG appearance to typical common
.
ductionblockresultsina<10%rateofrecurrence.279However, .. flutter.286,287
.
theincidenceofAFishighinthelong-term.280WhentypicalCTI- ..
.
dependentatrialflutterensuesduringantiarrhythmicdrugtherapy .. 11.1.4.2Non-cavotricuspidisthmus-dependentmacro(cid:2)re-entrantatrial
.
(class IC or amiodarone) for AF, CTI ablation is a reasonable .. tachycardia
.
choicetoensurethatantiarrhythmicdrugscanbe continued for .. The terms non-CTI-dependent MRAT and atypical flutter are
.
AFcontrol.262,263 .. usedinterchangeably,anddescribeflutterwavesintheECGnot
.
Although no procedure-related mortality had been detected in .. suggestiveoftypicalcircuits.Thepitfallwiththisusecomesfrom
. early studies,203,204 in recent studies, mortality and stroke rates of .. theatypicalECGthatmayhappenwhentypicalcircuitsdevelopin
. 0.2-0.34 and 0.19-0.5%, respectively, have been reported .. diseasedatria,mostfrequentlyaftersurgeryorextensiveablation,
.
(Table11).12,206Inarecentregistry,ablationforflutterhadahigher .. orundertheeffectsofantiarrhythmicdrugs.Conversely,upper-
.
.
mortalitythanthatforAF(0.3vs.0.05%),butthismighthavebeen . loop re-entry may mimic a typical flutter ECG pattern without .
duetothecomorbiditiesoradvancedagesofpatientsreferredfor .. beingCTI-dependent.283Trueatypicalflutterisactuallyaposthoc .
flutterablation.207 .. diagnosiswhenthecircuithasbeenoutlinedanddependenceon
.
.
. CTIhasbeenruledout.
.
. 11.1.4.1.5 Chronic therapy. Rate control is part of the therapeutic ..
.
approach,usingAVnodalblockingagentssuchasdiltiazem,verapamil, .. 11.1.4.2.1Rightatriummacro2re-entrantatrialtachycardia.Atrial
.
or beta-blockers (Figure 12). When ablation is not feasible or the .. suturesandpatchesusedforcomplexcongenitalheartdiseasesur-
.
patient’spreference,antiarrhythmicdrugsmayalsobeusedtomaintain .. gery, together with progressive atrial damage, create multiple
.
sinusrhythm.Dofetilide257andsotalol281areuseful,buttherearecon- .. obstaclesandprotectedisthmusesthatconstitutethesubstratefor
.
cerns about pro-arrhythmia. Amiodarone may have a role,263 but it .. complexandmultipleMRAT.288,289ThisusuallyhappensaroundRA
.
shouldberestrictedtocasesofHForsignificantstructuralheartdisease. .. freewallscars.However,inpatientswithcomplexcongenitalheart
.
.. disease,thepresenceofextensiveatrialscarshindersthedifferential
.
11.1.4.1.6 Anticoagulation. Data about the embolic risk of atrial .. diagnosisoffocalorMRAT.290
.
flutterhaveusuallybeenderivedinthepresenceofconcomitant .. Figure-of-eightdouble-looptachycardiasmimickingtheECGpat-
.
AF, thus making individualized risk stratification difficult. Left .. tern of a common atrial flutter may also occur following surgical
.
atrial (LA) appendage ‘stunning’ and thrombi seem to be lower .. atriotomy.291
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 28 ---
682 ESCGuidelines
Atrial flutter/MRAT
Symptomatic and
recurrent
Yes No
Drug therapy
desirable
Yes No
Beta-blocker
Catheter
or diltiazem ablation
or verapamil
(IIa B)
(IIa C)
If ineffective
CTI dependent Amiodarone
flutter If ineffective (IIb C)
or not tolerated
Yes No
Catheter Catheter ablation
ablation in experienced
(I A) centres (I B)
Figure12Chronictherapyofatrialflutter/macro-re-entrantatrialtachycardia.
CTI=cavotricuspidisthmus;MRAT=macro-re-entrantatrialtachycardia.
.
.
RAMRATmayalsooccurintheabsenceofpreviousinterven- .. Owingtoitswidespreaduse,AFablationistheprocedurethatfre-
.
tion. Most of these are sustained around areas of ‘electrical .. quentlycausesthelesionsabletosustainre-entrycircuits,usuallyafter
.
silence’ in the RA free wall, probably due to fibrosis.224,264,266 .. linearablationorextensivedefragmentation.Pre-existingatrialdisease
.
Atypicalatrialfluttercouldalsoarisefromupperloopre-entryin .. is also predictive of macro-re-entry.293 Localized segmental PV dis-
. the right atrium with conduction through the gap in the crista .. connectionmaycausefocaltachycardias,294andcircumferentialantral
.
terminalis.269 .. ablationmayalso create MRAT due to gaps in the lines.295(cid:2)299 AT
.
Rate control is oftendifficult due to the regularity and usually .. duetoasmallre-entrantcircuitafterablationofAFmaypossiblybe
.
slowrateofthetachycardia.Antiarrhythmicdrugsareofteninef- .. distinguishedfrommacro-re-entrybyashorterP-waveduration.RA
.
fective,ortheiruseislimitedbecauseofstructuralheartdisease .. MRATshaveahigherincidenceofnegativepolarityinatleastonepre-
.
andcomorbidities.Radiofrequencyablationofoftenseveralcrit- .. cordialleadcomparedwithLAmacro-re-entry.300(cid:2)302
.
ical isthmuses is the most effective treatment. Circuits around .. Atrial circuits are also created after surgery for different condi-
.
.
scars of longitudinal atriotomy can be mapped and ablated with . tions, including mitral valve disease, and are related to incisions or
.
goodlong-termresults.267,292However,owingtothecomplexity .. cannulation.303SurgerytotreatAFmayalsoresultinmacro-re-entry
.
ofpossiblesubstratesanddifficultyofreachingcriticalisthmuses, .. circuitsandfocalAT.304
.
.
ablation procedures for these patients should be restricted to . CircuitscausingatypicalleftMRATmayalsooccurintheLAwith-
.
.
experiencedoperatorsandcentres. . outpriorintervention,commonly,butnotinvariably,associatedwith
.
.. significantleftheartdisease.305Thesearebasedonareasofelectrical
.
.
11.1.4.2.2Leftatriummacro2re-entrantatrialtachycardia.Circuits .. silence,probablyduetofibrosis,engaginganatomicalobstaclessuch
.
sustainingLAatypicalflutter/MRATaremostusuallyduetoelectri- . astheostiaofthePVsorthemitralannulus,andmaybeablatedby
.
callysilentareasofabnormaltissue,followingmedicalinterventions .. interruptingcriticalisthmuses.265,306Circuitsmayalsohappeninthe
.
.
or progressive atrial degeneration/fibrosis.268 Anatomical obstacles .. LAseptumduetoslowconductioncausedbyatrialdiseaseorantiar-
.
suchastheostiaofPVs,andmitralannulus,areofteninvolved. .. rhythmicdrugs.307
.
9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 29 ---
ESCGuidelines 683
.
.
Peri-mitral flutter, sometimes incorporating silent areas at the .. circuitforallformsofAVNRTbasedontheconceptofatrionodal
.
roofoftheLA,isablatedinasimilarwaytoperi-tricuspidcircuits. .. inputshavebeenproposed.47,317
.
However,thedeploymentofastablelineofblockatcriticalisth- .. Onset of AVNRT seems to occur bimodally over time. In
.
muses is more challenging.308(cid:2)310 Circuits around the PVs are .. manypatients,attacksindeedmanifestearlyinlife,whereasinasub-
.
also frequently recognized and ablated.280,295,296 Intervention to .. stantial proportion of patients AVNRT starts later, e.g. in the
.
treat these tachycardias after the initial procedure should be .. fourthorfifthdecadeoflife.318One-halfofthepatientswithminimal
.
delayed, if possible, for >_3 months. As part of the maturation .. symptoms and short-lived, infrequent episodes of tachycardia may
.
processofthedeployedlesions,sometachycardiasmaybetransi- .. become asymptomatic within the next 13 years.319 AVNRT may
.
entinnature,311andinitialratecontroland/oruseofantiarrhyth- .. resultinAFthatusually,althoughnotinvariably,iseliminatedfollow-
.
micdrugsisfavoured. .. ing catheter ablation of AVNRT.320 Familial AVNRT should be
.
.. considered.321
.
11.2 Atrioventricular junctional ..
.
.
arrhythmias . 11.2.1.1Diagnosis
.
.
.
11.2.1Atrioventricularnodalre-entranttachycardia .
.
AVNRTdenotesre-entryintheareaoftheAVN,buttheexactcir-
.. 11.2.1.1.112leadelectrocardiogramduringtachycardia.Typically,
.
. AVNRTisanarrowcomplextachycardia,i.e.QRSduration<120ms,
cuitremainselusive.TheAVNisathree-dimensionalstructurewith .
.
. unlessthereisaberrantconduction,whichisusuallyoftheRBBBtype,
greatervariabilityinthespaceconstantoftissue,andpoorgapjunc- ..
. orapreviousconductiondefectexists(Figure13).AVdissociationis
tionconnectivityduetodifferentialexpressionofconnexinisoforms, ..
. exceptionallyuncommon,butitcanoccurasneithertheatrianorthe
conditionsthatprovideanexplanationfordualconductionandnodal ..
re-entrantarrhythmogenesis.312(cid:2)314 There hasalso beenconsider- ... ventriclesarenecessaryforthere-entrycircuit.Thus,coexistencewith
ablehistologicalandelectrophysiologicalevidencethattherightand
... AF or AV conduction block is possible but rare.66,322 ST-segment
leftinferiorextensionsofthehumanAVN,andtheatrionodalinputs
... depressionmaybeseenduringorafterthetachycardia.
thattheyfacilitate,mayprovidetheanatomicalsubstratefortheslow
... InthetypicalformofAVNRT(alsocalledslow(cid:2)fastAVNRT),
pathway.315,316 Thus, comprehensive models of the tachycardia .. retrogradePwavesareconstantlyrelatedtotheQRSand,inthe
A B C
I
II
III
aVR
aVL
aVF
V1
V2
V3
V4
V5
V6
25 mm/sec
Figure13 Atrioventricularnodalre-entranttachycardia.(A)Typicalatrioventricularnodalre-entranttachycardia.(B)Atypicalatrioventricularnodalre-
entranttachycardia.(C)AtypicalAVNRTwith(unusual)leftbundlebranchblockaberration.RetrogradePwavesareindicatedbyarrows.
9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 30 ---
684 ESCGuidelines
.
.. patientsmaycoexistwiththetypicalform.329Ahigherincidenceof
T ena tb rl ae n1 t2 tachC yl ca as rs difi iaca tt yi po en so 32f 4atrioventricularnodalre- ....
atypical AVNRT has been documented in athletes.330 In the so-
.
. called‘fast(cid:2)slowformofAVNRT,retrogradeatrialelectrograms
.
HA VA(His) AH/HA .. begin well after ventricular activation with an AH/HA ratio <1,
.
TypicalAVNRT <_70ms <_60ms >1 .. indicating that retrograde conduction is slower than antegrade
.
AtypicalAVNRT >70ms >60ms Variable .. conduction. The AH interval is <185(cid:2)200 ms. The VA interval
.
.
Atypicalatrioventricularnodalre-entranttachycardiahasbeentraditionallyclassi- .. measuredfromtheonsetofventricularactivationonsurfaceECG
fiedasfast(cid:2)slow(His(cid:2)atrial>70ms,ventriculoatrial>60,atrial(cid:2)His/His(cid:2)atrial .. totheearliestdeflectionoftheatrialactivationintheHisbundle
.
<1,andatrial(cid:2)His<200ms)orslow(cid:2)slow(His(cid:2)atrial>70ms,ventriculoatrial .
. electrogramis>60ms.Earliestretrogradeatrialactivationhasgen-
interval>60ms,atrial(cid:2)His/His(cid:2)atrial>1,andatrial(cid:2)His>200ms).Intermediate, ..
unclassifiedtypesmayalsoexist.AH=atrial(cid:2)Hisinterval;AVNRT=atrioven- .. erallybeenreportedatthebaseofthetriangleofKoch,nearthe
.
tricularnodalre-entranttachycardia;HA=His(cid:2)atrialinterval;VA=ventriculoa- .. coronarysinusostium,butitcanbevariable,witheccentricatrial
trialintervalmeasuredfromtheonsetofventricularactivationonsurfaceECGto .
theearliestdeflectionoftheatrialactivationontheHisbundleelectrogram.
... activation at the lower septum or even the distal coronary
.. sinus.328,331,332 In the ‘slow(cid:2)slow’ form, the AH/HA ratio is >1
.
.. andtheAHinterval>200ms,buttheVAintervalis>60ms,sug-
.
.. gestingthattwoslowpathwaysareutilizedforbothanterograde
.
majorityofcases,areindiscernibleorveryclosetotheQRScom-
... and retrograde activation. Earliest retrograde atrial activation is
plex. Thus, P waves are either masked by the QRS complex or
... usuallyatthecoronarysinusostium,butvariantsofleft-sidedatrial
seen as a small terminal P’ wave that is not present during sinus
... retrogradeactivationhavealsobeenpublished.333,334Thedistinc-
rhythm.323 ... tionbetween‘fast(cid:2)slow’and‘slow(cid:2)slow’formsisofnopractical
.. significance,andcertaincasesofatypicalAVNRTcannotbeclassi-
IntheatypicalformofAVNRT,Pwavesareclearlyvisiblebefore .
.. fiedaccordingtodescribedcriteria.324Thereisalsoevidencethat
theQRS,i.e.RP>PR,denotingalongRPtachycardia,andarenegative .
orshallowinleadsII,III,aVF,andV6,butpositiveinV1.317 ... the‘fast’pathwayduringslow(cid:2)fastAVNRTisnotidenticaltothe
.. ‘fast’ component of so-called fast(cid:2)slow AVNRT.329 Therefore,
Tachycardia-relatedST-segmentdepression,RR-intervalvaria- .
.
. AVNRTcanbeclassifiedastypicaloratypicalaccordingtotheHA
tion, as well as QRS alternans may be seen. Specific, although .
.
. interval, or—when a His bundle electrogram is not reliably
modestly sensitive, ECG criteria for AVNRT, as opposed to AT .
.
. recorded—accordingtotheVAintervalmeasuredontheHisbun-
and AVRT, are a pseudo Rdeflection inlead V1and a pseudo S .
.. dlerecordingelectrode.322Table12presentsaconventionalclassi-
waveintheinferiorleads,anotchinleadaVL,andapseudoRin .
aVR.45Ifthetachycardiaisinitiatedbyatrialectopicbeats,theini-
... ficationsystem.Otherapproacheshavealsobeenpublished.335
.
.
tial (ectopic) P wave usually differs from the subsequent (retro- ..
. 11.2.1.2Therapy
grade)Pwaves. .
11.2.1.1.2 Electrophysiology study. Heterogeneity of both fast and Recommendationsforthemanagementofatrioventric-
slowconductionpatternshasbeenwelldescribed,andallformsof ularnodalre-entranttachycardia(AVNRT)
AVNRTmaydisplayanterior,posterior,andmiddle,orevenLAret-
Recommendation Classa Levelb
rograde,activationpatterns.322(cid:2)324Thus,specificelectrophysiologi-
calmanoeuvresmayberequiredfordifferentialdiagnosisoftypical Acutetherapy
and, especially, atypical AVNRT from focal AT or AVRT due to a Haemodynamicallyunstablepatients
concealedseptalpathway.45Therareformofverapamil-sensitiveAT
SynchronizedDCcardioversionisrecommended
isduetore-entryintheatrialtissueclosetotheAVN,butnotthe forhaemodynamicallyunstablepatients.86(cid:2)88 I B
AVnodalconductingsystem.325
Haemodynamicallystablepatients
Vagalmanoeuvres,preferablyinthesupineposi-
11.2.1.1.3Typicalatrioventricularnodalre-entranttachycardia.In I B
tionwithlegelevation,arerecommended.41,89(cid:2)91
theslow(cid:2)fastformofAVNRT,theonsetofatrialactivationappears
Adenosine(6(cid:2)18mgi.v.bolus)isrecommended
before,attheonsetof,orjustaftertheQRScomplex,thusmaintain- I B
ifvagalmanoeuvresfail.92(cid:2)94
inganAH/His(cid:2)atrial(HA)ratio>1.TheVAintervalmeasuredfrom
Verapamilordiltiazemi.v.shouldbeconsideredif
the onset of ventricular activation on surface ECG to the earliest IIa B
vagalmanoeuvresandadenosinefail.92,94(cid:2)98
deflectionoftheatrialactivationintheHisbundleelectrogramis<_60
ms. Although, the earliest retrograde atrial activation is typically Beta-blockers(i.v.esmololormetoprolol)should
recorded at the His bundle electrogram, careful mapping studies beconsideredifvagalmanoeuvresandadenosine IIa C
havedemonstratedthatposteriororevenleftseptalfastpathways
fail.97,99,100
mayoccurin<_7.6%inpatientswithtypicalAVNRT.326(cid:2)328 SynchronizedDCcardioversionisrecommended
whendrugtherapyfailstoconvertorcontrolthe I B
11.2.1.1.4 Atypical atrioventricular nodal re-entrant tachycardia.
tachycardia.87,88
AtypicalAVNRTisseenin(cid:4)6%ofallAVNRTcases,317andinsome Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 31 ---
ESCGuidelines 685
.
.. theyarelesssuccessfulinAVNRTthaninAVRT.89,90,102Asingle
Chronictherapy .
.
. doseoforaldiltiazem(120mg)plusabeta-blocker(i.e.proprano-
Catheterablationisrecommendedforsympto-
I B
...
lol 80 mg) may convert <_94% of patients, but there is a risk of
matic,recurrentAVNRT.208,336(cid:2)339 ...
hypotension, transient AV block, or—rarely—syncope.342,343
Diltiazemorverapamil,inpatientswithoutHFrEF, ..
. Cautionisneededintheelderly,andinpatientswithknownsinus
orbeta-blockersshouldbeconsideredifablation IIa B ..
. orAVnodalconductiondisturbances.Asingledoseoforalflecai-
isnotdesirableorfeasible.340(cid:2)342 ...
nide(3mg/kg)mayalsobeeffective,albeitatalowerrate.342,344
.
Abstinencefromtherapyshouldbeconsidered .. Intranasal etripamil is promising (see section 10.1.1).129 Rarely,
.
forminimallysymptomaticpatientswithvery IIa C .
.. when vagal manoeuvres and adenosine cannot terminate the
infrequent,short-livedepisodesoftachycardia.319 .
.. tachycardiaandhypotensionensues,synchronizedDCcardiover-
.
i.v.verapamilanddiltiazemarecontraindicatedinthepresenceofhypotensionor
.. sionisindicated101(Figure14).
.
HFrEF. .
.
i.v.beta-blockersarecontraindicatedinthepresenceofdecompensatedheart ..
.
failure. . 11.2.1.2.2 Catheter ablation. A recent randomized clinical trial
.
DC=direct-current;HF=heartfailure;HFrEF=heartfailurewithreducedejec- .. (RCT) that compared catheter ablation asfirst-line treatment with
tionfraction;i.v.=intravenous. ..
aClassofrecommendation. .. antiarrhythmicdrugsdemonstratedsignificantbenefitsinarrhythmia-
bLevelofevidence. .. relatedhospitalizations.336Furthermore,catheterablationforSVTin
. .
. general,andAVNRTinparticular,isthecurrenttreatmentofchoice
.
.
. forsymptomaticpatientsbecauseitsubstantiallyimprovesqualityof
.
.. life28,345,346 and reduces costs.347(cid:2)349Slow-pathwaymodificationis
.
AVNRT .. effectiveinbothtypicalandatypicalAVNRT.338Usually,acombined
.
.
. anatomicalandmappingapproachisemployed,withablationlesions
.
.
. deliveredattheinferiorpartofthetriangleofKoch,eitherfromthe
.
.
. rightortheleftseptalside.337(cid:2)339,350,351Thisapproachoffersasuc-
.
Patient out .
of hospital
.. cess rate of 97%, has an (cid:4)1.3(cid:2)4% recurrence rate, and has been
.
Yes No
... associated with a risk of AV block of <1% in previous
.. reports.203,204,352,353Recentexperienceindicatesthatinexperienced
.
.. centres,theprocedurecanbeaccomplishedinbothtypicalandatypi-
manV oa eg ua vl
res
Hae inm sto ad by iln ita ymic ....
calAVNRTwithalmostnoriskofAVblock,bytargetingtheinferior
(I B) .. nodal extension and avoiding the mid-septum, and the roof of the
No Yes .
.. coronarysinus.208,338,354,355 Success rates are lower(82%) and the
.
.. riskofheartblockhigher(14%)inpatientswithadultcongenitalheart
Vagal Synchronized .
manoeuvres cardioversion .. disease(ACHD).356Usually,recurrencesareseenwithin3months
.
(I B) (I B) .. followingasuccessfulprocedureinsymptomaticpatientswhoexpe-
.
If ineffective
... riencefrequentepisodesoftachycardia,317,329,336,338butintheyoung,
.. aged <_18 years, recurrences may be seen as long as 5 years
.
i.v. adenosine .. post-ablation.357 IST may occur, but is usually transient and not (I B) ... frequentfollowingslow-pathwayablation.358Advancedageisnota
.
.. contraindication for slow-pathway ablation.359 The pre-existence
If ineffective .
. . of first-degree heart block carries a higher risk for late AV block
.
. . and avoidance of extensive slow pathway ablation is preferable
.
.. under such conditions.360 There is almost no procedure-related
i. ov r. v de ir lta ip aza em mil
i.v. beta-blocker
....
mortality.11,13,203(cid:2)205,208CryoablationmaycarryalowerriskofAV
(IIa C) .
(IIa B) . block, but is associated with a significantly higher recurrence
.
.. rate.361(cid:2)363Itsfavourablesafetyprofileandhigherlong-termsuccess
.
.
. rate in younger patients make it especially attractive for the treat- .
If ineffective ... ment of children.364 AVNRT is a cause of inappropriate shocks
.
.. in patients with implantable cardioverter defibrillators (ICDs) and,
Figure 14 Acute therapy of atrioventricular nodal re-entrant .
.. in the case of frequent episodes, catheter ablation is clearly
tachycardia. .
.. indicated.365
AVNRT = atrioventricular nodal re-entrant tachycardia; i.v. = .
.
intravenous. ..
.. 11.2.1.2.3 Chronic therapy. Patients with minimal symptoms and
.
.. short-lived,infrequentepisodesoftachycardiacanbefollowed-up
.
11.2.1.2.1 Acute therapy. Most data on the effectiveness of vagal .. withouttheneedforablationorlong-termpharmacologicalther-
.
manoeuvres and adenosine for acute termination of tachycardia .. apy (Figure 15). Approximately one-half of them may become
.
arederivedfrommixedpopulationsofSVT,asdescribedinsection .. asymptomaticwithinthenext13years.319Chronicadministration
.
10.1.1 on the acute therapy of SVT in general, but it seems that .. ofantiarrhythmicdrugsdecreasesthefrequency anddurationof
.
9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by guest
on
22
January
2026
--- Страница 32 ---
686 ESCGuidelines
.
.
. propranolol370 or, in the absence of ischaemic or structural
.
.. heart disease, flecainide380 and propafenone,381 may be tried.
AVNRT ..
. Selective catheter ablation at the site of the earliest retrograde
.
.
. atrial activation is feasible, but carries a lower success rate and
.
.. higher AV block risk compared with AVNRT (5-10%).369,382
.
.. Cryoablationissafer.375,383
Symptomatic and ..
recurrent .. Non-paroxysmaljunctionaltachycardiawasfrequentlydiag-
.
. nosedinthepastasajunctionalrhythmofgradualonsetandter-
.
.
.. mination,witharatebetween70(cid:2)130b.p.m.,andwasconsidered
Yes No .
.. atypicalexampleofdigitalis-inducedDADsandtriggeredactivity
.
.. in the AVN.3 The RP interval during tachycardia is variable.
.
.. Myocardial ischaemia, hypokalaemia, chronic obstructive pulmo-
.
.. narydisease,andmyocarditisarealsoassociatedconditions.
.
Catheter .. Non-re-entrant AV nodal tachycardia caused by simultane-
ab (l Ia Btio )n
No Dr du eg
s
t irh ae br la epy ......
o dou us blm e-u firlt eip ple athn oo lod ga yl op rat dh uw alay AVco nn od du ac lti to acn hy( co af rt de in
a)
c isalle ad
n
.
.. uncommon mechanism of AV nodal tachycardia,384,385 and has
.
Yes .. been associated with repetitive retrograde concealment or
.
.. ‘linking’ phenomena.386(cid:2)388These are expressed in the form
.
.. of ventricular pauses with consistent AV relationship after the
.
Diltiazem or verapamil .. pause,andcanoftenbemisdiagnosedasAF.389Theseextremely
.
If ineffective or beta-blocker .. raretachycardiasmaycauseTCMandrespondtoslow-pathway
or diltiazem ..
plus beta-blocker .. ablation.
(IIa B) ..
.
.
.. 11.3 Atrioventricular arrhythmias
.
.
Figure15 Chronictherapyofatrioventricularnodalre-entranttachy- .. AVRTsuseananatomicallydefinedre-entrantcircuitthatconsistsof
.
cardia. .. two limbs:first, theAVN(cid:2)HPS, and second, anAPalsocalled the
.
AVNRT=atrioventricularnodalre-entranttachycardia. .. bypasstract.Thetwolimbsarecharacterizedbydifferencesinrefrac-
.
.. torinessandconductiontimes,withcriticallytimedprematureatrial
.
.. or ventricularbeatsinitiating re-entranttachycardia.Onrareocca-
.
AVNRT,buthasavariablesuccessratein abolishingtachycardia .. sions,thecircuitconsistsoftwoAPs.
.
episodes,rangingfrom13-82%,and<_20%ofpatientsmaydiscon- ..
.
tinuetherapy.323Inviewoftheexcellentsuccessrateandminimal ..
riskofcatheterablationinsymptomaticcases,thevalueoflong-
... 11.3.1Accessorypathways
termantiarrhythmicdrugtherapyseemsverylimited.
... APsaresingleormultiplestrandsofmyocardialcellsthatbypass
.. the physiological conduction system, and directly connect atrial
. .. andventricularmyocardium.390TheseAVconnectionsaredueto
.
11.2.2Non-re-entrantjunctionaltachycardias .. incompleteembryologicaldevelopmentoftheAVannuli,without
.
.
Junctionalectopictachycardia(JET),orfocaljunctionaltachy- . complete separation of the atria and ventricles. While there are .
.
cardia, is an uncommon arrhythmia that arises from abnormal . differenttypesofAPs,themostcommonarethosethatconnect .
.
automaticityattheAVNorproximalHisbundle.Focaljunctional . theatriumandtheventriclealongthemitralortricuspidannulus.
.
.
tachycardiainchildrenmaybeseenasacongenitalarrhythmiaor, . Approximately 60% are located along the mitral valve and are
.
more often, early after infant open-heart surgery.366,367 .. referredtoasleftfreewallAPs,25%insertalongtheseptalaspect
.
.
Congenital junctional tachycardia carries considerable morbidity . ofthemitralortricuspidannulus,and(cid:4)15%insertalongtheright
.
and mortality.368 Junctional tachycardia can also be seen in adult .. freewall.391(cid:2)393Becauseventricularmuscleislackingintheprox-
.
patientswithastructurallynormalheart,369,370andhasinthepast .. imityoftheanteriorleafletofthemitralvalve,left-sidedAPsare
.
beenassociatedwithnon-fibrinolysedacuteMI.371TheusualECG .. usually limited to the region of the mitral annulus at the attach-
.
.
findinginJETisanarrowQRStachycardiawithashortRPinterval . mentofthemural(posterior)leaflet.APslocatedinthesupero-
.
.
orAVdissociation.Occasionally,thetachycardiamightbeirregu- . paraseptalareaincloseproximitytotheHisbundleandAVNmay
.
.
larandresembleAF. .. alsooccur.394
.
Propranolol(i.v.)withorwithoutprocainamide,370verapamil, .. APspresentcharacteristicelectrophysiologicalfeaturesthatdiffer
.
orprocainamide,372orflecainide,373maybeusedforacutether- .. fromAVnodalconductionproperties.Theytypicallyexhibitfastcon-
.
apy,butdataarescarce.Amiodarone(i.v.)isthedrugofchoice .. duction(withtheexceptionofatypicalpathways-seesection11.3.9),
.
forpost-operativeJETaswellasforpreventingearlyJETinchil- .. dependentona sodiumcurrentsimilar to that ofmyocardialcells.
.
dren afteropen-heartsurgery.374,375 Inchildrenwith congenital .. Moreover,althoughamajorityofAPsconductbothantegradelyand
.
junctional tachycardia, amiodarone alone, or with propafenone .. retrogradely,somepropagateimpulsesinonlyonedirection.Those
.
or ivabradine, appears effective.368,376(cid:2)379 For chronic therapy, . thatconductintheantegradedirectiononlyareuncommon(<_10%),
9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 33 ---
ESCGuidelines 687
.
.
whereas those that conduct in the retrograde direction only are . QRS complex (>120 ms). In most cases, APs giving rise to the
.
.
morefrequent(<_50%).WhentheAPconductsantegradely,ventric- . WPWpatternareseeninstructurallynormalhearts.Rare,familial
.
.
ularpre-excitationisusuallyevidentatrestduringsinusrhythmand . formsofpre-excitationassociatedwithLVhypertrophyandmulti-
.
.
theAPisreferredtoas‘manifest’.Conversely,APsarereferredtoas . system disease [mutations in the protein kinase adenosine
.
.
‘concealed’iftheyexclusivelyconductretrogradely.ConcealedAPs . monophosphate-activated non-catalytic subunit gamma 2
.
mayhave decrementalproperties.395The term‘latentAP’denotes .. (PRKAG2) gene, Danon and Fabry disease, and others] have also
.
.
anAPthatisnot,orisbarely,visibleduetolocationorfasterconduc- . beendescribed.398
.
.
tionthroughtheAVN. .. SeveralsurfaceECGalgorithmshavebeendevelopedthatcanbe
.
MultipleAPsoccurin<_12%ofpatientswithpre-excitation,andin .. applied for the localization of APs in the presence of overt pre-
.
<_50%inpatientswithEbstein’sanomaly.396 .. excitation (Figures 16and 17).399(cid:2)401 Pre-excitation on thesurface
.
AVRTisthemostcommontachycardiaassociatedwithAPs.Two .. ECG can be intermittent and can even disappear permanently (in
.
mechanismsofre-entryarepossibleaccordingtotheantegradeor .. <_35% of cases) over time. Furthermore, various degrees of pre-
.
retrograde conduction over the AVN(cid:2)HPS, and are classified as .. excitationarepossibledependingonthelocationoftheAPaswellas
.
orthodromicandantidromicAVRT. .. onAVNconductionproperties.
.
.
.
.
.
11.3.2Wolff(cid:2)Parkinson(cid:2)Whitesyndrome .. 11.3.3Orthodromicatrioventricularre-entrant
. WPWsyndromereferstothepresenceofanovert(manifest)AP, .. tachycardia
.
thusresultingintheso-calledpre-excitation,incombinationwith .. Orthodromic AVRT accounts for >90% of AVRTs and for
.
usuallyrecurrenttachyarrhythmias.397Duringsinusrhythm,atyp- .. 20-30%of all sustainedSVTs.The re-entrantimpulse conducts
.
icalpatternintherestingECGwiththefollowingcharacteristicsis .. fromtheatriumtotheventriclethroughtheAVN(cid:2)HPS,whichis
.
present:(i)ashortPRinterval(<_120ms);(ii)slurredupstroke(or .. the anterograde limb of the re-entrant circuit, whereas the AP
.
downstroke) ofthe QRScomplex(‘deltawave’);and (iii)awide . conducts from the ventricle to the atrium, and serves as the
Figure16 TheStGeorge’salgorithmforthelocalizationofaccessorypathways.399þve=QRScomplex-positive;(cid:2)ve=QRScomplex-negative;þ/-=
QRScomplexequiphasic;AP=accessorypathway;LAL=leftanterolateral;LP=leftposterior;LPL=leftposterolateral;LPS=leftposteroseptal;MS=
mid-septal;RAS=rightanteroseptal;RL=rightlateral;RP=rightposterior;RPS=rightposteroseptal.
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 34 ---
688 ESCGuidelines
Figure17 Localizationofaccessorypathwaysinthepresenceofmaximum(spontaneousorevoked)pre-excitation.400Accessorypathwaylocations
aregreenwhenright-sidedandredwhenleft-sided.Leftposterolateralaccessorypathwayscanhave0,1,or2inferiorleadswithpositivepolarity,whereas
nodo-Hisianaccessorypathwayscanhave1,2,or3inferiorleadswithpositivepolarity.Right-sidedaccessorypathwaysareframedorangeoryellowwhen
theV3leadisnegativeorpositive,respectively.LeftposterioraccessorypathwaysareframedbluewhentheV1/Iratiois<1orpurplewhenV1/Iratiois
>_1.AP=accessorypathway;DCS=deepcoronarysinus;LL=leftlateral;LPL=leftposterolateral;LPS=leftparaseptal;NH=nodo-Hisian;RA=right
anterior;RL=rightlateral;RP=rightposterior;RPS=rightparaseptal.
.
.
retrograde limb of the re-entrant circuit. Orthodromic .. difficult to assess as the retrograde P wave is usually inscribed
.
AVRT tends to be a rapid tachycardia, with frequencies .. withintheST-Tsegment.
.
ranging from 150 to, rarely, >220 b.p.m. During tachycardia ..
.
(Figure 18), the following ECG features can be present: (i) RP .. 11.3.5Accessorypathwayasabystander
.
intervalconstantand,usuallybutnotinvariably,uptoone-halfof ... InthepresenceoffocalAT,atrialflutter,AF,orAVNRT,theQRS
the tachycardia CL; (ii) narrow QRS; (iii) functional BBB usually ... complexescanbepre-excitedwhentheAPactsasabystander,and
associatedwithanAPipsilateraltotheblockedbundle,especially ...
isnotacriticalpartofthere-entrycircuit.
in young patients (aged <40 years); and (iv) ST-segment ..
.
depression. ..
. 11.3.6Pre-excitedatrialfibrillation
.
.
.. ParoxysmalAFhasbeenfoundin50%ofpatientswithWPW,and
.
11.3.4Antidromicatrioventricularre-entranttachycardia .. may be the presenting arrhythmia in affected patients.405,406
.
Antidromic AVRT occurs in 3-8% of patients with WPW syn- .. These patients are typically young and have no structural heart
.
drome.402(cid:2)404There-entrantimpulsetravelsfromtheatriumto .. disease. High-rate AVRT may potentially initiate AF. AF with
.
theventriclethroughtheAPwithanterogradeconduction;mean-
.. fastventricularresponseoveranovertAPwithashortanterog-
.
while, retrograde conduction occurs over the AVN or another .. raderefractoryperiodisapotentiallylife-threateningarrhythmia
.
AP, usually located in a contralateral position to ensure longer ... in patients with WPW syndrome, due to potential degeneration
traveldistances,thusallowingforsufficientrecoveryofrefractori-
... intoVF.
.
ness of the respective elements of the re-entrant circuit. In ..
.
30-60%ofpatientswithspontaneousantidromicAVRT,multiple .. 11.3.7Concealedaccessorypathways
.
APs(manifestorconcealed),whichcouldactornotastheretro- .. ConcealedAPsgiveriseonlytoorthodromicAVRT.Theirtrueprev-
.
gradelimbduringtheAVRT,maybedetected.AntidromicAVRT .. alence is unknown because they are not detectable on the resting
.
hasthefollowingECGfeatures,illustratedinFigure18:(i)awide .. surface ECG, but only at occurrence of AVRT, or during electro-
.
QRS complex (fully pre-excited) and (ii) an RP interval that is . physiologytesting.45Nosexpredilectionisfoundandthesepathways
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 35 ---
ESCGuidelines 689
I
I
II
II
III
III
aVR
aVR aVL
aVL aVF
aVF
V1
V1
V2
V2
V3
V3
V4
V4
V5
V5
V6
V6
Figure18 Atrioventricularre-entranttachycardia.Left:othodromicatrioventricularre-entranttachycardiaduetoaconcealedposteroseptalaccessory
pathway.RetrogradePwavesarenegativeduringtachycardiaintheinferiorleads(arrows).Right:Antidromicatrioventricularre-entranttachycardiadue
toanatriofascicularaccessorypathway.Theaxisduringtachycardiaduetoatypicalpathwaysdependsonthewayofinsertionintotherightbundleand
fusionovertheleftanteriorfascicle.
.
.
tendtooccurmorefrequentlyinyoungerpatientsthaninthosewith .. OtherpotentialcausesoflongRPtachycardiasaresinustachycar-
.
AVNRT;however,significantoverlapexists.3ConcealedAPsarepre- .. dia,AT,atypicalAVRT,andJETwith1:1retrogradeconduction.
.
dominantlylocalizedalongtheleftfreewall(64%),andlessfrequently ..
.
atseptal(31%)andrightfreewalllocations.395Clinicalpresentation .. 11.3.9Atypicalformsofpre-excitation
.
is with AVRT. Concealed pathways are not associated with an .. OtherAPsarepostulatedtoresultincardiacpre-excitation.Atypical
. increased riskof sudden cardiac death. The management of AVRT .. APs(also called Mahaim fibers)are connectionsbetween the right
.
duetoaconcealedAPissimilartothatofanovertAP,butinthis .. atriumortheAVNandtherightventricle,intoorclosetotheright
.
caseisrelatedtosymptomswithoutsignificantprognosticrelevance .. bundlebranch.409(cid:2)414Mostofthemareatriofascicularornodoven-
.
inmostcases. .. tricular (as initially described), but they can also be atriofascicular, .
.. atrioventricular, nodofascicular, or nodoventricular, depending on
.
.. theirvariableproximalanddistalinsertions.413,414Left-sidedatypical
.
11.3.8Permanentjunctionalreciprocatingtachycardia
.. pathwayshavealsobeendescribedbutareextremelyrare.415(cid:2)417
.
PJRTisarareformofAVreciprocatingtachycardiausingaconcealed .. Atypical pathways usually contain accessory nodal tissue, which
.
AP.UsuallytheseAPs,originallydescribedbyCoumel,arelocatedin .. resultsindecrementalproperties,andconnecttheatriumtothefas-
.
theposteroseptalregionandareassociatedwithretrogradedecre- .. ciclesbycrossingthelateralaspectofthetricuspidannulus,butpost-
.
mentalconductionproperties.407PJRTisalongRPtachycardiadue .. eroseptal locations can also be found in rare cases. Conduction is
.
totheslowconductionpropertiesoftheAP,andischaracterizedby ... usually anterograde only, but concealed fibres have also been
deeplyinvertedretrogradePwavesinleadsII,III,andaVFduetothe ... described.412,418 The following properties define the behaviour of
.
retrogradenature ofatrialactivation.The incessantnature ofPJRT .. atypicalpathways:
.
mayresultinTCMthatusuallyresolvesaftersuccessfultreatmentby ...
• Baseline normal QRS or different degrees of manifest pre-
radiofrequency catheter ablation, particularly in younger ..
excitationwithLBBBmorphology;
.
patients.407,408Catheterablationisstronglyrecommendedinsymp- ..
• Programmed atrial pacing, leading to obvious manifest pre-
.
tomaticpatientsorincaseswithimpairedLVejectionfractionlikely .. excitation following an increase in AV interval along with short-
.
relatedtoTCM. . eningoftheHVintervalatshorterpacingCLs;
9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 36 ---
690 ESCGuidelines
.
.
• AntidromicAVRTduetoanatriofascicularpathwayusuallypro- . conductioncouldalsoinduceventricularfibrillation,thereforeelectrical
.
ducesahorizontalorsuperiorQRSaxis,butanormalaxismay .. cardioversionshouldalwaysbeavailable.Duringorthodromicandanti-
.
alsooccur,dependingonthewayofinsertionintotherightbun- .. dromicAVRT,drugtherapycouldbedirectedatoneofthecomponents
.
dleandfusionovertheleftanteriorfascicle. ..
ofthe circuit,the AVN (beta-blockers,diltiazem, verapamil,or etripa-
.
• RightbundleelectrogramprecedingHisbundleactivationduring .. mil),100,129,419,420ortheAP(ibutilide,procainamide,propafenone,orfle-
.
anterogradepre-excitationandSVT. .. cainide)421,422(Figure19).AntidromicAVRTisassociatedwithmalignant
.
.
Mapping identifies the proximal and distal insertion ofaccessory .. WPWsyndromeduetoaveryfast-conductingAP,403anddrugsacting
.
fibres,anddemonstratespathwaypotentialsinmostcasesthatthen .. mainlyontheAPshouldbepreferred.Inaddition,incaseofantidromic
.
guideablation.409,411Catheterablationisassociatedwithahighsuc- .. AVRTwithAPsrepresentingboththeanterogradeandretrogradelimb,
.
cessrateandlowrecurrencerates,andisthereforerecommended .. drugsactingontheAVNareineffective.Indrug-refractoryantidromic
.
for all patients with recurrent symptomatic tachycardia, and espe- .. AVRT,amiodaronemayalsobeconsidered.423(cid:2)425
.
cially incessant tachycardias due to concealed nodofascicular or .. Inpatientspresentingwithpre-excitedAF,urgentcardioversionis
.
nodoventricularpathways.418Preventiveablationforprognosticrea- .. usuallyrequiredandthethresholdfortheuseofelectricalcardiover-
.
sonsisnotroutinelyrecommended,noteveninpatientswithpre- .. sionislower.Conductionofelectricalimpulsescanoccurpreferen-
.
excitationorBBBinthesurfaceECG,asfastconductionviatheAPis
.. tiallyviatheAPduetoitsshorterRPcomparedwiththeAVN.426
.
unlikelyduetodecrementalconductionproperties. .. Accordingly,anyAVN-modulatingagents(adenosine,verapamil,dil-
.
.. tiazem,beta-blockers,ordigoxin)shouldbeavoidedinpre-excited
.
.. AF asthey maycontributeto a riskofventricular fibrillation.427,428
11.3.10Therapy ..
. Pharmacologicalcardioversionofpre-excitedAFordelayedAPcon-
11.3.10.1Acutetherapy ...
ductioncanbeachievedwithibutilide(Figure20).421Drugssuchas
Adenosine should be used with caution for the treatment of AVRT ..
. procainamide, propafenone, or flecainide, which affect conduction
becauseofpotentialinductionoffastAF.119,120,272AFwithfastventricular .
Recommendationsforthetherapyofatrioventricularre-entranttachycardiaduetomanifestorconcealedaccessory
pathways
Recommendation Classa Levelb
Acutetherapy
Haemodynamicallyunstablepatients
SynchronizedDCcardioversionisrecommendedforhaemodynamicallyunstablepatients.86(cid:2)88 I B
Haemodynamicallystablepatients
Vagalmanoeuvres,preferablyinthesupinepositionwithlegelevation,arerecommended.41,89(cid:2)91 I B
InorthodromicAVRT,adenosine(6(cid:2)18mgi.v.bolus)isrecommendedifvagalmanoeuvresfailandthetachycardiais
I B
orthodromic.92(cid:2)94
InorthodromicAVRT,i.v.verapamilordiltiazemshouldbeconsideredifvagalmanoeuvresandadenosinefail.92,94(cid:2)98 IIa B
InorthodromicAVRT,i.v.beta-blockers(esmololormetoprolol)shouldbeconsideredintheabsenceofdecompensatedHF,if
IIa C
vagalmanoeuvresandadenosinefail.97,99,100
InantidromicAVRT,i.v.ibutilideorprocainamideori.v.flecainideorprofanenoneorsynchronizedDCcardioversionshouldbe
IIa B
consideredifvagalmanoeuvresandadenosinefail.421,422,429,437
InantidromicAVRT,i.v.amiodaronemaybeconsideredinrefractorycases.423(cid:2)425,435 IIb B
SynchronizedDCcardioversionisrecommendedwhendrugtherapyfailstoconvertorcontrolthetachycardia.87,88 I B
Chronictherapy
CatheterablationofAP(s)isrecommendedinpatientswithsymptomatic,recurrentAVRT.391(cid:2)393,438(cid:2)441 I B
Beta-blockersornon-dihydropyridinecalcium-channelblockers(verapamilordiltiazemintheabsenceofHFrEF)shouldbeconsid-
IIa B
eredifnosignsofpre-excitationarepresentonrestingECG,ifablationisnotdesirableorfeasible.340,341,442,443
PropafenoneorflecainidemaybeconsideredinpatientswithAVRTandwithoutischaemicorstructuralheartdisease,ifablation
IIb B
isnotdesirableorfeasible.429,444,445
Digoxin,beta-blockers,diltiazem,verapamil,andamiodaronearenotrecommendedandarepotentiallyharmfulinpatientswith
III B
pre-excitedAF.427,428,432(cid:2)434,446
i.v.verapamilanddiltiazemarecontraindicatedinthepresenceofhypotensionorHFrEF.
i.v.beta-blockersarecontraindicatedinthepresenceofdecompensatedheartfailure.
i.v.ibutilideiscontraindicatedinpatientswithprolongedQTcinterval.
i.v.procainamideprolongstheQTcintervalbutmuchlessthanclassIIIagents.
i.v.flecainideandpropafenonearecontraindicatedinpatientswithischaemicorstructuralheartdisease.TheyalsoprolongtheQTcintervalbutmuchlessthanclassIIIagents.
i.v.amiodaroneprolongstheQTcbuttorsadesdespointesisrare.
AF=atrialfibrillation;AP=accessorypathway;AVRT=atrioventricularre-entranttachycardia;DC=direct-current;ECG=electrocardiogram;HFrEF=heartfailurewith
reducedejectionfraction;i.v.=intravenous.
aClassofrecommendation.
bLevelofevidence.
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 37 ---
ESCGuidelines 691
AVRT
Patient out
of hospital
Yes No
Vagal
manoeuvres Haemodynamic
(I B) instability
No Yes
Vagal Synchronized
manoeuvres cardioversion
(I B) (I B)
If ineffective
Orthodromic
Yes No
i.v. adenosine i.v. ibutilide
(I B) or procainamide If ineffective
or i.v. propafenone or flecainide
or synchronized, cardioversion
If ineffective
(IIa B)
i.v. verapamil
i.v. beta-blocker
or diltiazem
(IIa C)
(IIa B)
If ineffective
Figure19Acutetherapyofatrioventricularre-entranttachycardia.
AVRT=atrioventricularre-entranttachycardia;i.v.=intravenous.
Recommendationsfortheacutetherapyofpre-excitedatrialfibrillation
Recommendation Classa Levelb
Haemodynamicallyunstablepatients
SynchronizedDCcardioversionisrecommendedinhaemodynamicallyunstablepatients.86,130 I B
Haemodynamicallystablepatients
Ibutilideorprocainamide(i.v.)shouldbeconsidered.421,430,436 IIa B
Flecainideorpropafenone(i.v.)maybeconsidered.429,431 IIb B
SynchronizedDCcardioversionisrecommendedifdrugtherapyfailstoconvertorcontrolthetachycardia.86,130 I B
Amiodarone(i.v.)isnotrecommended.432(cid:2)435 III B
i.v.ibutilideiscontraindicatedinpatientswithprolongedQTcinterval.
i.v.procainamideprolongstheQTcintervalbutmuchlessthanclassIIIagents.
i.v.flecainideandpropafenonearecontraindicatedinpatientswithischaemicorstructuralheartdisease.TheyalsoprolongtheQTcintervalbutmuchlessthanclassIIIagents.
DC=directcurrent.
aClassofrecommendation.
bLevelofevidence.
9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 38 ---
692 ESCGuidelines
Pre-excited AF AVRT
Haemodynamic Symptomatic and
instability recurrent
Yes No
No Yes
Catheter Drug therapy
ablation No desirable
(I B)
Synchronized
cardioversion
Yes
(I B)
Orthodromic
i.v. ibutilide i.v. flecainide or AVRT
or procainamide propafenone
No Yes
(IIa B) (IIb B)
Diltiazem Propafenone
If ineffective or verapamil
or flecainide
If ineffective (IIb B) ineffeIf
ctive
or be (t IIa a- b Blo )cker
Figure20Acutetherapyofpre-excitedatrialfibrillation.
AF=atrialfibrillation;i.v.=intravenous.
Figure21 Chronictherapyofatrioventricularre-entranttachycardia.
AVRT=atrioventricularre-entranttachycardia.
overthe AP,mayalsobe used,even if theymaynotrestore sinus
rhythm.429(cid:2)431However,classIcdrugsshouldbeusedwithcaution ...
The 2015 American College of Cardiology/American Heart
.
astheydoexertaneffectontheAVN.Inpre-excitedAF,i.v.amio- .. Association/HeartRhythmSocietyGuidelinefortheManagement
.
daronemaynotbeassafeaspreviouslythought,becauseenhanced .. of Adult Patients With Supraventricular Tachycardia reported
.
pathwayconductionandventricularfibrillationhavebeenreported, .. major complication rates after radiofrequency catheter ablation
and should not be considered.432(cid:2)435 Procainamide appears to be ... of3.0and2.8%forAVNRTandAVRT,respectively.2Theserates
.
saferinthissetting.436 ..
are much higher than those reported by experienced electro-
.
.
. physiologistsinthecurrentera,assummarizedinTable9,butthe
.
11.3.10.2Catheterablation .. procedure still carries a very small, non-negligible, mortality
.
Thetreatmentofchoiceforpatientswithsymptomaticandrecur- .. risk.203,205
.
rentAVRT,orpre-excitedAF,iscatheterablation(Figure21).For ..
.
otherpatientswithasymptomaticandinfrequentepisodes,thera- .. 11.3.10.3Chronictherapy
.
peuticdecisionsshouldbebalancedbetweentheoverallrisksand .. If ablation is not desirable or feasible in patients with pre-
.
benefits of the invasive nature ofablation vs.long-term commit- .. excitationandsymptomaticantidromicAVRT,andinwhomstruc-
.
ment to pharmacological therapy. Ablation of the AP has a high .. turalorischaemicheartdiseasehasbeenexcluded,classICantiar-
.
acutesuccessrateandisassociatedwithalowcomplicationrate .. rhythmic drugs act mainly on the AP and can be used in
. dependingonthepathwaylocation(Table9).391(cid:2)393,438(cid:2)440Major ... antidromic tachycardia (Figure 21).429,437,444,445 In cases of pre-
complications include cardiactamponade (0.13(cid:2)1.1%) and com- ... excitedAF,cautionshouldbetakennottotransformitintoatrial
pleteAVblock(0.17(cid:2)2.7%)inpatientsinwhomablationofseptal ... flutterandinduce1:1conduction.ApartfromclassICdrugs,beta-
.
APsisattempted.WithseptalAPsclosetotheAVN,theECGtyp- .. blockers,diltiazem,orverapamilmayalsobeconsideredincaseof
.
icallydisplaysapositivedeltawaveinleadsavFandavL,andanar- .. orthodromic tachycardias if no signs of pre-excitation are
.
rowpositivedeltawaveinleadV1thathasaprominentlynegative .. observedontherestingECG.340,341,442,443
QRScomplex.394 ..
.
.
Whentargetingseptalpathwaysandapplyingcryoenergy,theinci- .
.
denceofAVblockislowercomparedwithradiofrequencyenergy.447 ... 11.3.11Theasymptomaticpatientwithpre-excitation
.
However, recurrence of previously blocked pathways has been .. Most patients with an asymptomatic WPW pattern will go
reported to be significantly higher when cryoenergy is applied.438 ... throughlifewithoutanyclinicaleventsrelatedtotheirventricular
.
Twoapproachesareavailableforleft-sidedpathways:anantegrade .. pre-excitation.Approximatelyoneinfivepatientswilldevelopan
.
transseptalandaretrogradeaorticapproach.Thereisevidencethat .. arrhythmiarelated totheirAPduringfollow-up. Themostcom-
.
the transseptal approach, in experienced hands, results in reduced .. monarrhythmiainpatientswithWPWsyndromeisAVRT(80%),
.
radiationandproceduretimes.441,448 . followed by a 20(cid:2)30% incidence of AF. Sudden cardiac death
9102
CSE© 9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 39 ---
ESCGuidelines 693
secondarytopre-excitedAFthatconductsrapidlytotheventricle
Recommendationsforthemanagementofpatientswith
overtheAP,resultinginventricularfibrillation,isthemostfeared asymptomaticpre-excitation
manifestationofWPWsyndrome.Theriskofcardiacarrest/ven-
tricular fibrillation has been estimated at 2.4 per 1000 person- Recommendation Classa Levelb
years (95% confidence interval 1.3(cid:2)3.9), but no deaths were
PerformanceofanEPS,withtheuseofisopre-
reported in a registry of 2169 patients over an 8 year follow-up
naline,isrecommendedtoriskstratifyindivid-
period.439 However, in a Danish registry of 310 individuals with
ualswithasymptomaticpre-excitationwho
pre-excitation(agerange8(cid:2)85years),therewasagreaterriskof I B
havehigh-riskoccupations/hobbies,candthose
AFandHF,drivenbyarightanteroseptalAP,andinpatientsaged
whoparticipateincompetitive
>65 years there was also a statistically significant higher risk of
athletics.439,450(cid:2)452,454(cid:2)460
death.22
Catheterablationisrecommendedinasymp-
Clinical and electrophysiological features associated with an
tomaticpatientsinwhomelectrophysiology
increased risk of sudden cardiac death include younger
testingwiththeuseofisoprenalineidentifies
age,439,449,450 inducibility of AV-reciprocating tachycardia during I B
high-riskproperties,suchasSPERRI<_250ms,
EPS,450(cid:2)454 multiple APs,450,451,455,456 and demonstration of a
APERP<_250ms,multipleAPs,andaninduci-
capability of the AP to allow rapid conduction to the ven-
bleAP-mediatedtachycardia.439,450,452,454(cid:2)460
tricles.439,450,451,453(cid:2)456Thesevariablesincludetheshortestpre-
Catheterablationisrecommendedinhigh-risk
excitedRRintervalduringAF(SPERRI)of<_250msatbaselineor
patientswithasymptomaticpre-excitation
a short antegrade effective refractory period (ERP) of the AP
(<_250ms).439,450(cid:2)452,454(cid:2)460Withnon-invasivetesting,identifica- afterdiscussingtherisks,especiallyofheart
I C
blockassociatedwithablationofanteroseptal
tion of an abrupt and complete normalization of the PR interval
orMSAPs,andbenefitsofthe
withlossofdeltawaveduringexercisetesting,orfollowingpro-
procedure.439,440,473(cid:2)476
cainamide, propafenone, or dispopyramide administration, has
been considered a marker of low risk.459,461(cid:2)463 Catecholamine PerformanceofanEPStoriskstratifyindividu-
sensitivityisamajorlimitingfactorofalltests,bothinvasive452,460 alswithasymptomaticpre-excitationshould IIa B
andnon-invasive,includingexercisetesting.459,461,462Intermittent beconsidered.439,450(cid:2)452,454(cid:2)460
lossofpre-excitationonarestingECGorambulatorymonitoring Non-invasiveevaluationoftheconducting
hasalsobeenassociatedwithAPswithlongerERPs,andhasbeen propertiesoftheAPinindividualswithasymp-
IIb B
accepted as a credible risk-stratification tool.2,464 However, a tomaticpre-excitationmaybe
numberofrecentstudies,whichhaveincludedbothsymptomatic
considered.459,461(cid:2)463,465(cid:2)469
and asymptomatic patients, have indicated that more than one- InvasiveriskstratificationwithanEPSisrec-
fifth of patients with intermittent pre-excitation have AP ERPs ommendedinpatientswithout‘low-risk’char-
I C
<250ms.Thus,intermittent pre-excitationisnowrecognized as acteristicsatnon-invasiverisk
animperfectmarkerofalow-riskAP.406,462,465(cid:2)469 stratification.462,463,465(cid:2)469,477
Over the past 30 years, a considerable body of literature has Clinicalfollow-upshouldbeconsideredina
been published that has focused on the important topic of the patientwithasymptomaticpre-excitationand
IIa C
evaluation and management of patients with asymptomatic pre- alow-riskAPatinvasiverisk
excitation.Thesepublicationsincludethosethatdescribetheclin- stratification.450,452,456,463,477
ical and electrophysiological characteristics of patients with pre- Catheterablationmaybeconsideredina
excitation who have experienced a cardiac arrest,439,451,455,459 patientwithasymptomaticpre-excitation,and
IIb C
andseriesofpatientswithpre-excitationwhoareeithersympto- alow-riskAPatinvasiveornon-invasiverisk
matic or asymptomatic, and are followed for variable periods of stratification.405,450,452,456,463,477
time.22,405,439,449,450,454,456,470(cid:2)472Amongthesestudies,therehas
Catheterablationshouldbeconsideredin
been one prospective RCT of catheter ablation (37 patients) vs.
patientswithasymptomaticpre-excitationand
IIa C
clinicalfollow-upwithouttreatment(35patients)ofpatientswith
LVdysfunctionduetoelectrical
asymptomatic pre-excitation.453 Catheter ablation reduced the dyssynchrony.478(cid:2)481
frequencyofarrhythmicevents(7vs.77%,P<0.001)over5years.
Catheterablationmaybeconsideredin
Onepatientinthecontrolgrouphadanepisodeofcardioverted
patientswithlow-riskasymptomaticpre-exci-
ventricularfibrillation.
tationinappropriatelyexperiencedcentres IIb C
Figure22summarizestherecommendationsforthescreeningand
accordingtopatient
managementofpatientswithasymptomaticpre-excitation. preferences.203,439,450,453,454,471,474,482
AP=accessorypathway;EPS=electrophysiologystudy;ERP=effectiverefrac-
toryperiod;LV=leftventricular;MS=mid-septal;SPERRI=shortestpre-excited
RRintervalduringatrialfibrillation.
aClassofrecommendation.
bLevelofevidence
cSuchaspilotsandprofessionaldrivers.
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 40 ---
694 ESCGuidelines
.
Invasive screening with an EPS should be performed in patients .. toolortheuseofnon-invasivescreeningwithexercisetesting,drug
.
withasymptomaticpre-excitationwhoeitherhavehigh-riskoccupa- .. testing,andambulatorymonitoringasrisk-stratificationtools.
.
tions or are competitive athletes (Figure 22). Variables on the EPS .. IfapatientundergoesscreeningwithanEPSandisfoundtohave
.
.
thatidentifypatientswithahigh-riskAPincludeaSPERRI<_250ms, . anAPwith‘high-risk’characteristics,catheterablationshouldbeper-
.
.
APERP<_250ms,multipleAPs,andaninducibleAP-mediatedtachy- . formed.CatheterablationofanAP,whenperformedbyanexperi-
.
.
cardia in the baseline state orduring isoproterenol infusion, which . encedoperator,isassociatedwithahighcurerate(>95%)andlow
.
shouldalwaysbetried.452,460Theoptionsforscreeningpatientswho .. risk (<0.5%) of major complications (see also Section
.
donotfallintothesegroupsincludetheuseofEPSasarisk-stratifying .. 11.1.2.3).438(cid:2)440 However, it should be noted that even invasive
.
.
Asymptomatic
pre-excitation
Yes No
High-risk occupation
or competitive athlete?
EPS for
risk stratification
(I B)
EPS for Non-invasive
High-risk features risk stratification risk stratification
(IIa B) (IIb B)
Yes No
No
Catheter ablation
Low-risk features
(I C)
Yes
Clinical follow-up Catheter ablation
(IIa C) (IIb C)
Figure22 Riskstratificationandtherapyofpatientswithasymptomaticpre-excitation.High-riskfeaturesatelectrophysiologystudyareshortestpre-
excitedRRintervalduringatrialfibrillation<_250ms,accessorypathwayeffectiverefractoryperiod<_250ms,multipleaccessorypathways,andinducible
atrioventricularre-entranttachycardia.Low-riskfeaturesatnon-invasiveriskstratificationareinducedorintermittentlossofpre-excitationonexerciseor
drugtesting,restingelectrocardiogram,andambulatoryelectrocardiogrammonitoring.
EPS=electrophysiologystudy.
9102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 41 ---
ESCGuidelines 695
.
studiesdonotconferabsolutecertaintyaboutriskassessment.Ina .. tachycardia, and ventricular tachycardia.488 However,even patients
.
recent retrospective study in 912 young patients (aged <_21years) .. withusuallynon-complexlesionssuchasatrialseptaldefectshavean
.
withWPWsyndrome,96experiencedlife-threateningevents,405of .. increasedliferiskofatrialarrhythmias.
.
.
whom49% hadrapidlyconducted pre-excitedAF.Inpatients with . In addition to being related to symptoms, SVTs have been
.
.
events subjected to EPS risk stratification, 22 of 60 (37%) did not . reported as risk factors for sudden cardiac death in patients with
.
.
have EPS-determined high-risk characteristics, and 15 of 60 (25%) . ACHD.Thisissueparticularlyaffectspatientswithobstructivelesions
.
.
hadneitherconcerningpathwaycharacteristicsnorinducibleAVRT. . ofthesystemicventricle,tetralogyofFallot,afterFontanoperation,
.
TherehasalsobeenevidencesupportingthenotionofLVdysfunc- .. and a systemic right ventricle.489,490 Unfortunately, diagnosis and
.
.
tionrelatedtoelectricalasynchronyinpatients,especiallychildren, . treatment of arrhythmias in ACHD patients is complicated by the
.
withasymptomaticpre-excitation.478(cid:2)481Itseemsreasonabletorec- .. unusual nature of tachycardia, complex intracardiac anatomy, and
.
.
ommendEPSandconsiderablationifalinkbetweenpre-excitation . especially by difficulties in accessing the heart, for example due to
.
.
andLVdysfunctioncanbemade. . abnormalvenousanatomy(e.g.azygoscontinuityorpreviousFontan
.
.
Catheterablationofanasymptomatic ‘low-risk’APalsoappears . operation). As a consequence, specific expertise in patients with .
.
reasonable in appropriately experienced centres according to .. ACHD and access to adequate electrophysiological tools are
.
informedpatientchoice.However,whenadecisionismadetoper- .. required when performing catheter ablation procedures in these
.
formcatheterablation,itisimportanttorecognisethatablationof .. patients.
.
APsintheanteroseptalormid-septal(MS)regionisassociatedwitha ..
.
smallriskofAVblock.Theriskofheartblockassociatedwithablation ..
.
ofanteroseptalorMSAPsmayprecludeablationofananteroseptal ...
12.1 Pharmacological antiarrhythmic
orMSAPinanasymptomaticpatient. ..
Thus,theapproachforpatientswithasymptomaticpre-excitation
... therapy
.
thatdoesnotexhibithigh-riskcharacteristicsatEPSdependsonthe .. Acute therapyofSVTinthe contextofACHD is asdescribed for
.
experienceandexpertiseoftheelectrophysiologistperformingthe .. narrowQRSSVT,ingeneral.491,492Randomizedcontrolledtrialsof
.
procedure,aswellasthepreferencesandvaluesofthepatient.Inthe .. chronicantiarrhythmictherapyinpatientswithcomplexACHDare
.
CASPEDregistryinvolving182childrenandadolescentswithasymp- .. lacking.Allantiarrhythmicdrugscarryaproarrhythmicrisk,andmany
.
tomaticpre-excitation,catheterablationachieveda91%successrate .. patients with ACHD have underlying sinus node dysfunction or a
.
withoutsignificantcomplications.482 .. predispositionforAVNdisease.Antiarrhythmicdrugsshouldthere-
.
.. forebeusedwithparticularcaution,andaregenerallyreservedfor
.
.. symptomaticpatientsafteroptionsforcatheterablationprocedures
.
12 Supraventricular tachycardia in .. andhaemodynamicoptimization(e.g.correctionofunderlyingvalvu-
.
.. larproblems) have beenexhausted.Beta-blockersmay be used to
adults with congenital heart .
.. slowAVnodalconductionandmaybeconsidered,withcaution,in
.
disease .. patientswithtranspositionofthegreatarteriesaftertheatrialswitch
.
.. operation.Thisissupportedbystudiesreportingareductioninven-
.
.
Thenumberofadultswithcongenitalheartdiseaseisincreasingata . tricularfibrillationand/orappropriateICDshocksinpatientstreated
.
rateof(cid:4)60%perdecadeindevelopedcountries.483,484Currently,it .. with beta-blocking drugs.493,494 However, care is needed as these
.
.
isestimatedthat(cid:4)1millionadultswithcongenitalheartdiseaselive . patientsmaysufferfromchronotropicincompetenceandcannottol-
. intheEuropeanUnion.Despiteongoingadvancesinpaediatricsur- .. eratebeta-blockade.495Owingtorecognizedpro-arrhythmiceffects,
.
.
geryandcardiology,allowing>90%ofchildrenbornwithcongenital . classICdrugsshouldbeusedwithappropriatecautionintheACHD
. heartdiseasetosurvivetoadulthood,485thesepatientsusuallycon- .. setting.Similarconsiderationsrefer toquinidine,disopyramide,and
.
.
tinuetobeafflictedbylatecomplicationsleadingtoincreasedmor- . sotalol.IntherecentreportoftheDAREstudycohort,amiodarone,
.
.
bidity and mortality. Alongside HF, cardiac arrhythmias are a . flecainide,andsotalolwereclearlyfoundtobepro-arrhythmic,espe-
.
commonlatecomplicationinadultswithcongenitalheartdefects.486 .. cially in the presence of a prolonged QT, in older women, and in
.
. This is due to the underlying cardiac defect, previous or persisting . patientswithunderlyingcardiovascularcomorbidity,familyhistoryof
.
.
haemodynamicissues,andprevioussurgicalinterventionsresultingin . sudden death, and hypokalaemia.496 Flecainide is highly effective in
.
.
myocardialdamageandscarring.487Arrhythmicburdenrangesfrom .. infantswithSVT,butthereareconcernsaboutitstoxicityatolder
.
bradycardia arrhythmias to SVTs, and life-threatening VTs or .. ages.496,497 Most centres have a lower threshold for the use of
.
fibrillation. .. amiodaroneinpatientswithACHDasitisperceivedtobelesspro-
.
Owingtoprecedingoperationsandunderlyinganatomy,patients .. arrhythmic.However,itiscommonlyassociatedwiththyroiddisor-
.
withtetralogyofFallot,Ebstein’sanomaly,transpositionofthegreat .. ders and less commonly with other well-described potentially
.
arteriesafteratrialswitchprocedure,andcomplexpatientswithuni- .. life-changing complications. These considerations should severely
.
ventricularheartsandFontanpalliationareespeciallypronetolate .. limititslong-termuseinpatientswithACHD,thusfurthersupport-
.
developmentofarrhythmias,suchasincisionalorintra-atrialre-entry . ingthefirst-lineuseofablationattemptswhereverpossible.498
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 42 ---
696 ESCGuidelines
Recommendationsforthetherapyofsupraventriculartachycardiaincongenitalheartdiseaseinadults
Recommendation Classa Levelb
AnticoagulationforfocalAToratrialfluttershouldbesimilartothatforpatientswithAF.241,242,499 I C
Acutetherapy
Haemodynamicallyunstablepatients
SynchronizedDCcardioversionisrecommendedforhaemodynamicallyunstablepatients.86(cid:2)88,491,492 I B
Haemodynamicallystablepatients
Vagalmanoeuvres,preferablyinthesupinepositionwithlegelevation,arerecommended.41,89(cid:2)91 I B
Adenosine(6(cid:2)18mgi.v.bolus)isrecommendedifvagalmanoeuvresfail.92(cid:2)94 I B
i.v.verapamilordiltiazemshouldbeconsidered,ifvagalmanoeuvresandadenosinefail.92,94(cid:2)98 IIa B
i.v.beta-blockersesmololormetoprolol)shouldbeconsideredifvagalmanoeuvresandadenosinefail.97,99,100 IIa C
SynchronizedDCcardioversionisrecommendedwhendrugtherapyfailstoconvertorcontrolthetachycardia.87,88 I B
Chronictherapy
Catheterablationinexperiencedcentresshouldbeconsidered.292,500,501 IIa C
Beta-blockersshouldbeconsideredforrecurrentfocalAToratrialflutter,ifablationisnotpossibleorsuccessful.237 IIa C
InpatientswithSVTplannedforsurgicalrepairofacongenitalheartdiseaseanomaly,pre-operativecatheterablationorintraopera-
IIa C
tivesurgicalablationshouldbeconsidered.502(cid:2)504
Amiodaronemaybeconsideredforpreventionifablationisnotpossibleorsuccessful.505 IIb C
Sotalolisnotrecommendedasafirst-lineantiarrhythmicdrugasitisrelatedtoanincreasedriskofpro-arrhythmiasandmortality.496 III C
Flecainideandpropafenonearenotrecommendedasfirst-lineantiarrhythmicdrugsinpatientswithventriculardysfunctionand
III C
severefibrosis.497
i.v.verapamilanddiltiazemarecontraindicatedinthepresenceofhypotensionorHFrEF.
i.v.beta-blockersarecontraindicatedinthepresenceofdecompensatedheartfailure.
AF=atrialfibrillation;AT=atrialtachycardia;DC=direct-current;HF=heartfailure;HFrEF=heartfailurewithreducedejectionfraction;i.v.=intravenous;SVT=supraven-
triculartachycardia.
aClassofrecommendation.
bLevelofevidence
.
12.2 Catheter and surgical ablation .. mechanismisCTI-dependenttachycardiaandthisisgenerallysuscepti-
.
Owingtounderlyinganatomyandpreviousoperations,interventional
... bletocatheterablation.However,CTI-dependentand‘incisional’atrial
access for ablation procedures may be challenging in patients with
... fluttermaycoexist.Closureofanexistingatrialseptaldefect,inisola-
ACHD.Inaddition,thenatureofSVTisoftenatypical,andrelatedto
... tion,isgenerallyinsufficienttoabolishanexistingATandcatheterabla-
multiplere-entrantcircuitsandfibroticatrialtissue.Asaconsequence,
... tionshouldbeconsideredbeforedefectclosure.Mid-termrecurrence
.
specialexpertiseandexperiencewithablationofcomplextachyarrhyth- .. ratesof 40(cid:2)44% have beenreported in atrial septal defectpatients
miasandscar-relatedproceduresarenecessary.506Itisrecommended ... post-flutter or AF ablation508,509; however, this should not preclude
.
thatpatientswithcomplexincisionaltachycardiasarereferredtospe- .. ablationprocedureswhereverpossible.
. cialist centres with adequate experience, volumes of ablation proce- ..
.. 12.3.2Ebstein’sanomaly
dures,andadvancedmappingcapabilities.Catheterablationprocedures .
.. ATs are common in Ebstein’s anomaly, occurring in 25(cid:2)65% of
inthesettingofACHDareassociatedwithlowersuccessratescom- .
paredwiththegeneralcohortofpatientswithAForatrialflutter.484
... patients.501,510(cid:2)512Thetypesofarrhythmiaincludeatrialflutter,focalAT,
.. andAF.Inaddition,10(cid:2)45% ofpatientshaveright-sidedAPs,including
However, ablation of CTI-related arrhythmias has been reported to .
.. WPWsyndrome.MorethanoneAPiscommoninthissetting,andcanin
haveahighacutesuccessrate(>95%),althoughthemid-termrecur- .
rence rate may approach 20%.507 Pre-operative catheter ablation or
... itselfincreasetheriskofhaemodynamiccompromiseandsuddencardiac
.. death.CatheterablationofAPshasahighsuccessrate;however,ablation
concomitantarrhythmiasurgeryshouldbeconsideredinpatientswith .
.. proceduresmaybechallengingandrepeatproceduresmaybenecessary
ACHD undergoing cardiac surgery, as its incorporation can result in .
.. assomepatientshavemultipleablationtargets.Inaddition,patientsmay
improved functionalclassand potentiallydecreasedrequirementsfor .
chronicantiarrhythmicmedicationinthisvulnerablepopulation.502(cid:2)504
... developdifferentarrhythmiamechanismsfollowingablation.501Inpatients
.. undergoing surgical repair, routine pre-operative EPS can be recom-
.
.. mendedasthediagnosticandtherapeuticyieldinthispopulationishigh.513
12.3 Specific disease states ..
.
.
12.3.1Atrialseptaldefect .. 12.3.3Transpositionofthegreatarteries(dextro-
.
Theincidenceofatrialarrhythmiasinpatientswithatrialseptaldefects .. transpositionofthegreatarteries)afteratrialswitch
.
rangesbetween5(cid:2)15%.508Theexactimpactofatrialseptaldefectclo- .. operation(MustardorSenning)
.
sure,especiallyoflateclosure,ontheriskofdevelopingATiscontro- .. Owingtoprevioussurgeryandscarring,atrialre-entranttachycardias
.
versial. Patients commonly present with RA MRAT. The leading . arecommoninpatientswithaMustardorSenningrepair.Inaddition,
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 43 ---
ESCGuidelines 697
.
.
sinusnodedysfunctionmayoccurasaconsequenceoftheatrialredi- . milkcansubstantiallymodifytheabsorptionofthedrugand,asfeed-
.
rectionprocedure.495Astachycardiaisnotwelltoleratedinpatients .. ingschedulestendtobeerratic,canaffecteffectivedrugavailability.
.
.
withasystemicrightventricularanddiastolicdysfunction,maintaining . Furthermore,manydrugshavetobepreparedatspecializedpharma-
.
.
long-termsinusrhythmishighlydesirableinthissetting.Useofantiar- . cies,addingtotheriskofincorrectdosing,anddrugsolutionsmay
.
.
rhythmicdrugsislimitedduetoventricularandsinusnodedysfunction, . also need to be stored under special conditions to maintain their
.
.
and pro-arrhythmic risk. Ablation procedures in patients with a . stability. This can be inconvenient when long-term treatment is
.
.
Mustard or Senning repair have a high acute success rate; however, . requiredas,forexample,aportablecoolerbagmustbecarried.In
.
.
recurrenceratesapproach30%duringlong-termfollow-up.500,514(cid:2)516 . addition,thelong-termeffectsofsomedrugs,astheyaccumulate,are
.
.
.. especially dangerous in growing bodies. This is of special interest
.
12.3.4TetralogyofFallot .. regardingamiodarone,whichcanchronicallyprovokethesamesec-
.
SVTsarenotuncommoninpatientswithtetralogyofFallot.Inadditionto .. ondaryeffectsasitdoesinadults.Verapamilhastobeavoidedwhen-
.
beingrelatedtosymptoms,theoccurrenceofsupraventriculararrhyth- .. ever possible or given very carefully to small patients as it can
.
miashasbeenlinkedtoastatisticallyhigherriskofsuddencardiacdeathin .. provokeseverehypotension.522Adecreasedresponseofadenosine
.
thispopulation.517Ascatheterablationhasahighproceduralsuccessrate, .. inyoungerchildrenhasalsobeensuggested.528
.
itshouldbeconsideredasafirst-lineoptioninthissetting.518Inaddition, .. Invasive techniques are possible and effective even in very small
.
patients with new-onset atrial arrhythmias should be thoroughly eval- .. children,whenindicated,butthereareseverallimitingfactors.First,
.
uatedtoexcludeaddressablehaemodynamiclesionssuchasseverepul- .. radiofrequency lesion formation in immature sheep myocardium is
.
monary valve regurgitation, which may be amenable to surgical or .. similartothatinadultsheepmyocardiumacutely,butisassociated
.
interventionaltherapyleadingindirectlytoreducedarrhythmiaburden. .. with late lesion enlargement and fibrous tissue invasion of normal
.
.. myocardium. These observations may have implications for clinical
.
12.3.5Fontanrepairs ... radiofrequency ablation procedures in infants529 and avoidance of
.
ATiscommoninpatientspost-Fontanpalliation.Patientswithaclassic .. radiofrequencyablation,ifatallpossible,inthefirst2yearsoflifeis
.
(atriopulmonary)FontanprocedureareatespeciallyhighriskforAT, .. prudent.Second,nospecificcathetersandtoolsexistforthepaediat-
.
with<_60%developingSVTsafter15yearsoffollow-up.519Inadditionto .. ricpopulation.Currently,availablecatheters(minimum5Frenchfor
.
symptomsandtheriskofcardiacthromboembolism,ATispoorlytoler- .. non-irrigated radiofrequency tips) and curves are, in general, too
.
atedhaemodynamicallyinpatientswithuniventricularhearts,andmay .. large.Thisisparticularlylimitinginsmallchildrenneedinganablation
.
leadtoacutedeteriorationandovertHFinthissetting.520Catheterabla- .. toresolveincessanttachycardia.Finally,theexperienceoftheopera-
.
tionisofteneffectivebutchallenging,duetothenatureofthearrhythmia .. torandthecentreiscrucial.Smallpatientsrequiringablationshould
.
circuitsaswellasissueswithcardiacaccess.514,515Varioussurgicalmodi- .. be referred to experienced reference centres for treatment. The
.
fications, such as the conversion to total cavopulmonary connection, .. numberofcathetersused,andproceduralandradiationtimes,should
.
haveevolvedandcanamelioratetheriskofatrialarrhythmias.521 .. beminimizedinthesegrowingbodies.530Electroanatomicalmapping
.
.. systemsaremostvaluableinthissetting.
.
.
.
13 Supraventricular tachycardia in .. 13.1 Foetal arrhythmias
.
.
the paediatric population .. Foetal arrhythmias can be detected at an early gestational age, with
.
.. incessant, rapid SVTs associated with foetal death due to hydrops.
. Specific detailed recommendations for paediatric patients are pub- .. Therefore,aspecialefforthastobemadetodetectandcontrolfoetal
.
lishedelsewhere522,523andarebeyondthescopeofthisdocument. .. arrhythmias.Astrongcorrelationbetweenpost-natalSVTandlaterges-
.
Ingeneral,certainaspectsaredifferentinthepaediatricpopulation .. tational age at foetal SVT diagnosis has been reported.531 Diagnosis .
andshouldbetakenintoaccount. .. reliesonechocardiographyasfoetalECGsarenotavailableinmostclin- .
.
Immaturityofthecardiacstructures,includingconductiontissue, . ics(itisusedinjustafewcentresworldwideandprimarilyforresearch
.
may lead to modifications in the electrophysiology of the heart. .. purposes).532Whensustainedfoetaltachycardiaisobserved,treatment
.
.
Therefore,someAPspresentinthefirstmonthsoflife(eventhose . ismandated.Thereareseveralprotocolsforthispurpose,andtheyare
.
.
associatedwithtachycardias)maydisappearbeforethefirstyearof . mostlybasedondigoxin,flecainide,andsotalolaloneorincombination
.
age.522 Actually, AVRT due to WPW that begins in infancy may .. dependingonthetypeoftachycardia.Thesedrugshavetobegivento
.
.
resolve in (cid:4)90% of patients, but may recur in later childhood in . themother,withafractionreachingthefoetus.Thismeansthatthesec-
.
.
30-50%ofpatients;however,ifthetachycardiaispresentafterthe . ondary effects of these drugs can manifest in both the foetus and
.
ageof5,itpersistsin>75%ofpatients.524 .. mother.Closefollow-upisthereforeneeded.522,533,534
.
.
Itisclearthatsmallchildrenmaynotcomplainofsymptoms,so .
.
.
indirectsignshavetobeassessedwhenSVTissuspected,i.e.irritabil- ..
. 14 Supraventricular tachycardia in
ity,failuretothrive,andevenflatgrowingcurves.Itisnotuncommon ..
.
todiscoveranincessantSVTinapatientpresentingwithcardiogenic .. pregnancy
.
shock due to TCM. This most frequently occurs in relatively slow ..
.
SVTs,suchasPJRTandfocalAT.525,526 .. SustainedSVTbecomesmorefrequentduringpregnancy,occurring
.
Pharmacokineticsandpharmacodynamicsinchildrenaredifferent .. in 22(cid:2)24/100000 pregnancies. It may even manifest for the first
.
tothoseinadults;therefore,specialattentionhastobegivenwhen .. time,particularlyinthethirdtrimesterorperi-partum,accordingto
.
prescribing drugs.527 This is particularly important in newborns as . comprehensive discharge data from hospitals.535 The overall
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 44 ---
698 ESCGuidelines
.
frequencyofanyarrhythmiaisgreaterinwomenaged41(cid:2)50years .. 14.2 Therapy
.
(199/100000)thaninthoseaged18(cid:2)30years(55/100000),which ...
14.2.1Antiarrhythmicdrugs
maybeduetomoreprevalentAFandVT,whereasSVTseemsstable ...
Treatment with antiarrhythmic drugs for the prevention of SVT
over time.535 Arrhythmias are also more frequent among women ...
should,ingeneral,bereservedforSVTscausinghaemodynamiccom-
.
with congenital heart disease, particularly atrial flutter, compared .. promiseorsignificantsymptoms.Themajorconcernregardingthe
withwomenwithoutcongenitaldefects.536 ...
use of antiarrhythmic drugs during pregnancy is potential adverse
.
Assubstantiveprospectiveorrandomizedstudiesareunavailable, .. effectsonthefoetus.Whilethefirsttrimesterisassociatedwiththe
.
recommendations are primarily based on small cohorts or case .. greatestteratogenicrisk,drugexposurelaterinpregnancymayresult
.
reportsinconjunctionwithexpertopinion. .
. inadverseeffectsonfoetalgrowthanddevelopment,andonuterine
.
.
. contractility,andanincreasedriskofpro-arrhythmia.Therisksand
.
.
. benefitsofcontinuingvs.stoppingmedicationmustbecarefullycon-
.
14.1 Maternal, obstetric, and offspring .. sideredintermsoftheriskofrecurringSVT,andthepotentialfor
.
. risk . haemodynamic compromise. Decisions should be individualized,
.
.
. basedontheclinicalsituationandpossibleadditionalstructuralheart
SVTisassociatedwithanincreasedriskofdeathduringpregnancy, .
.
. disease.Majorcontrolledstudiesofantiarrhythmicdrugsduringpreg-
andthereportedfrequencyis68per100000pregnancy-relatedhos- .
.
. nancyarelacking.Ifnon-invasivemanoeuvresfail,adenosineshould
pitalizations for any arrhythmia, 22 per 100000 for SVT, 4 per .
.
. bethefirst-linedrugfortreatmentifneededduringthesecondand
100000foratrialflutter,27per100000forAF,2per100000for .
.
ventricularfibrillation,and16per100000forVT.535 .. thirdtrimesters.ThereisapaucityofdataonmanagementofSVTin
.
Identificationandtreatmentofunderlyingconditionsarethefirst
.. the first trimester.542 All beta-blockers can cause bradycardia and
.
priorities.AlthoughmostoftheexacerbationsofSVTduringpreg-
.. hypoglycaemia in the foetus. As beta-1 selective beta-blockers are
.
nancyarebenignandcanbetreatedeffectivelywithstandardmedical
.. lesslikelytoaffectuterinerelaxation,theyarepreferred.546Maternal
.
therapy,537thecircumstancesthatshouldbeconsideredincludethe ... use of beta-blockers in the first trimester has not been associated
well-beingofthefoetusandtheeffectsonlabour,delivery,andlacta-
... with a large increase in the risk for overall or cardiac malforma-
tion.Thehaemodynamiceffectoftachycardia,aswellassideeffects
... tions.548,553 However, in the EUROmediCAT study, an association
of treatments, must be balanced and addressed for the foetus.
... betweenalpha/beta-adrenergicblockeruseinthefirsttrimesterwith
Catheterablationshouldthereforebeconsideredbeforepregnancy
... multicystic renal dysplasia was reported.554 There have been con-
when possible in patients with a known history of symptomatic
... cerns about ‘low weight for gestational age’ with beta-blockers,
tachyarrhythmia.Trialsevaluatingthelevelofsurveillanceatdelivery
... althoughtheeffectsreportedmaynotbelargeenoughtobeofclini-
areneeded.
.. cal importance. Exposure to atenolol has been associated with a
Recommendationsforthetherapyofsupraventriculartachycardiainpregnancy
Recommendation Classa Levelb
CatheterablationisrecommendedinsymptomaticwomenwithrecurrentSVTwhoplantobecomepregnant.538 I C
Acutetherapy
Immediateelectricalcardioversionisrecommendedforanytachycardiawithhaemodynamicinstability.539,540 I C
Vagalmanoeuvresand,ifthesefail,adenosinearerecommendedforacuteconversionofSVT.541,542 I C
Ani.v.beta-1selectiveblocker(exceptatenolol)shouldbeconsideredforacuteconversionorratecontrolofSVT.542,543 IIa C
i.v.digoxininthelatestpocketGlsversionshouldbeconsideredforratecontrolofATifbeta-blockersfail.542,543 IIa C
i.v.ibutilideinthelatestpocketGlsversionmaybeconsideredforterminationofatrialflutter.544,545 IIb C
Chronictherapy
Duringthefirsttrimesterofpregnancy,itisrecommendedthatallantiarrhythmicdrugsshouldbeavoided,ifpossible. I C
Beta-1selective(exceptatenolol)beta-blockersorverapamil,inorderofpreference,shouldbeconsideredforpreventionof
IIa C
SVTinpatientswithoutWPWsyndrome.543,546(cid:2)548
FlecainideorpropafenoneshouldbeconsideredforpreventionofSVTinpatientswithWPWsyndrome,andwithoutischaemic
IIa C
orstructuralheartdisease.549
FlecainideorpropafenoneinpatientswithoutischaemicorstructuralheartdiseaseshouldbeconsideredifAVnodalblocking
IIa C
agentsfailtopreventSVT.533,543
DigoxinorverapamilshouldbeconsideredforratecontrolofATifbeta-blockersfailinpatientswithoutWPWsyndrome.543 IIa C
Amiodaroneisnotrecommendedinpregnantwomen.153,543 III C
Fluorolesscatheterablationshouldbeconsideredincasesofdrug-refractoryorpoorlytoleratedSVT,inexperienced
IIa C
centres.550(cid:2)552
i.v.ibutilideiscontraindicatedinpatientswithprolongedQTcinterval.
AT=atrialtachycardia;AV=atrioventricular;i.v.=intravenous;SVT=supraventriculartachycardia;WPW=Wolff(cid:2)Parkinson(cid:2)White.
aClassofrecommendation.
bLevelofevidence
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 45 ---
ESCGuidelines 699
.
higherriskofinfantsbornsmallfortheirgestationalagecompared .. 15.3 Diagnosis
.
with metoprolol and propranolol, consistent with this association ..
TCMisoneoftheveryfewreversiblecausesofHFanddilatedcardi-
.
notbeingaclasseffect.543,555Diltiazemhasbeenfoundtobeterato- ..
omyopathy,andshouldbeconsideredinanypatientwithnewonset
.
genicinanimals,withonlylimitedhumandata,anditsuseisnotgen- ..
ofLVdysfunction.Inthepresenceofpersistentorfrequenttachycar-
.
erally recommended in pregnancy. Verapamil is considered safer ...
dia,orfrequentprematureventricularcontractions,ahighindexof
thandiltiazemandcouldbeusedasasecond-linedrug.153,543 ...
suspicion should be maintained. The diagnosis is established by
.
.. excludingothercausesofcardiomyopathy,anddemonstratingrecov-
.
.. eryofLVfunctionaftereradicationofthearrhythmiaorcontrolof
14.2.2Electricalcardioversion .
.. theventricularrate.TypicallyinTCM,LVejectionfractionis<30%,
Electricalcardioversionshouldbethefirstchoicewhenarrhythmias .
.. LVend-diastolicdiameteris<65mm,andLVend-systolicdiameteris
are haemodynamically unstable. Cardioversion seems safe in all .
.. <50 mm.557 More dilated ventricular volumes suggest underlying
phases ofpregnancy asit does not compromise foetal bloodflow, .
.. dilatedcardiomyopathy,althoughsomeoverlappingofthetwocon-
andhaslowriskofinducingfoetalarrhythmiasorinitiatingpre-term .
labour.539Thefoetalheartrateshouldberoutinelycontrolledafter
... ditionscanoccur.InpatientswithsuspectedTCM,cardiacmagnetic
.. resonance(CMR)isadvisabletoexcludeintrinsicstructuralchange.
cardioversion. .
.. SerialassessmentofN-terminalpro-B-typenatriureticpeptide(NT-
.
.
. proBNP) and estimationoftheratio ofNT-proBNP atbaseline to
.
.
14.2.3Catheterablation .. NT-proBNPduringfollow-upcanhelpdifferentiateTCMfromirre-
.
Catheter ablation should be postponed to the second trimester if .. versibleidiopathicdilatedcardiomyopathy.
.
possible, but may be necessary in the case of drug-refractory and ..
.
poorlytoleratedtachycardia.Itshouldthenbeperformedatanexpe- . 15.4 Therapy
rienced centre using non-fluoroscopic electroanatomical mapping
and catheter navigation systems.556 Catheter ablation of recurrent, Recommendationsforthetherapyofsupraventricular
tachycardiainpatientswithsuspectedorestablished
drug-refractoryAVNRT,AVRT,focalAT,andCTI-dependentatrial
heartfailureduetotachycardiomyopathy
flutterhasbeensuccessfulduringpregnancy.550(cid:2)552
Recommendation Classa Levelb
CatheterablationisrecommendedforTCM
15 Tachycardia-induced I B
duetoSVT.196,233,418,525
cardiomyopathy
Beta-blockers(fromthelistwithprovedmor-
talityandmorbiditybenefitsinHFrEF)arerec-
15.1 Definition I A
ommendedforTCMduetoSVT,when
Tachycardia-induced cardiomyopathy (TCM), or more accurately catheterablationfailsorisnotapplicable.567
arrhythmia-inducedcardiomyopathy,isareversiblecauseofimpaired ItisrecommendedthatTCMisconsideredin
LVfunctionduetopersistenttachycardiaorveryfrequentventricular apatientwithreducedLVejectionfraction
I B
premature beats that can lead to HF and death. The incidence of withanelevatedheartrate(>100
TCMisunknownbuthasbeenreportedinallagegroups,fromfoe- b.p.m.).557(cid:2)561
tusestotheelderly. 24h(ormultiday)ambulatoryECGmonitor-
ingshouldbeconsideredfordiagnosisofTCM
IIa B
15.2 Mechanism byidentifyingsubclinicalorintermittent
arrhythmias.526,557,568
ThesyndromewasinitiallydescribedwithPJRT,butwenowknow
AVnodalablationwithsubsequentpacing
that any chronic cardiac arrhythmia may cause TCM. Incessant
(‘ablateandpace’),eitherbiventricularorHis-
AVRTsduetoseptalAPs,rapidAF,idiopathicVT,AT,andpersistent
ectopic beats are best described.196,233,526,557(cid:2)563 In patients aged bundlepacing,isrecommendedifthetachy- I C
<18years,focalATisthecommonestcause.408 cardiaresponsiblefortheTCMcannotbe
ablatedorcontrolledby
Rapid pacing in animal models induces cytoskeletal changes and
drugs.526,557,564,569(cid:2)572
remodelling of the extracellular matrix attributed to abnormal cal-
ciumcycling,increasedcatecholamines,decreasedbeta-1adrenergic b.p.m.=beatsperminute;ECG=electrocardiogram;HFrEF=heartfailurewith
receptor density, oxidative stress, depletion of myocardial energy reducedejectionfraction;LV=leftventricular;SVT=supraventriculartachycar-
stores,andmyocardialischaemiaduetoincreasedheartrate.559,564 dia;TCM=tachycardiomyopathy.
aClassofrecommendation.
Endomyocardial biopsy specimens from patients with TCM exhibit bLevelofevidence.
features distinct from those of other types of cardiomyopathy,
including deranged cardiomyocyte and mitochondrial morphology,
andmacrophage-dominatedcardiacinflammation.565However,ithas In TCM, LV function frequently improves after (cid:4)3 months of
notbeenfullyestablishedhowthemajorityofpatientswithfrequent restorationofanormalheartrate.InIST,beta-blockersareindicated.
premature ventricular contractions have a benign course, whereas Catheter ablation is indicated when TCM is due to another SVT.
<_30%ofthemmaydevelopcardiomyopathy.566 When the tachycardia itself cannot be ablated, AV nodal ablation
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 46 ---
700 ESCGuidelines
.
witheitherbiventricularorHis-bundlepacingisappropriate.569(cid:2)572 .. performed in those with high-risk features.577 Asymptomatic
.
.
Long-term medical therapy with beta-blockers, and angiotensin- . patientsstratifiedatlowriskareallowedtopracticecompetitive
.
.
convertingenzymeinhibitorsorangiotensinIIreceptorblockers,is . sports.
.
.
indicatedbeforeandaftersuccessfulablationfortheknownbeneficial . AVNRT,orthodromicAVRToveraconcealedAP,andATare
.
.
effectsofthesedrugsontheLVremodellingprocess.Giventherisk . notlistedamongthecausesofsuddencardiacdeathduringexer-
.
.
of recurrence of arrhythmias, long-term monitoring of patients is . cise in patients with a structurally normal heart. However, their
.
.
recommended. . occurrenceduringsportsactivitymaybeassociatedwithveryhigh
.
.
. heartratebecauseofsympatheticstimulationandmaycausehae-
.
.
. modynamicimpairmenteveninpatientswithstructurallynormal
.
.
16 Supraventricular tachycardia in .. hearts.Accordingly,catheterablationshouldgenerallyberecom-
.
sports
.. mendedforallathleteswithahistoryofparoxysmalSVT.Athletes
.
.. with SVT who do not wish to undergo catheter ablation, or in
.
Athletes with frequent supraventricular arrhythmias should be
... whom the procedure has been unsuccessful, may be considered
assessed to exclude the presence of anunderlying cardiac disease,
... eligibleforcompetitivesportsactivityifthearrhythmiaissporadic,
electrolyteimbalance,thyroiddysfunction,andtheuseofstimulants
... unrelated to cardiac disease, well tolerated, and unrelated to
orperformance-enhancingdrugs.Table13outlinestherecommenda-
... exercise,andwhenthesportsactivitydoesnothaveahighintrin-
tionsforsportseligibilityofpatientswithSVT.573,574 ... sic risk of loss of consciousness (such as divers, pilots, horse
.. riders,etc.).578
Ventricularpre-excitation(WPWsyndrome)isararecauseof .
suddencardiacdeathinyoungathletes.575Althoughmanyindivid- ... TreatmentofparoxysmalSVTwithbeta-blockersorsodiumchan-
.. nel blockers is discouraged in athletes, because these drugs may
uals with ventricular pre-excitation remain asymptomatic .
.. reduceperformanceduringsportsandhavelimitedabilitytoprevent
throughout their lives, symptomatic AVRT may occur. Patients .
.
. arrhythmia recurrence during sports activity. Moreover, beta-
withWPWmayalsodevelopotherarrhythmias,suchasAF,which .
.
. blockersarelistedbytheWorldAnti-DopingAgencyasprohibited
could degenerate into ventricular fibrillation and sudden cardiac .
.
. drugsinparticularsports.
death. Because sports activity has been associated with an .
.
increased risk of AF,576 athletes with ventricular pre-excitation ..
.
.
have an increased risk of sudden cardiac death if the AP has the .
.. 17 Supraventricular tachycardia
potentialforfastantegradeconduction.Thus,catheterablationof .
.
.
the AP is currently recommended in symptomatic athletes with . and driving restrictions
.
.
ventricular pre-excitation. Asymptomatic athletes with intermit- ..
.
tent pre-excitation (at rest or during exercise) or abrupt disap- .. Thefrequencyofwhichmedicalcausescontributetomotorvehicle
.
pearance of pre-excitation during stress testing may be .. accidentsisnotpreciselyknown.Dataonarrhythmiasasacauseof
.
consideredtobeatlowrisk(seesection11.3.11forreservations), .. motor vehicle accidents are hard to obtain due to the difficulty of
.
butshouldbefurtherevaluatedastheymaybeeligibleforcom- .. documenting such events in the general population. However, the
.
petitivesportsactivity.Inasymptomaticathleteswithventricular .. proportionisbelievedtobesmall,with(cid:4)1-3%ofallmotorvehicle
.
pre-excitation,invasiveriskstratificationshouldbeconductedas .. accidents established as being due to a driver’s sudden incapacita-
.
described in section 11.3.11 and catheter ablation should be . tion.579Oftheseaccidents,5-10%arerelatedtocardiaccauses,with
Table13 Recommendationsforsportsparticipationinathleteswithventricularpre-excitationandsupraventricular
arrhythmias
Criteriaforeligibility Eligibility
Prematureatrialbeats Nosymptoms,nocardiacdisease Allsports
AVRTorAFinthecontextofWPWsyndrome Ablationismandatory.Sportsareallowed1monthafter Allsports
ablationiftherearenorecurrences
Asymptomaticventricularpre-excitation Ablationismandatoryinpatientsathighrisk.Sportsare Allsports
allowed1monthafterablationiftherearenorecurrences
ParoxysmalSVT(AVNRT,AVRTover Ablationisrecommended.Sportsareallowed1month Allsports
aconcealedAP,andAT) afterablationiftherearenorecurrences
Ablationundesirableornotfeasible Allsports,exceptthose
withhighintrinsicriskof
lossofconsciousness
AF=atrialfibrillation;AP=accessorypathway;AT=atrialtachycardia;AVNRT=atrioventricularnodalre-entranttachycardia;AVRT=atrioventricularre-entranttachycardia;
SVT=supraventriculartachycardia;WPW=Wolff(cid:2)Parkinson(cid:2)White
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 47 ---
ESCGuidelines 701
Table14 EuropeanWorkingGroup2013reportondrivingandcardiovasculardisease:drivinginarrhythmiasandcon-
ductiondisorders:supraventriculartachycardia
Conductiondisorder/ Group1 Group2
arrhythmia
AF/atrialflutter/focalAT Drivingmaycontinueprovidednohistoryofsyncope. Drivingmaycontinueprovidednohistoryofsyncopeand
Ifhistoryofsyncope,drivingmustceaseuntilthecon- anticoagulationguidelinesareadheredto.
ditionhasbeensatisfactorilycontrolled/treated. Ifhistoryofsyncope,drivingmustceaseunlesstheunder-
lyingcauseistreatedandtheriskofrecurrenceislow.
Ratecontrolduringtachycardiashouldbeadequate.
Drivingcanonlyberesumedaftermedicalassessment.
AVNRT,AVRT,andWPW Ifhistoryofsyncope,drivingmustceaseuntilthecon- Drivingmaycontinueprovidednohistoryofsyncopeor
ditionhasbeensatisfactorilycontrolled/treated. othersignificantsymptoms(e.g.palpitationswith
dizziness).
Ifso,drivingmustceaseuntiltheunderlyingcauseis
treatedsothattheriskofrecurrenceislow.
Incaseofpre-excitation,drivingmayonlybeallowedafter
specialistassessment.
AF = atrial fibrillation; AT = atrial tachycardia; AVNRT = atrioventricular nodal re-entrant tachycardia; AVRT = atrioventricular re-entrant tachycardia; WPW =
Wolff-Parkinson-White.
.
orwithoutsyncope,while<2%ofcasesofreportedsuddendriver .. • AVNRT, typical or atypical, can now be ablated with almost no
.
incapacitationhaveresultedininjuryordeathtobystanders,orother .. riskofAVblock.
.
roadusers.579 .. • DonotusesotalolinpatientswithSVT.
.
. • Do not use flecainide or propafenone in patients with LBBB, or
In2013,aWorkingGroupoftheESCpublisheddetailedrecom- .
mendationsondrivingrestrictioninpatientswithSVT(Table14).580 ... ischaemicorstructuralheartdisease.
.. • Donotuseamiodaroneinpre-excitedAF.
Twogroupsofdriversareconsidered.Group1comprisesdriversof .
.. • One in five patients with asymptomatic pre-excitation will
motorcycles,cars,andothersmallvehicleswithandwithoutatrailer. .
. developanarrhythmiarelatedtotheirAPduringfollow-up.
.
Group 2 includes drivers of vehicles over 3500 kg or passenger- .
. • The risk of cardiac arrest/ventricular fibrillation in a patient with
.
carryingvehiclesexceedingeightseatsexcludingthedriver.Drivers .. asymptomaticpre-excitationis(cid:4)2.4per1000person-years.
.
oftaxicabs,smallambulances,andothervehiclesformanintermedi- .. • Non-invasive screening may be used for risk stratification of
.
atecategorybetweentheordinaryprivatedriverandthevocational .. patientswithasymptomaticpre-excitation,butitspredictiveabil-
.
driver. . ityremainsmodest.
.
. . • InvasiveassessmentwithanEPSisrecommendedinpatientswith
.
.. asymptomatic pre-excitation who either have high-risk occupa-
.
18 Key messages .. tionsorarecompetitiveathletes.
. . • If a patient undergoes assessment with an EPS and is found to
.
. • NotallSVTsarearrhythmiasoftheyoung. .. have an AP with ‘high-risk’ characteristics, catheter ablation
. • Vagal manoeuvres and adenosine are the treatments of choice . shouldbeperformed.
.
for the acute therapy of SVT, and may also provide important .. • Ifpossible,avoidallantiarrhythmicdrugsduringthefirsttrimester
.
diagnosticinformation. .. of pregnancy. If beta-blockers are necessary, use only beta-1
.
• VerapamilisnotrecommendedinwideQRS-complextachycar- .. selectiveagents(butnotatenolol).
.
diaofunknownaetiology. .. • If ablation is necessary during pregnancy, use non-fluoroscopic
• Considerusingivabradine,whenindicated,togetherwithabeta- .. mapping.
.
blocker. .. • ConsiderTCMinpatientswithreducedLVfunctionandSVT.
.
• In all re-entrant and most focal arrhythmias, catheter ablation .. • Ablation is the treatment of choice for TCM due to SVT. AV
.
should be offered as an initial choice to patients, after having .. nodalablationwithsubsequentbiventricularorHis-bundlepacing
.
explainedindetailthepotentialrisksandbenefits. .. (‘ablate and pace’) should be considered if the SVT cannot be
• Patients with macro-re-entrant tachycardias following atrial sur- .. ablated.
.
.
geryshouldbereferredtospecializedcentresforablation. .
.
• In post-AF ablation ATs, focal or macro-re-entrant, ablation ..
.
should be deferred for >_3 months after AF ablation, when .. 19 Gaps in the evidence
.
possible. .
.
.
• AblateAVNRT,typicaloratypical,withlesionsintheanatomical . • Thedistinctionbetweentriggeredactivityandenhancedautoma-
.
.
area of the nodal extensions, either from the right or left . ticity is not straightforward, as the two mechanisms share many
.
septum. . similar responses and characteristics, such as enhancement by
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 48 ---
702 ESCGuidelines
.
adrenergic activation and suppressed by L-type Ca2þ current .. • The proper management of asymptomatic pre-excitation and
.
blockade. . strictcatheterablationindicationshavenotbeenestablished.
.
.
• Re-entrant circuits may be microscopic or simulate foci by sur- . • The genetics of SVT have not been adequately studied. There
.
face ‘breakthrough’ of transmural propagation. Thus, mapping .. has been evidence for familial forms of AVNRT, AVRT, sinus
.
maybe inadequate todistinguishthemfromautomatic/triggered .. tachycardia,andAT,butdataarescarce.
.
activity. .. • Novelelectroanatomicalmappingsystemsnowallowthesimulta-
.
• TheexactcircuitofAVNRT,themostcommonregulararrhyth- . neous visualization of activation and voltage. The implications
.
.
miainthehuman,remainsunresolved. . that this may have on characterizing the tachycardia substrate,
.
• The potential role of connexin proteins in AVNRT, and SVT in .. andnotjustthecircuit,requirefutureresearch.
.
general,isunderinvestigation. .. • Mathematical modelling and numerical analysis of recorded
.
• Both invasive and non-invasive tests for the risk assessment of .. ECGs,usingfastFourierandGaussianmodels,maybehelpfulfor
.
patientswithasymptomaticpre-excitationhavelimitations,being . the future of artificial intelligence applications in the differential
.
.
dependentontheautonomictone.Moreaccuraterisk-stratifica- . diagnosis of narrow and wide QRS-complex tachycardias, but
.
tionmodelsareneeded. .. experienceislimited.
20 ‘What to do’ and ‘what not to do’ messages from the Guidelines
‘Whattodo’messages
RecommendationsfortheacutemanagementofnarrowQRStachycardiaintheabsenceofanestablisheddiagnosis
Recommendation Classa Levelb
Haemodynamicallyunstablepatients
Synchronizeddirect-currentcardioversionisrecommendedforhaemodynamicallyunstablepatients. I B
Haemodynamicallystablepatients
A12-leadECGduringtachycardiaisrecommended. I C
Vagalmanoeuvres,preferablyinthesupinepositionwithlegelevation,arerecommended. I B
Adenosine(6(cid:2)18mgi.v.bolus)isrecommendedifvagalmanoeuvresfail. I B
Synchronizeddirect-currentcardioversionisrecommendedwhendrugtherapyfailstoconvertorcontrolthetachycardia. I B
RecommendationsfortheacutemanagementofwideQRStachycardiaintheabsenceofanestablisheddiagnosis
Haemodynamicallyunstablepatients
Synchronizeddirect-currentcardioversionisrecommendedinhaemodynamicallyunstablepatients. I B
Haemodynamicallystablepatients
A12-leadECGduringtachycardiaisrecommended. I C
Vagalmanoeuvres,preferablyinthesupinepositionwithlegelevation,arerecommended. I C
Synchronizeddirect-currentcardioversionisrecommendedifdrugtherapyfailstoconvertorcontrolthetachycardia. I B
Recommendationsforthetherapyofsinustachycardias
Inappropriatesinustachycardia
Evaluationandtreatmentofreversiblecausesisrecommended.139,144,162 I C
RecommendationsforthetherapyoffocalAT
Acutetherapy
Haemodynamicallyunstablepatients
SynchronizedDCcardioversionisrecommendedforhaemodynamicallyunstablepatients. I B
Haemodynamicallystablepatients
SynchronizedDCcardioversionisrecommendedwhendrugtherapyfailstoconvertorcontrolthetachycardia. I B
Chronictherapy
CatheterablationisrecommendedforrecurrentfocalAT,especiallyifincessantorcausingtachycardiomyopathy. I B
RecommendationsforthetherapyofmultifocalAT
Acutetherapy
Treatmentofanunderlyingconditionisrecommendedasafirststep,iffeasible. I C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 49 ---
ESCGuidelines 703
RecommendationsforthetherapyofmultifocalAT
AnticoagulationasinAFisrecommendedforpatientswithatrialflutterandconcomitantAF. I B
Acutetherapy
Haemodynamicallyunstablepatients
SynchronizedDCcardioversionisrecommendedforhaemodynamicallyunstablepatients. I B
Haemodynamicallystablepatients
Intravenousibutilideori.v.ororal(in-hospital)dofetilideisrecommendedforconversiontosinusrhythmintheabsenceofQTc
I B
intervalprolongation.
Low-energy(<_100Jbiphasic)electricalcardioversionisrecommendedforconversiontosinusrhythm. I B
High-rateatrialpacingisrecommendedforterminationofatrialflutterinthepresenceofanimplantedpacemakeror
I B
defibrillator.
Long-termtherapy
Catheterablationisrecommendedforsymptomatic,recurrentepisodesofcavotricuspidisthmus-dependentflutter. I A
Catheterablationinexperiencedcentresisrecommendedforsymptomatic,recurrentepisodesofnon-CTI-dependentflutter. I B
CatheterablationisrecommendedinpatientswithpersistentatrialflutterorinthepresenceofdepressedLVsystolicfunction
I B
duetotachycardiomyopathy.
RecommendationsforthemanagementofAVNRT
Acutetherapy
Haemodynamicallyunstablepatients
SynchronizedDCcardioversionisrecommendedforhaemodynamicallyunstablepatients.86-88 I B
Haemodynamicallystablepatients
Vagalmanoeuvres,preferablyinthesupinepositionwithlegelevation,arerecommended.41,89-91 I B
Adenosine(6(cid:2)18mgi.v.bolus)isrecommendedifvagalmanoeuvresfail.92-94 I B
SynchronizedDCcardioversionisrecommendedwhendrugtherapyfailstoconvertorcontrolthetachycardia.87,88 I B
Long-termtherapy
Catheterablationisrecommendedforsymptomatic,recurrentAVNRT.208,336-339 I B
RecommendationsforthetherapyofAVRTduetomanifestorconcealedAPs
Acutetherapy
Haemodynamicallyunstablepatients
SynchronizedDCcardioversionisrecommendedforhaemodynamicallyunstablepatients. I B
Haemodynamicallystablepatients
Vagalmanoeuvres,preferablyinthesupinepositionwithlegelevation,arerecommended. I B
Adenosine(6(cid:2)18mgi.v.bolus)isrecommendedifvagalmanoeuvresfailandthetachycardiaisorthodromic. I B
SynchronizedDCcardioversionisrecommendedwhendrugtherapyfailstoconvertorcontrolthetachycardia. I B
Chronictherapy
CatheterablationofAP(s)isrecommendedinpatientswithsymptomatic,recurrentAVRT. I B
Recommendationsfortheacutetherapyofpre-excitedAF
Haemodynamicallyunstablepatients
SynchronizedDCcardioversionisrecommendedinhaemodynamicallyunstablepatients. I B
Haemodynamicallystablepatients
SynchronizedDCcardioversionisrecommendedifdrugtherapyfailstoconvertorcontrolthetachycardia. I B
Recommendationsforthemanagementofpatientswithasymptomaticpre-excitation
PerformanceofanEPS,withtheuseofisoprenaline,isrecommendedtoriskstratifyindividualswithasymptomaticpre-excitation
I B
whohavehighriskoccupations/hobbies,candthosewhoparticipateincompetitiveathletics.
Catheterablationisrecommendedinasymptomaticpatientsinwhomelectrophysiologytestingwiththeuseofisoprenalineiden-
I B
tifieshigh-riskproperties,suchasSPERRI<_250ms,APERP<_250ms,multipleAPs,andaninducibleAP-mediatedtachycardia.
Catheterablationisrecommendedinhigh-riskpatientswithasymptomaticpre-excitationafterdiscussingtherisks,especiallyof
I C
heartblockassociatedwithablationofanteroseptalormid-septalAPs,andbenefitsoftheprocedure.
InvasiveriskstratificationwithanEPSisrecommendedinpatientswithout“lowrisk”characteristicsatnon-invasiverisk
I C
stratification.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 50 ---
704 ESCGuidelines
RecommendationsforthetherapyofSVTsincongenitalheartdiseaseinadults
AnticoagulationforfocalAToratrialfluttershouldbesimilartopatientswithAF. I C
Acutetherapy
Haemodynamicallyunstablepatients
SynchronizedDCcardioversionisrecommendedforhaemodynamicallyunstablepatients. I B
Haemodynamicallystablepatients
Vagalmanoeuvres,preferablyinthesupinepositionwithlegelevation,arerecommended. I B
Adenosine(6(cid:2)18mgi.v.bolus)isrecommendedifvagalmanoeuvresfail. I B
SynchronizedDCcardioversionisrecommendedwhendrugtherapyfailstoconvertorcontrolthetachycardia. I B
RecommendationsforthetherapySVTinpregnancy
CatheterablationisrecommendedinsymptomaticwomenwithrecurrentSVTwhoplantobecomepregnant. I C
Acutetherapy
Immediateelectricalcardioversionisrecommendedforanytachycardiawithhaemodynamicinstability. I C
Vagalmanoeuvresand,ifthesefail,adenosinearerecommendedforacuteconversionofSVT. I C
Chronictherapy
Duringthefirsttrimesterofpregnancyitisrecommendedtoavoidallantiarrhythmicdrugs,ifpossible. I C
RecommendationsforthetherapyofSVTinpatientswithsuspectedorestablishedheartfailureduetotachycardiomyopathy
Recommendation Classa Levelb
CatheterablationisrecommendedfortachycardiomyopathyduetoSVT. I B
Beta-blockers(fromthelistwithprovenmortalityandmorbiditybenefitsinHFrEF)arerecommendedfortachycardiomyopathy
I A
duetoSVT,whencatheterablationfailsorisnotapplicable.
ItisrecommendedtoconsidertachycardiomyopathyinpatientwithreducedLVejectionfractionwithanelevatedheartrate
I B
(>100bpm).
AVnodalablationwithsubsequentpacing(“ablateandpace”),eitherbiventricularorHis-bundlepacing,isrecommendedifthe
I C
tachycardiaresponsibleforthetachycardiomyopathycannotbeablatedorcontrolledbydrugs.
‘Whatnottodo’messages
RecommendationsfortheacutemanagementofwideQRStachycardiaintheabsenceofanestablisheddiagnosis
VerapamilisnotrecommendedinwideQRS-complextachycardiaofunknownaetiology. III B
RecommendationsforthetherapyofMRATs
Acutetherapy
Propafenoneandflecainidearenotrecommendedforconversiontosinusrhythm. III B
RecommendationsforthetherapyofAVRTduetomanifestorconcealedAPs
Chronictherapy
Digoxin,beta-blockers,diltiazem,verapamil,andamiodaronearenotrecommendedandarepotentiallyharmfulinpatientswith
III B
pre-excitedAF.
Recommendationsfortheacutetherapyofpre-excitedAF
Haemodynamicallystablepatients
Amiodarone(i.v.)isnotrecommended. III B
RecommendationsforthetherapyofSVTsincongenitalheartdiseaseinadults
Chronictherapy
Sotalolisnotrecommendedasafirst-lineantiarrhythmicdrugasitisrelatedtoanincreasedriskofpro-arrhythmiasand
III C
mortality.
Flecainideandpropafenonearenotrecommendedasfirst-lineantiarrhythmicdrugsinpatientswithventriculardysfunctionand
III C
severefibrosis.
RecommendationsforthetherapyofSVTinpregnancy
Chronictherapy
Amiodaroneisnotrecommendedinpregnantwomen. III C
AF=atrialfibrillation;AP=accessorypathway;AT=atrialtachycardia;AVNRT=atrioventricularnodalre-entranttachycardia;AVRT=atrioventricularre-entranttachycardia;
CTI=cavotricuspidisthmus;DC=directcurrent;ECG=electrocardiogram;EPS=electrophysiologystudy;ERP=effectiverefractoryperiod;HF=heartfailure;i.v.=intrave-
nous; MRAT = macro-re-entrant atrial tachycardia; SPERRI = shortest pre-excited RR interval during atrial fibrillation; SVT = supraventricular tachycardia; TCM =
tachycardiomyopathy.
aClassofrecommendation.
bLevelofevidence.
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 51 ---
ESCGuidelines 705
.
21 Areas for further research .. identifiedasapotentialfirstclinicalmanifestationofconcealedBrugada
.
.. syndrome,particularlyinfemalepatients.595Ithasbeenpostulatedthat
.
With the advent of catheter ablation in the 1990s, resulting in the .. geneticvariantsthatreducethesodiumcurrentmaypredisposeindivid-
.
successful elimination of APs in symptomatic patients, AVRT now .. uals to expression of both phenotypes. Cellular electrophysiology is
.
represents<20%ofallSVTs.11,13ThefrequencyofAVNRT,which .. now being integrated into genetic analysis. The coupling of whole-
.
used to account for 50% of all SVT cases,14 has changed to .. exomesequencingwithcellularelectrophysiologicalfunctionalanalysis
.
(cid:4)30%,11,13andtheproliferationofAFablationwillunavoidablyresult .. mayelucidatetheunderlyingpathophysiologicalmechanismresponsible
.
.
inmoreiatrogenicleftatrialMRAT.Moreover,theprolongedsurvival . forcertainphenotypes.596Recently,afamilialformofISTwasshownto
.
.
of paediatric and ACHD patients is expected to impose a further .. beassociatedwithagain-of-functionmutationintheHCN4pacemaker
.
challenge on electrophysiologists, who will encounter even more .. channel(R524Q),conferringanincreasedsensitivitytothesecondmes-
.
complexMRATs.Severalimportantadvancesinthefieldofanatomi- .. senger cyclic AMP, which is a key mediator in sympathetic modula-
.
calandelectricalmapping,aswellasourappreciationofscartissue .. tion.597 These developments may have important implications for a
.
and the transmurality of ablation lesions, should improve our effi- .. morespecificdiagnosticandpersonalizedtherapeuticapproachinSVT.
.
ciencyintreatingthesepatients. .. Future research should define actionable patient-specific molecular
.
Thepastdecadehaswitnessedarapidevolutionofablationequip- .. arrhythmia mechanisms, clarify the responses of the underlying sub-
.
mentandelectrode-guidingsystems,whichhasresultedinmorecon- .. stratestointerventions,andachieveselectivesupraventriculartargeting
.
trollableandsaferprocedures.Intracardiacechocardiography,robotic .. ofspecificarrhythmicmechanismswithdrugs.
.
techniques, and sophisticated anatomical navigation systems have .. SVTsarenotonlyaneverydayclinicalproblem,withAVNRTbeing
.
beendeveloped,anditisnowpossibletoperformablationwithout .. themostcommonregulararrhythmiainhumans.Theyalsoprovide
.
exposing the operator to radiation and ergonomically unfavourable .. thebackgroundforpropertrainingoffutureelectrophysiologistsby
.
positions.581Newmaterialsforelectrodesandotherequipmenthave .. means of their well-defined circuits, in most cases, and predictable
.
allowedtheconceptofaradiation-freeelectrophysiologylaboratory .. responsesintheelectrophysiologylaboratory.Intheeraofcompu-
.
withtheuseofCMR.Thevisionofafullyradiation-free,magneticlab- .. terizedapproachesthatarenowavailableforAF,complexAT,and
.
oratoryinthefutureisnotsciencefictionanymore.582 .. VT ablation, this is very important for a rational, Aristotelian
.
Therevolutionincomputertechnologyoffersnotonlyimproved .. approachtotheartofmedicine.598
.
mappingandelectrode-movingsystems,butalsotheenhancementof ..
.
.
specific SVT classification schemes with fully automated algorithms .
.
.
that may greatly assist emergency departments, ambulances, and . 22 Supplementary data
.
monitoredpatients.583Mathematicalmodellingandnumericalanaly- ..
.
.
ses have also been employed in the investigation of the circuit of . Supplementary Data with additional Supplementary Figures and text
.
AVNRT.317,329FurtheranalysisofrecordedECGsusingfastFourier .. complementingthefulltext,aswellassectionsontheelectrophysiologi-
.
.
andGaussianmodelsmayalsoprovideusefuldiagnosticinformation . calmechanismsofSVT,tachycardiacircuits,andcardiacanatomyforthe
.
aboutthenatureofthetachycardia.Novelelectroanatomicalmap- .. electrophysiologist,alongwiththerelatedsupplementaryreferences,are
.
pingsystemsare beingdevelopedtoassisttheidentificationofthe .. availableontheEuropeanHeartJournalwebsiteandviatheESCwebsiteat
.
. www.escardio.org/guidelines.
tachycardiamechanismandoptimalablationsiteofSVT,and,espe- .
.
.
cially,complexatrialmacro-re-entranttachycardias,withreducedflu- .
.
. oroscopy times.584(cid:2)589 Systems are now available that allow the .. 23 Appendix
.
simultaneousvisualizationofactivationandvoltage.Theimplications ..
.
thatthesemayhaveoncharacterizingthetachycardiasubstrate,and .. Author/TaskForceMemberAffiliations .
notjustthecircuit,requirefutureresearch. .. Elena Arbelo, Arrhythmia Unit, Cardiovascular Institute, Hospital .
NewdataonthegeneticsofSVTcontinuallyappearsincetheidentifi- .. Clinic de Barcelona, Universitat de Barcelona, Spain; Cardiovascular
.
cationofamissensemutationinthePRKAG2gene,whichencodesthe .. Institute,HospitalCl(cid:2)ınic,UniversitatdeBarcelona,Barcelona,Spain;and
.
regulatory c-subunit of adenosine monophosphate (AMP)-activated .. Institut d’Investigacio(cid:2) August Pi i Sunyer (IDIBAPS), Centro de
.
protein kinase, as a cause of familial WPW syndrome.590,591 The .. Investigacio(cid:2)n Biome´dica en Red de Enfermedades; Barcelona, Spain;
.
R302QmutationinPRKAG2hasbeenassociatedwithMahaimfibers.592 ..
Fernando Arribas, Department of Cardiology, Hospital 12 de
.
AnovelformofWPWsyndromeisassociatedwithmicrodeletionof .. Octubre,Madrid,Spain;JeroenJ.Bax,Cardiology,LeidenUniversity
.
theBMP2gene,whichencodesbonemorphogeneticprotein-2,amem- .. Medical Center, Leiden, Netherlands; Carina Blomstro¨m-
.
berofthetransforminggrowthfactor-betagenesuperfamily,andaffects .. Lundqvist, Department of Medical Science and Cardiology, Uppsala
.
thedevelopmentofannulusfibrosus.593Otherrare,geneticformsof ..
University,Uppsala,Sweden;HughCalkins,Cardiology,JohnHopkins
.
pre-excitation have also been described.398 Whether this kind of ... MedicalInstitutions,Baltimore,UnitedStatesofAmerica;SpyridonG.
.
geneticpredispositiontranslatesintoahigherventricularfibrillationrisk .. Deftereos, 2nd Department of Cardioloy, National and Kapodistrian
.
remainstobeseen.GeneticanimalmodelsofWPWthatexpressmuta- .. University of Athens, Athens, Greece; Gerhard-Paul Diller,
.
tions(suchasofthegeneencodingtheAMP-activatedproteinkinase) .. CardiologyIII,UniversityHospitalMuenster,Muenster,Germany;Juan
.
responsibleforafamilialformofWPWsyndromewithaphenotype .. J. Gomez-Doblas, Cardiology, Hospital Universitario Virgen de la
.
identicaltothatofthehumansyndromehavebeendeveloped,andmay .. Victoria, CIBERG, Malaga, Spain; Bulent Gorenek, Cardiology
.
provideinsightintothedevelopmentandpropertiesofthecardiaccon- .. Department,EskisehirOsmangaziUniversity,Turkey;AndrewGrace,
duction system and APs.594 Spontaneous AVNRT has also been .. DepartmentofCardiology,RoyalPapworthHospitalNHSFoundation
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 52 ---
706 ESCGuidelines
.
.
Trust, Cambridge University Health Partners, Cambridge, United . Kosovo(Republicof):KosovoSocietyofCardiology,HakiJashari;
.
.
Kingdom; Siew Yen Ho, Cardiac Morphology, Royal Brompton . Kyrgyzstan:KyrgyzSocietyofCardiology,OlgaLunegova;Latvia:
.
.
Hospital,London,UnitedKingdom;Juan-CarlosKaski,Molecularand . Latvian Society ofCardiology, Kristine Jubele; Lebanon: Lebanese
.
.
ClinicalSciencesResearchInstitute,StGeorge’sUniversityofLondon, . Society of Cardiology, Marwan M. Refaat; Lithuania: Lithuanian
.
.
London, United Kingdom; Karl-Heinz Kuck, Cardiology, Asklepios . Society of Cardiology, Aras Puodziukynas; Luxembourg:
.
.
Klinik St. Georg, Hamburg, Germany; Pier David Lambiase, . Luxembourg Society of Cardiology, Laurent Groben; Moldova
.
.
Cardiology, UCL & Barts Heart Centre, London, United Kingdom; . (Republic of): Moldavian Society of Cardiology, Aurel Grosu;
.
.
Frederic Sacher, Service de Rythmologie, IHU LIRYC/Bordeaux . Montenegro:MontenegroSocietyofCardiology,NikolaPavlovic;
.
.
UniversityHospital,Bordeaux,France;GeorgiaSarquella-Brugada, .. Morocco: Moroccan Society of Cardiology, Fellat Ibtissam;
.
Arrhythmia,InheritedCardiacDiseaseandSuddenDeathUnit,Hospital .. Netherlands:NetherlandsSocietyofCardiology,SergeA.Trines;
.
SantJoandeDe´u,Barcelona,Spain;PiotrSuwalski,CentralClinical .. North Macedonia: North Macedonian Society of Cardiology,
.
Hospital of the Ministry of Interior and Administration, Centre of .. LidijaPoposka;Norway:NorwegianSocietyofCardiology,Kristina
.
Postgraduate Medical Education, Warsaw, Poland; Antonio Zaza, .. H. Haugaa; Poland: Polish Cardiac Society, Oskar Kowalski;
.
Universit(cid:3)a degliStudiMilano-Bicocca,DipartimentodiBiotecnologiee .. Portugal: Portuguese Society of Cardiology, Diogo Cavaco;
.
Bioscienze,BldgU3, p.zadellaScienza2,20126Milano,Italy. .. Romania: Romanian Society of Cardiology, Dan Dobreanu;
.
.. Russian Federation: Russian Society of Cardiology, Evgeny N.
.
ESC Committee for Practice Guidelines (CPG): Stephan .. Mikhaylov;SanMarino:SanMarinoSocietyofCardiology,Marco
.
Windecker (Chairperson) (Switzerland), Victor Aboyans (France), .. Zavatta; Serbia: Cardiology Society of Serbia, Mujovi(cid:2)c Neboj(cid:4)sa;
.
ColinBaigent(UnitedKingdom),Jean-PhilippeCollet(France),Veronica .. Slovakia:SlovakSocietyofCardiology,PeterHlivak;Spain:Spanish
.
Dean (France), Victoria Delgado (Netherlands), Donna Fitzsimons .. SocietyofCardiology,IgnacioFerreira-Gonzalez;Sweden:Swedish
.
.
(United Kingdom), Chris P. Gale (United Kingdom), Diederick E. . Society of Cardiology, Tord Juhlin; Switzerland: Swiss Society of
.
.
Grobbee (Netherlands), Sigrun Halvorsen (Norway), Gerhard . Cardiology,TobiasReichlin;Tunisia:TunisianSocietyofCardiology
.
.
Hindricks(Germany),BernardIung(France),PeterJu¨ni(Canada),Hugo . and Cardio-Vascular Surgery, Habib Haouala; Turkey: Turkish
.
.
A.Katus(Germany),UlfLandmesser(Germany),ChristopheLeclercq . SocietyofCardiology,TaylanAkgun;UnitedKingdomofGreat
.
.
(France),MaddalenaLettino(Italy),BasilS.Lewis(Israel),BelaMerkely . Britain and Northern Ireland: British Cardiovascular Society,
.
.
(Hungary),ChristianMueller(Switzerland),SteffenE.Petersen(United . DhirajGupta.
.
.
Kingdom), Anna Sonia Petronio (Italy), Dimitrios J. Richter (Greece), .
.
.
MarcoRoffi(Switzerland),EvgenyShlyakhto(RussianFederation),Iain .
. 24 References
.
A.Simpson(UnitedKingdom),MiguelSousa-Uva(Portugal),RhianM. .
.. 1. Blomstro¨m-LundqvistC,ScheinmanMM,AliotEM,AlpertJS,CalkinsH,Camm
Touyz(UnitedKingdom). .. AJ, Campbell WB, Haines DE, Kuck KH, Lerman BB, Miller DD, Shaeffer CW,
.
. StevensonWG,TomaselliGF.ACC/AHA/ESCguidelinesforthemanagementof
.
ESCNationalCardiacSocietiesactivelyinvolvedinthereview
.... p Aa mti ee rn it cs anw cit oh lles gu epr oa fve can rt dri ic ou lola gr y/a Ar mrh ey rt ih cm ania hs– ee ax rtec au ssti ov ce ias tiu om nm taa sr ky: foa rcr eep oo nrt pro af ctt ih ce
e
processofthe2019ESCGuidelinesforthemanagementofpatients .. guidelinesandtheEuropeansocietyofcardiologycommitteeforpracticeguide-
.
withsupraventriculartachycardia: .. lines (writing committee to develop guidelines for the management of patients
.. withsupraventriculararrhythmias)developedincollaborationwithNASPE-Heart
.. RhythmSociety.JAmCollCardiol2003;42:1493(cid:2)1531.
Algeria:AlgerianSocietyofCardiology,WalidAmara;Armenia: .. 2. PageRL,JoglarJA,CaldwellMA,CalkinsH,ContiJB,DealBJ,EstesNAM,Field
. Armenian Cardiologists Association, Svetlana Grigoryan; Austria: .. ME,GoldbergerZD,HammillSC,IndikJH,LindsayBD,OlshanskyB,RussoAM,
Austrian Society of Cardiology, Andrea Podczeck-Schweighofer;
... ShenW-K,TracyCM,Al-KhatibSM.2015ACC/AHA/HRSguidelinefortheman-
. agementofadultpatientswithsupraventriculartachycardia:executivesummary:a
Belarus: Belorussian Scientific Society of Cardiologists, Alexandr .. reportoftheAmericanCollegeofCardiology/AmericanHeartAssociationTask .
Chasnoits; Belgium: Belgian Society of Cardiology, Yves .. Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll
Vandekerckhove; Bosnia and Herzegovina: Association of
... Cardiol2016;67:1575(cid:2)1623.
. 3. KatritsisDG,BorianiG,CosioFG,HindricksG,JaisP,JosephsonME,KeeganR,
Cardiologists of Bosnia and Herzegovina, Sekib Sokolovich; .. Kim Y-H, Knight BP, Kuck K-H, Lane DA, Lip GYH, Malmborg H, Oral H,
.
Bulgaria:BulgarianSocietyofCardiology,VassilTraykov;Croatia: .. Pappone C, Themistoclakis S, Wood KA, Blomstro¨m-Lundqvist C. European
.. HeartRhythmAssociation(EHRA)consensusdocumentonthemanagementof
Croatian Cardiac Society, Bosko Skoric; Cyprus: Cyprus Society .
. supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-
.
ofCardiology,EliasPapasavvas;CzechRepublic:CzechSocietyof .. Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de
Cardiology, Josef Kautzner; Denmark: Danish Society of .. Estimulacio(cid:2)n Cardiaca y Electrofisiologia (SOLAECE). Eur Heart J
.
. 2018;39:1442(cid:2)1445.
Cardiology,SamRiahi;Estonia:EstonianSocietyofCardiology,Priit .
. 4. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M,
.
Kampus;Finland:FinnishCardiacSociety,HannuParikka;France: .. Diener H-C, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J,
French Society of Cardiology, Olivier Piot; Georgia: Georgian .. Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron
.
. EsquiviasG,BudtsW,CarerjS,CasselmanF,CocaA,DeCaterinaR,Deftereos
Society of Cardiology, Kakhaber Etsadashvili; Germany: German .
. S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M,
.
Cardiac Society, Christoph Stellbrink; Greece: Hellenic Society of .. HohnloserSH,KolhP,LipGYH,ManolisA,McMurrayJ,PonikowskiP,Rosenhek
.
Cardiology, Antonis S. Manolis; Hungary: Hungarian Society of . R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van
.
. Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC
Cardiology, Zolt(cid:2)an Csan(cid:2)adi; Iceland: Icelandic Society of .
.. Guidelines for the management of atrial fibrillation developed in collaboration
Cardiology, Kristjan Gudmundsson; Ireland: Irish Cardiac Society, .. withEACTS.EurHeartJ2016;37:2893(cid:2)2962.
.
John Erwin; Israel: Israel Heart Society, Alon Barsheshet; Italy: .. 5. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG,
. BadhwarV,BrugadaJ,CammJ,ChenPS,ChenSA,ChungMK,NielsenJC,Curtis
Italian Federation of Cardiology, Roberto De Ponti; Kazakhstan: ...
AB, Davies DW, Day JD, d’Avila A, de Groot N, DiBiaseL, Duytschaever M,
Association of Cardiologists of Kazakhstan, Ayan Abdrakhmanov; . Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP,
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 53 ---
ESCGuidelines 707
.
.
HainesDE,HaissaguerreM,HelmRH,HylekE,JackmanWM,JalifeJ,KalmanJM, . 23. Granada J, Uribe W, Chyou P-H, Maassen K, Vierkant R, Smith PN, Hayes J,
.
KautznerJ, Kottkamp H, Kuck KH, Kumagai K, Lee R,LewalterT, Lindsay BD, . EakerE,VidailletH.Incidenceandpredictorsofatrialflutterinthegeneralpopu-
.
MacleL,MansourM,MarchlinskiFE,MichaudGF,NakagawaH,NataleA,Nattel .. lation.JAmCollCardiol2000;36:2242(cid:2)2246.
S,OkumuraK,PackerD,PokushalovE,ReynoldsMR,SandersP,ScanavaccaM, .. 24. Withers KL, White J, Carolan-Rees G, Patrick H, O’Callaghan P, Murray S,
.
Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T. 2017 HRS/ . Cunningham D, Wood KA, Lencioni M, Griffith M. Patient reported outcome
.
EHRA/ECAS/APHRS/SOLAECEexpertconsensusstatementoncatheterandsur- .. measuresforcardiacablationprocedures:amulticentrepilottodevelopanew
gicalablationofatrialfibrillation:executivesummary.Europace2018;20:157(cid:2)208. .. questionnaire.Europace2014;16:1626(cid:2)1633.
.
6. MairesseGH,MoranP,VanGelderIC,ElsnerC,RosenqvistM,MantJ,Banerjee . 25. WoodKA,StewartAL,DrewBJ,ScheinmanMM,FroelicherES.Patientpercep-
.
A, Gorenek B, Brachmann J, Varma N, Glotz de Lima G, Kalman J, Claes N, . tionofsymptomsandqualityoflifefollowingablationinpatientswithsupraven-
.
Lobban T, Lane D, Lip GYH, Boriani G; ESC Scientific Document Group. .. triculartachycardia.HeartLung2010;39:12(cid:2)20.
Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) .. 26. White J, Withers KL, Lencioni M, Carolan-Rees G, Wilkes AR, Wood KA,
.
consensusdocumentendorsedbytheHeartRhythmSociety(HRS),AsiaPacific . PatrickH,CunninghamD,GriffithM.Cardiffcardiacablationpatient-reported
.
HeartRhythmSociety(APHRS), andSociedadLatinoamericanadeEstimulacion . outcomemeasure(C-CAP):validationofanewquestionnairesetforpatients
.
CardiacayElectrofisiologia(SOLAECE).Europace2017;19:1589(cid:2)1623. .. undergoing catheter ablation for cardiac arrhythmias in the UK. Qual Life Res
.
7. LipGYH,ColletJP,HaudeM,HuberK.Managementofantithrombotictherapyin . 2016;25:1571(cid:2)1583.
.
AFpatientspresentingwithACSand/orundergoingPCI:asummaryoftheJoint . 27. BrachmannJ,LewalterT,KuckKH,AndresenD,WillemsS,SpitzerSG,Straube
.
Consensus Document of the European Heart Rhythm Association (EHRA), .. F, Schumacher B, Eckardt L, Danilovic D, Thomas D, Hochadel M, Senges J.
European Society of Cardiology Working Group on Thrombosis, European .. Long-term symptom improvement and patient satisfaction following catheter
.
AssociationofPercutaneousCardiovascularInterventions(EAPCI)andEuropean . ablationofsupraventriculartachycardia:insightsfromtheGermanablationregis-
.
Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm . try.EurHeartJ2017;38:1317(cid:2)1326.
.
Society(HRS),Asia-PacificHeartRhythmSociety(APHRS),LatinAmericaHeart .. 28. Farkowski MM, Pytkowski M, Maciag A, Golicki D, Wood KA, Kowalik I,
Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa .. KuteszkoR,SzwedH.Gender-relateddifferencesinoutcomesandresourceuti-
.
(CASSA).EurHeartJ2018;39:2847(cid:2)2850. . lizationinpatientsundergoingradiofrequencyablationofsupraventriculartachy-
.
8. Wit AL, Wellens HJ, Josephson ME. Electrophysiological foundations of cardiac .. cardia:resultsfromPatients’PerspectiveonRadiofrequencyCatheterAblation
arrhythmias.1sted.Minneapolis:CardiotextPublishing;2017. .. ofAVRTandAVNRTStudy.Europace2014;16:1821(cid:2)1827.
.
9. OrejarenaLA,VidailletH,DeStefanoF,NordstromDL,VierkantRA,SmithPN, . 29. FeldmanA,VoskoboinikA,KumarS,SpenceS,MortonJB,KistlerPM,SparksPB,
.
HayesJJ.Paroxysmalsupraventriculartachycardiainthegeneralpopulation.JAm . VohraJK,KalmanJM.Predictorsofacuteandlong-termsuccessofslowpathway
.
CollCardiol1998;31:150(cid:2)157. .. ablationforatrioventricularnodalreentranttachycardia:asinglecenterseriesof
10. Wu M-H, Chen H-C, Kao F-Y, Huang S-K. Postnatal cumulative incidence of .. 1,419consecutivepatients.PacingClinElectrophysiol2011;34:927(cid:2)933.
.
supraventricular tachycardia in a general pediatric population: a national birth . 30. Zimetbaum P,JosephsonME.Evaluationof patients with palpitations.N Engl J
.
cohortdatabasestudy.HeartRhythm2016;13:2070(cid:2)2075. . Med1998;338:1369(cid:2)1373.
.
11. Garc(cid:2)ıa-Fern(cid:2)andezFJ,Ib(cid:2)a~nezCriadoJL,QuesadaDoradorA;collaboratorsofthe .. 31. PageRL,WilkinsonWE,ClairWK,McCarthy EA,PritchettEL.Asymptomatic
.
Spanish Catheter Ablation Registry; REGISTRY COLLABORATORS. Spanish . arrhythmiasinpatientswithsymptomaticparoxysmalatrialfibrillationandparox-
.
Catheter Ablation Registry. 17th Official Report of the Spanish Society of . ysmalsupraventriculartachycardia.Circulation1994;89:224(cid:2)227.
.
CardiologyWorkingGrouponElectrophysiologyandArrhythmias(2017).Rev .. 32. ThavendiranathanP,BagaiA,KhooC,DorianP,ChoudhryNK.Doesthispatient
EspCardiol(EnglEd)2018;71:941(cid:2)951. .. withpalpitationshaveacardiacarrhythmia?JAMA2009;302:2135(cid:2)2143.
.
12. HosseiniSM,RozenG,SalehA,VaidJ,BitonY,MoazzamiK,HeistEK,Mansour . 33. LeitchJW,KleinGJ,YeeR,LeatherRA,KimYH.Syncopeassociatedwithsupra-
.
MC,KaadanMI,VangelM,RuskinJN.Catheterablationforcardiacarrhythmias: . ventricular tachycardia. An expression of tachycardia rate or vasomotor
.
utilization and in-hospital complications, 2000 to 2013. JACC Clin Electrophysiol .. response?Circulation1992;85:1064(cid:2)1071.
2017;3:1240(cid:2)1248. .. 34. Thiruganasambandamoorthy V, Rowe BH, Sivilotti MLA, McRae AD, Arcot K,
.
13. Holmqvist F, Kesek M, Englund A, Blomstro¨m-Lundqvist C, Karlsson LO, . NemnomMJ,HuangL,MukarramM,KrahnAD,WellsGA,TaljaardM.Duration
.
Kenneb€ackG,Poc¸iD,Samo-AyouR,Sigurjo(cid:2)nsdo(cid:2)ttirR,RingbornM,HerczkuC, .. ofelectrocardiographicmonitoringofemergencydepartmentpatientswithsyn-
CarlsonJ,FengsrudE,TabriziF,Ho¨glundN,Lo¨nnerholmS,KongstadO,Jo¨nsson .. cope.Circulation2019;139:1396(cid:2)1406.
.
A,InsulanderP.AdecadeofcatheterablationofcardiacarrhythmiasinSweden: . 35. RazaviM,LuriaDM,JahangirA,HodgeDO,LowPA,ShenW-K.Acuteblood
.
ablationpracticesandoutcomes.EurHeartJ2019;40:820(cid:2)830. . pressurechangesaftertheonsetofatrioventricularnodalreentranttachycardia:
.
14. PorterMJ,MortonJB,DenmanR,LinAC,TierneyS,SantucciPA,CaiJJ,Madsen .. atime-courseanalysis.JCardiovascElectrophysiol2005;16:1037(cid:2)1040.
N,WilberDJ.Influenceofageandgenderonthemechanismofsupraventricular .. 36. AbeH,NagatomoT,KobayashiH,MiuraY,ArakiM,KuroiwaA,NakashimaY.
.
tachycardia.HeartRhythm2004;1:393(cid:2)396. . Neurohumoralandhemodynamicmechanismsofdiuresisduringatrioventricular
. 15. Gonzalez-TorrecillaE,AlmendralJ,ArenalA,AtienzaF,AteaLF,delCastilloS, . nodalreentranttachycardia.PacingClinElectrophysiol1997;20(11):2783-2788.
.
Fernandez-Aviles F. Combined evaluation of bedside clinical variables and the .. 37. ChinenS,MiuraM,TamameT,MatsuokaM,OhkiH,SumitomoN.Life-threat-
electrocardiogram for the differential diagnosis of paroxysmal atrioventricular .. eningatrialtachycardiaaftertheSenningoperationinapatientwithtransposition
.
reciprocating tachycardias in patients without pre-excitation. J Am Coll Cardiol . ofthegreatarteries.HeartVessels2012;27:424(cid:2)427. .
2009;53:2353(cid:2)2358. .. 38. Gu¨rsoyS,SteurerG,BrugadaJ,AndriesE,BrugadaP.Thehemodynamicmecha-
16. LiubaI,Jo¨nssonA,S€afstro¨mK,WalfridssonH.Gender-relateddifferencesinpatients .. nismofpoundingintheneckinatrioventricularnodalreentranttachycardia.N
. withatrioventricularnodalreentrytachycardia.AmJCardiol2006;97:384(cid:2)388. . EnglJMed1992;327:772(cid:2)774.
.
17. Rosano GMC, Leonardo F, Rosano GMC, De Luca F, Sarrel PM, Beale CM, . 39. Contreras-Valdes FM, Josephson ME. IMAGES IN CLINICAL MEDICINE.
.
Collins P. Cyclical variation in paroxysmal supraventricular tachycardia in .. “Frog sign” in atrioventricular nodal reentrant tachycardia. N Engl J Med
women.Lancet1996;347:786(cid:2)788. .. 2016;374:e17.
.
18. ChangS-H,KuoC-F,ChouI-J,SeeL-C,YuK-H,LuoS-F,ChiouM-J,ZhangW, . 40. Lessmeier TJ, Gamperling D, Johnson-Liddon V, Fromm BS, Steinman RT,
.
DohertyM,WenM-S,ChenW-J,YehY-H.Outcomesassociatedwithparoxysmal . MeissnerMD,LehmannMH.Unrecognizedparoxysmalsupraventriculartachy-
.
supraventriculartachycardiaduringpregnancy.Circulation2017;135:616(cid:2)618. .. cardia: potential for misdiagnosis as panic disorder. Arch Intern Med
.
19. KrahnAD,ManfredaJ,TateRB,MathewsonFL,CuddyT.Thenaturalhistoryof . 1997;157:537(cid:2)543.
.
electrocardiographic preexcitation in men:the Manitoba Follow-up Study. Ann . 41. AppelboamA,ReubenA,MannC,GaggJ,EwingsP,BartonA,LobbanT,Dayer
.
InternMed1992;116:456(cid:2)460. .. M,VickeryJ,BengerJ.PosturalmodificationtothestandardValsalvamanoeuvre
20. VidailletHJJ,PressleyJC,HenkeE,HarrellFEJ,GermanLD.Familialoccurrence .. for emergency treatment of supraventricular tachycardias (REVERT): a rando-
.
ofaccessoryatrioventricularpathways(preexcitationsyndrome).NEnglJMed . misedcontrolledtrial.Lancet2015;386:1747(cid:2)1753.
.
1987;317:65(cid:2)69. . 42. WangR,BlackburnG,DesaiM,PhelanD,GillinovL,HoughtalingP,GillinovM.
.
21. LuC-W,WuM-H,ChenH-C,KaoF-Y,HuangS-K.Epidemiologicalprofileof .. Accuracyofwrist-wornheartratemonitors.JAMACardiol2017;2:104(cid:2)106.
Wolff(cid:2)Parkinson(cid:2)White syndrome in a general population younger than 50 .. 43. KatritsisDG,MarkDB,GershBJ.Revascularizationinstablecoronarydisease:
.
years of age in an era of radiofrequency catheter ablation. Int J Cardiol . evidenceanduncertainties.NatRevCardiol2018;15:408(cid:2)419.
.
2014;174:530(cid:2)534. .. 44. Michowitz Y, Tovia-Brodie O, Heusler I, Sabbag A, Rahkovich M, Shmueli H,
22. SkovMW,RasmussenPV,GhouseJ,HansenSM,GraffC,OlesenMS,Pietersen .. GlickA,BelhassenB.DifferentiatingtheQRSmorphologyofposteriorfascicular
.
A, Torp-Pedersen C,Haunsø S,Køber L, Svendsen JH, Holst AG, NielsenJB. . ventriculartachycardia fromrightbundlebranchblockandleftanteriorhemi-
.
Electrocardiographicpreexcitationandriskofcardiovascularmorbidityandmor- . blockaberrancy.CircArrhythmElectrophysiol2017;10:e005074.
.
tality. Results from the Copenhagen ECG Study. Circ Arrhythm Electrophysiol .. 45. KatritsisDG,JosephsonME.Differentialdiagnosisofregular,narrow-QRStachy-
2017;10:e004778. . cardias.HeartRhythm2015;12:1667(cid:2)1676.
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 54 ---
708 ESCGuidelines
.
.
46. Roberts-ThomsonKC,KistlerPM,KalmanJM.FocalatrialtachycardiaI:clinical . 70. KindwallKE,BrownJ,JosephsonME.Electrocardiographiccriteriaforventricular
.
features,diagnosis,mechanisms,andanatomiclocation.PacingClinElectrophysiol . tachycardiainwidecomplexleftbundlebranchblockmorphologytachycardias.
.
2006;29:643(cid:2)652. .. AmJCardiol1988;61:1279(cid:2)1283.
47. KatritsisDG,BeckerA.Theatrioventricularnodalreentranttachycardiacircuit: .. 71. VereckeiA,DurayG,Sze´n(cid:2)asiG,AltemoseGT,MillerJM.Newalgorithmusing
.
aproposal.HeartRhythm2007;4:1354(cid:2)1360. . onlyleadaVRfordifferentialdiagnosisofwideQRScomplextachycardia.Heart
.
48. Ja¨ısP,MatsuoS,KnechtS,WeerasooriyaR,HociniM,SacherF,WrightM,Nault .. Rhythm2008;5:89(cid:2)98.
I,LelloucheN,KleinG,Cle´mentyJ,Ha¨ıssaguerreM.Adeductivemappingstrat- .. 72. PavaLF,Peraf(cid:2)anP,BadielM,ArangoJJ,MontL,MorilloCA,BrugadaJ.R-wave
.
egyforatrialtachycardiafollowingatrialfibrillationablation:importanceoflocal- . peaktimeatDII:anewcriterionfordifferentiatingbetweenwidecomplexQRS
.
izedreentry.JCardiovascElectrophysiol2009;20:480(cid:2)491. . tachycardias.HeartRhythm2010;7:922(cid:2)926.
.
49. GreenM,HeddleB,DassenW,WehrM,AbdollahH,BrugadaP,WellensHJ. .. 73. SteurerG,GursoyS,FreyB,SimonisF,AndriesE,KuckK,BrugadaP.Thediffer-
ValueofQRSalterationindeterminingthesiteoforiginofnarrowQRSsupra- .. ential diagnosis on the electrocardiogram between ventricular tachycardia and
.
ventriculartachycardia.Circulation1983;68:368(cid:2)373. . preexcitedtachycardia.ClinCardiol1994;17:306(cid:2)308.
.
50. ChenSA,TaiCT,ChiangCE,ChangMS.Roleofthesurfaceelectrocardiogram . 74. JastrzebskiM,MoskalP,KuklaP,FijorekK,KisielR,CzarneckaD.Specificityof
.
in the diagnosis of patients with supraventricular tachycardia. Cardiol Clin .. wideQRScomplextachycardiacriteriaandalgorithmsinpatientswithventricu-
.
1997;15:539(cid:2)565. . larpreexcitation.AnnNoninvasiveElectrocardiol2018;23:e12493.
.
51. MoradyF.SignificanceofQRSalternansduringnarrowQRStachycardias.Pacing . 75. Alberca T, Almendral J, Sanz P, Almazan A, Cantalapiedra JL, Delc(cid:2)an JL.
.
ClinElectrophysiol1991;14:2193(cid:2)2198. .. Evaluation of the specificity of morphological electrocardiographic criteria for
52. CrawfordTC,MukerjiS,GoodE,ChughA,BogunF,PelosiF,OralH,MoradyF, .. thedifferentialdiagnosisofwideQRScomplextachycardiainpatientswithintra-
.
JongnarangsinK.Utilityofatrialandventricularcyclelengthvariabilityindeter- . ventricularconductiondefects.Circulation1997;96:3527(cid:2)3533.
.
mining the mechanism of paroxysmal supraventricular tachycardia. J Cardiovasc . 76. CeresnakSR,LibermanL,AvasaralaK,TanelR,MotonagaKS,DubinAM.Are
.
Electrophysiol2007;18:698(cid:2)703. .. wide complex tachycardia algorithms applicable in children and patients with
53. BogossianH,NiniosI,FrommeyerG,BandorskiD,EckardtL,LemkeB,ZarseM. .. congenitalheartdisease?JElectrocardiol2010;43:694(cid:2)700.
.
Uwaveduringsupraventriculartachycardia:simulationofalongRPtachycardia . 77. JastrzebskiM,KuklaP,CzarneckaD,Kawecka-JaszczK.Specificityofthewide
.
and hiding the common type AVNRT. Ann Noninvasive Electrocardiol .. QRScomplextachycardiaalgorithmsinrecipientsofcardiacresynchronization
2015;20:292(cid:2)295. .. therapy.JElectrocardiol2012;45:319(cid:2)326.
.
54. NagashimaK,WatanabeI,OkumuraY,KanekoY,SonodaK,KogawaR,Sasaki . 78. LauEW,NgGA.Comparisonoftheperformanceofthreediagnosticalgorithms
.
N, Iso K, Takahashi K, Kurokawa S, Nakai T, Ohkubo K, Hirayama A. . for regular broad complex tachycardia in practical application. Pacing Clin
.
Ventriculoatrial intervals <_70 ms in orthodromic atrioventricular reciprocating .. Electrophysiol2002;25:822(cid:2)827.
tachycardia.PacingClinElectrophysiol2016;39:1108(cid:2)1115. .. 79. IsenhourJL,CraigS,GibbsM,LittmannL,RoseG,RischR.Wide-complextachy-
.
55. Letsas KP, Weber R, Herrera Siklo(cid:2)dy C, Mihas CC, Stockinger J, Blum T, . cardia: continued evaluation of diagnostic criteria. Acad Emerg Med
.
Kalusche D, Arentz T. Electrocardiographic differentiation of common type . 2000;7:769(cid:2)773.
.
atrioventricular nodal reentrant tachycardia from atrioventricular reciprocating .. 80. BaxiRP,HartKW,VereckeiA,MillerJ,ChungS,ChangW,GottesmanB,Hunt
.
tachycardia via a concealed accessory pathway. Acta Cardiologica . M, Culyer G, Trimarco T, Willoughby C, Suarez G, Lindsell CJ, Collins SP.
.
2010;65:171(cid:2)176. . Vereckeicriteriaasadiagnostictoolamongstemergencymedicineresidentsto
.
56. Kalbfleisch SJ, el-Atassi R, Calkins H, Langberg JJ, Morady F. Differentiation of .. distinguish between ventricular tachycardia and supra-ventricular tachycardia
paroxysmalnarrowQRScomplextachycardiasusingthe12-leadelectrocardio- .. withaberrancy.JCardiol2012;59:307(cid:2)312.
.
gram.JAmCollCardiol1993;21:85(cid:2)89. . 81. JastrzebskiM,SasakiK,KuklaP,FijorekK,StecS,CzarneckaD.Theventricular
.
57. TaiCT,ChenSA,ChiangCE,LeeSH,WenZC,ChiouCW,UengKC,ChenYJ, . tachycardiascore:anovelapproachtoelectrocardiographicdiagnosisofventric-
.
Yu WC, Chang MS. A new electrocardiographic algorithm using retrograde P .. ulartachycardia.Europace2016;18:578(cid:2)584.
wavesfordifferentiatingatrioventricularnodereentranttachycardiafromatrio- .. 82. Yadav AV, Nazer B, Drew BJ, Miller JM, El Masry H, Groh WJ, Natale A,
.
ventricularreciprocatingtachycardiamediatedbyconcealedaccessorypathway. . MarroucheN,BadhwarN,YangY,ScheinmanMM.Utilityofconventionalelec-
.
JAmCollCardiol1997;29:394(cid:2)402. .. trocardiographiccriteriainpatientswithidiopathicventriculartachycardia.JACC
58. DiToroD,HadidC,Lo(cid:2)pezC,FuselliJ,LuisV,LabadetC.UtilityoftheaVLlead .. ClinElectrophysiol2017;3:669(cid:2)677.
.
intheelectrocardiographicdiagnosisofatrioventricularnodere-entranttachy- . 83. KnightBP,ZivinA,SouzaJ,GoyalR,ManKC,StrickbergerA,MoradyF.Useof
.
cardia.Europace2009;11:944(cid:2)948. . adenosine in patients hospitalized in a university medical center. Am J Med
.
59. HaghjooM,BahramaliE,SharifkazemiM,ShahrzadS,PeighambariM.Valueof .. 1998;105:275(cid:2)280.
theaVRleadindifferentialdiagnosisofatrioventricularnodalreentranttachycar- .. 84. JolobeOMP.Caveatsinpreexcitation-relatedatrialfibrillation.AmJEmergMed
.
dia.Europace2012;14:1624(cid:2)1628. . 2010;28:252(cid:2)253.
. 60. Knight BP, Ebinger M, Oral H, Kim MH, Sticherling C, Pelosi F, Michaud GF, . 85. Murman DH, McDonald AJ, Pelletier AJ, Camargo CA. U.S. Emergency
.
StrickbergerSA,MoradyF.Diagnosticvalueoftachycardiafeaturesandpacing .. Department Visits for Supraventricular Tachycardia, 1993(cid:2)2003. Acad Emerg
maneuvers during paroxysmal supraventricular tachycardia. J Am Coll Cardiol .. Med2007;14(6):578-581.
.
2000;36:574(cid:2)582. . 86. Roth A, Elkayam I, Shapira I, Sander J, Malov N, Kehati M, Golovner M. .
61. MarkowitzSM,SteinKM,MittalS,SlotwtnerDJ,LermanBB.Differentialeffects .. Effectivenessofprehospitalsynchronousdirect-currentcardioversionforsupra-
of adenosine on focal and macroreentrant atrial tachycardia. J Cardiovasc .. ventriculartachyarrhythmiascausingunstablehemodynamicstates.AmJCardiol
. Electrophysiol1999;10:489(cid:2)502. . 2003;91:489(cid:2)491.
.
62. AlzandBSN,ManusamaR,GorgelsAPM,WellensHJJ.An“almostwide”QRS . 87. WittwerMR,RajendranS,KealleyJ,ArstallMA.ASouthAustralianregistryof
.
tachycardia.CircArrhythmElectrophysiol2009;2:e1(cid:2)e3. .. biphasiccardioversionsofatrialarrhythmias:efficacyandpredictorsofsuccess.
63. AlzandBSN,CrijnsHJ.DiagnosticcriteriaofbroadQRScomplextachycardia: .. HeartLungCirc2015;24:342(cid:2)347.
.
decadesofevolution.Europace2011;13:465(cid:2)472. . 88. ReisingerJ,GstreinC,WinterT,ZeindlhoferE,Ho¨llingerK,MoriM,SchillerA,
.
64. StewartRB,BardyGH,GreeneH.Widecomplextachycardia:misdiagnosisand . WinterA,GeigerH,SiostrzonekP.Optimizationofinitialenergyforcardiover-
.
outcomeafteremergenttherapy.AnnInternMed1986;104:766(cid:2)771. .. sion of atrial tachyarrhythmias with biphasic shocks. Am J Emerg Med
.
65. WellensHJJ.Ventriculartachycardia:diagnosisofbroadQRScomplextachycar- . 2010;28:159(cid:2)165.
.
dia.Heart2001;86:579(cid:2)585. . 89. Smith GD, Fry MM, Taylor D, Morgans A, Cantwell K. Effectiveness of the
.
66. WillemsS,ShenasaM,BorggrefeM,HindricksG,ChenX,RotmanB,Kottkamp .. Valsalva Manoeuvre for reversion of supraventricular tachycardia. Cochrane
H,HaverkampW,BreithardtG.Atrioventricularnodalreentrytachycardia:elec- .. DatabaseSystRev2015;2:CD009502.
.
trophysiologiccomparisonsinpatientswithandwithout2:1infra-Hisblock.Clin . 90. LimSH,AnantharamanV,TeoWS,GohPP,TanATH.Comparisonoftreatment
.
Cardiol1993;16:883(cid:2)888. . ofsupraventriculartachycardiabyValsalvamaneuverandcarotidsinusmassage.
.
67. RangerS,TalajicM,LemeryR,RoyD,VillemaireC,NattelS.Kineticsofuse- .. AnnEmergMed1998;31:30(cid:2)35.
dependent ventricular conduction slowing by antiarrhythmic drugs in humans. .. 91. SmithG,MorgansA,BoyleM.UseoftheValsalvamanoeuvreintheprehospital
.
Circulation1991;83:1987(cid:2)1994. . setting:areviewoftheliterature.EmergMedJ2009;26:8(cid:2)10.
.
68. JastrzebskiM,KuklaP,CzarneckaD,Kawecka-JaszczK.Comparisonoffiveelec- .. 92. BradyWJJ,DeBehnkeDJ,WickmanLL,LindbeckG.Treatmentofout-of-hospital
trocardiographicmethodsfordifferentiationofwideQRS-complextachycardias. .. supraventricular tachycardia: adenosine vs verapamil. Acad Emerg Med
.
Europace2012;14:1165(cid:2)1171. . 1996;3(6):574-585.
.
69. BrugadaP,BrugadaJ,MontL,SmeetsJ,AndriesEW.Anewapproachtothedif- . 93. GlatterKA,ChengJ,DorostkarP,ModinG,TalwarS,Al-NimriM,LeeRJ,Saxon
.
ferentialdiagnosisofaregulartachycardiawithawideQRScomplex.Circulation .. LA,LeshMD,ScheinmanMM.Electrophysiologiceffectsofadenosineinpatients
1991;83:1649(cid:2)1659. . withsupraventriculartachycardia.Circulation1999;99:1034(cid:2)1040.
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 55 ---
ESCGuidelines 709
.
.
94. DelaneyB,LoyJ,KellyA-M.Therelativeefficacyofadenosineversusverapamil . 120.GarrattCJ,GriffithMJ,O’NunainS,WardDE,CammAJ.Effectsofintravenous
.
forthetreatmentofstableparoxysmalsupraventriculartachycardiainadults:a . adenosine on antegrade refractoriness of accessory atrioventricular connec-
.
meta-analysis.EurJEmergMed2011;18:148(cid:2)152. .. tions.Circulation1991;84:1962(cid:2)1968.
95. DoughertyAH,JackmanWM,NaccarelliGV,FridayKJ,DiasVC.Acuteconver- .. 121.Coli S, Mantovani F, Ferro J, Gonzi G, Zardini M, Ardissino D. Adenosine-
.
sionofparoxysmalsupraventriculartachycardiawithintravenousdiltiazem.AmJ . induced severe bronchospasm in a patient without pulmonary disease. Am J
.
Cardiol1992;70:587(cid:2)592. .. EmergMed2012;30:2082.e3(cid:2)2082.e5.
96. HoodMA,SmithWM.Adenosineversusverapamilinthetreatmentofsupra- .. 122.CerqueiraMD,VeraniMS,SchwaigerM,HeoJ,IskandrianAS.Safetyprofileof
.
ventricular tachycardia: A randomized double-crossover trial. Am Heart J . adenosinestressperfusionimaging:resultsfromtheadenoscanmulticentertrial
.
1992;123:1543(cid:2)1549. . registry.JAmCollCardiol1994;23:384(cid:2)389.
.
97. GuptaA,NaikA,VoraA,LokhandwalaY.Comparisonofefficacyofintravenous .. 123.Balan KK, Critchley M. Is the dyspnea during adenosine cardiac stress test
diltiazem and esmolol in terminating supraventricular tachycardia. J Assoc .. causedbybronchospasm?AmHeartJ2001;142:142(cid:2)145.
.
PhysiciansIndia1999;47:969(cid:2)972. . 124.CushleyMJ,TattersfieldAE,HolgateST.Inhaledadenosineandguanosineon
.
98. LimSH,AnantharamanV,TeoWS,ChanYH.Slowinfusionofcalciumchannel . airway resistance in normal and asthmatic subjects. Br J Clin Pharmacol
.
blockerscomparedwithintravenousadenosineintheemergencytreatmentof .. 2004;58:S751(cid:2)S755.
.
supraventriculartachycardia.Resuscitation2009;80:523(cid:2)528. . 125.BurkiNK,AlamM,LeeL-Y.Thepulmonaryeffectsofintravenousadenosinein
.
99.DasG,TschidaV,GrayR,DhurandharR,LesterR,McGrewF,AskenaziJ,Kaplan . asthmaticsubjects.RespiratoryResearch2006;7:139(cid:2)139.
.
K,EmanueleM,TurlapatyP,HuaTA,HoffJ,AllinD,LadduA.Efficacyofesmolol .. 126.BurkhartKK.Respiratoryfailurefollowingadenosineadministration.AmJEmerg
inthetreatmentandtransferofpatientswithsupraventriculartachyarrhythmiasto .. Med1993;11:249(cid:2)250.
.
alternateoralantiarrhythmicagents.JClinPharmacol1988;28:746(cid:2)750. . 127.DeGroff CG, Silka MJ. Bronchospasm after intravenous administration of
.
100. AmsterdamEA,KulcyskiJ,RidgewayMG.Efficacyofcardioselectivebeta-adre- . adenosineinapatientwithasthma.JPediatr1994;125:822(cid:2)823.
.
nergicblockadewithintravenouslyadministeredmetoprololinthetreatment .. 128.Brubaker S, Long B, Koyfman A. Alternative treatment options for
ofsupraventriculartachyarrhythmias.JClinPharmacol1991;31:714(cid:2)718. .. atrioventricular-nodal-reentry tachycardia: an emergency medicine review.
.
101. SmithG,TaylorDM,MorgansA,CameronP.Prehospitalsynchronizedelectri- . JEmergMed2018;54:198(cid:2)206.
.
cal cardioversion of a poorly perfused SVT patient by paramedics. Prehosp .. 129.StamblerBS,DorianP,SagerPT,WightD,DouvilleP,PotvinD,ShamszadP,
DisasterMed2013;28:301(cid:2)304. .. Haberman RJ, Kuk RS, Lakkireddy DR, Teixeira JM, Bilchick KC, Damle RS,
.
102.Wen Z-C, Chen S-A, Tai C-T, Chiang C-E, Chiou C-W, Chang M-S. . BernsteinRC,LamWW,O’NeillG,NoseworthyPA,VenkatachalamKL,Coutu
.
Electrophysiologicalmechanismsanddeterminantsofvagalmaneuversfortermi- . B,MondesertB,PlatF.Etripamilnasalsprayforrapidconversionofsupraventricu-
.
nationofparoxysmalsupraventriculartachycardia.Circulation1998;98:2716(cid:2)2723. .. lartachycardiatosinusrhythm.JAmCollCardiol2018;72:489(cid:2)497.
103. TaylorDM,WongLF.IncorrectinstructionintheuseoftheValsalvamanoeu- .. 130.OlasveengenTM,deCaenAR,ManciniME,MaconochieIK,AickinR,AtkinsDL,
.
vre for paroxysmal supra-ventricular tachycardia is common. Emergency . BergRA,BinghamRM,BrooksSC,Castre´nM,ChungSP,ConsidineJ,CoutoTB,
.
Medicine2004;16(4):284-287. . EscalanteR,GazmuriRJ,GuerguerianAM,HatanakaT,KosterRW,KudenchukPJ,
.
104. Smith G, Boyle MJ. The 10 mL syringe is useful in generating the recom- .. LangE,LimSH,LøfgrenB,MeaneyPA,MontgomeryWH,MorleyPT,MorrisonLJ,
.
mended standard of 40 mmHg intrathoracic pressure for the Valsalva . NationKJ,NgKC,NadkarniVM,NishiyamaC,NuthallG,OngGY,PerkinsGD,
.
manoeuvre.EmergMedAustralas2009;21:449(cid:2)454. . ReisAG,RistagnoG,SakamotoT,SayreMR,SchexnayderSM,SierraAF,Singletary
.
105. LaylandJ,CarrickD,LeeM,OldroydK,BerryC.Adenosine:physiology,phar- .. EM,ShimizuN,SmythMA,StantonD,TijssenJA,TraversA,VaillancourtC,Vande
macology,andclinicalapplications.JACCCardiovascInterv2014;7:581(cid:2)591. .. VoordeP,HazinskiMF,NolanJP;ILCORCollaborators.2017internationalconsen-
.
106. Lerman BB, Markowitz SM, Cheung JW, Liu CF, Thomas G, Ip JE. . sus on cardiopulmonary resuscitation and emergency cardiovascular care science
.
Supraventriculartachycardia.CircArrhythmElectrophysiol2018;11:e006953. . withtreatmentrecommendationssummary.Circulation2017;136:e424(cid:2)e440.
.
107. CammAJ,GarrattCJ.Adenosineandsupraventriculartachycardia.NEnglJMed .. 131.PrioriSG,Blomstro¨m-LundqvistC,MazzantiA,BlomN,BorggrefeM,CammJ,
1991;325:1621(cid:2)1629. .. ElliottPM,FitzsimonsD,HatalaR,HindricksG,KirchhofP,KjeldsenK,KuckK-
.
108. NgGA,MartinW,RankinAC.Imagingofadenosinebolustransitfollowingintrave- . H, Hernandez-Madrid A, Nikolaou N, Norekva˚l TM, Spaulding C, Van
.
nousadministration:insightsintoantiarrhythmicefficacy.Heart1999;82:163(cid:2)169. .. VeldhuisenDJ,KolhP,LipGYH,AgewallS,Baro(cid:2)n-EsquiviasG,BorianiG,Budts
109. AlabedS,SabouniA,ProvidenciaR,AtallahE,QintarM,ChicoTJA.Adenosine .. W,BuenoH,CapodannoD,CarerjS,Crespo-LeiroMG,CzernyM,DeatonC,
.
versusintravenouscalciumchannelantagonistsforsupraventriculartachycardia. . DobrevD,ErolC¸,GalderisiM,GorenekB,KriebelT,LambiaseP,LancellottiP,
.
CochraneDatabaseSystRev2017;10:CD005154. . Lane DA, Lang I, Manolis AJ, Morais J, Moreno J, Piepoli MF, Rutten FH,
.
110. CabalagMS,TaylorDM,KnottJC,BuntineP,SmitD,MeyerA.Recentcaffeine .. SredniawaB,ZamoranoJL,ZannadF.2015ESCGuidelinesforthemanagement
ingestionreducesadenosineefficacyinthetreatmentofparoxysmalsupraven- .. ofpatientswithventriculararrhythmiasandthepreventionofsuddencardiac
.
triculartachycardia.AcadEmergMed2010;17:44(cid:2)49. . death. The Task Force for the Management of Patients with Ventricular
. 111. KarydesHC,BryantSM.Adenosineandcaffeine-inducedparoxysmalsupraven- . Arrhythmias and the Prevention of Sudden Cardiac Death of the European
.
triculartachycardia.AcadEmergMed2010;17:570(cid:2)570. .. SocietyofCardiology(ESC)Endorsedby:AssociationforEuropeanPaediatric
112. Burki NK, Wheeler JD, Lu-Yuan L. Intravenous adenosine and dyspnea in .. andCongenitalCardiology(AEPC).EurHeartJ2015;36:2793(cid:2)2867.
.
humans.JApplPhysiol(1985)2005;98:180(cid:2)185. . 132.OrtizM,MartinA,ArribasF,Coll-VinentB,DelArcoC,PeinadoR,Almendral .
113. FragakisN,AntoniadisAP,KorantzopoulosP,KyriakouP,KoskinasKC,Geleris .. J;PROCAMIOStudyInvestigators.Randomizedcomparisonofintravenouspro-
P.Sinusnodalresponsetoadenosinerelatestotheseverityofsinusnodedys- .. cainamide vs. intravenous amiodarone for the acute treatment of tolerated
. function.Europace2012;14:859(cid:2)864. . wideQRStachycardia:thePROCAMIOstudy.EurHeartJ2017;38:1329(cid:2)1335.
.
114. Ellenbogen KA, Thames MD, DiMarco JP, Sheehan H, Lerman BB. . 133.BuxtonAE,MarchlinskiFE,DohertyJU,FloresB,JosephsonME.Hazardsofintrave-
.
Electrophysiological effects of adenosine in the transplanted human heart. .. nousverapamilforsustainedventriculartachycardia.AmJCardiol1987;59:1107(cid:2)1110.
Evidenceofsupersensitivity.Circulation1990;81:821(cid:2)828. .. 134.Dancy M, Camm AJ, Ward D. Misdiagnosis of chronic recurrent ventricular
.
115. ToftJ,MortensenJ,HesseB.Riskofatrioventricularblockduringadenosinepharma- . tachycardia.Lancet1985;326:320(cid:2)323.
.
cologicstresstestinginhearttransplantrecipients.AmJCardiol1998;82:696(cid:2)697. .. 135.CrijnsHJ,LieKI.Haemodynamicdeteriorationaftertreatmentwithadenosine.
116. Flyer JN, Zuckerman WA, Richmond ME, Anderson BR, Mendelsberg TG, .. BrHeartJ1995;73:103.
.
McAllisterJM,LibermanL,AddonizioLJ,SilverES.Prospectivestudyofadeno- . 136.GorgelsAPM,vandenDoolA,HofsA,MulleneersR,SmeetsJLRM,VosMA,
.
sineonatrioventricularnodalconductioninpediatricandyoungadultpatients . Wellens HJJ. Comparison of procainamide and lidocaine in terminating sus-
.
afterhearttransplantation.Circulation2017;135:2485(cid:2)2493. .. tainedmonomorphicventriculartachycardia.AmJCardiol1996;78:43(cid:2)46.
117. IpJE,CheungJW,ChungJH,LiuCF,ThomasG,MarkowitzSM,LermanBB. .. 137.Scheinman MM, Levine JH, Cannom DS, Friehling T, Kopelman HA, Chilson
.
Adenosine-induced atrial fibrillation. Insights into mechanism. Circ Arrhythm . DA,PlatiaEV,WilberDJ,KoweyPR.Dose-rangingstudyofintravenousamio-
.
Electrophysiol2013;6:e34(cid:2)e37. . daroneinpatientswithlife-threateningventriculartachyarrhythmias.Circulation
.
118. LiN,CsepeTA,HansenBJ,SulLV,KalyanasundaramA,ZakharkinSO,ZhaoJ, .. 1995;92:3264(cid:2)3272.
Guha A, Van Wagoner DR, Kilic A, Mohler PJ, Janssen PML, Biesiadecki BJ, .. 138.Levine JH, Massumi A, Scheinman MM, Winkle RA, Platia EV, Chilson DA,
.
Hummel JD, Weiss R, Fedorov VV. adenosine-induced atrial fibrillation. . GomesJA,WoosleyRL.Intravenousamiodaroneforrecurrentsustainedhypo-
.
Localizedreentrantdriversinlateralrightatriaduetoheterogeneousexpres- .. tensiveventriculartachyarrhythmias.JAmCollCardiol1996;27:67(cid:2)75.
sion of adenosine A1 receptors and GIRK4 subunits in the human heart. .. 139.Olshansky B, Sullivan RM. Inappropriate sinus tachycardia. Europace
.
Circulation2016;134:486(cid:2)498. . 2019;21:194(cid:2)207.
.
119. TurleyAJ,MurrayS,ThambyrajahJ.Pre-excitedatrialfibrillationtriggeredby . 140.Still A-M, Raatikainen P, Ylitalo A, Kauma H, Ik€aheimo M, Kes€aniemi YA,
.
intravenousadenosine:acommonlyuseddrugwithpotentiallylife-threatening .. Huikuri HV. Prevalence, characteristics and natural course of inappropriate
adverseeffects.EmergMedJ2008;25:46(cid:2)48. . sinustachycardia.Europace2005;7:104(cid:2)112.
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 56 ---
710 ESCGuidelines
.
.
141. Baruscotti M, Bucchi A, Milanesi R, Paina M, Barbuti A, Gnecchi-Ruscone T, . JuanateyJR,Valderr(cid:2)abanoM.Ablationofinappropriatesinustachycardia:asys-
.
BiancoE,Vitali-SerdozL,CappatoR,DiFrancescoD.Again-of-functionmuta- . tematicreviewoftheliterature.JACCClinElectrophysiol2017;3:253(cid:2)265.
.
tion in the cardiac pacemaker HCN4 channel increasing cAMP sensitivity is .. 162.KleinI,OjamaaK.Thyroid hormoneandthecardiovascularsystem.NEnglJ
associated with familial Inappropriate Sinus Tachycardia. Eur Heart J .. Med2001;344:501(cid:2)509.
.
2017;38:280(cid:2)288. . 163.Gomes JA, Hariman RJ, Kang PS, Chowdry IH. Sustained symptomatic sinus
.
142. RuziehM,MoustafaA,SabbaghE,KarimMM,KarimS.Challengesintreatment .. node reentrant tachycardia: Incidence, clinical significance, electrophysiologic
ofinappropriatesinustachycardia.CurrCardiolRev2018;14:42(cid:2)44. .. observations and the effects of antiarrhythmic agents. J Am Coll Cardiol
.
143. BrunnerS,HerbelR,DrobeschC,PetersA,MassbergS,KaabS,SinnerMF. . 1985;5:45(cid:2)57.
.
Alcoholconsumption,sinustachycardia,andcardiacarrhythmiasattheMunich . 164.MalikAK,ChingCK,LiewR,ChongDT,TeoWS.Successfulablationofsinus
.
Octoberfest:resultsfromtheMunichBeerRelatedElectrocardiogramWorkup .. nodereentranttachycardiausingremotemagneticnavigationsystem.Europace
Study(MunichBREW).EurHeartJ2017;38:2100(cid:2)2106. .. 2012;14:455(cid:2)456.
.
144. ShenWK.Howtomanagepatientswithinappropriatesinustachycardia.Heart . 165.Cossu SF, Steinberg JS. Supraventricular tachyarrhythmias involving the sinus
.
Rhythm2005;2:1015(cid:2)1019. .. node: clinical and electrophysiologic characteristics. Prog Cardiovasc Dis
145. FosterMC,LevinePA.Useofverapamiltocontrolaninappropriatechronic .. 1998;41:51(cid:2)63.
.
sinustachycardia.Chest1984;85:697(cid:2)699. . 166.SandersWEJr,SorrentinoRA,GreenfieldRA,ShenasaH,HamerME,Wharton
.
146. Cappato R, Castelvecchio S, Ricci C, Bianco E, Vitali-Serdoz L, Gnecchi- . JM.Catheterablationofsinoatrialnodereentranttachycardia.JAmCollCardiol
.
RusconeT,PittalisM,DeAmbroggiL,BaruscottiM,GaetaM,FurlanelloF,Di .. 1994;23:926(cid:2)934.
FrancescoD,LupoPP.Clinicalefficacyofivabradineinpatientswithinappropri- .. 167.FuQ,VanGundyTB,ShibataS,AuchusRJ,WilliamsGH,LevineBD.Exercise
.
ate sinus tachycardia: a prospective, randomized, placebo-controlled, double- . trainingversuspropranololinthetreatmentoftheposturalorthostatictachy-
.
blind,crossoverevaluation.JAmCollCardiol2012;60:1323(cid:2)1329. . cardiasyndrome.Hypertension2011;58:167(cid:2)175.
.
147. PtaszynskiP,KaczmarekK,RutaJ,KlingenhebenT,WraniczJK.Metoprololsuc- .. 168.FuQ,VanGundyTB,GalbreathMM,ShibataS,JainM,HastingsJL,BhellaPS,
cinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in .. Levine BD. Cardiac originsof the postural orthostatic tachycardia syndrome.
.
patients unresponsive to previous pharmacological therapy. Europace . JAmCollCardiol2010;55:2858(cid:2)2868.
.
2013;15:116(cid:2)121. .. 169.WinkerR,BarthA,BidmonD,PonocnyI,WeberM,MayrO,RobertsonD,
148. Benezet-Mazuecos J, Rubio JM, Farr(cid:2)E J, QuiN~Ones MA(cid:2), Sanchez-Borque P, .. Diedrich A, Maier R, Pilger A, Haber P, Ru¨diger HW. Endurance exercise
Mac(cid:2)IAE.Long-termoutcomesofivabradineininappropriatesinustachycardia .. training in orthostatic intolerance. A randomized, controlled trial 2005;45:
.
patients:appropriateefficacyorinappropriatepatients.PacingClinElectrophysiol . 391(cid:2)398.
.
2013;36:830(cid:2)836. .. 170.JacobG,ShannonJR,BlackB,BiaggioniI,Mosqueda-GarciaR,RobertsonRM,
149. Calo(cid:3) L, Rebecchi M, Sette A, Martino A, de Ruvo E, Sciarra L, De Luca L, .. RobertsonD.Effectsofvolumeloadingandpressoragentsinidiopathicortho-
.
ZuccaroLM,GiuntaG,CiccaglioniA,LioyE,FedeleF.Efficacyofivabradine . statictachycardia.Circulation1997;96:575(cid:2)580.
.
administration in patients affected by inappropriate sinus tachycardia. Heart . 171.RajSR,BiaggioniI,YamhurePC,BlackBK,ParanjapeSY,ByrneDW,Robertson
.
Rhythm2010;7:1318(cid:2)1323. .. D.Renin-aldosteroneparadoxandperturbedbloodvolumeregulationunderly-
.
150. PtaszynskiP,KaczmarekK,RutaJ,KlingenhebenT,WraniczJK.Ivabradinein . ingposturaltachycardiasyndrome.Circulation2005;111:1574(cid:2)1582.
.
the treatment of inappropriate sinus tachycardia in patients after successful . 172.RajSR,BlackBK,BiaggioniI,ParanjapeSY,RamirezM,DupontWD,Robertson
.
radiofrequencycatheterablationofatrioventricularnodeslowpathway.Pacing .. D.Propranololdecreasestachycardiaandimprovessymptomsinthepostural
ClinElectrophysiol2013;36:42(cid:2)49. .. tachycardiasyndrome.Lessismore.Circulation2009;120:725(cid:2)734.
.
151. DiasdaSilvaVJ,TobaldiniE,RocchettiM,WuMA,MalfattoG,MontanoN, . 173.Kanjwal K, Karabin B, Sheikh M, Elmer L, Kanjwal Y, Saeed B, Grubb BP.
.
ZazaA.Modulationofsympatheticactivityandheartratevariabilitybyivabra- . Pyridostigmine in the treatment of postural orthostatic tachycardia:A single-
.
dine.CardiovascRes2015;108:31(cid:2)38. .. centerexperience.PacingClinElectrophysiol2011;34:750(cid:2)755.
152. PtaszynskiP,KaczmarekK,RutaJ,KlingenhebenT,CygankiewiczI,WraniczJK. .. 174.Raj SR, Black BK, Biaggioni I, Harris PA, Robertson D. Acetylcholinesterase
.
Ivabradineincombinationwithmetoprololsuccinateinthetreatmentofinap- . inhibition improves tachycardia in postural tachycardia syndrome. Circulation
.
propriatesinustachycardia.JCardiovascPharmacolTher2013;18:338(cid:2)344. .. 2005;111:2734(cid:2)2740.
153. Regitz-ZagrosekV,Roos-HesselinkJW,BauersachsJ,Blomstro¨m-LundqvistC, .. 175.McDonaldC,FrithJ,NewtonJL.Singlecentreexperienceofivabradineinpos-
C(cid:2)ıfkov(cid:2)aR,DeBonisM,IungB,JohnsonMR,KintscherU,KrankeP,LangIM, .. turalorthostatictachycardiasyndrome.Europace2011;13:427(cid:2)430.
.
MoraisJ,PieperPG,PresbiteroP,PriceS,RosanoGMC,SeelandU,Simoncini . 176.GlukhovAV,HageLT,HansenBJ,Pedraza-ToscanoA,Vargas-PintoP,Hamlin
.
T,SwanL,WarnesCA;ESCScientificDocumentGroup.2018ESCGuidelines .. RL,WeissR,CarnesCA,BillmanGE,FedorovVV.Sinoatrialnodereentryina
for the management of cardiovascular diseases during pregnancy. Eur Heart J .. caninechronicleftventricularinfarctmodel:roleofintranodalfibrosisandhet-
.
2018:39:3165(cid:2)3241. . erogeneityofrefractoriness.CircArrhythmElectrophysiol2013;6:984(cid:2)994.
. 154. YuJ,ZhouZ,Tay-SontheimerJ,LevyRH,Ragueneau-MajlessiI.Riskofclinically . 177.SheldonRS,GrubbBP,OlshanskyB,ShenW-K,CalkinsH,BrignoleM,RajSR,
.
relevantpharmacokinetic-baseddrug-druginteractionswithdrugsapprovedby .. KrahnAD,MorilloCA,StewartJM,SuttonR,SandroniP,FridayKJ,HachulDT,
theU.S.FoodandDrugAdministrationbetween2013and2016.DrugMetab .. CohenMI,LauDH,MayugaKA,MoakJP,SandhuRK,KanjwalK.2015Heart
.
Dispos2018;46:835(cid:2)845. . RhythmSocietyexpertconsensusstatementonthediagnosisandtreatmentof .
155. ManKC,KnightB,TseH-F,PelosiF,MichaudGF,FlemmingM,StrickbergerSA, .. postural tachycardiasyndrome,inappropriatesinustachycardia,andvasovagal
MoradyF.Radiofrequencycatheterablationofinappropriatesinustachycardia .. syncope.HeartRhythm2015;12:e41(cid:2)e63.
. guidedbyactivationmapping.JAmCollCardiol2000;35:451(cid:2)457. . 178.BryarlyM,PhillipsLT,FuQ,VerninoS,LevineBD.Posturalorthostatictachy-
.
156. MarroucheNF,BeheiryS,TomassoniG,ColeC,BashD,DresingT,SalibaW, . cardiasyndrome:JACCFocusSeminar.JAmCollCardiol2019;73:1207(cid:2)1228.
.
Abdul-KarimA,TchouP,SchweikertR,LeonelliF,NataleA.Three-dimensional .. 179.BenarrochEE.Posturaltachycardiasyndrome:aheterogeneousandmultifacto-
nonfluoroscopicmappingandablationofinappropriatesinustachycardia:pro- .. rialdisorder.MayoClinicProceedings2012;87:1214(cid:2)1225.
.
cedural strategies and long-term outcome. J Am Coll Cardiol . 180.Tomichi Y,KawanoH,MukainoA,ChibaA,DoiY,Arakawa S,IshimatsuT,
.
2002;39:1046(cid:2)1054. .. FukaeS,AbiruN,MaemuraK.Posturalorthostatictachycardiainapatientwith
157. CallansDJ,RenJ-F,SchwartzmanD,GottliebCD,ChaudhryFA,MarchlinskiFE. .. type2diabeteswithdiabeticneuropathy.IntHeartJ2018;59:1488(cid:2)1490.
.
Narrowing of the superior vena cava(cid:2)right atrium junction during radiofre- . 181.Low PA, Sandroni P, Joyner M, Shen WK. Postural tachycardia syndrome
.
quencycatheterablationforinappropriatesinustachycardia:analysiswithintra- . (POTS).JCardiovascElectrophysiol2009;20:352(cid:2)358.
.
cardiacechocardiography.JAmCollCardiol1999;33:1667(cid:2)1670. .. 182.FedorowskiA.Posturalorthostatictachycardiasyndrome:clinicalpresentation,
158. Takemoto M, Mukai Y, Inoue S, Matoba T, Nishizaka M, Ide T, Chishaki A, .. aetiology,andmanagement.JInternMed2018;285:352(cid:2)366.
.
Sunagawa K. Usefulness of non-contact mapping for radiofrequency catheter . 183.Poutiainen AM, Koistinen MJ, Airaksinen KE, Hartikainen EK, Kettunen RVJ,
.
ablationofinappropriatesinustachycardia:newproceduralstrategyandlong- . Karjalainen JE, Huikuri HV. Prevalence and natural course of ectopic atrial
.
termclinicaloutcome.InternMed2012;51:357(cid:2)362. .. tachycardia.EurHeartJ1999;20:694(cid:2)700.
159. KoplanBA,ParkashR,CouperG,StevensonWG.Combinedepicardial-endo- .. 184.KistlerPM,SandersP,FynnSP,StevensonIH,HussinA,VohraJK,SparksPB,
.
cardial approach to ablation of inappropriate sinus tachycardia. J Cardiovasc . KalmanJM.Electrophysiologicalandelectrocardiographiccharacteristicsoffocal
.
Electrophysiol2004;15:237(cid:2)240. .. atrial tachycardia originating from the pulmonary veins: acute and long-term
160. JacobsonJT,KrausA,LeeR,GoldbergerJJ.Epicardial/endocardialsinusnode .. outcomesofradiofrequencyablation.Circulation2003;108:1968(cid:2)1975.
.
ablation after failed endocardial ablation for the treatment of inappropriate . 185.HaissaguerreM,JaisP,ShahDC,TakahashiA,HociniM,QuiniouG,GarrigueS,
.
sinustachycardia.JCardiovascElectrophysiol2014;25:236(cid:2)241. . LeMourouxA,LeMetayerP,ClementyJ.Spontaneousinitiationofatrialfibril-
.
161. Rodr(cid:2)ıguez-Ma~nero M, Kreidieh B, Al Rifai M, Ibarra-Cortez S, Schurmann P, .. lation by ectopic beats originating in the pulmonary veins. N Engl J Med
A(cid:2)lvarezPA,Fern(cid:2)andez-Lo(cid:2)pezXA,Garc(cid:2)ıa-SearaJ,Mart(cid:2)ınez-SandeL,Gonz(cid:2)alez- . 1998;339:659(cid:2)666.
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 57 ---
ESCGuidelines 711
.
.
186. KistlerPM,Roberts-ThomsonKC,HaqqaniHM,FynnSP,SingarayarS,Vohra . Morady F, John RM, StevensonWG. End-points for successful slow pathway
.
JK,MortonJB,SparksPB,KalmanJM.P-wavemorphologyinfocalatrialtachy- . catheterablationintypicalandatypicalatrioventricularnodalreentranttachy-
.
cardia:developmentofanalgorithmtopredicttheanatomicsiteoforigin.JAm .. cardia: a contemporary, multicenter study. JACC Clin Electrophysiol
CollCardiol2006;48:1010(cid:2)1017. .. 2019;5:113(cid:2)119.
.
187. ChenSA,ChiangCE,YangCJ,ChengCC,WuTJ,WangSP,ChiangBN,Chang . 209.KastorJA.Multifocalatrialtachycardia.NEnglJMed1990;322:1713(cid:2)1717.
.
MS.Sustainedatrialtachycardiainadultpatients.Electrophysiologicalcharacter- .. 210.BradleyDJ,FischbachPS,LawIH,SerwerGA,DickMII.Theclinicalcourseof
istics,pharmacologicalresponse,possiblemechanisms,andeffectsofradiofre- .. multifocal atrial tachycardia in infants and children. J Am Coll Cardiol
.
quencyablation.Circulation1994;90:1262(cid:2)1278. . 2001;38:401(cid:2)408.
.
188. MehtaAV,SanchezGR,SacksEJ,CastaA,DunnJM,DonnerRM.Ectopicauto- . 211.IseriLT,FairshterRD,HardemannJL,BrodskyMA.Magnesiumandpotassium
.
maticatrialtachycardiainchildren:clinicalcharacteristics,managementandfol- .. therapyinmultifocalatrialtachycardia.AmHeartJ1985;110:789(cid:2)794.
low-up.JAmCollCardiol1988;11:379(cid:2)385. .. 212.Marchlinski FE, Miller JM. Atrial arrhythmias exacerbated by theophylline:
.
189. HohnloserSH,ZabelM.Short-andlong-termefficacyandsafetyofflecainide . response to verapamil and evidence for triggered activity in man. Chest
.
acetateforsupraventriculararrhythmias.AmJCardiol1992;70:A3(cid:2)A10. .. 1985;88:931(cid:2)934.
190. KunzeK-P,KuckK-H,Schlu¨terM,BleifeldW.Effectofencainideandflecainide .. 213.SalernoDM,AndersonB,SharkeyPJ,IberC.Intravenousverapamilfortreat-
.
onchronicectopicatrialtachycardia.JAmCollCardiol1986;7:1121(cid:2)1126. . ment of multifocal atrial tachycardia with and without calcium pretreatment.
.
191. EidherU,FreihoffF,KaltenbrunnerW,SteinbachK.Efficacyandsafetyofibuti- . AnnInternMed1987;107:623(cid:2)628.
.
lide for the conversion of monomorphic atrial tachycardia. Pacing Clin .. 214.ArsuraE,LefkinAS,ScherDL,SolarM,TesslerS.Arandomized,double-blind,
Electrophysiol2006;29:358(cid:2)362. .. placebo-controlledstudyofverapamilandmetoprololintreatmentofmultifo-
.
192. Vietti-RamusG,VeglioF,MarchisioU,BurzioP,LatiniR.Efficacyandsafetyof . calatrialtachycardia.AmJMed1988;85:519(cid:2)524.
.
shortintravenousamiodaroneinsupraventriculartachyarrhythmias.IntJCardiol . 215.PierceWJ,McGroaryK.MultifocalatrialtachycardiaandIbutilide.AmJGeriatr
.
1992;35:77(cid:2)85. .. Cardiol2001;10:193(cid:2)195.
193. Salem JE, Dureau P, Funck-Brentano C, Hulot JS, El-Aissaoui M, Aissaoui N, .. 216.UengKC,LeeSH,WuDJ,LinCS,ChangMS,ChenSA.Radiofrequencycathe-
.
UrienS,FaisyC.Effectivenessofheartratecontrolonhemodynamicsincrit- . termodificationofatrioventricularjunctioninpatientswithCOPDandmedi-
.
ically ill patients with atrial tachyarrhythmias managed by amiodarone. .. callyrefractorymultifocalatrialtachycardia.Chest2000;117:52(cid:2)59.
PharmacolRes2017;122:118(cid:2)126. .. 217.HazardPB,BurnettCR.Verapamilinmultifocalatrialtachycardia:hemodynamic
.
194. Anguera I, Brugada J, Roba M, Mont Ls, Aguinaga L, Geelen P, Brugada P. . andrespiratorychanges.Chest1987;91:68(cid:2)70.
.
Outcomes after radiofrequency catheter ablation of atrial tachycardia. Am J . 218.Levine JH,Michael JR, Guarnieri T.Treatment of multifocal atrialtachycardia
.
Cardiol2001;87:886(cid:2)890. .. withverapamil.NEnglJMed1985;312:21(cid:2)25.
195. BivianoAB,BainW,WhangW,LeitnerJ,DizonJ,HickeyK,GaranH.Focalleft .. 219.HazardPB,BurnettCR.Treatmentofmultifocalatrialtachycardiawithmeto-
.
atrialtachycardiasnotassociatedwithpriorcatheterablationforatrialfibrilla- . prolol.CritCareMed1987;15:20(cid:2)25.
.
tion: clinical and electrophysiological characteristics. Pacing Clin Electrophysiol . 220.SaoudiN,CosioF,WaldoA,ChenS-A,IesakaY,LeshM,SaksenaS,SalernoJ,
.
2012;35:17(cid:2)27. .. SchoelsW.Classificationofatrialflutterandregularatrialtachycardiaaccording
.
196. Medi C, Kalman JM, Haqqani H, Vohra JK, Morton JB, Sparks PB, Kistler PM. . toelectrophysiologicmechanismandanatomicbases:astatementfromajoint
.
Tachycardia-mediatedcardiomyopathysecondarytofocalatrialtachycardia:long- . expert group from the Working Group of Arrhythmias of the European
.
termoutcomeaftercatheterablation.JAmCollCardiol2009;53:1791(cid:2)1797. .. Society of Cardiology and the North American Society of Pacing and
197. OuyangF,MaJ,HoSY,B€anschD,SchmidtB,ErnstS,KuckK-H,LiuS,Huang .. Electrophysiology.JCardiovascElectrophysiol2001;12:852(cid:2)866.
.
H, Chen M, Chun J, Xia Y, Satomi K, Chu H, Zhang S, Antz M. Focal atrial . 221.Saoudi N, Nair M, Abdelazziz A, Poty H, Daou A, Anselme F, Letac B.
.
tachycardiaoriginatingfromthenon-coronaryaorticsinus:electrophysiological . Electrocardiographicpatternsandresultsofradiofrequencycatheterablationof
.
characteristicsandcatheterablation.JAmCollCardiol2006;48:122(cid:2)131. .. clockwisetypeIatrialflutter.JCardiovascElectrophysiol1996;7:931(cid:2)942.
198. HeuschA,KramerHH,KrogmannON,RammosS,BourgeoisM.Clinicalexpe- .. 222.OlginJE,KalmanJM,FitzpatrickAP,LeshMD.Roleofrightatrialendocardial
.
rience with propafenone for cardiac arrhythmias in the young. Eur Heart J . structures as barriers to conduction during human type I atrial flutter.
.
1994;15:1050(cid:2)1056. .. Activationandentrainmentmappingguidedbyintracardiacechocardiography.
199. Meles E, Carbone C, Maggiolini S, Moretti P, CC DECGentile G, Gnecchi- .. Circulation1995;92:1839(cid:2)1848.
.
Ruscone T. A case of atrial tachycardia treated with ivabradine as bridge to . 223.Chugh A, Latchamsetty R, Oral H, Elmouchi D, Tschopp D, Reich S, Igic P,
.
ablation.JCardiovascElectrophysiol2015;26:565(cid:2)568. . LemerandT,GoodE,BogunF,PelosiFJr,MoradyF.Characteristicsofcavotri-
.
200. BohoraS,LokhandwalaY,ParekhP,VasavdaA.Reversaloftachycardiomyop- .. cuspidisthmus-dependentatrialflutterafterleftatrialablationofatrialfibrilla-
athy due to left atrial tachycardia by ivabradine. J Cardiovasc Electrophysiol .. tion.Circulation2006;113:609(cid:2)615.
.
2011;22:340(cid:2)342. . 224.StevensonIH,KistlerPM,SpenceSJ,VohraJK,SparksPB,MortonJB,Kalman
. 201. GuccioneP,PaulT,GarsonAJr.Long-termfollow-upofamiodaronetherapy . JM. Scar-related right atrial macroreentrant tachycardia in patients without
.
in the young: continued efficacy, unimpaired growth, moderate side effects. .. prior atrial surgery: electroanatomic characterization and ablation outcome.
JAmCollCardiol1990;15:1118(cid:2)1124. .. HeartRhythm2005;2:594(cid:2)601.
.
202. vonBernuthG,EngelhardtW,KramerHH,SingerH,SchneiderP,UlmerH, . 225.Havr(cid:2)anek S, Simek J, Stov(cid:2)ıcek P, Wichterle D. Distribution of mean cycle .
Brodherr-HeberleinS,KienastW,LangD,LindingerA,SchmidtK.Atrialauto- .. length in cavo-tricuspid isthmus dependent atrial flutter. Physiol Res 2012;61:
matictachycardiaininfancyandchildhood.EurHeartJ1992;13:1410(cid:2)1415. .. 43(cid:2)51.
. 203. Spector P,Reynolds MR,CalkinsH,SondhiM,XuY,MartinA,WilliamsCJ, . 226.Barbato G,Carinci V,TomasiC,FrassinetiV, Margheri M, DiPasquale G.Is
.
SledgeI.Meta-analysisofablationofatrialflutterandsupraventriculartachycar- . electrocardiography a reliable tool for identifying patients with isthmus-
.
dia.AmJCardiol2009;104:671(cid:2)677. .. dependentatrialflutter?Europace2009;11:1071(cid:2)1076.
204. Bohnen M, Stevenson WG, Tedrow UB, Michaud GF, John RM, Epstein LM, .. 227.Halligan SC, Gersh BJ, Brown RD Jr, Rosales AG, Munger TM, Shen WK,
.
AlbertCM,KoplanBA.Incidenceandpredictorsofmajorcomplicationsfrom . HammillSC,FriedmanPA.Thenaturalhistoryofloneatrialflutter.AnnIntern
.
contemporary catheter ablation to treat cardiac arrhythmias. Heart Rhythm .. Med2004;140:265(cid:2)268.
2011;8:1661(cid:2)1666. .. 228.ChinitzJS,GerstenfeldEP,MarchlinskiFE,CallansDJ.Atrialfibrillationiscom-
.
205. KeeganR,AguinagaL,FenelonG,UribeW,RodriguezDiezG,ScanavaccaM, . mon after ablation ofisolatedatrialflutter duringlong-term follow-up.Heart
.
PateteM,CarhuazRZ,LabadetC,DeZuloagaC,PozzerD,ScazzusoF.The . Rhythm2007;4:1029(cid:2)1033.
.
firstLatinAmericanCatheterAblationRegistry.Europace2015;17:794(cid:2)800. .. 229.Pe´rezFJ,SchubertCM,ParvezB,PathakV,EllenbogenKA,WoodMA.Long-
206. Steinbeck G, Sinner MF, Lutz M, Muller-Nurasyid M, Kaab S, Reinecke H. .. term outcomes after catheter ablation of cavo-tricuspid isthmus dependent
.
Incidenceofcomplicationsrelatedtocatheterablationofatrialfibrillationand . atrialflutter.Ameta-analysis.CircArrhythmElectrophysiol2009;2:393(cid:2)401.
.
atrial flutter: a nationwide in-hospital analysis of administrative data for . 230.Reithmann C, Hoffmann E, Spitzlberger G, Dorwarth U, Gerth A, Remp T,
.
Germanyin2014.EurHeartJ2018;39:4020(cid:2)4029. .. SteinbeckG.Catheterablationofatrialflutterduetoamiodaronetherapyfor
207. Konig S, Ueberham L, Schuler E, Wiedemann M, Reithmann C, Seyfarth M, .. paroxysmalatrialfibrillation.EurHeartJ2000;21:565(cid:2)572.
Sause A, Tebbenjohanns J, Schade A, Shin DI, Staudt A, Zacharzowsky U, .. 231.BertagliaE,BonsoA,ZoppoF,ProclemerA,VerlatoR,CorO(cid:3) L,MantovanR,
.
AndrieR,WetzelU,NeuserH,WunderlichC,KuhlenR,TijssenJGP,Hindricks .. ThemistoclakisS,RavieleA,PascottoP.Differentclinicalcoursesandpredic-
G,BollmannA.In-hospitalmortalityofpatientswithatrialarrhythmias:insights .. torsofatrialfibrillationoccurrenceaftertransisthmicablationinpatientswith
.
fromtheGerman-wideHelioshospitalnetworkof161502patientsand34025 . preablation lone atrial flutter, coexistent atrial fibrillation, and drug induced
.
arrhythmia-relatedprocedures.EurHeartJ2018;39:3947(cid:2)3957. . atrialflutter.PacingClinElectrophysiol2004;27:1507(cid:2)1512.
.
208. KatritsisDG,ZografosT,SiontisKC,GiannopoulosG,MuthalalyRG,LiuQ, .. 232.NabarA,RodriguezLM,TimmermansC,vanMechelenR,WellensHJJ.Class
Latchamsetty R, Varga Z, Deftereos S, Swerdlow C, Callans DJ, Miller JM, . IC antiarrhythmic drug induced atrial flutter: electrocardiographic and
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 58 ---
712 ESCGuidelines
.
.
electrophysiologicalfindingsandtheirimportanceforlongtermoutcomeafter . 256.Vos MA, Golitsyn SR, Stangl K, Ruda MY, Van Wijk L, Harry JD, Perry KT,
.
rightatrialisthmusablation.Heart2001;85:424(cid:2)429. . Touboul P,Steinbeck G, Wellens HJJ. Superiority ofibutilide(a newclass III
.
233. LuchsingerJA,SteinbergJS.Resolutionofcardiomyopathyafterablationofatrial .. agent) over dl-sotalol in converting atrial flutter and atrial fibrillation. Heart
flutter.JAmCollCardiol1998;32:205(cid:2)210. .. 1998;79:568(cid:2)575.
.
234. PizzaleS,LemeryR,GreenMS,GollobMH,TangASL,BirnieDH.Frequency . 257.SinghS,ZobleRG,YellenL,BrodskyMA,FeldGK,BerkM,BillingCB.Efficacy
.
andpredictorsoftachycardia-inducedcardiomyopathyinpatientswithpersis- .. andsafetyoforaldofetilideinconvertingtoandmaintainingsinusrhythmin
tentatrialflutter.CanJCardiol2009;25:469(cid:2)472. .. patients with chronic atrial fibrillation or atrial flutter. The Symptomatic Atrial
.
235. Ellenbogen KA, Dias VC, Cardello FP, Strauss WE, Simonton CA, Pollak SJ, . Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study 2000;102:
.
Wood MA, Stambler BS. Safety and efficacy of intravenousdiltiazem in atrial . 2385(cid:2)2390.
.
fibrillationoratrialflutter.AmJCardiol1995;75:45(cid:2)49. .. 258.PetersRW,ShorofskySR,PeliniM,OlsovskyM,GoldMR.Overdriveatrialpac-
236. Salerno DM, Dias VC, Kleiger RE, Tschida VH, Sung RJ, Sami M, Giorgi LV. .. ingforconversionofatrialflutter:comparisonofpostoperativewithnonposto-
.
Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation . perativepatients.AmHeartJ1999;137:100(cid:2)103.
.
andatrialflutter.AmJCardiol1989;63:1046(cid:2)1051. .. 259.Gillis AM, Unterberg-Buchwald C, Schmidinger H, Massimo S, Wolfe K,
237. PlatiaEV,MichelsonEL,PorterfieldJK,DasG.Esmololversusverapamilinthe .. Kavaney DJ, Otterness MF, Hohnloser SH. Safety and efficacy of advanced
.
acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol . atrial pacing therapies for atrial tachyarrhythmias in patients with a new
.
1989;63:925(cid:2)929. . implantabledualchambercardioverter-defibrillator.JAmCollCardiol2002;40:
.
238. Ellenbogen KA, Dias VC, Plumb VJ, Heywood JT, Mirvis DM. A placebo- .. 1653(cid:2)1659.
controlledtrialofcontinuousintravenousdiltiazeminfusionfor24-hourheart .. 260.MitchellAR,SpurrellPA,CheatleL,SulkeN.Effectofatrialantitachycardiapac-
.
ratecontrolduringatrialfibrillationandatrialflutter:amulticenterstudy.JAm . ingtreatmentsinpatientswithanatrialdefibrillator:randomisedstudycompar-
.
CollCardiol1991;18:891(cid:2)897. . ingsubthresholdandnominalpacingoutputs.Heart2002;87:433(cid:2)437.
.
239. Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, .. 261.RhodesLA,WalshEP,SaulJP.Conversionofatrialflutterinpediatricpatients
Gschwandtner M, Siostrzonek P, Heinz G. Amiodarone versus diltiazem for .. bytransesophagealatrialpacing:asafe,effective,minimallyinvasiveprocedure.
.
ratecontrolincriticallyillpatientswithatrialtachyarrhythmias.CritCareMed . AmHeartJ1995;130:323(cid:2)327.
.
2001;29:1149(cid:2)1153. .. 262.Natale A, Newby KH, Pisano(cid:2) E, Leonelli F, Fanelli R, Potenza D, Beheiry S,
240. ClemoHF,WoodMA,GilliganDM,EllenbogenKA.Intravenousamiodarone .. Tomassoni G. Prospective randomized comparison of antiarrhythmic therapy
.
foracuteheartratecontrolinthecriticallyillpatientwithatrialtachyarrhyth- . versusfirst-lineradiofrequencyablationinpatientswithatrialflutter.JAmColl
.
mias.AmJCardiol1998;81:594(cid:2)598. . Cardiol2000;35:1898(cid:2)1904.
.
241. GhaliWA,WasilBI,BrantR,ExnerDV,CornuzJ.Atrialflutterandtheriskof .. 263.DaCostaA,The´veninJ,RocheF,Romeyer-BouchardC,AbdellaouiL,Messier
thromboembolism: a systematic review and meta-analysis. Am J Med .. M,DenisL,FaureE,GonthierR,KruszynskiG,PagesJM,BonijolyS,Lamaison
.
2005;118:101(cid:2)107. . D, Defaye P, Barthe´lemy JC, Gouttard T, Isaaz K. Results from the Loire-
.
242. VadmannH,NielsenPB,HjortshøjSP,RiahiS,RasmussenLH,LipGYH,Larsen . Arde`che-Droˆme-Ise`re-Puy-de-Doˆme(LADIP)trialonatrialflutter,amulticen-
.
TB. Atrial flutter and thromboembolic risk: a systematic review. Heart .. tricprospectiverandomizedstudycomparingamiodaroneandradiofrequency
.
2015;101:1446(cid:2)1455. . ablation after the first episode of symptomatic atrial flutter. Circulation
.
243. Seidl K, Hauer B, Schwick NG, Zellner D, Zahn R, Senges J. Risk of throm- . 2006;114:1676(cid:2)1681.
.
boemboliceventsinpatientswithatrialflutter.AmJCardiol1998;82:580(cid:2)583. .. 264.SatomiK,ChunKRJ,TilzR,BanschD,ErnstS,AntzM,SchmidtB,KuckK-H,
244. Wood KA, Eisenberg SJ, Kalman JM, Drew BJ, Saxon LA, Lee RJ, Lesh MD, .. OuyangF.Catheterablation ofmultiple unstablemacroreentranttachycardia
.
ScheinmanMM.Riskofthromboembolisminchronicatrialflutter.AmJCardiol . withintherightatriumfreewallinpatientswithoutpreviouscardiacsurgery.
.
1997;79:1043(cid:2)1047. . CircArrhythmElectrophysiol2010;3:24(cid:2)31.
.
245. LinYS,ChenYL,ChenTH,LinMS,LiuCH,YangTY,ChungCM,ChenMC. .. 265.JaisP,ShahDC,HaissaguerreM,HociniM,PengJT,TakahashiA,GarrigueS,Le
Comparisonofclinicaloutcomesamongpatientswithatrialfibrillationoratrial .. Metayer P, Clementy J. Mapping and ablation of left atrial flutters. Circulation
.
flutterstratifiedbyCHA2DS2-VAScscore.JAMANetwOpen2018;1:e180941. . 2000;101:2928(cid:2)2934.
.
246. ChenYL,LinYS,WangHT,LiuWH,ChenHC,ChenMC.Clinicaloutcomes .. 266.KallJG,RubensteinDS,KoppDE,BurkeMC,VerdinoRJ,LinAC,JohnsonCT,
ofsolitaryatrialflutterpatientsusinganticoagulationtherapy:anationalcohort .. CookePA,WangZG,FumoM,WilberDJ.Atypicalatrialflutteroriginatingin
.
study.Europace2019;21:313(cid:2)321. . therightatrialfreewall.Circulation2000;101:270(cid:2)279.
.
247. Schmidt H, von der Recke G, Illien S, Lewalter T, Schimpf R, Wolpert C, . 267.NakagawaH,ShahN,MatsudairaK,OverholtE,ChandrasekaranK,Beckman
.
BecherH,Lu¨deritzB,OmranH.Prevalenceofleftatrialchamberandappend- .. KJ,SpectorP,CalameJD,RaoA,HasdemirC,OtomoK,WangZ,LazzaraR,
agethrombiinpatientswithatrialflutteranditsclinicalsignificance.JAmColl .. Jackman WM. Characterization of reentrant circuit in macroreentrant right
.
Cardiol2001;38:778(cid:2)784. . atrialtachycardiaaftersurgicalrepairofcongenitalheartdisease:isolatedchan-
. 248. GallagherMM,GuoX-H,PolonieckiJD,GuanYapY,WardD,CammAJ.Initial . nelsbetweenscarsallow"focal"ablation.Circulation2001;103:699(cid:2)709.
.
energysetting,outcomeandefficiencyindirectcurrentcardioversionofatrial .. 268.OuyangF,ErnstS,VogtmannT,GoyaM,VolkmerM,SchaumannA,BanschD,
fibrillationandflutter.JAmCollCardiol2001;38:1498(cid:2)1504. .. AntzM,KuckK-H.Characterizationofreentrantcircuitsinleftatrialmacro-
.
249. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of . reentrant tachycardia: critical isthmus block can prevent atrial tachycardia .
uneventfulcardioversionandmaintenanceofsinusrhythmfromdirect-current .. recurrence.Circulation2002;105:1934(cid:2)1942.
electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol .. 269.TaiC-T,HuangJ-L,LinY-K,HsiehM-H,LeeP-C,DingY-A,ChangM-S,Chen
. 1991;68:41(cid:2)46. . S-A. Noncontact three-dimensional mapping and ablation of upper loop re-
.
250. CrijnsHJGM,VanGelderIC,KingmaJH,DunselmanPHJM,GosselinkATM,Lie . entryoriginatingintherightatrium.JAmCollCardiol2002;40:746(cid:2)753.
.
KI.AtrialfluttercanbeterminatedbyaclassIIIantiarrhythmicdrugbutnotby .. 270.Blackshear JL, StamblerBS, Strauss WE, Roy D, Dias VC, Beach CL, Ebener
aclassICdrug.EurHeartJ1994;15:1403(cid:2)1408. .. MK.Controlofheartrateduringtransitionfromintravenoustooraldiltiazem
.
251. StamblerBS,WoodMA,EllenbogenKA,PerryKT,WakefieldLK,VanderLugt . inatrialfibrillationorflutter.AmJCardiol1996;78:1246(cid:2)1250.
.
JT.Efficacyandsafetyofrepeatedintravenousdosesofibutilideforrapidcon- . 271.BrodskyMA,AllenBJ,GrimesJA,GoldC.Enhancedatrioventricularconduc-
.
versionofatrialflutterorfibrillation.Circulation1996;94:1613(cid:2)1621. .. tion during atrial flutter after intravenous adenosine. N Engl J Med
.
252. EllenbogenKA,StamblerBS,WoodMA,SagerPT,WesleyRC,MeissnerMD, . 1994;330:288(cid:2)289.
.
ZobleRG,WakefieldLK,PerryKT,VanderlugttJT,IbutilideI.Efficacyofintra- . 272.StrickbergerSA,ManKC,DaoudEG,GoyalR,BrinkmanK,KnightBP,WeissR,
.
venous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a .. BahuM,MoradyF.Adenosine-inducedatrialarrhythmia:aprospectiveanalysis.
dose-responsestudy.JAmCollCardiol1996;28:130(cid:2)136. .. AnnInternMed1997;127:417(cid:2)422.
.
253. FalkMDFRH,PollakMDA,SinghMDFSN,FriedrichMDT.Intravenousdofeti- . 273.CrozierIG,IkramH,KenealyM,LevyL.Flecainideacetateforconversionof
.
lide,aclassIIIantiarrhythmicagent,fortheterminationofsustainedatrialfibril- . acute supraventricular tachycardia to sinus rhythm. Am J Cardiol
.
lationorflutter.JAmCollCardiol1997;29:385(cid:2)390. .. 1987;59:607(cid:2)609.
254. StamblerBS,WoodMA,EllenbogenKA.Antiarrhythmicactionsofintravenous .. 274.Murdock CJ, Kyles AE, Yeung-Lai-Wah JA, Qi A, Vorderbrugge S, Kerr CR.
.
ibutilidecomparedwithprocainamideduringhumanatrialflutterandfibrillation: . Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J
.
electrophysiological determinants of enhanced conversion efficacy. Circulation .. Cardiol1990;66:755(cid:2)757.
1997;96:4298(cid:2)4306. .. 275.BianconiL,CastroA,DinelliM,AlboniP,PappalardoA,RichiardiE,Santini
.
255. Volgman AS, Carberry PA, Stambler B, Lewis WR, Dunn GH, Perry KT, . M.Comparisonof intravenously administered dofetilideversusamiodarone
.
VanderLugtJT,KoweyPR.Conversionefficacyandsafetyofintravenousibuti- . in the acute termination of atrial fibrillation and flutter. A multicentre,
.
lidecomparedwithintravenousprocainamideinpatientswithatrialflutteror .. randomized, double-blind, placebo-controlled study. Eur Heart J
fibrillation.JAmCollCardiol1998;31:1414(cid:2)1419. . 2000;21:1265(cid:2)1273.
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 59 ---
ESCGuidelines 713
.
.
276. Kafkas NV, Patsilinakos SP, Mertzanos GA, Papageorgiou KI, Chaveles JI, . 298.Barbhaiya CR, Baldinger SH, Kumar S, Chinitz JS, Enriquez AD, John R,
.
DagadakiOK,KelesidisKM.Conversionefficacyofintravenousibutilidecom- . Stevenson WG, Michaud GF. Downstream overdrive pacing and intracardiac
.
paredwithintravenousamiodaroneinpatientswithrecent-onsetatrialfibrilla- .. concealed fusion to guide rapid identification of atrial tachycardia after atrial
tionandatrialflutter.IntJCardiol2007;118:321(cid:2)325. .. fibrillationablation.Europace2018;20:596(cid:2)603.
.
277. HeiselA,JungJ,StoppM,SchiefferH.Facilitatinginfluenceofprocainamideon . 299.JohnerN,ShahDC,JoussetF,Dall’AglioPB,NamdarM.Electrophysiological
.
conversionofatrialflutterbyrapidatrialpacing.EurHeartJ1997;18:866(cid:2)869. .. andanatomicalcorrelatesofsiteswithpostpacingintervalsshorterthantachy-
278. Katritsis DG, Josephson ME. Anticoagulation for cardioversion of acute onset .. cardia cycle length in atypical atrial flutter. Circ Arrhythm Electrophysiol
.
atrialfibrillation:timetoreviseguidelines?JACCClinElectrophysiol2016;2:495(cid:2)497. . 2019;12:e006955.
.
279. SchwartzmanD,CallansDJ,GottliebCD,DillonSM,MovsowitzC,Marchlinski . 300.Yokokawa M, Latchamsetty R, Ghanbari H, Belardi D, Makkar A, Roberts B,
.
FE.Conductionblockintheinferiorvenacaval-tricuspidvalveisthmus:associa- .. Saint-Phard W, Sinno M, Carrigan T, Kennedy R, Suwanagool A, Good E,
tionwithoutcomeofradiofrequencyablationoftypeIatrialflutter.JAmColl .. CrawfordT,JongnarangsinK,PelosiF,BogunF,OralH,MoradyF,ChughA.
.
Cardiol1996;28:1519(cid:2)1531. . Characteristicsofatrialtachycardiaduetosmallvslargereentrantcircuitsafter
.
280. DeBortoliA,ShiLB,OhmOJ,HoffPI,SchusterP,SolheimE,ChenJ.Incidence .. ablationofpersistentatrialfibrillation.HeartRhythm2013;10:469(cid:2)476.
andclinicalpredictorsofsubsequentatrialfibrillationrequiringadditionalabla- .. 301.ChangS-L,TsaoH-M,LinY-J,LoL-W,HuY-F,TuanT-C,TsaiW-C,ChangC-
.
tion after cavotricuspid isthmus ablation for typical atrial flutter. Scand . J, Suenari K, Huang S-Y, Tai C-T, Li C-H, Chao T-F, Wu T-J, Chen S-A.
.
CardiovascJ2017;51:123(cid:2)128. . Differentiatingmacroreentrantfromfocalatrialtachycardiasoccurredaftercir-
.
281. BendittDG,WilliamsJH,JinJ,DeeringTF,ZuckerR,BrowneK,Chang-SingP, .. cumferential pulmonary vein isolation. J Cardiovasc Electrophysiol
SinghBN.Maintenanceofsinusrhythmwithorald,l-Sotaloltherapyinpatients .. 2011;22:748(cid:2)755.
.
with symptomatic atrial fibrillation and/or atrial flutter. d,l-Soltalol Atrial . 302.GerstenfeldEP,DixitS,BalaR,CallansDJ,LinD,SauerW,GarciaF,CooperJ,
.
Fibrillation/FlutterStudyGroup.AmJCardiol1999;84:270(cid:2)277. . Russo AM, Marchlinski FE. Surface electrocardiogram characteristics of atrial
.
282. GrimmRA,StewartWJ,ArheartKL,ThomasJD,KleinAL.Leftatrialappendage .. tachycardias occurring after pulmonary vein isolation. Heart Rhythm
“stunning”afterelectricalcardioversionofatrialflutter:anattenuatedresponse .. 2007;4:1136(cid:2)1143.
.
compared with atrial fibrillation as the mechanism forlowersusceptibilityto . 303.MarkowitzSM,BrodmanRF,SteinKM,MittalS,SlotwinerDJ,IwaiS,DasMK,
.
thromboembolicevents.JAmCollCardiol1997;29:582(cid:2)589. .. Lerman BB. Lesional tachycardias related to mitral valve surgery. J Am Coll
283. BochoeyerA,YangY,ChengJ,LeeRJ,KeungEC,MarroucheNF,NataleA, .. Cardiol2002;39:1973(cid:2)1983.
.
Scheinman MM. Surface electrocardiographic characteristics of right and left . 304.TakahashiK,MiyauchiY,HayashiM,IwasakiY-k,YodogawaK,TsuboiI,Hayashi
.
atrialflutter.Circulation2003;108:60(cid:2)66. . H,OkaE,ItoHagiwaraK,FujimotoY,ShimizuW.Mechanismsofpostoperative
.
284. ChengJ,CabeenWRJr,ScheinmanMM.Rightatrialflutterduetolowerloop .. atrialtachycardiafollowingbiatrialsurgicalablationofatrialfibrillationinrela-
reentry:mechanismandanatomicsubstrates.Circulation1999;99:1700(cid:2)1705. .. tiontothesurgicallesionsets.HeartRhythm2016;13:1059(cid:2)1065.
.
285. Zhang S, Younis G, Hariharan R, Ho J, Yang Y, Ip J, Thakur RK, Seger J, . 305.ZhangJ,TangC,ZhangY,HanH,LiZ,SuXI.Electroanatomiccharacterization
.
ScheinmanMM,ChengJ.Lowerloopreentryasamechanismofclockwiseright . andablationoutcomeofnonlesionrelatedleftatrialmacroreentranttachycar-
.
atrialflutter.Circulation2004;109:1630(cid:2)1635. .. dia in patients without obvious structural heart disease. J Cardiovasc
.
286. YangY,ChengJ,BochoeyerA,HamdanMH,KowalRC,PageR,LeeRJ,Steiner . Electrophysiol2013;24:53(cid:2)59.
.
PR,SaxonLA,LeshMD,ModinGW,ScheinmanMM.Atypicalrightatrialflutter . 306.FukamizuS,SakuradaH,HayashiT,HojoR,KomiyamaK,TanabeY,TejimaT,
.
patterns.Circulation2001;103:3092(cid:2)3098. .. Nishizaki M, Kobayashi Y, Hiraoka M. Macroreentrant atrial tachycardia in
287. YangY,VarmaN,BadhwarN,TanelRE,SundaraS,LeeRJ,LeeBK,TsengZH, .. patientswithoutpreviousatrialsurgeryorcatheterablation:clinicalandelec-
.
MarcusGM,KimAM,OlginJE,ScheinmanMM.Prospectiveobservationsinthe . trophysiologicalcharacteristicsofscar-relatedleftatrialanteriorwallreentry.
.
clinical and electrophysiological characteristics of intra-isthmus reentry. . JCardiovascElectrophysiol2013;24:404(cid:2)412.
.
JCardiovascElectrophysiol2010;21:1099(cid:2)1106. .. 307.MarroucheNF,NataleA,WazniOM,ChengJ,YangY,PollackH,VermaA,
288. Zrenner B, Dong JUN, Schreieck J, Ndrepepa G, Meisner H, Kaemmerer H, .. UrsellP,ScheinmanMM.Leftseptalatrialflutter:electrophysiology,anatomy,
.
Scho¨migA,HessJ,SchmittC.Delineationofintra-atrialreentranttachycardia . andresultsofablation.Circulation2004;109:2440(cid:2)2447.
.
circuitsaftermustardoperationfortranspositionofthegreatarteriesusingbia- .. 308.Sawhney N, Anand K, Robertson CE, Wurdeman T, Anousheh R, Feld GK.
trial electroanatomic mapping and entrainment mapping. J Cardiovasc .. Recovery of mitral isthmus conduction leads to the development of macro-
.
Electrophysiol2003;14:1302(cid:2)1310. . reentrant tachycardia after left atrial linear ablation for atrial fibrillation. Circ
.
289. Ueda A, Suman-Horduna I, Mantziari L, Gujic M, Marchese P, Ho SY, Babu- . ArrhythmElectrophysiol2011;4:832(cid:2)837.
.
NarayanSV,ErnstS.Contemporaryoutcomesofsupraventriculartachycardia .. 309.MiyazakiS,ShahAJ,HociniM,Ha¨ıssaguerreM,Ja¨ısP.Recurrentspontaneous
ablationincongenitalheartdisease:asingle-centerexperiencein116patients. .. clinicalperimitralatrialtachycardiainthecontextofatrialfibrillationablation.
.
CircArrhythmElectrophysiol2013;6:606(cid:2)613. . HeartRhythm2015;12:104(cid:2)110.
. 290. AkcaF,BauernfeindT,DeGrootNMS,ShalganovT,SchwagtenB,Szili-Torok . 310.AmmarS,LuikA,HesslingG,BruhmA,ReentsT,SemmlerV,BuiattiA,Kathan
.
T. Thepresence of extensive atrial scars hinders the differential diagnosis of .. S,HofmannM,KolbC,SchmittC,DeisenhoferI.Ablationofperimitralflutter:
focalormacroreentrantatrialtachycardiasinpatientswithcomplexcongenital .. acute and long-term success of the modified anterior line. Europace
.
heartdisease.Europace2014;16:893(cid:2)898. . 2015;17:447(cid:2)452. .
291. Shah D, Jais P,Takahashi A,Hocini M,Peng JT,ClementyJ,HaissaguerreM. .. 311.Chugh A, Oral H, Lemola K, Hall B, Cheung P, Good E, Tamirisa K, Han J,
Dual-loopintra-atrialreentryinhumans.Circulation2000;101:631(cid:2)639. .. BogunF,PelosiF,MoradyF.Prevalence,mechanisms,andclinicalsignificanceof
. 292. Scaglione M, Caponi D, Ebrille E, Di Donna P, Di Clemente F, Battaglia A, . macroreentrant atrial tachycardia during and following left atrial ablation for
.
Raimondo C, Appendino M, Gaita F. Very long-term results of . atrialfibrillation.HeartRhythm2005;2:464(cid:2)471.
.
electroanatomic-guidedradiofrequencyablationofatrialarrhythmiasinpatients .. 312.NikolaidouT,AslanidiOV,ZhangH,EfimovIR.Structure(cid:2)functionrelationship
withsurgicallycorrectedatrialseptaldefect.Europace2014;16:1800(cid:2)1807. .. inthesinusandatrioventricularnodes.PediatrCardiol2012;33:890(cid:2)899.
.
293. Gucuk Ipek E, Marine JE, Habibi M, Chrispin J, Lima J, Rickard J, Spragg D, . 313.HuckerWJ,McCainML,LaughnerJI,IaizzoPA,EfimovIR.Connexin43expres-
.
ZimmermanSL,ZipunnikovV,BergerR,CalkinsH,NazarianS.Associationof . siondelineatestwodiscretepathwaysinthehumanatrioventricularjunction.
.
leftatrialfunctionwithincidentatypicalatrialflutterafteratrialfibrillationabla- .. AnatRec(Hoboken)2008;291:204(cid:2)215.
.
tion.HeartRhythm2016;13:391(cid:2)398. . 314.KatritsisDG,EfimovIR.Cardiacconnexingenotypingforidentificationofthecir-
.
294. Gerstenfeld EP, Callans DJ, Dixit S, Russo AM, Nayak H, Lin D, Pulliam W, . cuitofatrioventricularnodalre-entranttachycardia.Europace2018;21:190(cid:2)191.
.
Siddique S, Marchlinski FE. Mechanisms of organized left atrial tachycardias .. 315.KatritsisDG,BeckerAE,EllenbogenKA,GiazitzoglouE,KorovesisS,CammAJ.
occurringafterpulmonaryveinisolation.Circulation2004;110:1351(cid:2)1357. .. Effectofslowpathwayablationinatrioventricularnodalreentranttachycardia
.
295. WasmerK,Mo¨nnigG,BittnerA,DecheringD,ZellerhoffS,MilbergP,Ko¨beJ, . on the electrophysiologic characteristics of the inferior atrial inputs to the
.
Eckardt L. Incidence, characteristics, and outcome of left atrial tachycardias . humanatrioventricularnode.AmJCardiol2006;97:860(cid:2)865.
.
after circumferential antral ablation of atrial fibrillation. Heart Rhythm .. 316.KatritsisDG,EllenbogenKA,BeckerAE,CammAJ.Retrogradeslowpathway
2012;9:1660(cid:2)1666. .. conduction in patients with atrioventricular nodal re-entrant tachycardia.
.
296. Satomi K, B€ansch D, Tilz R, Chun J, Ernst S, Antz M, Greten H, Kuck K-H, . Europace2007;9:458(cid:2)465.
.
OuyangF.Leftatrialandpulmonaryveinmacroreentranttachycardiaassociated .. 317.KatritsisDG,SepahpourA,MarineJE,KatritsisGD,TanawuttiwatT,CalkinsH,
withdoubleconductiongaps:anoveltypeofman-madetachycardiaaftercir- .. RowlandE,JosephsonME.Atypicalatrioventricularnodalreentranttachycardia:
.
cumferentialpulmonaryveinisolation.HeartRhythm2008;5:43(cid:2)51. . prevalence,electrophysiologiccharacteristics,andtachycardiacircuit.Europace
.
297. Katritsis D, Wood MA, Shepard RK, Giazitzoglou E, Kourlaba G, Ellenbogen . 2015;17:1099(cid:2)1106.
.
KA.Atrialarrhythmiasfollowingostialorcircumferentialpulmonaryveinabla- .. 318.PentingaML,MeederJG,CrijnsHJGM,deMuinckED,WiesfeldACP,LieKI.
tion.JIntervCardElectrophysiol2006;16:123(cid:2)130. . Lateonsetatrioventricularnodaltachycardia.IntJCardiol1993;38:293(cid:2)298.
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 60 ---
714 ESCGuidelines
.
.
319. D’EsteD,ZoppoF,BertagliaE,ZerboF,PiccioloA,ScarabeoV,PascottoA, . 341.WinnifordMD,FultonKL,HillsLD.Long-termtherapyofparoxysmalsupra-
.
Pascotto P. Long-term outcome of patients with atrioventricular node reen- . ventriculartachycardia:arandomized,double-blindcomparisonofdigoxin,pro-
.
tranttachycardia.IntJCardiol2007;115:350(cid:2)353. .. pranololandverapamil.AmJCardiol1984;54:1138(cid:2)1139.
320. SauerWH,AlonsoC,ZadoE,CooperJM,LinD,DixitS,RussoA,VerdinoR, .. 342.AlboniP,TomasiC,MenozziC,BottoniN,PaparellaN,Fuc(cid:3)aG,BrignoleM,
.
JiS,GerstenfeldEP,CallansDJ,MarchlinskiFE.Atrioventricularnodalreentrant . CappatoR.Efficacyandsafetyofout-of-hospitalself-administeredsingle-dose
.
tachycardiainpatientsreferredforatrialfibrillationablation:responsetoabla- .. oraldrugtreatmentinthemanagementofinfrequent,well-toleratedparoxys-
tion that incorporates slow-pathway modification. Circulation .. malsupraventriculartachycardia.JAmCollCardiol2001;37:548(cid:2)553.
.
2006;114:191(cid:2)195. . 343.YehSJ,LinFC,ChouYY,HungJS,WuD.Terminationofparoxysmalsupraven-
.
321. MichowitzY,Anis-HeuslerA,ReinsteinE,Tovia-BrodieO,GlickA,Belhassen . tricular tachycardia with a single oral dose of diltiazem and propranolol.
.
B. Familial occurrence of atrioventricular nodal reentrant tachycardia. Circ .. Circulation1985;71:104(cid:2)109.
ArrhythmElectrophysiol2017;10:e004680. .. 344.MustoB,CavallaroC,MustoA,D’OnofrioA,BelliA,DeVincentisL.Flecainide
.
322. Katritsis DG, Josephson ME. Classification, electrophysiological features and . singleoraldoseformanagementofparoxysmalsupraventriculartachycardiain
.
therapyofatrioventricularnodalreentranttachycardia.ArrhythmElectrophysiol .. childrenandyoungadults.AmHeartJ1992;124:110(cid:2)115.
Rev2016;5:130(cid:2)135. .. 345.GoldbergAS,BathinaMN,MickelsenS,NawmanR,WestG,KusumotoFM.
.
323. KatritsisDG,CammAJ.Atrioventricularnodalreentranttachycardia.Circulation . Long-term outcomes on quality-of-life and health care costs in patients with
.
2010;122:831(cid:2)840. . supraventricular tachycardia (radiofrequency catheter ablation versus medical
.
324. KatritsisDG,JosephsonME.Classificationofelectrophysiologicaltypesofatrio- .. therapy).AmJCardiol2002;89:1120(cid:2)1123.
ventricular nodal re-entrant tachycardia: a reappraisal. Europace .. 346.Larson MS, McDonald K, Young C, Sung R, Hlatky MA. Quality of life
.
2013;15:1231(cid:2)1240. . beforeandafterradiofrequencycatheterablationinpatientswithdrugrefrac-
.
325. YamabeH,TanakaY,MorihisaK,UemuraT,EnomotoK,KawanoH,OgawaH. . tory atrioventricular nodal reentrant tachycardia. Am J Cardiol 1999;84:
.
Analysisoftheanatomicaltachycardiacircuitinverapamil-sensitiveatrialtachy- .. 471(cid:2)473.
cardiaoriginatingfromthevicinity ofthe atrioventricular node.CircArrhythm .. 347.Bathina M, Mickelsen S, Brooks C, Jaramillo J, Hepton T, Kusumoto F.
.
Electrophysiol2010;3:54(cid:2)62. . Radiofrequencycatheterablationversusmedicaltherapyforinitialtreatmentof
.
326. EngelsteinED,SteinKM,MarkowitzSM,LermanBB.Posteriorfastatrioventric- .. supraventricular tachycardia and its impact on quality of life and healthcare
ularnodepathways:Implicationsforradiofrequencycatheterablationofatrio- .. costs.AmJCardiol1998;82:589(cid:2)593.
.
ventricularnodereentranttachycardia.JAmCollCardiol1996;27:1098(cid:2)1105. . 348.Cheng CF, Sanders GD, Hlatky MA, Heidenreich P, McDonald KM, Lee BK,
.
327. KatritsisDG,EllenbogenKA,BeckerAE.Atrialactivationduringatrioventricular . LarsonMS,OwensDK.Cost-effectivenessofradiofrequencyablationforsupra-
.
nodal reentrant tachycardia: studies on retrograde fast pathway conduction. .. ventriculartachycardia.AnnInternMed2000;133:864(cid:2)876.
HeartRhythm2006;3:993(cid:2)1000. .. 349.KalbfleischSJ,CalkinsH,LangbergJJ,El-AtassiR,LeonA,BorganelliM,Morady
.
328. NamG-B,RheeK-S,KimJUN,ChoiK-J,KimY-H.Leftatrionodalconnections . F.Comparisonofthecostofradiofrequencycathetermodificationoftheatrio-
.
intypicalandatypicalatrioventricularnodalreentranttachycardias:activation . ventricularnodeandmedicaltherapyfordrug-refractoryatrioventricularnode
.
sequenceinthecoronarysinusandresultsofradiofrequencycatheterablation. .. reentranttachycardia.JAmCollCardiol1992;19:1583(cid:2)1587.
.
JCardiovascElectrophysiol2006;17:171(cid:2)177. . 350.KalbfleischSJ,StrickbergerSA,WilliamsonB,VorperianVR,ManC,Hummel
.
329. KatritsisDG,MarineJE,LatchamsettyR,ZografosT,TanawuttiwatT,Sheldon . JD,LangbergJJ,MoradyF.Randomized comparison ofanatomicandelectro-
.
SH,BuxtonAE,CalkinsH,MoradyF,JosephsonME.Coexistenttypesofatrio- .. grammappingapproachestoablationoftheslowpathwayofatrioventricular
ventricularnodalre-entranttachycardia.Implicationsforthetachycardiacircuit. .. nodereentranttachycardia.JAmCollCardiol1994;23:716(cid:2)723.
.
CircArrhythmElectrophysiol2015;8:1189(cid:2)1193. . 351.Katritsis DG, Giazitzoglou E, Zografos T, Ellenbogen KA, Camm AJ. An
.
330. MiljoenH,EctorJ,GarwegC,SaenenJ,HuybrechtsW,SarkozyA,WillemsR, . approach to left septal slow pathway ablation. J Interv Card Electrophysiol
.
Heidbuchel H. Differential presentation of atrioventricular nodal re-entrant .. 2011;30:73(cid:2)79.
tachycardiainathletesandnon-athletes.Europace2019;21:944(cid:2)949. .. 352.MoradyF.Catheterablationofsupraventriculararrhythmias:stateoftheart.
.
331. NawataH,YamamotoN,HiraoK,MiyasakaN,KawaraT,HiejimaK,HaradaT, . HeartRhythm2004;1:C67(cid:2)C84.
.
Suzuki F. Heterogeneity of anterograde fast-pathway and retrograde slow- .. 353.VanHareGF,JavitzH,CarmelliD,SaulJP,TanelRE,FischbachPS,KanterRJ,
pathwayconductionpatternsinpatientswiththefast(cid:2)slowformofatrioven- .. SchafferM,DunniganA,ColanS,SerwerG;PediatricElectrophysiologySociety.
.
tricular nodal reentrant tachycardia: electrophysiologic and electrocardio- . Prospective assessment after pediatric cardiac ablation: demographics, medical
.
graphicconsiderations.JAmCollCardiol1998;32:1731(cid:2)1740. . profiles,andinitialoutcomes.JCardiovascElectrophysiol2004;15:759(cid:2)770.
.
332. HwangC,MartinDJ,GoodmanJS,GangES,MandelWJ,SwerdlowCD,Peter .. 354.KatritsisDG.Catheterablationofatrioventricularnodalre-entranttachycardia:
CT, Chen P-S. Atypical atrioventricular node reciprocating tachycardia mas- .. factsandfiction.ArrhythmElectrophysiolRev2018;7:230(cid:2)231.
.
queradingastachycardiausingaleft-sidedaccessorypathway.JAmCollCardiol . 355.ChenH,ShehataM,MaW,XuJ,CaoJ,CingolaniE,SwerdlowC,ChenM,
. 1997;30:218(cid:2)225. . Chugh SS, Wang X. Atrioventricular block during slow pathway ablation:
.
333. Sakabe K, Wakatsuki T, Fujinaga H, Oishi Y, Ikata J, Toyoshima T, Hiura N, .. entirelypreventable?CircArrhythmElectrophysiol2015;8:739(cid:2)744.
NishikadoA,OkiT,ItoS.Patientwithatrioventricularnodereentranttachycar- .. 356.Papagiannis J, Beissel DJ, Krause U, Cabrera M, Telishevska M, Seslar S,
.
dia with eccentric retrograde left-sided activation: treatment with radiofre- . Johnsrude C, Anderson C, Tisma-Dupanovic S, Connelly D, Avramidis D, .
quencycatheterablation.JpnHeartJ2000;41:227(cid:2)234. .. Carter C, Kornyei L, Law I, Von Bergen N, Janusek J, Silva J, Rosenthal E,
334. VijayaramanP,KokLC,RheeB,EllenbogenKA.Unusualvariantofatrioventric- .. Willcox M, Kubus P, Hessling G, Paul T; Paediatric and Congenital
. ularnodalreentranttachycardia.HeartRhythm2005;2:100(cid:2)102. . Electrophysiology Society. Atrioventricular nodal reentrant tachycardia in
.
335. HeidbuchelH,JackmanWM.CharacterizationofsubformsofAVnodalreen- . patients with congenital heart disease. Outcome after catheter ablation. Circ
.
tranttachycardia.Europace2004;6:316(cid:2)329. .. ArrhythmElectrophysiol2017;10:e004869.
336. KatritsisDG,ZografosT,KatritsisGD,GiazitzoglouE,VachliotisV,PaxinosG, .. 357.Backhoff D, Klehs S, Mu¨ller MJ, Schneider HE, Kriebel T, Paul T, Krause U.
.
CammAJ,JosephsonME.Catheterablationvs.antiarrhythmicdrugtherapyin . Long-termfollow-upaftercatheterablationofatrioventricularnodalreentrant
.
patients with symptomatic atrioventricular nodal re-entrant tachycardia: a . tachycardiainchildren.CircArrhythmElectrophysiol2016;9:e004264.
.
randomized,controlledtrial.Europace2017;19:602(cid:2)606. .. 358.Skeberis V, Simonis F, Tsakonas K, Celiker Alp AY, Andries E, Brugada P.
.
337. KatritsisDG,JohnRM,LatchamsettyR,MuthalalyRG,ZografosT,KatritsisGD, . InappropriatesinustachycardiafollowingradiofrequencyablationofAVnodal
.
Stevenson WG, Efimov IR, Morady F. Left septal slow pathway ablation for . tachycardia: incidence and clinical significance. Pacing Clin Electrophysiol
.
atrioventricular nodal reentrant tachycardia. Circ Arrhythm Electrophysiol .. 1994;17:924(cid:2)927.
2018;11:e005907. .. 359.Rostock T, Risius T, Ventura R, Klemm HU, Weiss C, Keitel A, Meinertz T,
.
338. Katritsis DG, Marine JE, Contreras FM, Fujii A, Latchamsetty R, Siontis KC, . WillemsS.Efficacyandsafetyofradiofrequencycatheterablationofatrioven-
.
Katritsis GD, Zografos T, John RM, Epstein LM, Michaud GF, Anter E, . tricular nodal reentrant tachycardia in the elderly. J Cardiovasc Electrophysiol
.
Sepahpour A, Rowland E, Buxton AE, Calkins H, Morady F, Stevenson WG, .. 2005;16:608(cid:2)610.
Josephson ME. Catheter ablation of atypical atrioventricular nodal reentrant .. 360.LiYG,GronefeldG,BenderB,MachuraC,HohnloserSH.Riskofdevelopment
.
tachycardia.Circulation2016;134:1655(cid:2)1663. . of delayed atrioventricular block after slow pathway modification in patients
.
339. StavrakisS,JackmanWM,LockwoodD,NakagawaH,BeckmanK,ElkholeyK, .. withatrioventricularnodalreentranttachycardiaandapre-existingprolonged
WangZ,PoSS.Slow/fastatrioventricularnodalreentranttachycardiausingthe .. PRinterval.EurHeartJ2001;22:89(cid:2)95.
.
inferolateralleftatrialslowpathway.CircArrhythmElectrophysiol2018;11:e006631. . 361.Deisenhofer I, Zrenner B, Yin Y-h, Pitschner H-F, Kuniss M, Grossmann G,
.
340. RinkenbergerRL,PrystowskyEN,HegerJJ,TroupPJ,JackmanWM,ZipesDP. . StillerS,LuikA,VeltmannC,FrankJ,LinnerJ,EstnerHL,PflaumerA,WuJ,von
.
Effectsofintravenousandchronicoralverapamiladministrationinpatientswith .. Bary C, Ucer E, Reents T, Tzeis S, Fichtner S, Kathan S, Karch MR, Jilek C,
supraventriculartachyarrhythmias.Circulation1980;62:996(cid:2)1010. . Ammar S, Kolb C, Liu Z-C, Haller B, Schmitt C, Hessling G. Cryoablation
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 61 ---
ESCGuidelines 715
.
.
versus radiofrequency energy for the ablation of atrioventricular nodal reen- . 385.PeikerC,PottC,EckardtL,KelmM,ShinDI,WillemsS,MeyerC.Dualatrio-
.
tranttachycardia(theCYRANOStudy):resultsfromalargemulticenterpro- . ventricularnodalnon-re-entranttachycardia.Europace2016;18:332(cid:2)339.
.
spectiverandomizedtrial.Circulation2010;122:2239(cid:2)2245. .. 386.YokoshikiH,SasakiK,ShimokawaJ,SakuraiM,TsutsuiH.Nonreentrantatrio-
362. HanninenM,Yeung-Lai-WahN,MasselD,GulaLJ,SkanesAC,YeeR,Klein .. ventricularnodaltachycardiaduetotriplenodalpathwaysmanifestedbyradio-
.
GJ, Manlucu J, Leong-Sit P. Cryoablation versus RF ablation for AVNRT: a . frequencyablationatcoronarysinusostium.JElectrocardiol2006;39:395(cid:2)399.
.
meta-analysis and systematic review. J Cardiovasc Electrophysiol .. 387.ItagakiT,OhnishiY,InoueT,YokoyamaM.Linkingphenomenonindualatrio-
2013;24:1354(cid:2)1360. .. ventricularnodalpathways.JpnCircJ2001;65:937(cid:2)940.
.
363. MattaM,AnselminoM,ScaglioneM,VitoloM,FerrarisF,DiDonnaP,Caponi . 388.ArenaG,BongiorniMG,SoldatiE,GherarducciG,MarianiM.Incessantnon-
.
D,CastagnoD,GaitaF.Coolingdynamics:anewpredictoroflong-termeffi- . reentrant atrioventricular nodal tachycardia due to multiple nodal pathways
.
cacyofatrioventricularnodalreentranttachycardiacryoablation.JIntervCard .. treated by radiofrequency ablation of the slow pathways. J Cardiovasc
Electrophysiol2017;48:333(cid:2)341. .. Electrophysiol1999;10:1636(cid:2)1642.
.
364. Pieragnoli P, Paoletti Perini A, Checchi L, Carrassa G, Giomi A, Carrai P, . 389.WangNC.Dualatrioventricularnodalnonreentranttachycardia:asystematic
.
MichelucciA,PadelettiL,RicciardiG.CryoablationoftypicalAVNRT:younger .. review.PacingClinElectrophysiol2011;34:1671(cid:2)1681.
ageandadministrationofbonusablationfavorlong-termsuccess.HeartRhythm .. 390.HoSY.Accessoryatrioventricular pathways:getting totheorigins.Circulation
.
2015;12:2125(cid:2)2131. . 2008;117:1502(cid:2)1504.
.
365. EnriquezA,EllenbogenKA,BolesU,BaranchukA.Atrioventricularnodalreen- . 391.Jackman WM, Wang XZ, Friday KJ, Roman CA, Moulton KP, Beckman KJ,
.
tranttachycardiainimplantablecardioverterdefibrillators:diagnosisandtrou- .. McClelland JH, Twidale N, Hazlitt HA, Prior MI, Margolis PD, Calame JD,
bleshooting.JCardiovascElectrophysiol2015;26:1282(cid:2)1288. .. OverholtED,LazzaraR.Catheterablationofaccessoryatrioventricularpath-
.
366. WalshEP,SaulJP,ShollerGF,TriedmanJK,JonasRA,MayerJE,WesselDL. . ways (Wolff-Parkinson-White syndrome)by radiofrequency current. N Engl J
.
Evaluationofastagedtreatmentprotocolforrapidautomaticjunctionaltachy- . Med1991;324:1605(cid:2)1611.
.
cardia after operation for congenital heart disease. J Am Coll Cardiol .. 392.KatritsisD,BashirY,HealdS,PolonieckiJ,WardDE.Radiofrequencyablation
1997;29:1046(cid:2)1053. .. ofaccessorypathways:implicationsofaccumulatedexperienceandtimededi-
.
367. CoolsE,MissantC.Junctional ectopictachycardia aftercongenitalheartsur- . catedtoprocedures.EurHeartJ1994;15:339(cid:2)344.
.
gery.ActaAnaesthesiolBelg2014;65:1(cid:2)8. .. 393.SchluterM,GeigerM,SiebelsJ,DuckeckW,KuckKH.Catheterablationusing
368. Collins KK, Van Hare GF, Kertesz NJ, Law IH, Bar-Cohen Y, Dubin AM, .. radiofrequency current to cure symptomatic patients with tachyarrhythmias
.
EtheridgeSP,BerulCI,AvariJN,TuzcuV,SreeramN,SchafferMS,FournierA, . relatedtoanaccessoryatrioventricularpathway.Circulation1991;84:1644(cid:2)1661.
.
SanataniS,SnyderCS,SmithRTJr,ArabiaL,HamiltonR,ChunT,LibermanL, . 394.Liu Q, Shehata M, Lan DZ, Ehdaie A, Cingolani E, Chugh SS, Fu G, Jiang C,
.
Kakavand B, Paul T, Tanel RE. Pediatric nonpost-operative junctional ectopic .. WangX.Accuratelocalizationandcatheterablationofsuperoparaseptalacces-
tachycardiamedicalmanagementandinterventionaltherapies.JAmCollCardiol .. sorypathways.HeartRhythm2018;15:688(cid:2)695.
.
2009;53:690(cid:2)697. . 395.KuckKH,FridayKJ,KunzeKP,SchluterM,LazzaraR,JackmanWM.Sitesof
.
369. HamdanM,VanHareGF,FisherW,GonzalezR,DorostkarP,LeeR,LeshM, . conduction block in accessory atrioventricular pathways. Basis for concealed
.
SaxonL,KalmanJ,ScheinmanM.Selectivecatheterablationofthetachycardia .. accessorypathways.Circulation1990;82:407(cid:2)417.
.
focus in patients with nonreentrant junctional tachycardia. Am J Cardiol . 396.CappatoR,SchluterM,WeissC,AntzM,KoschykDH,HofmannT,KuckKH.
.
1996;78:1292(cid:2)1297. . Radiofrequency current catheter ablation of accessory atrioventricular path-
.
370. RuderMA,DavisJC,EldarM,AbbottJA,GriffinJC,SegerJJ,ScheinmanMM. .. waysinEbstein’sanomaly.Circulation1996;94:376(cid:2)383.
Clinical and electrophysiologiccharacterizationof automaticjunctional tachy- .. 397.Bhatia A, Sra J, Akhtar M. Preexcitation syndromes. Curr Probl Cardiol
.
cardiainadults.Circulation1986;73:930(cid:2)937. . 2016;41:99(cid:2)137.
.
371. FishenfeldJ,DesserKB,BenchimolA.Non-paroxysmalA-Vjunctionaltachycar- . 398.Koneru JN, Wood MA, Ellenbogen KA. Rare forms of preexcitation: a case
.
diaassociatedwithacutemyocardialinfarction.AmHeartJ1973;86:754(cid:2)758. .. study and brief overview of familial forms of preexcitation. Circ Arrhythm
372. KumagaiK,YamatoH,YamanouchiY,MatsuoK,TashiroN,HirokiT,ArakawaK. .. Electrophysiol2012;5:e82(cid:2)e87.
.
Automaticjunctionaltachycardiainanadult.ClinicalCardiology1990;13:813(cid:2)816. . 399.XieB,HealdSC,BashirY,KatritsisD,MurgatroydFD,CammAJ,RowlandE,
.
373. CookJR,SteinbergJS.Anincessantformofjunctionalectopictachycardiainan .. WardDE.Localizationofaccessorypathwaysfromthe12-leadelectrocardio-
adultresponsivetoaclass1Cagent.AmHeartJ1991;122:1487(cid:2)1489. .. gramusinganewalgorithm.AmJCardiol1994;74:161(cid:2)165.
.
374. AmrousyDE,ElshehabyW,FekyWE,ElshmaaNS.Safetyandefficacyofpro- . 400.Pambrun T, El Bouazzaoui R, Combes N, Combes S, Sousa P, Le Bloa M,
.
phylacticamiodaroneinpreventingearlyjunctionalectopictachycardia(JET)in . MassoullieG,ChenitiG,MartinR,PilloisX,DuchateauJ,SacherF,HociniM,
.
childrenaftercardiacsurgeryanddeterminationofitsriskfactor.PediatrCardiol .. JaisP,DervalN,BortoneA,BovedaS,DenisA,HaissaguerreM,AlbenqueJP.
2016;37:734(cid:2)739. .. Maximalpre-excitation basedalgorithmforlocalization ofmanifestaccessory
.
375. EntenmannA,Michel M,HerbergU, Haas N,Kumpf M, Gass M,Egender F, . pathwaysinadults.JACCClinElectrophysiol2018;4:1052(cid:2)1061.
. Gebauer R. Management of postoperative junctional ectopic tachycardia in . 401.BasiounyT,deChillouC,FarehS,KirkorianG,MessierM,SadoulN,ChevalierP,
.
pediatricpatients:asurveyof30centersinGermany,Austria,andSwitzerland. .. Magnin-PoullI,BlankoffI,ChenJ,TouboulP,AliotE.Accuracyandlimitationsof
EurJPediatr2017;176:1217(cid:2)1226. .. published algorithms using the twelve-lead electrocardiogram to localize overt
.
376. RajaP,HawkerRE,ChaikitpinyoA,CooperSG,LauKC,NunnGR,Cartmill . atrioventricularaccessorypathways.JCardiovascElectrophysiol1999;10:1340(cid:2)1349. .
TB,ShollerGF.Amiodaronemanagementofjunctionalectopictachycardiaafter .. 402.PackerDL,GallagherJJ,PrystowskyEN.Physiologicalsubstrateforantidromic
cardiacsurgeryinchildren.BrHeartJ1994;72:261(cid:2)265. .. reciprocatingtachycardia.Prerequisitecharacteristicsoftheaccessorypathway
. 377. Sarubbi B, Musto B, Ducceschi V, D‘Onofrio A, Cavallaro C, Vecchione F, . andatrioventricularconductionsystem.Circulation1992;85:574(cid:2)588.
.
MustoC,Calabro(cid:3)R.Congenitaljunctionalectopictachycardiainchildrenand . 403.Brembilla-PerrotB,PauriahM,SellalJM,ZinziusPY,SchwartzJ,deChillouC,
.
adolescents:a20yearexperiencebasedstudy.Heart2002;88:188(cid:2)190. .. CismaruG,BeurrierD,VoilliotD,SeltonO,LouisP,AndronacheM,NosuR,
378. DieksJ-K,KlehsS,Mu¨llerMJ,PaulT,KrauseU.Adjunctiveivabradineincombi- .. delaChaiseAT.Incidenceandprognosticsignificanceofspontaneousandindu-
.
nation with amiodarone: A novel therapy for pediatric congenital junctional . cibleantidromictachycardia.Europace2013;15:871(cid:2)876.
.
ectopictachycardia.HeartRhythm2016;13:1297(cid:2)1302. .. 404.CeresnakSR,TanelRE,PassRH,LibermanL,CollinsKK,VanHareGF,Gates
379. Al-GhamdiS,Al-FayyadhMI,HamiltonRM.Potentialnewindicationforivabra- .. GJ, Dubin AM. Clinical and electrophysiologic characteristics of antidromic
.
dine: treatment of a patient with congenital junctional ectopic tachycardia. . tachycardia in children with Wolff-Parkinson-White syndrome. Pacing Clin
.
JCardiovascElectrophysiol2013;24:822(cid:2)824. . Electrophysiol2012;35:480(cid:2)488.
.
380. KuckK-H,KunzeK-P,Schlu¨terM,DuckeckW.Encainideversusflecainidefor .. 405.Etheridge SP, Escudero CA, Blaufox AD, Law IH, Dechert-Crooks BE,
chronicatrialandjunctionalectopictachycardia.AmJCardiol1988;62:L37(cid:2)L44. .. StephensonEA,DubinAM,CeresnakSR,MotonagaKS,SkinnerJR,Marcondes
.
381. PaulT,ReimerA,JanousekJ,KallfelzH-C.Efficacyandsafetyofpropafenonein . LD,PerryJC,CollinsKK,SeslarSP,CabreraM,UzunO,CannonBC,AzizPF,
.
congenitaljunctionalectopictachycardia.JAmCollCardiol1992;20:911(cid:2)914. . KubusP,TanelRE,ValdesSO,SamiS,KerteszNJ,MaldonadoJ,EricksonC,
.
382. HamdanMH,BadhwarN,ScheinmanMM.Roleofinvasiveelectrophysiologic .. Moore JP, Asakai H, Mill L, Abcede M, Spector ZZ, Menon S, Shwayder M,
testingintheevaluationandmanagementofadultpatientswithfocaljunctional .. BradleyDJ,CohenMI,SanataniS.Life-threateningeventriskinchildrenwith
.
tachycardia.CardElectrophysiolRev2002;6:431(cid:2)435. . Wolff-Parkinson-Whitesyndrome:amulticenterinternationalstudy.JACCClin
.
383. Law IH, Von Bergen NH, Gingerich JC, Saarel EV, Fischbach PS, Dick M. .. Electrophysiol2018;4:433(cid:2)444.
Transcathetercryothermalablationofjunctionalectopictachycardiainthenor- .. 406.GemmaLW,SteinbergLA,PrystowskyEN,PadanilamBJ.Developmentofrapid
.
malheart.HeartRhythm2006;3:903(cid:2)907. . preexcitedventricularresponsetoatrialfibrillationinapatientwithintermit-
.
384. Jackowska-Zduniak B, Forys U. Mathematical model of the atrioventricular . tentpreexcitation.JCardiovascElectrophysiol2013;24:347(cid:2)350.
.
nodaldoubleresponsetachycardiaanddouble-firepathology.MathBiosciEng .. 407.KangKT,PottsJE,RadbillAE,LaPageMJ,PapagiannisJ,GarnreiterJM,KubusP,
2016;13:1143(cid:2)1158. . Kantoch MJ, Von Bergen NH, Fournier A, Coˆte´ J-M, Paul T, Anderson CC,
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 62 ---
716 ESCGuidelines
.
.
CannonBC,MiyakeCY,BlaufoxAD,EtheridgeSP,SanataniS.Permanentjunc- . 431.CrijnsHJGM,denHeijerP,vanWijkLM,LieKI.Successfuluseofflecainidein
.
tional reciprocating tachycardia in children: a multicenter experience. Heart . atrialfibrillationwithrapidventricularrateintheWolff-Parkinson-Whitesyn-
.
Rhythm2014;11:1426(cid:2)1432. .. drome.AmHeartJ1988;115:1317(cid:2)1321.
408.MooreJP,PatelPA,ShannonKM,AlbersEL,SalernoJC,SteinMA,StephensonEA, .. 432.BorianiG,BiffiM,FrabettiL,AzzoliniU,SabbataniP,BronzettiG,CapucciA,
.
MohanS,ShahMJ,AsakaiH,PflaumerA,CzosekRJ,EverittMD,GarnreiterJM, . Magnani B. Ventricular fibrillation after intravenous amiodarone in Wolff-
.
McCantaAC,PapezAL,EscuderoC,SanataniS,CainNB,KannankerilPJ,Bratincsak .. Parkinson-White syndrome with atrial fibrillation. Am Heart J
A,MandapatiR,SilvaJNA,KnechtKR,BalajiS.Predictorsofmyocardialrecoveryin .. 1996;131:1214(cid:2)1216.
.
pediatrictachycardia-inducedcardiomyopathy.HeartRhythm2014;11:1163(cid:2)1169. . 433.Schu¨tzenbergerW,LeischF,GmeinerR.Enhancedaccessorypathwayconduc-
.
409. Kottkamp H, Hindricks G, Shenasa H, Chen X, Wichter T, Borggrefe M, . tionfollowingintravenousamiodaroneinatrialfibrillation.Acasereport.IntJ
.
Breithardt G. Variants of preexcitation–specialized atriofascicular pathways, .. Cardiol1987;16:93(cid:2)95.
nodofascicularpathways,andfasciculoventricularpathways: electrophysiologic .. 434.Tijunelis MA, Herbert ME. Myth: intravenous amiodarone is safe in patients
.
findings and target sites for radiofrequency catheter ablation. J Cardiovasc . withatrialfibrillationandWolff-Parkinson-Whitesyndromeintheemergency
.
Electrophysiol1996;7:916(cid:2)930. .. department.CJEM2005;7:262(cid:2)265.
410. Gandhavadi M, Sternick EB, Jackman WM, Wellens HJJ, Josephson ME. .. 435.KappenbergerLJ,FromerMA,SteinbrunnW,ShenasaM.Efficacyofamio-
.
Characterization of the distal insertion of atriofascicular accessory pathways . darone in the Wolff-Parkinson-White syndrome with rapid ventricular
.
and mechanisms of QRS patterns in atriofascicular antidromic tachycardia. . response via accessory pathway during atrial fibrillation. Am J Cardiol
.
HeartRhythm2013;10:1385(cid:2)1392. .. 1984;54:330(cid:2)335.
411. HaissaguerreM,CauchemezB,MarcusF,LeMetayerP,LauribeP,PoquetF, .. 436.SimonianSM,LotfipourS,WallC,LangdorfMI.Challengingthesuperiorityof
.
GencelL,ClementyJ.Characteristicsoftheventricularinsertionsitesofacces- . amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation.
.
sorypathwayswithanterogradedecrementalconductionproperties.Circulation . InternEmergMed2010;5:421(cid:2)426.
.
1995;91:1077(cid:2)1085. .. 437.Kim SS, Lal R, Ruffy R. Treatment of paroxysmal reentrant supraventricular
412. HluchyJAN,SchlegelmilchP,SchickelS,Jo¨rgerURS,JurkovicovaO,SabinGV. .. tachycardiawithflecainideacetate.AmJCardiol1986;58:80(cid:2)85.
RadiofrequencyablationofaconcealednodoventricularMahaimfiberguidedby .. 438.BravoL,AtienzaF,EidelmanG,A(cid:2)vilaP,PellizaM,CastellanosE,LoughlinG,
.
adiscretepotential.JCardiovascElectrophysiol1999;10:603(cid:2)610. .. DatinoT,TorrecillaEG,AlmendralJ,S(cid:2)anchezPL,ArenalA(cid:2),Mart(cid:2)ınez-Alzamora
413. KatritsisDG,WellensHJ,JosephsonME.Mahaimaccessorypathways.Arrhythm .. N, Fern(cid:2)andez-Avile´s F. Safety and efficacy of cryoablation vs. radiofrequency
.
ElectrophysiolRev2017;6:29(cid:2)32. . ablationofseptalaccessorypathways:systematicreviewoftheliteratureand
.
414. de Alencar Neto JN, Ramalho de Moraes SR, Back Sternick E, Wellens HJJ. . meta-analyses.Europace2017:20:1334(cid:2)1342.
.
Atypicalbypasstracts:cantheyberecognizedduringsinusrhythm?Europace .. 439.PapponeC,VicedominiG,MangusoF,SavianoM,BaldiM,PapponeA,Ciaccio
2019;21:208(cid:2)218. .. C,GiannelliL,IonescuB,PetrettaA,VitaleR,CukoA,CalovicZ,FundaliotisA,
.
415. FranciaP,PittalisMC,AliH,CappatoR.Electrophysiologicalstudyandcatheter . MoscatielloM,TavazziL,SantinelliV.Wolff-Parkinson-Whitesyndromeinthe
.
ablationofaMahaimfibrelocatedatthemitralannulus-aortajunction.JInterv . era of catheter ablation: insights from a registry study of 2169 patients.
.
CardElectrophysiol2008;23:153(cid:2)157. .. Circulation2014;130:811(cid:2)819.
.
416. JohnsonCT,BrooksC,JaramilloJ,MickelsenS,KusumotoFM.Aleftfree-wall, . 440.XueY,ZhanX,WuS,WangH,LiuY,LiaoZ,DengH,DuanX,ZengS,Liang
.
decrementallyconducting,atrioventricular(Mahaim)fiber:diagnosisatelectro- . D,ElvanA,FangX,LiaoH,RamdatMisierAR,SmitJJJ,MetznerA,HeegerC-H,
.
physiological study and radiofrequency catheter ablation guided by direct .. LiuF,WangF,ZhangZ,KuckK-H,YenHoS,OuyangF.Experimental,patho-
recordingofaMahaimpotential.PacingClinElectrophysiol1997;20:2486(cid:2)2488. .. logic, and clinical findings of radiofrequency catheter ablation of para-Hisian
.
417. Yamabe H, Okumura K, Minoda K, Yasue H. Nodoventricular Mahaim fiber . regionfromtherightventricleindogsandhumans.CircArrhythmElectrophysiol
.
connectingtotheleftventricle.AmHeartJ1991;122:232(cid:2)234. . 2017;10:e005207.
.
418.HanFT,RilesEM,BadhwarN,ScheinmanMM.Clinicalfeaturesandsitesofablation .. 441.KatritsisD,GiazitzoglouE,KorovesisS,ZambartasC.Comparisonofthetrans-
forpatientswithincessantsupraventriculartachycardiafromconcealednodofascicu- .. septalapproachtothetransaorticapproachforablationofleft-sidedaccessory
.
larandnodoventriculartachycardias.JACCClinElectrophysiol2017;3:1547(cid:2)1556. . pathways in patients with Wolff-Parkinson-White syndrome. Am J Cardiol
.
419. HamerA,PeterT,PlattM,MandelWJ.Effectsofverapamilonsupraventricular .. 2003;91:610(cid:2)613.
tachycardiainpatients withovertandconcealedWolff-Parkinson-Whitesyn- .. 442.MauritsonDR,WinnifordMD,WalkerW,RudeRE,CaryJR,HillisL.Oralvera-
.
drome.AmHeartJ1981;101:600(cid:2)612. . pamil for paroxysmal supraventricular tachycardia: a long-term, double-blind
.
420. HuyckeEC,SungRJ,DiasVC,MilsteinS,HarimanRJ,PlatiaEV.Intravenousdil- . randomizedtrial.AnnInternMed1982;96:409(cid:2)412.
.
tiazem for termination of reentrant supraventricular tachycardia: a placebo- .. 443.SakuraiM,YasudaH,KatoN,NomuraA,FujitaM,NishinoT,FujitaK,KoikeY,
controlled, randomized, double-blind, multicenter study. J Am Coll Cardiol .. Saito H. Acute and chronic effects of verapamil in patients with paroxysmal
.
1989;13:538(cid:2)544. . supraventriculartachycardia.AmHeartJ1983;105:619(cid:2)628.
. 421. GlatterKA,DorostkarPC,YangY,LeeRJ,VanHareGF,KeungE,ModinG, . 444.VassiliadisI,PapoutsakisP,KallikazarosI,StefanadisC.Propafenoneinthepre-
.
ScheinmanMM.Electrophysiologicaleffectsofibutilideinpatientswithacces- .. vention of non-ventricular arrhythmias associated with the Wolff-Parkinson-
sorypathways.Circulation2001;104:1933(cid:2)1939. .. Whitesyndrome.IntJCardiol1990;27:63(cid:2)70.
.
422. SellersTDJr,CampbellRW,BashoreTM,GallagherJJ.Effectsofprocainamide . 445.CockrellJL,ScheinmanMM,TitusC,HelmyI,LangbergJJ,LeeMA,GriffinJC. .
and quinidine sulfate in the Wolff-Parkinson-White syndrome. Circulation .. Safetyandefficacyoforalflecainidetherapyinpatientswithatrioventricularre-
1977;55:15(cid:2)22. .. entranttachycardia.AnnInternMed1991;114:189(cid:2)194.
. 423. WellensHJJ,BrugadaP,AbdollahH.Effectofamiodaroneinparoxysmalsupra- . 446.Schu¨tzenbergerW,LeischF,GmeinerR.Enhancedaccessorypathwayconduc-
.
ventriculartachycardiawithorwithoutWolff-Parkinson-Whitesyndrome.Am . tionfollowingintravenousamiodaroneinatrialfibrillation.Acasereport.IntJ
.
HeartJ1983;106:876(cid:2)880. .. Cardiol1987;16:93(cid:2)95.
424. HoltP,CrickJCP,DaviesDW,CurryP.Intravenousamiodaroneintheacute .. 447.MarazzatoJ,FonteG,MarazziR,DoniLA,MitacchioneG,VilottaM,DePonti
.
terminationofsupraventriculararrhythmias.IntJCardiol1985;8:67(cid:2)76. . R.Efficacyandsafetyofcryoablationofpara-Hisianandmid-septalaccessory
.
425. LevyS,RicardP.Usingtherightdrug:atreatmentalgorithmforregularsupra- . pathways using a specific protocol: single-center experience in consecutive
.
ventriculartachycardias.EurHeartJ1997;18:27(cid:2)32. .. patients.JIntervCardElectrophysiol2019;55:47(cid:2)54.
.
426. FujimuraO,KuoC-S,SmithBA.Pre-excitedRRintervalsduringatrialfibrillation . 448.ManolisAS,WangPJ,EstesNAIII.Radiofrequencyablationofleft-sidedacces-
.
intheWolff-Parkinson-Whitesyndrome:influenceoftheatrioventricularnode . sory pathways: transaortic versus transseptal approach. Am Heart J
.
refractoryperiod.JAmCollCardiol1991;18:1722(cid:2)1726. .. 1994;128:896(cid:2)902.
427. MoradyF,DiCarloLAJr,BaermanJM,DeBuitleirM.Effectofpropranololon .. 449.ObeyesekereMN,Leong-SitP,MasselD,ManlucuJ,ModiS,KrahnAD,Skanes
.
ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syn- . AC,YeeR,GulaLJ,KleinGJ.Riskofarrhythmiaandsuddendeathinpatientswith
.
drome.PacingClinElectrophysiol1987;10:492(cid:2)496. . asymptomaticpreexcitation.Ameta-analysis.Circulation2012;125:2308(cid:2)2315.
.
428. SellersTDJr,BashoreTM,GallagherJJ.Digitalisinthepre-excitationsyndrome. .. 450.Santinelli V, Radinovic A, Manguso F, Vicedomini G, Gulletta S, Paglino G,
Analysisduringatrialfibrillation.Circulation1977;56:260(cid:2)267. .. Mazzone P, Ciconte G, Sacchi S, Sala S, Pappone C. The natural history of
.
429. LudmerPL,McGowanNE,AntmanEM,FriedmanPL.Efficacyofpropafenone . asymptomatic ventricular pre-excitation: a long-term prospective follow-up
.
inWolff-Parkinson-Whitesyndrome:electrophysiologicfindingsandlong-term .. studyof184asymptomaticchildren.JAmCollCardiol2009;53:275(cid:2)280.
follow-up.JAmCollCardiol1987;9:1357(cid:2)1363. .. 451.Klein GJ, Bashore TM, Sellers TD, Pritchett ELC, Smith WM, Gallagher JJ.
.
430. BoaheneKA,KleinGJ,YeeR,SharmaAD,FujimuraO.Terminationofacute . Ventricularfibrillation in theWolff-Parkinson-White syndrome.N Engl JMed
.
atrialfibrillationintheWolff-Parkinson-Whitesyndromebyprocainamideand . 1979;301:1080(cid:2)1085.
.
propafenone: importance of atrial fibrillatory cycle length. J Am Coll Cardiol .. 452.Kubu(cid:4)sP,V(cid:2)ıtP,GebauerRA,MaternaO,Janou(cid:4)sekJ.Electrophysiologicprofile
1990;16:1408(cid:2)1414. . and results of invasive risk stratification in asymptomatic children and
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 63 ---
ESCGuidelines 717
.
.
adolescents with the Wolff(cid:2)Parkinson(cid:2)White electrocardiographic pattern. . 472.CainN,IrvingC,WebberS,BeermanL,AroraG.NaturalhistoryofWolff-
.
CircArrhythmElectrophysiol2014;7:218(cid:2)223. . Parkinson-White syndrome diagnosed in childhood. Am J Cardiol
.
453.Pappone C, Santinelli V, Manguso F, Augello G, Santinelli O, Vicedomini G, .. 2013;112:961(cid:2)965.
Gulletta S, Mazzone P, Tortoriello V, Pappone A, Dicandia C, Rosanio S. A .. 473.BrugadaJ,PuigfelM,MontL,Garcia-BolaoI,FigueiredoM,MatasM,Navarro-
.
randomizedstudyofprophylacticcatheterablationinasymptomaticpatientswith . LopezF.Radiofrequencyablationofanteroseptal,para-Hisian,andmid-septal
.
theWolff-Parkinson-WhiteSyndrome.NEnglJMed2003;349:1803(cid:2)1811. .. accessorypathwaysusingasimplifiedfemoralapproach.PacingClinElectrophysiol
454. Santinelli V, Radinovic A, Manguso F, Vicedomini G, Ciconte G, Gulletta S, .. 1998;21:735(cid:2)741.
.
Paglino G,SacchiS,Sala S,CiaccioC,PapponeC. Asymptomatic ventricular . 474.CalkinsH,YongP,MillerJM,OlshanskyB,CarlsonM,SaulJP,HuangSK,Liem
.
preexcitation: a long-term prospective follow-up study of 293 adult patients. . LB, Klein LS, Moser SA, Bloch DA, Gillette P, Prystowsky E. Catheter
.
CircArrhythmElectrophysiol2009;2:102(cid:2)107. .. ablation of accessory pathways, atrioventricular nodal reentrant tachycardia,
455.MontoyaPT,BrugadaP,SmeetsJ,TalajicM,DellaBellaP,LezaunR,DoolAVD, .. andtheatrioventricularjunction:finalresultsofaprospective,multicenterclini-
.
WellensHJJ,DeLunaAB,OterR,BreithardtG,BorggrefeM,KleinH,KuckKH, . cal trial. The Atakr Multicenter Investigators Group. Circulation 1999;99:
.
KunzeK,CoumelP,LeclercqJF,ChoutyF,FrankR,FontanineG.Ventricularfibril- .. 262(cid:2)270.
lationintheWolff-Parkinson-Whitesyndrome.EurHeartJ1991;12:144(cid:2)150. .. 475.Schaffer MS, Silka MJ, Ross BA, Kugler JD. Inadvertent atrioventricular block
.
456. PapponeC,VicedominiG,MangusoF,BaldiM,PapponeA,PetrettaA,VitaleR, . during radiofrequency catheter ablation. Results of the Pediatric
.
Saviano M, Ciaccio C, Giannelli L, Calovic Z, Tavazzi L, Santinelli V. Risk of . Radiofrequency Ablation Registry. Pediatric Electrophysiology Society.
.
malignant arrhythmias in initially symptomatic patients with Wolff-Parkinson- .. Circulation1996;94:3214(cid:2)3220.
White syndrome: results of a prospective long-term electrophysiological .. 476.BravoL,AtienzaF,EidelmanG,A(cid:2)vilaP,PellizaM,CastellanosE,LoughlinG,
follow-upstudy.Circulation2012;125:661(cid:2)668. .. DatinoT,TorrecillaEG,AlmendralJ,S(cid:2)anchezPL,ArenalA(cid:2),Mart(cid:2)ınez-Alzamora
.
457. LeitchJW,KleinGJ,YeeR,MurdockC.Prognosticvalueofelectrophysiology . N, Fern(cid:2)andez-Avile´s F. Safety and efficacy of cryoablation vs. radiofrequency
.
testing in asymptomatic patients with Wolff-Parkinson-White pattern. .. ablationofseptalaccessorypathways:systematicreviewoftheliteratureand
Circulation1990;82:1718(cid:2)1723. .. meta-analyses.Europace2017;20:1334(cid:2)1342.
.
458. RinneC,KleinGJ,SharmaAD,YeeR,MilsteinS,RattesMF.Relationbetween . 477.Al-KhatibSM,ArshadA,BalkEM,DasSR,HsuJC,JoglarJA,PageRL.Riskstrat-
.
clinical presentation and induced arrhythmias in the Wolff-Parkinson-White .. ificationforarrhythmiceventsinpatientswithasymptomaticpre-excitation:a
syndrome.AmJCardiol1987;60:576(cid:2)579. .. systematicreviewforthe2015ACC/AHA/HRSguidelineforthemanagement
.
459. SharmaAD,YeeR,GuiraudonG,KleinGJ.Sensitivityandspecificityofinvasive . of adult patients with supraventricular tachycardia:a report of the American
.
andnoninvasivetestingforriskofsuddendeathinWolff-Parkinson-Whitesyn- . College of Cardiology/American Heart Association Task Force on Clinical
.
drome.JAmCollCardiol1987;10:373(cid:2)381. .. Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol
460. MooreJP,KannankerilPJ,FishFA.Isoproterenoladministrationduringgeneral .. 2016;67:1624(cid:2)1638.
.
anesthesia for the evaluation of children with ventricular preexcitation. Circ . 478.DaiC,GuoB,LiW,XiaoY,JinM,HanL,DongJ.Theeffectofventricularpre-
.
ArrhythmElectrophysiol2011;4:73(cid:2)78. . excitation on ventricular wall motion and left ventricular systolic function.
.
461. DaubertC,OllitraultJ,DescavesC,MaboP,RitterP,GouffaultJ.Failureofthe .. Europace2018;20:1175(cid:2)1181.
.
exercise test to predict the anterograde refractory period of the accessory . 479.KohliU,PumphreyKL,AhmedA,DasS.Pre-excitationinducedventriculardys-
.
pathway in Wolff Parkinson White syndrome. Pacing Clin Electrophysiol . functionandsuccessfulberlinheartexplantationafteraccessorypathwayabla-
.
1988;11:1130(cid:2)1138. .. tion.JElectrocardiol2018;51:1067(cid:2)1070.
462. WackelP,IrvingC,WebberS,BeermanL,AroraG.RiskstratificationinWolff- .. 480.NagaiT,HamabeA,ArakawaJ,TabataH,NishiokaT.Theimpactofleftven-
.
Parkinson-Whitesyndrome:thecorrelationbetweennoninvasiveandinvasive . triculardeformationanddyssynchronyonimprovementofleftventricularejec-
.
testinginpediatricpatients.PacingClinElectrophysiol2012;35:1451(cid:2)1457. . tion fraction following radiofrequency catheter ablation in Wolff-Parkinson-
.
463. GaitaF,GiustettoC,RiccardiR,MangiardiL,BruscaA.Stressandpharmaco- .. Whitesyndrome:acomprehensivestudybyspeckletrackingechocardiography.
logic tests as methods to identify patients with Wolff-Parkinson-White syn- .. Echocardiography2017;34:1610(cid:2)1616.
.
dromeatriskofsuddendeath.AmJCardiol1989;64:487(cid:2)490. . 481.Kwon EN, Carter KA, Kanter RJ. Radiofrequency catheter ablation for
.
464. PediatricCongenitalElectrophysiologyS,HeartRhythmS,AmericanCollegeof .. dyssynchrony-induced dilated cardiomyopathy in an infant. Congenit Heart Dis
Cardiology F, American Heart A, American Academy of P, Canadian Heart .. 2014;9:E179(cid:2)E184.
.
RhythmSCohenMI,TriedmanJK,CannonBC,DavisAM,DragoF,JanousekJ, . 482.TelishevskaM, HebeJ, Paul T, Nurnberg JH, Krause U, Gebauer R, Gass M,
.
KleinGJ,LawIH,MoradyFJ,PaulT,PerryJC,SanataniS,TanelRE.PACES/HRS . BalmerC,BergerF,MolattaS,EmmelM,LawrenzW,KriebelT,HesslingG.
.
expert consensusstatement on themanagementof the asymptomatic young .. CatheterablationinASymptomaticPEDiatricpatientswithventricularpreexci-
patientwithaWolff-Parkinson-White(WPW,ventricularpreexcitation)elec- .. tation: results from the multicenter "CASPED" study. Clin Res Cardiol
.
trocardiographicpattern:developedinpartnershipbetweenthePediatricand . 2018;108:683(cid:2)690.
. CongenitalElectrophysiologySociety(PACES)andtheHeartRhythmSociety . 483.Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M.
.
(HRS). Endorsed by the governing bodies of PACES, HRS, the American .. Lifetimeprevalenceofcongenitalheartdiseaseinthegeneralpopulationfrom
College of Cardiology Foundation (ACCF), the American Heart Association .. 2000to2010.Circulation2014;130:749(cid:2)756.
.
(AHA), theAmericanAcademy ofPediatrics(AAP),andtheCanadianHeart . 484.Hernandez-MadridA,PaulT,AbramsD,AzizPF,BlomNA,ChenJ,ChessaM, .
RhythmSociety(CHRS).HeartRhythm2012;9:1006(cid:2)1024. .. Combes N, Dagres N, Diller G, Ernst S, Giamberti A, Hebe J, Janousek J,
465. Jastrzebski M, Kukla P, Pitak M, Rudzinski A, Baranchuk A, Czarnecka D. .. KriebelT,Moltedo J,MorenoJ,Peinado R,PisonL,RosenthalE, Skinner JR,
. Intermittentpreexcitationindicates"alow-risk"accessorypathway:timefora . ZeppenfeldK;ESCScientificDocumentGroup.Arrhythmiasincongenitalheart
.
paradigmshift?AnnNoninvasiveElectrocardiol2017;22:e12464. . disease:apositionpaperoftheEuropeanHeartRhythmAssociation(EHRA),
.
466. Kiger ME, McCanta AC, Tong S, Schaffer M, Runciman M, Collins KK. .. Association for European Paediatric and Congenital Cardiology (AEPC), and
Intermittent versus persistent Wolff-Parkinson-White syndrome in children: .. the European Society of Cardiology (ESC) Working Group on Grown-up
.
electrophysiologic properties and clinical outcomes. Pacing Clin Electrophysiol . CongenitalHeartDisease,endorsedbyHRS,PACES,APHRS,andSOLAECE.
.
2016;39:14(cid:2)20. .. Europace2018;20:1719(cid:2)1753.
467. CohenM.Intermittentpreexcitation:shouldwerethinkthecurrentguidelines? .. 485.MoonsP,BovijnL,BudtsW,BelmansA,GewilligM.Temporaltrendsinsur-
.
PacingClinElectrophysiol2016;39:9(cid:2)11. . vival to adulthood among patients born with congenital heart disease from
.
468. Mah DY, Sherwin ED, Alexander ME, Cecchin F, Abrams DJ, Walsh EP, . 1970to1992inBelgium.Circulation2010;122:2264(cid:2)2272.
.
TriedmanJK.Theelectrophysiologicalcharacteristicsofaccessorypathwaysin .. 486.Avila P, Mercier LA, Dore A, Marcotte F, Mongeon FP, Ibrahim R, Asgar A,
pediatric patients with intermittent preexcitation. Pacing Clin Electrophysiol .. MiroJ,AndelfingerG,MondesertB,deGuiseP,PoirierN,KhairyP.Adultcon-
.
2013;36:1117(cid:2)1122. . genitalheartdisease:agrowingepidemic.CanJCardiol2014;30:S410(cid:2)S419.
.
469. SparDS,SilverES,HordofAJ,LibermanL.Relationoftheutilityofexercise . 487.JansonCM,ShahMJ.Supraventriculartachycardiainadultcongenitalheartdis-
.
testingforriskassessmentinpediatricpatientswithventricularpreexcitationto .. ease: mechanisms, diagnosis, and clinical aspects. Card Electrophysiol Clin
pathwaylocation.AmJCardiol2012;109:1011(cid:2)1014. .. 2017;9:189(cid:2)211.
.
470. BeckmanKJ,GallasteguiJL,BaumanJL,HarimanRJ.Thepredictivevalueofelec- . 488.VerheugtCL,UiterwaalCS,vanderVeldeET,MeijboomFJ,PieperPG,Sieswerda
.
trophysiologic studies in untreated patients with Wolff-Parkinson-White syn- .. GT, Plokker HW, Grobbee DE, Mulder BJ. The emerging burden of hospital
drome.JAmCollCardiol1990;15:640(cid:2)647. .. admissionsofadultswithcongenitalheartdisease.Heart2010;96:872(cid:2)878.
.
471. Bunch TJ, May HT, Bair TL, Anderson JL, Crandall BG, Cutler MJ, Jacobs V, . 489.GallegoP,GonzalezAE,Sanchez-RecaldeA,PeinadoR,PoloL,Gomez-Rubin
.
MallenderC,MuhlesteinJB,OsbornJS,WeissJP,DayJD.Long-termnaturalhis- . C, Lopez-Sendon JL, Oliver JM. Incidence and predictors of sudden cardiac
.
tory of adult Wolff(cid:2)Parkinson(cid:2)White syndrome patients treated with and .. arrestinadults with congenitalheartdefects repaired beforeadult life. Am J
withoutcatheterablation.CircArrhythmElectrophysiol2015;8:1465(cid:2)1471. . Cardiol2012;110:109(cid:2)117.
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 64 ---
718 ESCGuidelines
.
.
490. KoyakZ,HarrisL,deGrootJR,SilversidesCK,OechslinEN,BoumaBJ,Budts . HeartRhythmSociety(HRS).EndorsedbythegoverningbodiesofPACES,HRS,
.
W,ZwindermanAH,VanGelderIC,MulderBJ.Suddencardiacdeathinadult . the American College of Cardiology (ACC), the American Heart Association
.
congenitalheartdisease.Circulation2012;126:1944(cid:2)1954. .. (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart
491. Lin JH, Kean AC, Cordes TM. The risk of thromboembolic complications in .. RhythmSociety(CHRS),andtheInternationalSocietyforAdultCongenitalHeart
.
Fontanpatients withatrialflutter/fibrillationtreatedwith electricalcardiover- . Disease(ISACHD).HeartRhythm2014;11:e102(cid:2)e165.
.
sion.PediatrCardiol2016;37:1351(cid:2)1360. .. 512.Khositseth A, Danielson GK, Dearani JA, Munger TM, Porter CJ.
492. Ammash NM, Phillips SD, Hodge DO, Connolly HM, Grogan MA, Friedman .. Supraventricular tachyarrhythmias in Ebstein anomaly: management and out-
.
PA,WarnesCA,AsirvathamSJ.Outcomeofdirectcurrentcardioversionfor . come.JThoracCardiovascSurg2004;128:826(cid:2)833.
.
atrial arrhythmias in adults with congenital heart disease. Int J Cardiol . 513.ShivapourJKL,SherwinED,AlexanderME,CecchinF,MahDY,TriedmanJK,
.
2012;154:270(cid:2)274. .. Marx GR, del Nido PJ, Walsh EP. Utility of preoperative electrophysiologic
493. IsraelCW,BaroldSS.Electricalstorminpatientswithanimplanteddefibrillator: .. studies in patients with Ebstein’s anomaly undergoing the Cone procedure.
.
amatterofdefinition.AnnNoninvasiveElectrocardiol2007;12:375(cid:2)382. . HeartRhythm2014;11:182(cid:2)186.
.
494. ShermanL,NiemannJ,YoungquistST,ShahAP,RosboroughJP.Beta-blockade . 514.CorreaR,WalshEP,AlexanderME,MahDY,CecchinF,AbramsDJ,Triedman
.
causesareductioninthefrequencyspectrumofVFbutimprovesresuscitation .. JK.Transbafflemappingandablationforatrialtachycardiasaftermustard,sen-
.
outcome:apotentiallimitationofquantitativewaveformmeasures.Resuscitation . ning,orFontanoperations.JAmHeartAssoc2013;2:e000325.
.
2012;83:511(cid:2)516. . 515.KrauseU,BackhoffD,KlehsS,SchneiderHE,PaulT.Transbafflecatheterabla-
.
495.KhairyP,ClairM,FernandesSM,BlumeED,PowellAJ,NewburgerJW,Landzberg .. tionofatrialre-entranttachycardiawithinthepulmonaryvenousatriuminadult
MJ,MayerJE.CardiovascularoutcomesafterthearterialswitchoperationforD- .. patientswithcongenitalheartdisease.Europace2016;18:1055(cid:2)1060.
.
transpositionofthegreatarteries.Circulation2013;127:331(cid:2)339. . 516.HouckCA,TeuwenCP,BogersAJ,deGrootNM.Atrialtachyarrhythmiasafter
.
496. CoughtrieAL,BehrER,LaytonD,MarshallV,CammAJ,ShakirSAW.Drugs . atrialswitchoperationfortranspositionofthegreatarteries:treatingoldsur-
.
and life-threatening ventricular arrhythmia risk: results from the DARE study .. gerywithnewcatheters.HeartRhythm2016;13:1731(cid:2)1738.
cohort.BMJOpen2017;7:e016627. .. 517.WuM-H,LuC-W,ChenH-C,ChiuS-N,KaoF-Y,HuangS-K.Arrhythmicbur-
.
497. ValentinoMA,PanakosA,RagupathiL,WilliamsJ,PavriBB.Flecainidetoxicity: . densinpatientswithtetralogyofFallot:anationaldatabasestudy.HeartRhythm
.
a case report and systematic review of its electrocardiographic patterns and .. 2015;12:604(cid:2)609.
management.CardiovascToxicol2017;17:260(cid:2)266. .. 518.de Groot NMS, Lukac P, Schalij MJ, Makowski K, Szili-Torok T, Jordaens L,
.
498. ThorneSA,BarnesI,CullinanP,SomervilleJ.Amiodarone-associatedthyroid . NielsenJC,JensenHK,GerdesJC,DelacretazE.Long-termoutcomeofablative
.
dysfunction. Risk factors in adults with congenital heart disease. Circulation . therapyofpost-operativeatrialtachyarrhythmiasinpatientswithtetralogyof
.
1999;100:149(cid:2)154. .. Fallot:aEuropeanmulti-centrestudy.Europace2012;14:522(cid:2)527.
499. PujolC,NiesertA-C,EngelhardtA,SchoenP,KusmenkovE,PittrowD,Ewert .. 519.WeipertJ,NoebauerC,SchreiberC,KostolnyM,ZrennerB,WackerA,Hess
.
P, Kaemmerer H. Usefulness of direct oral anticoagulants in adult congenital . J, Lange R. Occurrence and management of atrialarrhythmiaafter long-term
.
heartdisease.AmJCardiol2016;117:450(cid:2)455. . Fontancirculation.JThoracCardiovascSurg2004;127:457(cid:2)464.
.
500. WuJ,DeisenhoferI,AmmarS,FichtnerS,ReentsT,ZhuP,JilekC,KolbC, .. 520.MavroudisC,DealBJ.Fontanconversion:literaturereviewandlessonslearned
.
Hess J, Hessling G. Acute and long-term outcome after catheter ablation of . over20years.WorldJPediatrCongenitHeartSurg2016;7:192(cid:2)198.
.
supraventriculartachycardiainpatientsaftertheMustardorSenningoperation . 521.StewartRD,PasqualiSK,JacobsJP,BenjaminDK,JaggersJ,ChengJ,Mavroudis
.
forD-transpositionofthegreatarteries.Europace2013;15:886(cid:2)891. .. C,JacobsML.ContemporaryFontanoperation:associationbetweenearlyout-
501. RotenL,LukacP,DeGrootN,CosedisNielsenJ,Szili-TorokT,KjaerulfJensen .. come and type of cavopulmonary connection. Ann Thorac Surg
.
H,ZimmermannM,Delacre´tazE.CatheterablationofarrhythmiasinEbstein’s . 2012;93:1254(cid:2)1260;discussion1261.
.
anomaly:amulticenterstudy.JCardiovascElectrophysiol2011;22:1391(cid:2)1396. . 522.BrugadaJ,BlomN,Sarquella-BrugadaG,Blomstrom-LundqvistC,DeanfieldJ,
.
502. DealBJ,MavroudisC.Arrhythmiasurgeryforadultswithcongenitalheartdis- .. Janousek J, Abrams D, Bauersfeld U, Brugada R, Drago F, de Groot N,
ease.CardElectrophysiolClin2017;9:329(cid:2)340. .. HapponenJ-M,HebeJ,YenHoS,MarijonE,PaulT,PfammatterJ-P,Rosenthal
.
503. Shivapour JK, Sherwin ED, AlexanderME, Cecchin F, Mah DY, Triedman JK, . E. Pharmacological and non-pharmacological therapy for arrhythmias in the
.
Marx GR, del Nido PJ, Walsh EP. Utility of preoperative electrophysiologic .. pediatricpopulation:EHRAandAEPC-ArrhythmiaWorkingGroupjointcon-
studies in patients with Ebstein’s anomaly undergoing the Cone procedure. .. sensusstatement.Europace2013;15:1337(cid:2)1382.
.
HeartRhythm2014;11:182(cid:2)186. . 523.Philip Saul J, Kanter RJ, Writing C, Abrams D, Asirvatham S, Bar-Cohen Y,
.
504. DealBJ,MavroudisC,BackerCL,BuckSH,JohnsrudeC.Comparisonofana- . BlaufoxAD,CannonB,ClarkJ,DickM,FreterA,KerteszNJ,KirshJA,KuglerJ,
.
tomicisthmusblockwiththemodifiedrightatrialmazeprocedureforlateatrial .. LaPageM,McGowanFX,MiyakeCY,NathanA,PapagiannisJ,PaulT,Pflaumer
tachycardiainFontanpatients.Circulation2002;106:575(cid:2)579. .. A, Skanes AC, Stevenson WG, Von Bergen N, Zimmerman F. PACES/HRS
.
505. KoyakZ,KroonB,deGrootJR,WagenaarLJ,vanDijkAP,MulderBA,Van . expert consensus statement on the use of catheter ablation in children and
. GelderIC,PostMC,MulderBJM,BoumaBJ.Efficacyofantiarrhythmicdrugsin . patients with congenital heart disease: developed in partnership with the
.
adults with congenital heart disease and supraventricular tachycardias. Am J .. Pediatric and Congenital Electrophysiology Society (PACES) and the Heart
Cardiol2013;112:1461(cid:2)1467. .. RhythmSociety(HRS).EndorsedbythegoverningbodiesofPACES,HRS,the
.
506. CombesN,DervalN,HascoetS,ZhaoA,AmetD,LeBloaM,MaltretA,Heitz . American Academy of Pediatrics (AAP), the American Heart Association .
F,ThamboJB,MarijonE.Ablationofsupraventriculararrhythmiasinadultcon- .. (AHA),andtheAssociationforEuropeanPediatricandCongenitalCardiology
genital heart disease: a contemporary review. Arch Cardiovasc Dis .. (AEPC).HeartRhythm2016;13:e251(cid:2)e289.
. 2017;110:334(cid:2)345. . 524.Perry JC, Garson A Jr. Supraventricular tachycardia due to Wolff-Parkinson-
.
507. DallaglioPD,AngueraI,Jime´nez-CandilJ,PeinadoR,Garc(cid:2)ıa-SearaJ,Arcocha . Whitesyndromeinchildren:earlydisappearanceandlaterecurrence.JAmColl
.
MF, Mac(cid:2)ıas R, Herreros B, Quesada A, Hern(cid:2)andez-Madrid A, Alvarez M, Di .. Cardiol1990;16:1215(cid:2)1220.
MarcoA,FilgueirasD,Mat(cid:2)ıaR,CequierA,Sabate´X.Impactofpreviouscardiac .. 525.Bensler JM, Frank CM, Razavi M, Rasekh A, Saeed M, Haas PC, Nazeri A,
.
surgeryonlong-termoutcomeofcavotricuspidisthmus-dependentatrialflutter . MassumiA.Tachycardia-mediatedcardiomyopathyandthepermanentformof
.
ablation.Europace2016;18:873(cid:2)880. .. junctionalreciprocatingtachycardia.TexHeartInstJ2010;37:695(cid:2)698.
508. Wasmer K, Ko¨be J, Dechering DG, Bittner A, Mo¨nnig G, Milberg P, .. 526.Ellis ER, Josephson ME. What about tachycardia-induced cardiomyopathy?
.
BaumgartnerH,BreithardtG,EckardtL.Isthmus-dependentrightatrialflutter . ArrhythmElectrophysiolRev2013;2:82(cid:2)90.
.
as the leading cause of atrial tachycardias after surgical atrial septal defect . 527.RichardsonC,SilverES.Managementofsupraventriculartachycardiaininfants.
.
repair.IntJCardiol2013;168:2447(cid:2)2452. .. PaediatrDrugs2017;19:539(cid:2)551.
509. NieJ-G,DongJ-Z,SalimM,LiS-N,WuX-Y,ChenY-W,BaiR,LiuN,DuX, .. 528.LewisJ,AroraG,TudorascuDL,HickeyRW,SaladinoRA,ManoleMD.Acute
.
Ma C-S. Catheter ablation of atrial fibrillation in patients with atrial septal . managementofrefractoryandunstablepediatricsupraventriculartachycardia.
.
defect:long-termfollow-upresults.JIntervCardElectrophysiol2015;42:43(cid:2)49. . JPediatr2017;181:177(cid:2)182.e2.
.
510. Chauvaud SM, Brancaccio G, Carpentier AF. Cardiac arrhythmia in patients .. 529.SaulJP,HulseJE,PapagiannisJ,VanPraaghR,WalshEP.Lateenlargementof
undergoing surgical repair of Ebstein’s anomaly. Ann Thorac Surg .. radiofrequencylesionsininfantlambs.Implicationsforablationproceduresin
.
2001;71:1547(cid:2)1552. . smallchildren.Circulation1994;90:492(cid:2)499.
.
511. KhairyP,VanHareGF,BalajiS,BerulCI,CecchinF,CohenMI,DanielsCJ,Deal .. 530.Femen(cid:2)ıaF,Sarquella-BrugadaG,BrugadaJ.Single-catheterradiofrequencyabla-
BJ,DearaniJA,GrootNd,DubinAM,HarrisL,JanousekJ,KanterRJ,Karpawich .. tionofapermanentjunctionalreciprocatingtachycardiainaprematureneo-
.
PP,PerryJC,SeslarSP,ShahMJ,SilkaMJ,TriedmanJK,WalshEP,WarnesCA. . nate.CardiolYoung2012;22:606(cid:2)609.
.
PACES/HRSExpertConsensusStatementontheRecognitionandManagement . 531.HinkleKA,PeyvandiS,StiverC,KillenSAS,WengHY,EtheridgeSP,Puchalski
.
of Arrhythmias in Adult Congenital Heart Disease: Developed in partnership .. MD. Postnatal outcomes of fetal supraventricular tachycardia: a multicenter
betweenthePediatricandCongenitalElectrophysiologySociety(PACES)andthe . study.PediatrCardiol2017;38:1317(cid:2)1323.
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 65 ---
ESCGuidelines 719
.
.
532. FouronJ-C,FournierA,ProulxF,LamarcheJ,BigrasJL,BoutinC,BrassardM, . NevilleAJ,PieriniA,RandrianaivoH,RissmannA,TuckerD,WieselA,DolkH,
.
GamacheS.Managementoffetaltachyarrhythmiabasedonsuperiorvenacava/ . LoaneM,BakkerMK.Beta-blockeruseinpregnancyandriskofspecificcongen-
.
aortaDopplerflowrecordings.Heart2003;89:1211(cid:2)1216. .. ital anomalies: a European case-malformed control study. Drug Saf
533. Jaeggi ET, Carvalho JS, De Groot E, Api O, Clur S-AB, Rammeloo L, .. 2018;41:415(cid:2)427.
.
McCrindleBW,RyanG,ManlhiotC,BlomNA.Comparisonoftransplacental . 556.Razminia M, Willoughby MC, Demo H, Keshmiri H, Wang T, D’Silva OJ,
.
treatmentoffetalsupraventriculartachyarrhythmiaswithdigoxin,flecainide, .. ZheutlinTA,JibawiH,OkhumaleP,KehoeRF.Fluorolesscatheterablationof
and sotalol: results of a nonrandomized multicenter study. Circulation .. cardiac arrhythmias: a 5-year experience. Pacing Clin Electrophysiol
.
2011;124:1747(cid:2)1754. . 2017;40:425(cid:2)433.
.
534. PriceJF,KerteszNJ,SnyderCS,FriedmanRA,FenrichAL.Flecainideandsota- . 557.LishmanovA,ChockalingamP,SenthilkumarA,ChockalingamA.Tachycardia-
.
lol: a new combination therapy for refractory supraventricular tachycardia in .. inducedcardiomyopathy:evaluationandtherapeuticoptions.CongestHeartFail
children<1yearofage.JAmCollCardiol2002;39:517(cid:2)20. .. 2010;16:122(cid:2)126.
.
535. VaidyaVR,AroraS,PatelN,BadhekaAO,PatelN,AgnihotriK,BillimoriaZ, . 558.NerheimP,Birger-BotkinS,PirachaL,OlshanskyB.Heartfailureandsudden
.
TurakhiaMP,FriedmanPA,MadhavanM,KapaS,NoseworthyPA,ChaY-M, . death in patients with tachycardia-induced cardiomyopathy and recurrent
.
Gersh B, Asirvatham SJ, Deshmukh AJ. Burden of arrhythmia in pregnancy. .. tachycardia.Circulation2004;110:247(cid:2)252.
.
Circulation2017;135:619(cid:2)621. . 559.ShinbaneJS,WoodMA,JensenDN,EllenbogenKA,FitzpatrickAP,Scheinman
.
536. OpotowskyAR,SiddiqiOK,D’SouzaB,WebbGD,FernandesSM,Landzberg . MM.Tachycardia-inducedcardiomyopathy:areviewofanimalmodelsandclini-
.
MJ.Maternalcardiovasculareventsduringchildbirthamongwomenwithcon- .. calstudies.JAmCollCardiol1997;29:709(cid:2)715.
genitalheartdisease.Heart2012;98:145(cid:2)151. .. 560.EllisER,JosephsonME.Heartfailureandtachycardia-inducedcardiomyopathy.
.
537. SilversidesCK,HarrisL,HabererK,SermerM,ColmanJM,SiuSC.Recurrence . CurrHeartFailRep2013;10:296(cid:2)306.
.
rates of arrhythmias during pregnancy in women with previous tachyarrhy- . 561.Gopinathannair R, Etheridge SP, Marchlinski FE, Spinale FG, Lakkireddy D,
.
thmia and impact on fetal and neonatal outcomes. Am J Cardiol 2006;97: .. Olshansky B.Arrhythmia-induced cardiomyopathies:mechanisms,recognition,
1206(cid:2)1212. .. andmanagement.JAmCollCardiol2015;66:1714(cid:2)1728.
.
538. LeeSH,ChenSA,WuTJ,ChiangCE,ChengCC,TaiCT,ChiouCW,Ueng . 562.Callans DJ. Premature ventricular contraction-induced cardiomyopathy.
.
KC,ChangMS.Effectsofpregnancyonfirstonsetandsymptomsofparoxysmal .. ArrhythmElectrophysiolRev2017;6:153(cid:2)155.
supraventriculartachycardia.AmJCardiol1995;76:675(cid:2)678. .. 563.ClementyN,Casset-SenonD,GiraudeauC,CosnayP.Tachycardiomyopathy
.
539. Moore JS, Teefey P, Rao K, Berlowitz MS, Chae SH, Yankowitz J. Maternal . secondary to nonreentrant atrioventricular nodal tachycardia: recovery after
.
arrhythmia: a case report and review of the literature. Obstet Gynecol Surv . slowpathwayablation.PacingClinElectrophysiol2007;30:925(cid:2)928.
.
2012;67:298(cid:2)312. .. 564.GopinathannairR,SullivanRM,OlshanskyB.Tachycardia-mediatedcardiomy-
540. WangYC,ChenCH,SuHY,YuMH.Theimpactofmaternalcardioversionon .. opathy:recognitionandmanagement.CurrHeartFailRep2009;6:257(cid:2)264.
.
fetalhaemodynamics.EurJObstetGynecolReprodBiol2006;126:268(cid:2)269. . 565.Mueller KAL, Heinzmann D, Klingel K, Fallier-Becker P, Kandolf R, Kilias A,
.
541. ElkayamU,GoodwinTM.Adenosinetherapyforsupraventriculartachycardia . Walker-Allgaier B, Borst O, Kumbrink J, Kirchner T, Langer H, Geisler T,
.
duringpregnancy.AmJCardiol1995;75:521(cid:2)523. .. SchreieckJ,GramlichM,GawazM,SeizerP.Histopathologicalandimmunologi-
.
542. Ghosh N, Luk A, Derzko C, Dorian P, Chow CM. The acute treatment of . cal characteristics of tachycardia-induced cardiomyopathy. J Am Coll Cardiol
.
maternalsupraventriculartachycardiasduringpregnancy:areviewofthelitera- . 2017;69:2160(cid:2)2172.
.
ture.JObstetGynaecolCan2011;33:17(cid:2)23. .. 566.ChaY-M,LeeGK,KlarichKW,GroganM.Prematureventricularcontraction-
543. Halpern DG, Weinberg CR, Pinnelas R, Mehta-Lee S, Economy KE, Valente .. induced cardiomyopathy. A treatable condition. Circ Arrhythm Electrophysiol
.
AM. Use of medication for cardiovascular disease during pregnancy: JACC . 2012;5:229(cid:2)236.
.
State-of-the-ArtReview.JAmCollCardiol2019;73:457(cid:2)476. . 567.KotechaD,FlatherMD,AltmanDG,HolmesJ,RosanoG,WikstrandJ,Packer
.
544. Kockova R, Kocka V, Kiernan T, Fahy GJ. Ibutilide-induced cardioversion of .. M,CoatsAJS,ManzanoL,Bo¨hmM,vanVeldhuisenDJ,AnderssonB,WedelH,
atrialfibrillationduringpregnancy.JCardiovascElectrophysiol2007;18:545(cid:2)547. .. vonLuederTG,RigbyAS,HjalmarsonA˚,KjekshusJ,ClelandJGF.Heartrate
.
545. BurkartTA,KronJ,MilesWM,ContiJB,GonzalezMD.Successfultermination . andrhythmandthebenefitofbeta-blockersinpatientswithheartfailure.JAm
.
of atrial flutter by ibutilide during pregnancy. Pacing Clin Electrophysiol .. CollCardiol2017;69:2885(cid:2)2896.
2007;30:283(cid:2)286. .. 568.Sadron Blaye-Felice M, Hamon D, Sacher F, Pascale P, Rollin A, Duparc A,
.
546. LiuYL,NwosuUC,RicePJ.Relaxationofisolatedhumanmyometrialmuscle . MondolyP,DervalN,DenisA,CardinC,HociniM,Ja¨ısP,SchlaepferJ,Bongard
.
bybeta2-adrenergicreceptorsbutnotbeta1-adrenergicreceptors.AmJObstet . V, Carrie´ D, Galinier M, Pruvot E, Lellouche N, Ha¨ıssaguerre M, Maury P.
.
Gynecol1998;179:895(cid:2)898. .. Prematureventricularcontraction-inducedcardiomyopathy:relatedclinicaland
547. TanakaK,TanakaH,KamiyaC,KatsuragiS,SawadaM,TsuritaniM,YoshidaM, .. electrophysiologicparameters.HeartRhythm2016;13:103(cid:2)110.
.
IwanagaN,YoshimatsuJ,IkedaT.Beta-blockersandfetalgrowthrestrictionin . 569.SohinkiD,HoJ,SrinivasanN,CollinsLJ,ObelOA.Outcomesafteratrioven-
. pregnantwomenwithcardiovasculardisease.CircJ2016;80:2221(cid:2)2226. . tricularnodeablationandbiventricularpacinginpatientswithrefractoryatrial
.
548. BatemanBT,Heide-JorgensenU,EinarsdottirK,EngelandA,FuruK,GisslerM, .. fibrillationandheartfailure:acomparisonbetweennon-ischaemicandischae-
Hernandez-DiazS,KielerH,Lahesmaa-KorpinenAM,MogunH,NorgaardM, .. miccardiomyopathy.Europace2014;16:880(cid:2)886.
.
ReutforsJ,SelmerR,HuybrechtsKF,ZoegaH.Beta-blockeruseinpregnancy . 570.StavrakisS,GarabelliP,ReynoldsDW.Cardiacresynchronizationtherapyafter .
and the risk forcongenital malformations: aninternational cohort study.Ann .. atrioventricularjunctionablationforsymptomaticatrialfibrillation:ameta-anal-
InternMed2018;169:665(cid:2)673. .. ysis.Europace2012;14:1490(cid:2)1497.
. 549. JaeggiET,CarvalhoJS,DeGrootE,ApiO,ClurSA,RammelooL,McCrindle . 571.BrignoleM,BottoG,Mont L,IacopinoS,DeMarchiG,OddoneD,LuziM,
.
BW,RyanG,ManlhiotC,BlomNA.Comparisonoftransplacentaltreatmentof . Tolosana JM, Navazio A, Menozzi C. Cardiac resynchronization therapy in
.
fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: .. patientsundergoingatrioventricularjunctionablationforpermanentatrialfibril-
resultsofanonrandomizedmulticenterstudy.Circulation2011;124:1747(cid:2)1754. .. lation:arandomizedtrial.EurHeartJ2011;32:2420(cid:2)2429.
.
550. Driver K, Chisholm CA, Darby AE, Malhotra R, Dimarco JP, Ferguson JD. . 572.HuangW,SuL,WuS,XuL,XiaoF,ZhouX,EllenbogenKA.Benefitsofper-
.
Catheter ablation of arrhythmia during pregnancy. J Cardiovasc Electrophysiol . manentHisbundlepacingcombinedwithatrioventricularnodeablationinatrial
.
2015;26:698(cid:2)702. .. fibrillationpatientswithheartfailurewithbothpreservedandreducedleftven-
.
551. ChenG,SunG,XuR,ChenX,YangL,BaiY,YangS,GuoP,ZhangY,ZhaoC, . tricularejectionfraction.JAmHeartAssoc2017;6:e005309.
.
Wang DW, Wang Y. Zero-fluoroscopy catheter ablation of severe . 573.PellicciaA,FagardR,BjørnstadHH,AnastassakisA,ArbustiniE,AssanelliD,Biffi
.
drug-resistantarrhythmiaguidedbyEnsiteNavXsystemduringpregnancy:two .. A,BorjessonM,Carre`F,CorradoD,DeliseP,DorwarthU,HirthA,Heidbuchel
casereportsandliteraturereview.Medicine(Baltimore)2016;95:e4487. .. H,HoffmannE,MellwigKP,Panhuyzen-GoedkoopN,PisaniA,SolbergEE,van-
.
552. SzumowskiL,SzufladowiczE,OrczykowskiM,BodalskiR,DerejkoP,Przybylski . Buuren F, Vanhees L, Blomstrom-Lundqvist C, Deligiannis A, Dugmore D,
.
A, Urbanek P, Kusmierczyk M, Kozluk E, Sacher F, Sanders P, Dangel J, . Glikson M, Hoff PI, Hoffmann A, Hoffmann E, Horstkotte D, Nordrehaug JE,
.
HaissaguerreM,WalczakF.Ablationofseveredrug-resistanttachyarrhythmia .. OudhofJ,McKennaWJ,PencoM,PrioriS,ReybrouckT,SendenJ,SpataroA,
duringpregnancy.JCardiovascElectrophysiol2010;21:877(cid:2)882. .. ThieneG;StudyGroupofSportsCardiologyoftheWorkingGroupofCardiac
.
553. DuanL,NgA,ChenW,SpencerHT,NguyenJ,ShenAY,LeeMS.Beta-blocker . Rehabilitation and Exercise Physiology; Working Group of Myocardial and
.
exposure in pregnancy and risk of fetal cardiac anomalies. JAMA Intern Med .. PericardialDiseases of the European Society of Cardiology.Recommendations
2017;177:885(cid:2)887. .. forcompetitivesportsparticipationinathleteswithcardiovasculardisease:acon-
.
554. DuanL,NgA,ChenW,SpencerHT,LeeMS.Beta-blockersubtypesandriskof . sensusdocumentfromtheStudyGroupofSportsCardiologyoftheWorking
.
lowbirthweightinnewborns.JClinHypertens(Greenwich)2018;20:1603(cid:2)1609. . GroupofCardiacRehabilitationandExercisePhysiologyandtheWorkingGroup
.
555. BergmanJEH,LutkeLR,GansROB,AddorMC,BarisicI,Cavero-CarbonellC, .. ofMyocardialandPericardialDiseasesoftheEuropeanSocietyofCardiology.Eur
Garne E, Gatt M, Klungsoyr K, Lelong N, Lynch C, Mokoroa O, Nelen V, . HeartJ2005;26:1422(cid:2)1445.
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 66 ---
720 ESCGuidelines
.
.
574. Heidbu¨chel H, Panhuyzen-Goedkoop N, Corrado D, Hoffmann E, Biffi A, . 586.LatcuDG,BunSS,VieraF,DelassiT,ElJamiliM,AlAmouraA,SaoudiN.Selection
.
DeliseP,Blomstrom-LundqvistC,VanheesL,HoffPI,DorwarthU,PellicciaA; . ofcriticalisthmusinscar-relatedatrialtachycardiausinganewautomatedultrahigh
.
Study Group on Sports Cardiology of the European Association for .. resolutionmappingsystem.CircArrhythmElectrophysiol2017;10:e004510.
CardiovascularPreventionandRehabilitation.Recommendationsforparticipa- .. 587.Walsh KA, Galvin J, Keaney J, Keelan E, Szeplaki G. First experience with
.
tion in leisure-time physical activity and competitive sports in patients with . zero-fluoroscopicablationforsupraventriculartachycardiasusinganovelimpedance
.
arrhythmiasandpotentiallyarrhythmogenicconditionsPartI:supraventricular .. andmagnetic-field-basedmappingsystem.ClinResCardiol2018;107:578(cid:2)585.
arrhythmiasandpacemakers.EurJCardiovascPrevRehabil2006;13:475(cid:2)484. .. 588.LutherV,LintonNW,Koa-WingM,LimPB,Jamil-CopleyS,QureshiN,NgFS,
.
575. RaoAL,SalernoJC,AsifIM,DreznerJA.EvaluationandmanagementofWolff- . HayatS,WhinnettZ,DaviesDW,PetersNS,KanagaratnamP.Aprospective
.
Parkinson-White in athletes. Sports health: a multidisciplinary approach . studyofripplemappinginatrialtachycardias:anovelapproachtointerpreting
.
2014;6:326(cid:2)332. .. activationinlow-voltageareas.CircArrhythmElectrophysiol2016;9:e003582.
576. AbdullaJ,NielsenJR.Istheriskofatrialfibrillationhigherinathletesthaninthe .. 589.AnterE,McElderryTH,Contreras-ValdesFM,LiJ,TungP,LeshemE,Haffajee
.
general population? A systematic review and meta-analysis. Europace . CI,NakagawaH,JosephsonME.Evaluationofanovelhigh-resolutionmapping
.
2009;11:1156(cid:2)1159. . technology for ablation of recurrent scar-related atrial tachycardias. Heart
.
577. Heidbu¨chel H, Panhuyzen-Goedkoop N, Corrado D, Hoffmann E, Biffi A, .. Rhythm2016;13:2048(cid:2)2055.
DeliseP,Blomstrom-LundqvistC,VanheesL,IvarhoffP,DorwarthU,Pelliccia .. 590.GollobMH,GreenMS,TangAS-L,GollobT,KaribeA,HassanA-S,AhmadF,
.
A; Study Group on Sports Cardiology of the European Association for . LozadoR,ShahG,FananapazirL,BachinskiLL,TapscottT,GonzalesO,Begley
.
CardiovascularPreventionandRehabilitation.Recommendationsforparticipa- .. D, Mohiddin S, Roberts R. Identification of a gene responsible for familial
tion in leisure-time physical activity and competitive sports in patients with .. Wolff(cid:2)Parkinson(cid:2)Whitesyndrome.NEnglJMed2001;344:1823(cid:2)1831.
.
arrhythmiasandpotentiallyarrhythmogenicconditionsPartI:supraventricular . 591.WolfCM,AradM,AhmadF,SanbeA,BernsteinSA,TokaO,KonnoT,Morley
.
arrhythmiasandpacemakers.EurJCardiovascPrevRehabil2006;13:475(cid:2)484. . G, Robbins J, Seidman JG, Seidman CE, Berul CI. Reversibility of PRKAG2
.
578. Heidbu¨chel H, Corrado D, Biffi A, Hoffmann E, Panhuyzen-Goedkoop N, .. glycogen-storage cardiomyopathy and electrophysiological manifestations.
HoogsteenJ,DeliseP,HoffPI,PellicciaA;StudyGrouponSportsCardiology .. Circulation2008;117:144(cid:2)154.
.
oftheEuropeanAssociationforCardiovascularPreventionandRehabilitation. . 592.TanHL,vanderWalAC,CampianME,KruyswijkHH,tenHoveJansenB,van
.
Recommendationsforparticipationinleisure-timephysicalactivityandcompet- . Doorn D-J, Oskam HJ, Becker AE, Wilde AAM. Nodoventricular accessory
.
itivesportsofpatientswitharrhythmiasandpotentiallyarrhythmogeniccondi- .. pathwaysinPRKAG2-dependentfamilialpreexcitationsyndromerevealadisor-
tions. Part II: ventricular arrhythmias, channelopathies and implantable .. derincardiacdevelopment.CircArrhythmElectrophysiol2008;1:276(cid:2)281.
.
defibrillators.EurJCardiovascPrevRehabil2006;13:676(cid:2)686. . 593.LalaniSR,ThakuriaJV,CoxGF,WangX,BiW,BrayMS,ShawC,CheungSW,
.
579. KatritsisD,AndersonA,Webb-PeploeMM.Regulationsconcerningindividual .. ChinaultAC,BoggsBA,OuZ,BrundageEK,LupskiJR,GentileJ,WaisbrenS,
riskandpublicsafety.ESCTextbookofCardiology2018. .. Pursley A, Ma L, Khajavi M, Zapata G, Friedman R, Kim JJ, Towbin JA,
.
580. EuropeanWorkingGrouponDrivingandCardiovascularDisease.Newstand- . StankiewiczP,SchnittgerS,HansmannI,AiT,SoodS,WehrensXH,MartinJF,
.
ardsfordrivingandcardiovascular diseases. Reportof the Expert Groupon . Belmont JW, Potocki L. 20p12.3 microdeletion predisposes to
.
DrivingandCardiovascularDisease.https://ec.europa.eu/transport/road_safety/ .. Wolff(cid:2)Parkinson(cid:2)Whitesyndromewithvariableneurocognitivedeficits.JMed
sites/roadsafety/files/pdf/behavior/driving_and_cardiovascular_disease_final.pdf .. Genet2009;46:168(cid:2)175.
.
(dateaccessedMay2019). . 594.SidhuJS,RajawatYS,RamiTG,GollobMH,WangZ,YuanR,MarianAJ,DeMayo
.
581.NakagawaH,NataleA.Catheterablationofcomplextachyarrhythmiasusingremote . FJ, Weilbacher D, Taffet GE, Davies JK, Carling D, Khoury DS, Roberts R.
.
magneticcatheternavigationsystem.JCardiovascElectrophysiol2016;27:S3(cid:2)S4. .. Transgenicmousemodelofventricularpreexcitationandatrioventricularreentrant
.
582. HilbertS,SommerP,GutberletM,GasparT,FoldynaB,PiorkowskiC,Weiss . tachycardiainducedbyanAMP-activatedproteinkinaseloss-of-functionmutation
.
S, Lloyd T, Schnackenburg B, Krueger S, Fleiter C, Paetsch I, Jahnke C, . responsibleforWolff-Parkinson-Whitesyndrome.Circulation2005;111:21(cid:2)29.
.
HindricksG,GrothoffM.Real-timemagneticresonance-guidedablationoftypi- .. 595.HasdemirC,PayzinS,KocabasU,SahinH,YildirimN,AlpA,AydinM,Pfeiffer
calrightatrialflutterusingacombinationofactivecathetertrackingandpassive .. R,BurashnikovE,WuY,AntzelevitchC.HighprevalenceofconcealedBrugada
.
catheter visualization in man: initial results from a consecutivepatient series. . syndrome in patients with atrioventricular nodal reentrant tachycardia. Heart
.
Europace2016;18:572(cid:2)577. . Rhythm2015;12:1584(cid:2)1594.
.
583. PerlmanO,KatzA,AmitG,ZigelY.Supraventriculartachycardiaclassification .. 596.Weyhrauch DL, Ye D, Boczek NJ, Tester DJ, Gavrilova RH, Patterson MC,
in the 12-lead ECG using atrial waves detection and a clinically based tree .. Wieben ED, Ackerman MJ. Whole exome sequencing and heterologous
.
scheme.IEEEJBiomedHealthInform2016;20:1513(cid:2)1520. . cellularelectrophysiologystudieselucidateanovelloss-of-functionmutationinthe
.
584. Katritsis G, Luther V, Kanagaratnam P, Linton NW. Arrhythmia mechanisms .. CACNA1A-encodedneuronalP/Q-typecalciumchannelinachildwithcongenital
revealedbyripplemapping.ArrhythmElectrophysiolRev2018;7:261(cid:2)264. .. hypotoniaanddevelopmentaldelay.PediatrNeurol2016;55:46(cid:2)51.
.
585. Luther V, Cortez-Dias N, Carpinteiro L, de Sousa J, Balasubramaniam R, . 597.BaruscottiM,BiancoE,BucchiA,DiFrancescoD.Currentunderstandingofthe
.
AgarwalS,FarwellD,SopherM,BabuG,TillR,JonesN,TanS,ChowA,Lowe . pathophysiologicalmechanismsresponsibleforinappropriatesinustachycardia:
.
M,LaneJ,PappachanN,LintonN,KanagaratnamP.Ripplemapping:initialmul- .. roleoftheIf“funny”current.JIntervCardElectrophysiol2016;46:19(cid:2)28.
ticenterexperienceofanintuitiveapproachtoovercomingthelimitationsof .. 598.Josephson ME. Electrophysiology at a crossroads. Heart Rhythm 2007;4:
.
3Dactivationmapping.JCardiovascElectrophysiol2017;28:1285(cid:2)1294. . 658(cid:2)661.
Downloaded
from
https://academic.oup.com/eurheartj/article/41/5/655/5556821
by
guest
on
22
January
2026
--- Страница 67 ---
Delivering to 20+ European Countries.
To deliver the best
patient care, you
FREE CASE ANY LITTMANN® CARD IV
need the tools add code at the checkout to apply
FREECASE
to match.
SHOP NOW
™
Littmann® Cardiology IV
& Littmann® CORE Digital
Stethoscopes
LITTMANN
RATING
9/10
Keep your tools safe
with laser engraving.
LITTMANN
RATING
10+
♥☺♫★♠
FREE CASE ANY LITTMANN® CORE
add code at the checkout to apply
FREECASE
SHOP NOW
